

GPCR/G Protein


G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na⁺/H⁺ exchanger in the plasma membrane, and the lowering of intracellular Ca²⁺ levels.

Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system.

A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs.

References:

- [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
- [2] Tuteja N. Plant Signal Behav. 2009 Oct;4(10):942-7.
- [3] Williams C, et al. Methods Mol Biol. 2009;552:39-50.
- [4] Schiöth HB, et al. Gen Comp Endocrinol. 2005 May 15;142(1-2):94-101.





Target List in GPCR/G Protein

• 5-HT Receptor	4
Adenosine Receptor	28
Adenylate Cyclase	35
Adiponectin Receptor	37
Adrenergic Receptor	39
Angiotensin Receptor	59
Bombesin Receptor	67
Bradykinin Receptor	69
Cannabinoid Receptor	72
• CaSR	77
• CCR	79
CGRP Receptor	84
Cholecystokinin Receptor	87
• CRFR	90
• CXCR	93
Dopamine Receptor	98
• EBI2/GPR183	113
Endothelin Receptor	115
• GHSR	119
Glucagon Receptor	122
Glucocorticoid Receptor	127
GNRH Receptor	134

• GPCR19	137
• GPR109A	140
• GPR119	142
• GPR120	144
• GPR139	146
• GPR40	148
• GPR55	151
• GPR84	153
Guanylate Cyclase	155
Histamine Receptor	158
Imidazoline Receptor	172
Leukotriene Receptor	174
LPL Receptor	178
• mAChR	183
• MCHR1 (GPR24)	196
Melanocortin Receptor	198
Melatonin Receptor	201
• mGluR ·····	203
Motilin Receptor	210
Neurokinin Receptor	212
Neuropeptide Y Receptor	218
Neurotensin Receptor	222




Target List in GPCR/G Protein

Opioid Receptor	224
Orexin Receptor (OX Receptor)	232
Oxytocin Receptor	236
• P2Y Receptor	239
Prostaglandin Receptor	242
Protease-Activated Receptor (PAR)	252
• Ras	255
RGS Protein	261
Sigma Receptor	263
Somatostatin Receptor	266
• TSH Receptor	269
Urotensin Receptor	271
Vasopressin Receptor	273



5-HT Receptor

Serotonin Receptor;5-hydroxytryptamine Receptor



5-HT receptors (Serotonin receptors) are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems. Type: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7. They mediate both excitatory and inhibitory neurotransmission. The serotonin receptors are activated by the neurotransmitter serotonin, which acts as their natural ligand. The serotonin receptors modulate the release of many neurotransmitters, as well as many hormones. The serotonin receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, andthermoregulation. The serotonin receptors are the

target of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens.

5-HT Receptor Inhibitors & Modulators

(4E)-SUN92	221 Cat. No.: HY-U00		alonosetron Hydrochloride	Cat. No.: HY-A0021C
Bioactivity:	(4E)-SUN9221 is a potent antagonist of α 1-adrenergic receptor and 5-HT2 receptor , with antihypertensive and anti-platelet aggregation activities.	Bioactivit	ty: (R,R)-Palonosetron Hydrochloride i Palonosetron.	s the active enantiomer of
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical D Size:	99.61% Pata: No Development Reported 2 mg, 5 mg, 10 mg	O N H H-CI
(Z)-Thiothi	kene Cat. No.: HY-108		modulator 1	Cat. No. : HY-100290
Bioactivity:	(Z)-Thiothixene is an antagonist of serotonergic receptor extracted from patent US 20150141345 A1.	Bioactivit	ty: 5-HT1A modulator 1 displays very 1 5HT _{1A} , adrenergic α ₁ and dopam IC ₅₀ s of 2 ±0.3 nM, 10 ± 3 nM and	nigh affinities for the ine D₂ receptor with
Purity: Clinical Data: Size:	99.14% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	Purity: Clinical D	>98% Data: No Development Reported 1 mg, 5 mg, 10 mg	
5-HT2 anta	gonist 1 Cat. No.: HY-U00		antagonist 1	Cat. No.: HY-U00286
Bioactivity:	5-HT2 antagonist 1 is a potent antagonist of 5-HT2 receptor , with weak $\alpha 1$ adrenoceptor blocking activity.	Bioactivit	ty: 5-HT2A antagonist 1 is a 5-HT2A a patent US5728835A and JP 100772 useful in treatment of gastrointestin disorders.	ntagonist extracted from 7. 5-HT2A antagonist 1 may be
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical D Size:	>98% Data: No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	منحيوم
5-HT3 anta	gonist 1 Cat. No.: HY-U00		antagonist 2	Cat. No.: HY-U00408
Bioactivity:	5-HT3 antagonist 1 is a potent and selective antagonist of serotonin 3 (5-HT3) receptor .	Bioactivit	ty: 5-HT3 antagonist 2 is a 5-HT3 rece	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical D Size:	>98% Data: No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
5-HT3-In-1	Cat. No.: HY-U00		antagonist 1	Cat. No.: HY-100170
Bioactivity:	5-HT3-In-1 is extracted from patent EP0748807A1, compound example 8. It shows 5-HT3 inhibition activity.	Bioactivit	ty: 5-HT4 antagonist 1 is a 5-HT ₄ rece pK _i of 9.6.	ptor antagonist with a
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical D Size:	>98% Data: No Development Reported 1 mg, 5 mg, 10 mg	ಕ್ಷಾ ್ರ್ಯಾಂ

	ntagonist 1 Cat. No.: HY-101622	5-HT7 ago	nist 1	Cat. No.: HY-109
Bioactivity:	5-HT6/7 antagonist 1 is a multifunctional ligand that	Bioactivity:	5-HT7 agonist 1 is a selective 5-HT7 receptor	
	antagonizes 5-HT6/7/2A and D2 receptors, without interacting with M1 receptors and hERG channels.		an IC ₅₀ of 222.93 nM, can be used for the 5-H	17 receptor
	interacting with M1 receptors and nervo channels.		related disease, such as CNS disorders.	
	000/	D. N	000/	н
Purity:	>98%	Purity:	>98%	\square
Size:	No Development Reported	Size:	No Development Reported 250 mg, 500 mg	r ^k
bize.	250 mg, 500 mg	5120.	250 mg, 500 mg	
	<u> </u>			U.,
5HT6-ligan	d-1	8-OH-DPA	т	
	Cat. No.: HY-U00126	(8-Hydroxy-E		Cat. No.: HY-1120
Bioactivity:	5HT6-ligand-1 is a potent 5-HT6 receptor ligand with a K: of	Bioactivity:	8-OH-DPAT is a potent and selective 5-HT age	onist, with a
	1.43 nM.		pIC ₅₀ of 8.19 for 5-HT1A and a K _i of 466 nM f	
	1.45 HM.			
			8-OH-DPAT weakly binds to 5-HT1B (pIC 50, 5	.+2), J-MIT (PIC
			₅₀ <5).	
Purity:	>98%	Purity:	98.0%	~
	No Development Reported		No Development Reported	
Size:	1 mg, 5 mg, 10 mg, 20 mg	Size:	10mM x 1mL in DMSO,	
	τ _φ γ		5 mg, 10 mg, 25 mg, 50 mg, 100 mg	~
	, N~, /			
Abaperido	ne	Adoprazine	2	
	Cat. No.: HY-101619	(SLV313)		Cat. No.: HY-14
Bioactivity:	Abaperidone is a potent antagonist of 5-HT_{2A}receptor and dopamine D₂ receptor with IC₅₀s of 6.2 and 17 nM.	Bioactivity:	Adoprazine, a potential atypical antipsychotic D2 receptor antagonist and 5-HT1A receptor a	÷ ·
B 11				
Purity:	>98%	Purity:	98.13%	^N ∞
		Purity: Clinical Data:		
Clinical Data:				
Clinical Data:	No Development Reported	Clinical Data:	Phase 1	
Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Clinical Data: Size:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	, O C
Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Clinical Data: Size:	Phase 1 10mM x 1mL in DMSO,	
Purity: Clinical Data: Size: Agomelatii (S-20098)	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Clinical Data: Size:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride	Cat. No.: HY-1703
Clinical Data: Size: Agomelatii	No Development Reported ۱ mg, 5 mg, 10 mg, 20 mg	Clinical Data: Size: Agomelatin	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride	
Clinical Data: Size: Agomelatin (S-20098)	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg ne Cat. No.: HY-17038	Clinical Data: Size: Agomelatii (S-20098 hyd	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride)	t, which is
Clinical Data: Size: Agomelatin (S-20098)	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg Cat. No.: HY-17038 Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2	Clinical Data: Size: Agomelatii (S-20098 hyd	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressam	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatin (S-20098)	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg The Cat. No.: HY-17038 Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively)	Clinical Data: Size: Agomelatii (S-20098 hyd	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressan classified as a norepinephrine-dopamine disin	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatin (S-20098)	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg Cat. No.: HY-17038 Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2	Clinical Data: Size: Agomelatii (S-20098 hyd	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressan classified as a norepinephrine-dopamine disin	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatin (S-20098) Bioactivity:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg Cat. No.: HY-17038 Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2 (pKi, 5-HT2C); 6.6 (pKi, 5-HT2b) Target: 5-HT2C Receptor;	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressan classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49%	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatin (S-20098) Bioactivity: Purity:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg Cat. No.: HY-17038 Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2 (pKi, 5-HT2C); 6.6 (pKi, 5-HT2D) Target: 5-HT2C Receptor; 5-HT2B receptor It is classified as a norepinephrine-dopamine 99.88%	Clinical Data: Size: Agomelatin (S-20098 hyd Bioactivity:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressan classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49%	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatin S-20098) Bioactivity: Purity: Clinical Data:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg Cat. No.: HY-17038 Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2 (pKi, 5-HT2C); 6.6 (pKi, 5-HT2b) Target: 5-HT2C Receptor; 5-HT2B receptor It is classified as a norepinephrine-dopamine 99.88% Launched 10mM x 1mL in DMSO,	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressan classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO,	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatin (S-20098) Bioactivity: Purity: Clinical Data:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg Cat. No.: HY-17038 Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2 (pKi, 5-HT2C); 6.6 (pKi, 5-HT2b) Target: 5-HT2C Receptor; 5-HT2B receptor It is classified as a norepinephrine-dopamine 99.88% Launched	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressani classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatin (S-20098) Bioactivity: Bioactivity: Purity: Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg $f(x) = \frac{1}{2} \int_{-\infty}^{\infty} \frac{1}{2} \int_$	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data: Size:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressan classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO,	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatin (S-20098) Bioactivity: Bioactivity: Purity: Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg Cat. No.: HY-17038 Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). IC50 value: 6.2 (pKi, 5-HT2C); 6.6 (pKi, 5-HT2b) Target: 5-HT2C Receptor; 5-HT2B receptor It is classified as a norepinephrine-dopamine 99.88% Launched 10mM x 1mL in DMSO,	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressan classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO,	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatiu S-20098) Bioactivity: Purity: Clinical Data: Size: Agomelatiu	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg $f(x) = \frac{1}{2} \int_{-\infty}^{\infty} \frac{1}{2} \int_$	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data: Size:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressan classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO,	t, which is hibitor (NDDI) - с _{ссб}
Clinical Data: Size: Agomelatin (S-20098) Bioactivity: Purity: Clinical Data: Size: Agomelatin (S-20098 L(+)	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg f_{i} f_{i} f	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data: Size: Alniditan (Alnitidan)	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressam classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatin (S-20098) Bioactivity: Purity: Clinical Data: Size: Agomelatin	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg f_{i} f_{i	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data: Size: Alniditan	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressan classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO,	t, which is hibitor (NDDI)
Clinical Data: Size: Agomelatiu S-20098) Bioactivity: Purity: Clinical Data: Size: Agomelatiu S-20098 L(+)	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg f_{i} f_{i	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data: Size: Alniditan (Alnitidan)	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressam classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	t, which is hibitor (NDDI)
Agomelatin S-20098) Gioactivity: Purity: Linical Data: ize: Agomelatin S-20098 L(+)	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg f_{i} f_{i	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data: Size: Alniditan (Alnitidan)	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride Agomelatine hydrochloride is a antidepressam classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg Alniditan is a potent 5-HT_{1B/1D} receptors ago	t, which is hibitor (NDDI) $e_{ij} = e_{ij} = e_{ij}$ Cat. No.: HY-101 poist, with c_i value of 8.96
Clinical Data: Size: Agomelatin S-20098) Bioactivity: Durity: Clinical Data: Size: Agomelatin S-20098 L(+) Bioactivity:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg f_{i} f_{i} f	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data: Size: Alniditan (Alnitidan) Bioactivity:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressant classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg Alniditan is a potent 5-HT _{1B/1D} receptors ago IC ₅₀ of 1.7 and 1.3 nM in HEK293 cells, and pM and 9.40 for 5-HT _{1B/1D} receptors, respectively	t, which is hibitor (NDDI) $c_{ij} = c_{ij} + c_{ij}$ Cat. No.: HY-101 poist, with c_i value of 8.96
Clinical Data: Size: Agomelatiu S-20098) Bioactivity: Purity: Clinical Data: Size: Agomelatiu S-20098 L(+) Bioactivity: Purity:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg f_{i} f_{i} f	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data: Size: Alniditan (Alnitidan) Bioactivity: Purity:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg the hydrochloride rochloride Agomelatine hydrochloride is a antidepressant classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg Alniditan is a potent 5-HT_{1B/1D} receptors ago IC₅₀ of 1.7 and 1.3 nM in HEK293 cells, and pH and 9.40 for 5-HT _{1B/1D} receptors, respectively >98%	t, which is hibitor (NDDI) $c_{\rm triangle}({\rm NDDI})$ $c_{\rm triangle}({\rm NDDI})$ $c_{\rm triangle}({\rm NDDI})$ ${\rm Here}({\rm triangle}({\rm $
Clinical Data: Size: Agomelatiu S-20098) Bioactivity: Purity: Clinical Data: S-20098 L(+) Bioactivity: Purity: Clinical Data:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg $f_{in} = f_{in} = f_{i$	Clinical Data: Size: Agomelatin (S-20098 hyd Bioactivity: Purity: Clinical Data: Size: Alniditan (Alnitidan) Bioactivity: Purity: Clinical Data:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg ne hydrochloride rochloride) Agomelatine hydrochloride is a antidepressam classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg Alniditan is a potent 5-HT_{1B/1D} receptors age IC₅₀ of 1.7 and 1.3 nM in HEK293 cells, and pH and 9.40 for 5-HT _{1B/1D} receptors, respectively >98% No Development Reported	t, which is hibitor (NDDI) Cat. No.: HY-101 Cat. No.: HY-101 onist, with Ci value of 8.96
Clinical Data: Size: Agomelatiu S-20098) Bioactivity: Purity: Clinical Data: Size: Agomelatiu S-20098 L(+)	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg f_{i} f_{i} f	Clinical Data: Size: Agomelatii (S-20098 hyd Bioactivity: Purity: Clinical Data: Size: Alniditan (Alnitidan) Bioactivity: Purity:	Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg the hydrochloride rochloride Agomelatine hydrochloride is a antidepressant classified as a norepinephrine-dopamine disin due to its antagonism of the 5-HT2C receptor. 99.49% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg Alniditan is a potent 5-HT_{1B/1D} receptors ago IC₅₀ of 1.7 and 1.3 nM in HEK293 cells, and pH and 9.40 for 5-HT _{1B/1D} receptors, respectively >98%	t, which is hibitor (NDDI) $e_{ij} = e_{ij} = e_{ij}$ Cat. No.: HY-101 poist, with c_i value of 8.96

Alosetron (GR 68755; GI	R 68755X)	Cat. No. : HY-70050A		(<mark>(Z)-2-butenedioate)</mark> (GR 68755 edioate); GR 68755X ((Z)-2-butenedioate))	Cat. No.: HY-70050E
Bioactivity:	Alosetron (GR 68755) is a Serotonin 5HT3-r that is used in treatment of irritable bowel s Value: Target: 5-HT Receptor Alosetron has action on the 5-HT3 receptors of the entering the gastrointestinal tract. While being a 5-H	syndrome. IC50 an antagonist c nervous system of	Bioactivity:	Alosetron (Z)-2-butenedioate (GR 68755 (Z)-2 a Serotonin 5HT3-receptor antagonist that is of irritable bowel syndrome. IC50 Value: N/A Receptor Alosetron has an antagonist action receptors of the enteric nervous system of the	used in treatment Target: 5-HT on the 5-HT3
Purity: Clinical Data:	>98%	1	Purity: Clinical Data:	>98%	
Size:	10 mg, 50 mg	S S N S NH	Size:	10 mg, 50 mg	Of Suran Co
Alosetron (Hydrochloride(1:X)) (GR 68755		Alosetron I	D3 Hydrochloride	
(Hydrochlorid	le(1:X)); GR 68755X (Hydrochloride(1:X)))	Cat. No.: HY-70050	(GR-68755C I	03)	Cat. No.: HY-70050C
Bioactivity:	Alosetron Hydrochloride(1:X) (GR 68755 Hy a Serotonin 5HT3-receptor antagonist that of irritable bowel syndrome. IC50 Value: N/. Receptor Alosetron has an antagonist actio receptors of the enteric nervous system of t	is used in treatment A Target: 5-HT3 n on the 5-HT3	Bioactivity:	Alosetron D3 Hydrochloride (GR-68755C D3) Alosetron, which is a serotonin 5HT3-recepto	
Purity: Clinical Data: Size:	>98%		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	
	Hydrochloride (GR 68755C; GR 68755 (I Iydrochloride))	Hydrochloride); Cat. No.: HY-70050C	Alprenolol ((RS)-Alpreno	olol; dl-Alprenolol)	Cat. No.: HY-B151
Bioactivity:	Alosetron Hydrochloride (GR 68755 Hydroc Serotonin 5HT3-receptor antagonist that is of irritable bowel syndrome. IC50 Value: Tar Alosetron has an antagonist action on the 5 the enteric nervous system of the gastroint	used in treatment rget: 5-HT Receptor 5-HT3 receptors of	Bioactivity:	Alprenolol is a non-selective beta blocker as v receptor antagonist.	vell as 5-HT1A
Purity: Clinical Data: Size:	99.72%		Purity: Clinical Data: Size:	99.87% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	
-	hydrochloride ((RS)-Alprenolol hydroc hydrochloride)	hloride; Cat. No.: HY-B1517A	Alverine cit (NSC 35459)	trate	Cat. No.: HY-B0500
Bioactivity:	Alprenolol (hydrochloride) is a non-selective well as 5-HT1A receptor antagonist.		Bioactivity:	Alverine citrate is a ${\bf 5-HT}_{1A}$ receptor antagon ${\bf IC}_{{\bf 50}}$ of 101 nM.	
Purity: Clinical Data: Size:	98.98% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg	H-CI	Purity: Clinical Data: Size:	98.71% Launched 10mM x 1mL in DMSO, 5 g, 10 g	
AM9405		Cat. No. : HY-112707	Ansofaxine (LY03005; LPM	hydrochloride	Cat. No.: HY-U00096
Bioactivity:	AM9405 is a novel peripherally active cann and serotonin type 3 receptor agonist. AN contraction of the ileum and the colon with 0.076 nM, respectively.	abinoid type 1 (CB1) /19405 inhibits twitch	Bioactivity:	Ansofaxine hydrochloride (LY03005; LPM5700 reuptake inhibitor; inhibits serotonin , dopam norepinephrine reuptake with IC₅₀ values of nM, respectively.	65) is a triple ine and
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg		Purity: Clinical Data: Size:	>98%	H-C

AP521		Cat. No. : HY-100166	AR-A 2 (AR-A 000002	2)	Cat. No. : HY-10701
Bioactivity:	AP521 is an agonist of human 5-HT_{1A} recep		Bioactivity:	AR-A 2 is a selective 5-HT_{1B} receptor	antagonist, with high
	of 94 nM.			affinity to guinea pig cortex 5HT_{1B/1D}	
				guinea pig 5-HT_{1B} receptors (K _i =0.24	
Purity:	>98%		Purity:	10-fold lower affinity to guinea pig 5-F >98%	II _{1D} receptor (K
	No Development Reported			No Development Reported	Ó
Size:	1 mg, 5 mg, 10 mg	H-01	Size:	250 mg, 500 mg	¢04C
Aripiprazol	e		Aripiprazol	e D8	
(OPC-14597)		Cat. No.: HY-14546	(OPC-14597 [Cat. No.: HY-14546
Bioactivity:	Aripiprazole (OPC-14597) is a human 5-HT1A agonist with a Ki of 4.2 nM.	receptor partial	Bioactivity:	Aripiprazole D8 (OPC-14597 D8) is the Aripiprazole, which is a human 5-HT1A with a Ki of 4.2 nM.	
Purity:	99.98%	¢,	Purity:	>98%	ÇÇ.
Clinical Data: Size:	Launched 10mM x 1mL in DMSO,	¢ ¯	Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg	
Size.	100 mg, 200 mg, 500 mg, 1 g	a state a	5126.	1 mg, 5 mg, 10 mg	a Na
Asenapine			Asenapine	hydrochloride	
(Org 5222)		Cat. No.: HY-10121			Cat. No.: HY-1656
Bioactivity:	Asenapine(Org 5222) inhibits adrenergic rece	eptor (α1, α2Α,	Bioactivity:	Asenapine maleate, an antipsychotic, is	a 5-HT (1A, 1B, 2A,
	α 2B, α 2C) with Ki of 0.25-1.2 nM and also inh			2B, 2C, 5A, 6, 7) and Dopamine (D₂, D	3, D4) receptor
	receptor (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) with Ki on N. IC50 Value: 0.25-1.2 nM(Ki for adrenergie			antagonist with K _i values of 0.03-4.0 nl	
	0.03-4.0 nM(Ki for 5-HT receptor) Target: 5-H			0.42, 1.1 nM for Dopamine receptor, re	spectively.
Purity: Clinical Data:	>98% Launched	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data:	99.39% Launched	$\cap^{\circ}O$
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	HI HI	Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	H-C
Asenapine	malaata		AVN-492		
(Org 5222 ma		Cat. No.: HY-11100	AVIN-452		Cat. No.: HY-10192
Bioactivity:	Asenapine maleate is a 5-HT (1A, 1B, 2A, 2B,	2C, 5A, 6, 7)	Bioactivity:	AVN-492 is a very specific and highly-s	elective antagonist
	and D2 antagonist with \mathbf{K}_{i} values of 0.03-4.0 respectively, and an antipsychotic.	nM, 1.3nM,		with picomolar affinity to $\textbf{5-HT6R}$ (\textbf{K}_{i} =	-91 pM).
Purity:	99.95%		Purity:	99.49%	
Clinical Data:		a-Q. ⁰ ,Q		No Development Reported	
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	H H HO COL	Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	
Azasetron I	hydrochloride		Befiradol		
(Y-25130 hyd		Cat. No.: HY-B0068	(NLX-112; F13	3640)	Cat. No.: HY-1478
Bioactivity:	Azasetron HCl is a selective 5-HT3 receptor a IC50 of 0.33 nM used in the management of induced by cancer chemotherapy.		Bioactivity:	Befiradol (NLX-112) is a selective 5-HT	1A receptor agonist.
Purity:	98.0%	CINO	Purity:	>98%	
Clinical Data:		ų, i		No Development Reported	ru ⁱ qui
Size:	10mM x 1mL in Water,	HN O	Size:	250 mg, 500 mg	, મંગ્રે
	10 mg, 50 mg, 100 mg, 200 mg	Z H-CI			

-	y drochloride Irochloride); F 13640 (hydrochloride))	Cat. No. : HY-14785A	Bemesetro (MDL 72222)	n	Cat. No.: HY-B1541
Bioactivity:	Befiradol hydrochloride (NLX-112 hydrochloride) 5-HT _{1A} receptor agonist.	is a selective	Bioactivity:	Bemesetron (MDL 72222) is a selective 5-HT₃ antagonist with an IC_{50} of 0.33 nM ^[1] . Neurope effect ^[2] .	
Purity: Clinical Data: Size:	99.22% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	randir. M	Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in DMSO, 10 mg	
Blonanserir (AD-5423)	1	Cat. No.: HY-13575	Brexpiprazo (OPC-34712)	ole	Cat. No. : HY-15780
Bioactivity: Purity: Clinical Data:		2 receptor Blonanserin	Bioactivity: Purity: Clinical Data:		.3 nM, ceptor
Size:	10mM x 1mL in DMSO, 10 mg, 25 mg, 100 mg		Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	⁸ aaf.
BRL 54443		Cat. No.: HY-13221	BRL-15572 (BRL-15572)	dihydrochloride	Cat. No.: HY-13200
Bioactivity:	BRL 54443 is a potent 5-HT1E/1F receptor agonis are 8.7 and 8.9 respectively); displays > 30-fold selectivity over other 5-HT and dopamine recept		Bioactivity:	BRL-15572 2Hcl is a 5-HT1D receptor antagoni 7.9, also shows a considerable affinity at 5-HT1 receptors, exhibiting 60-fold selectivity over 5- receptor.	A and 5-HT2B
Size:	98.86% No Development Reported 10mM × 1mL in DMSO, 10 mg, 50 mg	HO	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg	
Bromperido (R-11333)	ו	Cat. No.: HY-B0901	Buspirone	hydrochloride	Cat. No. : HY-B1115
Bioactivity:	Bromperidol is a butyrophenone derivative, is a p long-acting neuroleptic, used as an antipsychotic treatment of schizophrenia.		Bioactivity:	Buspirone hydrochloride is an anxiolytic psycho used to treat generalized anxiety disorder (GAL	
Purity: Clinical Data: Size:	96.36% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	,0 ¹⁰ 0*	Purity: Clinical Data: Size:	99.64% Launched 10mM x 1mL in DMSO, 100 mg	J. J
Cariprazine (RGH-188)		Cat. No.: HY-14763	Cariprazine (RGH188 hyd	e hydrochloride rochloride)	Cat. No.: HY-14763A
Bioactivity:	Cariprazine is a novel antipsychotic drug candida exhibits high affinity for the D_3 (K_i =0.085 nM) at K_i =0.49 nM) receptors, and moderate affinity for receptor (K_i =2.6 nM).	nd D₂ (Bioactivity:	Cariprazine hydrochloride is a novel antipsycho candidate that exhibits high affinity for the D_3 nM) and D_2 (K_i =0.49 nM) receptors, and mode for the 5-HT_{1A} receptor (K_i =2.6 nM).	(K_i =0.085
Purity: Clinical Data: Size:	99.35% Launched 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.89% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	ALA CARA

Chlorprom	azine D6 hydrochloride	Cat. No.: HY-B0407AS	Chlorprom	azine hydrochloride	Cat. No.: HY-B0407/
Bioactivity:	Chlorpromazine D6 hydrochloride is the deu Chlorpromazine. Chlorpromazine is an inhibi receptor, 5-HT receptor, potassium channel,	terium labeled tor of dopamine	Bioactivity:	Chlorpromazine Hydrochloride is an antagonist of dopamine D2, 5HT2A, potassium channel and channel. Chlorpromazine binds with D2 and 5H ¹ nM and 8.3 nM, respectively.	of the sodium
Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	D D D D D D D D D D D D D D D D D D D	Purity: Clinical Data: Size:	99.83% Launched 1 g, 5 g	
Cisapride			Clocaprami	ine	
(R 51619; (±)-	Cisaprid)	Cat. No.: HY-14149	(Clocarpramir	ne; 3-Chlorocarpipramine)	Cat. No.: HY-B207
Bioactivity:	Cisapride(R 51619) is a nonselective 5-HT4 rr it is also a potent hERG potassium channel ir Value: 0.14 µM(EC50 for 5-HT4 receptor) [1]; [2] Target: 5-HT4 Receptor in vitro: Cisapride inhibitory effects on a hERG current, as indica	hibitor. IC50 9.8 μM (Kv4.3) showed higher	Bioactivity:	Clocapramine is an antagonist of the D _{2'} 5-HT _{2/} receptors.	A
Purity: Clinical Data: Size:	99.72%		Purity: Clinical Data: Size:	>98% Launched 1 mg	HANGE CONCO
-	ine hydrochloride hydrate	Cat. No .: HY-B2073A	Clozapine I	N-oxide	Cat. No.: HY-1736
Bioactivity:	Clocapramine hydrochloride hydrate is an an D_2 and $5-HT_{2A}$ receptors.	tagonist of the	Bioactivity:	Clozapine N-oxide (CNO) is a major metabolite o anti-psychotic drug clozapine. Clozapine N-oxid for the chemogenetic Designer Receptors Exclus by Designer Drug (DREADD) system.	e is a agonist
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg	ала на	Purity: Clinical Data: Size:	99.98% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
CP-809101		Cat. No .: HY-15543	CP-809101	hydrochloride	Cat. No.: HY-15543
Bioactivity:	CP-809101 is a potent and selective 5-HT2C with pEC50 of 9.96/7.19/6.81 for human 5-H receptors respectively.		Bioactivity:	CP-809101 Hcl is a potent and selective 5-HT2C agonist with pEC50 of 9.96/7.19/6.81 for human 5-HT2C/5-HT2B/5-HT2A receptors respectively.	receptor
Purity: Clinical Data: Size:	>98% No Development Reported 10 mg, 50 mg	, Capit	Purity: Clinical Data: Size:	99.38% No Development Reported 10mM x 1mL in Water, 10 mg, 50 mg	o Conner
Cyclobenza (MK130 hydro	aprine hydrochloride ochloride)	Cat. No. : HY-B0740	Cyprohepta	adine hydrochloride	Cat. No.: HY-B0366
Bioactivity:	Cyclobenzaprine Hcl is a skeletal muscle rela central nervous system (CNS) depressant.	xant and a	Bioactivity:	Cyproheptadine is a histamine receptor antagon receptor with IC50 of 0.6 nM.	ist for 5-HT2
Purity: Clinical Data: Size:	99.92% Launched 10mM x 1mL in DMSO, 1 g, 5 g		Purity: Clinical Data: Size:	98.96% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g	

Cyproheptadine hydrochloride sesquihydrate Cat. No.: HY-B1165			Deramcicla (EGIS-3886)	ne	Cat. No.: HY-10163
Bioactivity:	Cyproheptadine hydrochloride sesquihydrate		Bioactivity:	Deramciclane has a high affinity for 5-HT ₂₄ and	
	and is an antagonist of serotonin and histami		2.eutiniy:	receptors; it acts as an antagonist at both reception and has inverse agonist properties at the 5-HT	tor subtypes
Purity:	99.20%	~~~~	Purity:	without direct stimulatory agonist. >98%	_
Clinical Data:		010	-	No Development Reported	
Size:	10mM x 1mL in DMSO,	(_N)	Size:	1 mg, 5 mg, 10 mg, 20 mg	
	100 mg	H–Cl 1.5H ₂ O			H /
Desipramir	ne hydrochloride		Dihydroerg	otamine mesylate	
		Cat. No.: HY-B1272			Cat. No.: HY-B0670
Bioactivity:	Desipramine hydrochloride is an inhibitor of a transporter (NET), 5-HT transporter (SERT dopamine transporter (DAT) with K _i s of 4, nM, respectively.) and	Bioactivity:	Dihydroergotamine mesylate is an ergot alkaloi migraines.	d used to treat
Purity:	99.68%		Purity:	99.91%	Dit.
Clinical Data:		My M	Clinical Data:		HO HO
Size:	10mM x 1mL in DMSO, 100 mg, 500 mg	н-сі мн	Size:	10mM x 1mL in DMSO, 10 mg, 50 mg	
		n-ci jii			K _{OH} Line
Dolasetron			Dolasetron	Mesylate	
MDL-73147)		Cat. No.: HY-B0750	(MDL-73147E	F)	Cat. No.: HY-B075
Bioactivity:	Dolasetron(MDL-73147) is a serotonin 5-HT3 used to treat nausea and vomiting following		Bioactivity:	Dolasetron Mesylate (MDL-73147EF) is a serotor receptor antagonist used to treat nausea and v following chemotherapy.	
Purity:	98.0%		Purity:	>98%	
Clinical Data:			Clinical Data:	Launched	°CH i
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg		Size:	10 mg, 50 mg	н — 8-он — 1
Dolasetron	Mesylate hydrate		Eletriptan l	nydrobromide	
(MDL-73147E	· · ·	Cat. No.: HY-B0750B	(Eletriptan HE		Cat. No.: HY-A00
Bioactivity:	Dolasetron(MDL-73147) is a serotonin 5-HT3 used to treat nausea and vomiting following		Bioactivity:	Eletriptan HBr is a selective 5-HT1B and 5-HT1L agonist with Ki of 0.92 nM and 3.14 nM, respec value: 0.82 nM/3.14 nM (5-HT1B/5-HT1D, Ki) [1 5-HT1B/5-HT1D in vitro: [3H]Eletriptan has a to binding sites (Bmax) of 2478 fmol/mg and 1576	tively. IC50] Target: tal number of
	99.0%	8	Purity:	95.0%	, moning iot
Purity:	Loundhad	° rational i	Clinical Data:	Launched 10mM x 1mL in DMSO,	and.
Clinical Data:				TOTHINI X THE IN DIVISO,	
Clinical Data:	10mM x 1mL in DMSO, 100 mg, 200 mg	H _P O H _P O H _P O	Size:	5 mg, 10 mg, 50 mg, 100 mg	\sim)
Clinical Data: Size:	10mM x 1mL in DMSO, 100 mg, 200 mg			5 mg, 10 mg, 50 mg, 100 mg	~
Purity: Clinical Data: Size: Eltoprazine	10mM x 1mL in DMSO, 100 mg, 200 mg	Cat. No - 44 16697	Eltoprazine	5 mg, 10 mg, 50 mg, 100 mg hydrochloride	Cat No - 44 1660
Clinical Data: Size: Eltoprazine (DU 28853)	10mM x 1mL in DMSO, 100 mg, 200 mg	Cat. No.: HY-16687	Eltoprazine (DU 28853 hy	5 mg, 10 mg, 50 mg, 100 mg hydrochloride drochloride)	Cat. No.: HY-1668
Clinical Data: Size: Eltoprazine DU 28853)	10mM x 1mL in DMSO, 100 mg, 200 mg	essive agent	Eltoprazine	5 mg, 10 mg, 50 mg, 100 mg hydrochloride	sive agent
Clinical Data: Size: Eltoprazine (DU 28853) Bioactivity: Purity:	10mM x 1mL in DMSO, 100 mg, 200 mg Eltoprazine(DU28853) is a serenic or antiaggr which as an agonist at the 5-HT1A and 5-HT1 an antagonist at the 5-HT2C receptor. 95.0%	essive agent	Eltoprazine (DU 28853 hy Bioactivity: Purity:	5 mg, 10 mg, 50 mg, 100 mg hydrochloride drochloride) Eltoprazine(DU28853) is a serenic or antiaggres which as an agonist at the 5-HT1A and 5-HT1B an antagonist at the 5-HT2C receptor. 99.35%	sive agent
Clinical Data: Size: Eltoprazine	10mM x 1mL in DMSO, 100 mg, 200 mg Eltoprazine(DU28853) is a serenic or antiaggr which as an agonist at the 5-HT1A and 5-HT1 an antagonist at the 5-HT2C receptor. 95.0%	essive agent	Eltoprazine (DU 28853 hy Bioactivity:	5 mg, 10 mg, 50 mg, 100 mg hydrochloride drochloride) Eltoprazine(DU28853) is a serenic or antiaggres which as an agonist at the 5-HT1A and 5-HT1B an antagonist at the 5-HT2C receptor. 99.35%	sive agent

Eplivanserii (SR-46349)	ւ Cat. No.: HY-10792	Eplivanseri (SR-46349 (m	
Bioactivity:	Eplivanserin is a potent, selective and orally available 5-HT₂ receptor antagonist, with an IC ₅₀ of 5.8 nM in rat cortical membrane, and a $\mathbf{K}_{\mathbf{d}}$ of 1.14 nM.	Bioactivity:	Eplivanserin mixture is a selective serotonin reuptake inhibitor and a 5-HT_{2A} receptor antagonist, extracted from patent WO 2005/002578 A1 ^[1] .
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg	Purity: Clinical Data: Size:	99.95% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Eptapirone (F 11440)	Cat. No.: HY-19946	Eucalyptol (1,8-Cineole)	
Bioactivity:	Eptapirone (F11440) is a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.	Bioactivity:	Eucalyptol is an inhibitor of 5-HT_3 receptor , potassium channel, TNF- α and IL-1 β .
Purity: Clinical Data: Size:	99.91% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.0% Phase 3 10mM x 1mL in DMSO, 50 mg
F-15599	Cat. No.: HY-19863	Ferulic acio (Sodium feru	
Bioactivity: Purity: Clinical Data: Size:	F-15599 is a highly selective G-protein biased 5-HT1A receptor agonist, with K ₁ of 3.4 nM. >98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Bioactivity: Purity: Clinical Data: Size:	Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a phenolic compound present in several plants with claimed beneficial effects in prevention and treatment of disorders linked to oxidative stress and inflammation. IC50 value: Target: 5-HT Receptor In vitro: In the present study we have showed that 99.74% No Development Reported 10mM x 1mL in DMSO, 1 g, 5 g
FK1052 hyc	Irochloride Cat. No.: HY-101638	Flibanserin (BIMT-17; BI	
Bioactivity:	FK1052 hydrochloride is a potent 5-HT3 and 5-HT4 receptor dual antagonist.	Bioactivity:	Flibanserin is a novel multifunctional serotonin agonist and antagonist (MSAA) that improves sexual functioning in premenopausal women who suffer from reduced sexual interest and desire.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	99.31% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Flopropion	e Cat. No.: HY-100562	Granisetro (BRL 43694)	n Cat. No.: HY-B0071
Bioactivity:	Flopropione is a 5-HT_{1A} receptor antagonist and also a catechol-o-methyltransferase (COMT) inhibitor.	Bioactivity:	Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
Purity: Clinical Data: Size:	98.37% No Development Reported 10mM x 1mL in DMSO, 100 mg	Purity: Clinical Data: Size:	>98% Launched 50 mg, 100 mg

Granisetror (BRL 43694A)	n Hydrochloride	Cat. No.: HY-B0071A	GSK163090)	Cat. No.: HY-1434
Bioactivity:	Granisetron Hcl(BRL 43694A) is a serotonin 5 antagonist used as an antiemetic to treat nau following chemotherapy.	-HT3 receptor	Bioactivity:	GSK163090 is a potent, selective, and orall, receptor antagonist with pKi of 9.4/8.5/9.7, 5-HT1A/B/D, and dopamine D2/D3, respec	/ active 5-HT1A/B/D and 6.3/6.7 for
Purity: Clinical Data: Size:	99.69% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	Ching the second	Purity: Clinical Data: Size:	99.95% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
Harmine (Telepathine)		Cat. No. : HY-N0737A	Idalopirdin (Lu AE58054)	e	Cat. No. : HY-1433
Bioactivity:	Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase ((DYRK)) anticancer and anti-inflammatory activities.		Bioactivity:	Idalopirdine (Lu AE58054) is a potent and s receptor antagonist with a \mathbf{K}_{i} of 0.83 nM.	
Purity: Clinical Data: Size:	99.78% No Development Reported 10mM x 1mL in DMSO, 500 mg	₽-{J}L(N	Purity: Clinical Data: Size:	>98% Phase 3 5 mg, 10 mg, 50 mg	-gr ^{z0-7}
	e Hydrochloride Hydrochloride))	Cat. No.: HY-14338A	Iloperidone (HP 873)	2	Cat. No.: HY-1741
Bioactivity:	Idalopirdine Hydrochloride (Lu AE58054 Hydr potent and selective 5-HT6 receptor antago 0.83 nM.		Bioactivity:	Iloperidone(HP 873) is a D2/5-HT2 recepto is an atypical antipsychotic for the treatme schizophrenia symptoms.	
Purity: Clinical Data: Size:	99.17% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	~gg~~	Purity: Clinical Data: Size:	99.93% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	-010- ₇ 0
Iloperidone (HP 873 hydro	e hydrochloride ochloride)	Cat. No .: HY-17410A	Intepirdine (SB-742457; C	5SK-742457; RVT-101)	Cat. No.: HY-1433
Bioactivity:	Iloperidone (hydrochloride) is a D(2)/5-HT(2) antagonistis, which is an atypical antipsychot treatment of schizophrenia symptoms.		Bioactivity:	Intepirdine (SB742457) is a highly selective antagonist with pKi of 9.63; exhibits >100-over other receptors.	
Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg, 100 mg	~Q_Q	Purity: Clinical Data: Size:	98.92% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	O ^{le} C ^h C
Irindalone (Lu 21-098)		Cat. No.: HY-101632	Isocorynox (7-Isocorynox		Cat. No.: HY-N077
Bioactivity:	Irindalone is a novel serotonin 5-HT₂ antago	nist.	Bioactivity:	Isocorynoxeine, an isorhynchophylline-rela exhibits a dose-dependent inhibition of 5- receptor-mediated current response with a	HT _{2A}
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	~0 ^{8.} 0~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data: Size:	99.52% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	

JNJ-180386	583 Cat. No.: HY-19889	Ketanserin (R41468)	Cat. No.: HY-10562
Bioactivity:	JNJ-18038683 is a 5-Hydroxytryptamine Type 7 (5-HT₇) receptor antagonist, with pK_is of 8.19, 8.20 for rat and human 5-HT ₇ in HEK293 cells, respectively.	Bioactivity:	Ketanserin is a selective 5-HT receptor antagonist. Ketanserin also blocks hERG current (I_{hERG}) in a concentration-dependent manner (IC_{50} =0.11 µM).
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Size:	98.86% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg
Ketanserin		Lasmiditan	
(R41468 tartra Bioactivity:	ate) Cat. No.: HY-10562A Ketanserin tartrate is a selective 5-HT receptor antagonist. Ketanserin tartrate also blocks hERG current (I _{hERG}) in a concentration-dependent manner (IC ₅₀ =0.11 μM).	(COL-144; LY! Bioactivity:	573144) Cat. No.: HY-1486: Lasmiditan (COL-144; LY573144) is a high-affinity, highly selective 5-HT1F receptor agonist(Ki=2.1 nM), compared with Ki of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively.
Purity: Clinical Data: Size:	99.97% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% Phase 3 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
-	e dihydrochloride hydrochloride) Cat. No.: HY-14537	Lesopitron (E4424)	dihydrochloride Cat. No.: HY-101609
Bioactivity: Purity: Clinical Data: Size:	Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α -adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid- β (A β) secretion. 99.75% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg	Bioactivity: Purity: Clinical Data: Size:	Lesopitron dihydrochloride is a full and selective 5-HT_{IA} receptor agonist with IC₅₀ of 125 nM in rat hippocampal membranes. >98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
Lidanserin (ZK-33839)	Cat. No.: HY-101815	Lintopride	Cat. No. : HY-U0012
Bioactivity:	Lidanserin is a drug which acts as a combined ${\bf 5-HT}_{2A}$ and ${\bf \alpha_1}\text{-adrenergic receptor}$ antagonist.	Bioactivity:	Lintopride is a 5HT4 antagonist with moderate 5HT3 antagonist properties.
Purity: Clinical Data: Size:	98.0% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	96.38% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
Loxapine	Cat. No.: HY-17390	Loxapine s	uccinate Cat. No.: HY-17390/
Bioactivity:	Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.	Bioactivity:	Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.
Purity: Clinical Data: Size:	99.86% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg

LP-211	C-4 N- 11/ 11/17	lumateperone Tosylate
	Cat. No. : HY-111455	(ITI-007) Cat. No.: HY-1973
Bioactivity:	LP-211 is a selective and blood-brain barrier penetrant 5-HT₇ receptor agonist, with a K _i of 0.58 nM, with high selectivity over 5-HT _{1A} receptor (K _i , 188 nM) and D ₂ receptor (K _i , 142 nM).	Bioactivity: Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM). IC50 value: 0.54 nM (Ki, for 5-HT2A receptor) Target: 5-HT2A receptor Lumateperone also possesses
Purity: Clinical Data: Size:	99.66% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	Purity: 99.21% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 5 mg, 10 mg
Lurasidone (SM-13496)	Cat. No.: HY-B0032A	Lurasidone Hydrochloride (SM-13496 (Hydrochloride)) Cat. No.: HY-B003
Bioactivity:	Lurasidone (SM-13496) is an antagonist of both dopamine	Bioactivity: Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an
	D ₂ and 5-HT ₇ with IC ₅₀ s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT _{1A} receptor with an IC ₅₀ of 6.75 nM.	antagonist of both dopamine D_2 and $5-HT_7$ with IC_{50} s of 1.68 and 0.495 nM, respectively. Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is also a partial agonist
Purity:	99.33%	Purity: 99.87%
Clinical Data: Size:	Launched 4567	Clinical Data: Launched Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg
LY 344864	Cat. No. 11/ 12709	LY 344864 hydrochloride
	Cat. No.: HY-13788	Cat. No.: HY-13788
Bioactivity:	LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. IC50 Value: 6 nM (Ki) [1] Target: 5-HT1F LY344864 possesses little affinity for the 56 other serotonergic and non-serotonergic neuronal binding sites examined [1]. in vitro: he 5-HT1A, 5-HT1B and	Bioactivity: LY 344864 hydrochloride is a selective 5-HT1F agonist with a K _i of 6 nM.
Purity: Clinical Data: Size:	99.75% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg
LY 344864	racemate Cat. No.: HY-13788C	LY 344864 S-enantiomer
Bioactivity:		Cat. No.: HY-13788 Bioactivity: LY 344864 S-enantiomer is the S-enantiomer of LY344864.
bioactivity.	LY 344864 racemate is a 5-HT_{1F} receptor agonist extracted from patent US 5708187 A.	LY344864 is a 5-HT1F receptor agonist.
Purity:	98.88%	Purity: 99.62%
	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 2 mg, 5 mg
LY310762	C + N - IN 1222	LY334370
Bioactivity:	Cat. No.: HY-13527 LY310762 is a 5-HT1D receptor antagonist with Ki of 249 nM, having a weaker affinity for 5-HT1B receptor.	Cat. No.: HY-10310 Bioactivity: LY334370 is a selective 5-HT _{1F} receptor agonist with a K _i of 1.6 nM.
Purity: Clinical Data: Size:	98.97% No Development Reported 10mM x 1mL in DMSO,	Purity: 99.70% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Metergolin			epin mesylate mesylate; Ro 8-6837 mesylate)	Cat. No.: HY-10783
Bioactivity: Purity: Clinical Data: Size:	Metergoline is a psychoactive drug of the ergoline chemical class which acts as a ligand for various serotonin and dopamine receptors. 99.74% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	Purity:	Methiothepin mesylate is a potent and non-s receptor antagonist, with p \mathbf{K}_{ds} of 7.10 (5-HT (5HT _{1B}), 7.56 (5HT _{1C}), 6.99 (5HT _{1D}), 7.0 (5-H (5-HT _{5B}), 8.74 (5-HT ₆), and 8.99 (5-HT ₇), and 99.32% a: No Development Reported 10mM x 1mL in DMSO, 10 mg	Γ _{1Α}), 7.28 IT _{5Α}), 7.8
MHP 133		Mirtazap		
Bioactivity:	Cat. No.: 1 MHP 133 is a drug with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with \mathbf{K}_{i} of 69 μ M; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.	HY-101653 (Org3770; (Bioactivity:	 -Azamianserin) Mirtazapine is a potent tetracyclic antidepress 	Cat. No.: HY-B035
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	• ↓ Clinical Dat Size:	99.77% a: Launched 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg	
Mosapride (TAK-370; AS-	4370) Cat. No.:	HY-B0189 (TAK-370 c	le citrate trate; AS-4370 citrate)	Cat. No.: HY-B0189
Bioactivity:	Mosapride is a gastroprokinetic agent that acts as a selectiv 5HT4 agonist.	/e Bioactivity:	Mosapride citrate is a gastroprokinetic agent selective 5HT4 agonist.	that acts as a
Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg	Purity: Clinical Dat Size:	99.74% a: Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	າງແມ່ງ ເຫຼັງ ເຫຼັງໃນ
Naftidrofur (Nafronyl oxa	-	HY-B1107 (PRX 00023		Cat. No.: HY-1484
Bioactivity: Purity:	Naftidrofuryl is a drug used in the management of periphe and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 recepto antagonist. 97.0%		Naluzotan is a novel, potent, and selective am 5-HT1A agonist with IC ₅₀ and K _i of appr 20 m used for the treatment of anxiety and depress hERG K⁺ channel blocker, with IC ₅₀ of 3800 >98%	nM and 5.1 nM, sion; Also a weak
Clinical Data: Size:			a: No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	0.4~~0 ^{.0} 1
NAN-190 h	ydrobromide Cat. No.: F	Naratript HY-19818A (GR-85548/		Cat. No.: HY-B019
Bioactivity:	NAN-190 hydrobromide is a serotonin receptor 5-HT antag NAN-190 is a selective antagonist of 5-HT1A.	jonist. Bioactivity:	Naratriptan is a selective 5-HT1 receptor subt is a triptan drug that is used for the treatmen headaches.	
Purity: Clinical Data: Size:	99.02% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg	Purity: Clinical Dat Size:	>98% a: Launched 10 mg, 50 mg	#.°~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Naratriptar (GR-85548A D	n D3 Hydrochloride ⁰³⁾	Cat. No.: HY-B0197AS		n <mark>hydrochloride</mark> nydrochloride)	Cat. No. : HY-B0197A
Bioactivity:	Naratriptan D3 Hydrochloride is the deuteriu Naratriptan, which is a selective 5-HT1 recept agonist.		Bioactivity:	Naratriptan hydrochloride is a selective 5-HT1 subtype agonist and is a triptan drug that is us treatment of migraine headaches.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	99.65% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	H o c c c c c c c c c c c c c c c c c c
Nefazodon (BMY-13754;	e hydrochloride MJ-13754-1)	Cat. No.: HY-B1396	Nelotanser (APD125)	in	Cat. No. : HY-10559
Bioactivity:	Nefazodone hydrochloride is an antidepressa	nt drug.	Bioactivity:	Nelotanserin is a potent 5-HT_{2A} inverse agon moderately potent 5-HT_{2C} partial inverse ago 5-HT_{2B} inverse agonist, with IC₅₀s of 1.7, 79, ²	nist and a weak
Purity: Clinical Data: Size:	99.71% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg		Purity: Clinical Data: Size:	accumulation assays, respectively. 99.59% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	
NEO 376 (SPI-376)		Cat. No.: HY-101583	Nexopamil	racemate	Cat. No.: HY-101727
Bioactivity:	NEO 376 is a selective modulator of 5-HT1 re receptor and dopamine receptor , with anti- actively.		Bioactivity:	Nexopamil racemate is the racemate of Nexop a combined Ca²⁺/5-HT₂ antagonist on thron vivo and on platelet aggregation in vitro.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	ç,	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
NPS ALX C	ompound 4a	Cat. No.: HY-103090	NRA-0160		Cat. No. : HY-101641
Bioactivity: Purity:	NPS ALX Compound 4a is a potent and select 5-hydroxytryptamine ₆ (5-HT ₆) receptor an IC_{50} of 7.2 nM, which also has a great binding K _i of 0.2 nM ^[1] . 99.0%	tagonist with an	Bioactivity: Purity:	NRA-0160 is a selective dopamine D4 recept with a \mathbf{K}_i value of 0.48 nM and with negligible dopamine D2 receptor (\mathbf{K}_i : >10000 nM), D3 \mathbf{K}_i : 39 nM), rat 5-HT2A receptor (\mathbf{K}_i : 180 nM) >98%	affinity for receptor (
Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 5 mg		Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	and the second s
Nuciferine		Cat. No.: HY-N0049	Ocaperidor (R79598)	ne	Cat. No. : HY-101094
Bioactivity: Purity:	Nuciferine is an antagonist at 5-HT_{2A} (IC_{50} = 5-HT_{2C} (IC_{50} =131 nM), and 5-HT_{2B} (IC_{50} = agonist at 5-HT₇ (IC_{50} =150 nM), a partial ag EC₅₀ =64 nM), D ₅ (EC_{50} =2.6 µM) and 5-HT ₆ 99.66%	1 μM), an inverse Jonist at D₂ (Bioactivity: Purity:	Ocaperidone is an effective antipsychotic ager potent 5-HT ₂ and dopamine D ₂ antagonist, a agonist, with K _i s of 0.14 nM, 0.46 nM, 0.75 nM nM for 5-HT ₂ , a $_1$ -adrenergic receptor, dopan 98.55%	and a 5-HT_{1A} I, 1.6 nM and 5.4
	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg			No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	qir o'io.

Olanzapine (LY170053)		Cat. No.: HY-14541	Ondansetro (GR 38032; SN		Cat. No.: HY-B0002
Bioactivity:	Olanzapine(LY170053) is a high affinity for 5-HT2 s and D2 dopamine receptor antagonist. IC50 Value: Receptor Olanzapine is a thienobenzodiazepine tha	erotonin Target: 5-HT at blocks	Bioactivity:	Ondansetron(GR 38032; SN 307) is a seroto antagonist used mainly as anantiemetic (to vomiting), often following chemotherapy. I	onin 5-HT3 receptor treat nausea and C50 Value: Target:
Purity: Clinical Data: Size:	especially the serontonin (5-hydroxytryptamine [5- and the dopamine D2 receptors (Ki values are 4 an 99.94% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg		Purity: Clinical Data: Size:	5- HT3 Receptor in vitro: 5-HT evoked tran currents (EC50 = 3.4 microM; Hill coefficier 98.55% Launched 10 mg, 50 mg, 100 mg	
	on hydrochloride /drochloride); SN 307 (hydrochloride))	C at. No. : HY-B0002		on hydrochloride dihydrate (GR 380 I 307 (hydrochloride dihydrate))	32 (hydrochloride Cat. No.: HY-B0002
Bioactivity:	Ondansetron hydrochloride (GR 38032 hydrochlori hydrochloride) is a serotonin 5-HT3 receptor antag mainly as anantiemetic (to treat nausea and vomiti following chemotherapy. Target: 5- HT Receptor IC vitro: 5-HT evoked transient inward currents (EC50	onist used ng), often 50 Value: in	Bioactivity:	Ondansetron hydrochloride dihydrate (GR dihydrate; SN 307 hydrochloride dihydrate; 5-HT3 receptor antagonist used mainly as treat nausea and vomiting), often following Target: 5- HT3 Receptor IC50 Value: in vitro) is a serotonin anantiemetic (to) chemotherapy.
Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg, 100 mg	H-CI	Purity: Clinical Data: Size:	99.56% Launched 50 mg, 100 mg, 1 g, 5 g	
Palonosetro		Cat. No.: HY-A0018	Palonosetro	on Hydrochloride	Cat. No.: HY-A002
Bioactivity:	Palonosetron is a 5-HT3 antagonist used in the pre treatment of chemotherapy-induced nausea and vo		Bioactivity:	Palonosetron Hcl is a 5-HT3 antagonist use and treatment of chemotherapy-induced n (CINV).	
Purity: Clinical Data: Size:	>98% Launched 10 mg, 100 mg		Purity: Clinical Data: Size:	99.98% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg	
Pancopride (LAS 30451)		Cat. No.: HY-19684	Pardoprune (SLV-308; DU		Cat. No.: HY-1495
Bioactivity:	Pancopride is a new potent and selective 5-HT₃ re antagonist.	ceptor	Bioactivity:	Pardoprunox(SLV-308) is a novel partial do receptor agonist and serotonin 5-HT1A rec (pKi = 8.1) and D3 receptor (pKi = 8.6) part 50% and 67%, respectively) and 5-HT1A re full agonist (IA = 100%); also binds to D4 (p	eptor agonist; D2 ial agonist (IA = ceptor (pKi = 8.5)
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	>98% Phase 3 5 mg, 10 mg, 50 mg, 100 mg	N N N N N N N N N N N N
	ox hydrochloride rochloride; DU-126891 hydrochloride) Ca	it. No. : HY-14958A	Peptide 40	1	Cat. No.: HY-1253
Bioactivity:	Pardoprunox hydrochloride is a novel partial dopar D3 receptor agonist and serotonin 5-HT1A recepto (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agon 5-HT1A receptor (pKi = 8.5) full agonist.	r agonist, D2	Bioactivity:	Peptide 401, a potent mast cell degranulati venom, suppresses the increased vascular intradermal injection of various smooth mu histamine , and 5-HT).	permeability due to
Purity: Clinical Data: Size:	98.89% Phase 3 5 mg, 10 mg, 50 mg, 100 mg	(N) N	Purity: Clinical Data: Size:	98.29% No Development Reported 500u g, 1 mg, 5 mg	

Perphenazi	ne	Cat. No.: HY-A0077	Perphenazi	ne D8 Dihydrochloride	Cat. No.: HY-A0077A
Bioactivity:	Perphenazine is a typical antipsychotic drug, ir 5-HT _{7A} receptor, Alpha-1A adrenergic recep	hibits	Bioactivity:	Perphenazine D8 Dihydrochloride is the deut Perphenazine, which is a typical antipsychotic	erium labeled
	receptor D2/D3, D2L receptor, and Histamii with K _i values of 5.6, 10, 0.765/0.13, 3.4, and 8	ne H1 receptor,		Dopamine receptor ligand).	
Purity:	99.90%	HO	Purity:	>98%	
Clinical Data: Size:	10mM x 1mL in DMSO, 1 g, 5 g	⊂, so a	Size:	No Development Reported 1 mg, 5 mg, 10 mg	H-CI H-CI H-CI
Phenylbigu (N-Phenylbigu	a nide uanide; PBG; 1-Phenylbiguanide)	Cat. No. : HY-101331	Piboserod (SB-207266)		Cat. No. : HY-1557
Bioactivity:	Phenylbiguanide is a $\textbf{5-HT}_3$ receptor selective an \textbf{EC}_{50} of 3.0±0.1 μ M.	e agonist with	Bioactivity:	Piboserod (SB 207266) is a selective 5-HT(4) antagonist.	receptor
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 100 mg	$\operatorname{reg}_{N} \operatorname{reg}_{N} \operatorname{reg}_{N} \operatorname{reg}_{N}$	Purity: Clinical Data: Size:	98.85% Phase 2 10mM x 1mL in DMSO, 10 mg, 50 mg	
Piboserod (SB-207266 h)	hydrochloride ydrochloride)	Cat. No.: HY-15574A	Pimavanser (ACP-103)	rin	Cat. No.: HY-1455
Bioactivity:	Piboserod (SB 207266) Hcl is a selective 5-HT(- antagonist.	4) receptor	Bioactivity:	Pimavanserin is a selective inverse agonist of receptor with \mathbf{plC}_{50} and \mathbf{pK}_{d} of 8.73 and 9.3,	
Purity: Clinical Data: Size:	>98% Phase 2 10 mg, 50 mg		Purity: Clinical Data: Size:	99.73% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg	Control of
Pimavanse			Pimethixen	e	
(ACP-103 tart Bioactivity:	rate) Pimavanserin tartrate (ACP-103) is a potent 5- inverse agonist with pIC₅₀ and pK_i of 8.73 and respectively.		(Pimetixene) Bioactivity:	Pimethixene is antihistamine and antiseroton acts as an antimigraine agent. Pimethixene is antagonist of 5-HT $_{1A'}$ 5-HT $_{2A'}$ 5-HT $_{2B'}$ 5-H histamine H $_1$, dopamine D $_2$ and D $_{4.4}$ as we	a highly potent
Purity: Clinical Data: Size:	99,50% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg	alion alionte	Purity: Clinical Data: Size:	>98%	
Pimethixen (Pimetixene n		Cat. No.: HY-B1101A	Pindolol (LB-46)		Cat. No.: HY-B098
Bioactivity:	Pimethixene maleate is antihistamine and anti compound, acts as an antimigraine agent. Pim is a highly potent antagonist of 5-HT $_{1A'}$ 5-HT 5-HT $_{2C'}$ histamine H $_1$, dopamine D $_2$ and D $_4$	serotonergic ethixene maleate _{2A} , 5-HT _{2B} ,	Bioactivity:	Pindolol (LB-46) is a nonselective β-blocker w beta-adrenergic receptor agonist activity, also 5-HT1A receptor weak partial agonist / antag	o functions as a
Purity: Clinical Data: Size:	>98% No Development Reported 10 mg		Purity: Clinical Data: Size:	99.84% Launched 10mM x 1mL in DMSO, 100 mg	HIN OH H

Pizotifen (BC-105; Pizot	tyline) Cat. No.: HY-B0115	Pizotifen malate (BC-105 (malate); Piz		Cat. No.: HY-B0115A
Bioactivity:	Pizotifen (BC-105) is a potent 5 - \mathbf{HT}_{2} receptor antagonist, with a high affinity for 5 - \mathbf{HT}_{1C} binding site.		ifen (malate) (BC-105 (malate)) is a potent otor antagonist, with a high affinity for 5-H	-
Purity: Clinical Data: Size:	99.65% Launched 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg	Purity:>98%Clinical Data:LauncSize:100 m		
Prucaloprid	le Cat. No.: HY-14151	Prucalopride suc	ccinate	Cat. No. : HY-12694
Bioactivity:	Prucalopride (R093877) is a drug acting as a selective, high affinity 5-HT4 receptor agonist(pKi=8.6/8.1 for 5-HT4a/4b); >150-fold higher affinity for 5-HT4 receptors than for other receptors. IC50 value: 8.6/8.1 for 5-HT4a/4b(pKi) Target: 5-HT4 receptor Prucalopride is a novel enterokinetic	Bioactivity: Pruca	llopride succinate is a selective, high affinit tor agonist with pKi of 8.6/8.1 for 5-HT4a/	y 5-HT4
Purity: Clinical Data: Size:	98.0%			
PRX-08066	Cat. No.: HY-15472	PRX933 hydroch (GW876167 hydroch	nloride hloride; BVT-933 hydrochloride)	Cat. No.: HY-100173
Bioactivity:	PRX-08066 is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR, IC50= 3.4 nM) antagonist that causes selective vasodilation of pulmonary arteries.		33 hydrochloride is a 5-HT_{2c} receptor ago patent WO 2014140631 A1.	onist extracted
Purity: Clinical Data: Size:	97.04% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg		6 evelopment Reported , 5 mg, 10 mg	
Puerarin	Cat. No. : HY-N0145	Pumosetrag Hyd (MKC-733; DDP-733		Cat. No.: HY-19650
Bioactivity:	Puerarin, an isoflavone extracted from Radix puerariae, is a 5-HT2C receptor antagonist.	availa	osetrag Hydrochloride (MKC-733; DDP-733 able 5-HT3 partial agonist developed for tl itable bowel syndrome and gastroesophag se.	he treatment
Purity: Clinical Data: Size:	98.14% Phase 2 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Size: 10mN	% evelopment Reported M x 1mL in DMSO, , 10 mg, 25 mg, 50 mg, 100 mg	
Quetiapine (ICI204636)	Cat. No. : HY-14544	Quetiapine D4 fu	umarate	Cat. No.: HY-B00315
Bioactivity:	Quetiapine (ICI204636) is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression.		iapine D4 fumarate is the deuterium labele n is an atypical antipsychotic.	ed Quetiapine,
Purity: Clinical Data: Size:	99.83% Launched 10 mg, 50 mg, 100 mg		6 evelopment Reported , 5 mg, 10 mg	

Quetiapine	fumarate Cat. No.: HY-B0031	Ramosetro	n Hydrochloride Cat. No.: HY-B0595
Bioactivity:	Quetiapine fumarate is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression.	Bioactivity:	Ramosetron Hydrochloride(YM060 Hydrochloride) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting. Target: 5-HT3 Receptor Ramosetron hydrochloride selectively blocks serotonin receptors (5-HT3). Serotonin
Purity: Clinical Data: Size:	99.54 د المحمد المحم المحمد المحمد الم المحمد المحمد ال	Purity: Clinical Data: Size:	plays a vital role in vomiting, serotonin-induced bradycardic 99.85% Launched 10m X 1mL in DMSO, 10 mg, 50 mg
Revexeprid	e Cat. No.: HY-U00373	RG-12915	Cat. No.: HY-1911(
Bioactivity:	Revexepride is a highly selective 5-HT4 receptor agonist, and a potential inducer of CYP3A4 enzyme , used for the treatment of gastroesophageal reflux disease.	Bioactivity:	RG-12915 is a selective 5-HT3 antagonist, with IC₅₀ value of 0.16 nM.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
Risperidon (R 64 766)	e Cat. No.: HY-11018	Risperidon (R 64 766 hyd	re hydrochloride drochloride) Cat. No.: HY-11018/
Bioactivity:	Risperidone is a serotonin 5-HT ₂ receptor blocker, P-Glycoprotein inhibitor and potent dopamine D_2 receptor antagonist, with K_is of 4.8, 5.9 nM for 5-HT _{2A} and dopamine D_2 receptor, respectively.	Bioactivity:	Risperidone hydrochloride is a serotonin 5-HT ₂ receptor blocker and a potent dopamine D_2 receptor antagonist, with K ₁ s of 0.16, 1.4 nM for 5-HT ₂ and D ₂ receptor,
Purity: Clinical Data: Size:	99.16%	Purity: Clinical Data: Size:	respectively. >8% Launched 10 mg, 50 mg, 100 mg
Risperidon (R 64 766 me	-	Roluperido (CYR-101; MI	one N-101; MT-210) Cat. No.: HY-1946
Bioactivity:	Risperidone mesylate(R 64 766 mesylate) is a serotonin 5-HT2 receptor blocker(Ki= 0.16 nM) and a potent dopamine D2 receptor antagonist(Ki= 1.4 nM).	Bioactivity:	Roluperidone (CYR-101) is a novel cyclic amide derivative that has high equipotent affinities for 5-HT_{2A} and sigma-2 receptors (K_i of 7.53 nM and 8.19 nM for 5-HT _{2A} and sigma-2, respectively).
Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.26% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
Rotigotine (N-0437; N-09	223) Cat. No.: HY-75502	Rotundine ((-)-Tetrahyd	ropalmatine; L-Tetrahydropalmatine) Cat. No.: HY-N0096
Bioactivity:	Rotigotine is a full agonist of dopamine receptor , a partial agonist of the 5-HT1A receptor , and an antagonist of the α2B-adrenergic receptor , with K_i s of 0.71nM, 4-15nM, and	Bioactivity:	Rotundine is an antagonist of dopamine D1 , D2 and D3 receptors with IC_{50} s of 166 nM, 1.4 μ M and 3.3 μ M, respectively. Rotundine is also an antagonist of 5-HT_{1A} with
Purity: Clinical Data: Size:	83nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor. 99.98% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	an IC ₅₀ of 370 nM. 99.88%

RS 127445 (MT 500)		Cat. No.: HY-15419	RU 24969		Cat. No.: HY-16688
Bioactivity:	RS 127445 is a novel high affinity, selective 5-HT receptor antagonist with \mathbf{pK}_{i} of 9.5.	28	Bioactivity:	RU 24969 is a selective agonist at the 5-H receptors.	T1A and 5-HT1B
Purity: Clinical Data: Size:	99.68% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg		Purity: Clinical Data: Size:	99.77% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	
Rupatadine (UR-12592)		Cat. No. : HY-13511	Rupatadine (UR-12592 (Fi		Cat. No.: HY-13511A
Bioactivity: Purity: Clinical Data: Size:	Rupatadine (UR-12592) is a potent dual PAF/H1 a Ki of 0.55/0.1 uM(rabbit platelet membranes/guir cerebellum membranes). ICS0 value: Target: PAF/ in vitro: Rupatadine competitively inhibited histar guinea pig ileum contraction (pA2 = 9.29 +/- 0.00 >98% Launched 100 mg, 500 mg	nea pig H1 antagonist nine-induced	Bioactivity: Purity: Clinical Data: Size:	Rupatadine Fumarate (UR-12592 Fumarat PAF/H1 antagonist with Ki of 0.55/0.1 uM membranes/guinea pig cerebellum meml Target: PAF/H1 antagonist in vitro: Rupat inhibited histamine-induced guinea pig il 99.34% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	(rabbit platelet pranes). IC50 value: adine competitively
Sarpogrelat (MCI-9042)	e hydrochloride	Cat. No. : HY-10564	SB 242084		Cat. No.: HY-13409
Bioactivity:	Sarpogrelate hydrochloride (MCI-9042), a selectiv antagonist, has been widely used as an anti-plate the treatment of PAD. Target: 5-HT2 Recepter Sar drug which acts as an antagonist at the SHT2A ar receptors. Sarpogrelate was shown to have the sa	let agent for pogrelate is a nd 5-HT2B	Bioactivity:	SB 242084 is a 5-HT2C receptor antagoni displays 158- and 100-fold selectivity ove receptors respectively.	
Purity: Clinical Data: Size:	98.39%		Purity: Clinical Data: Size:	99.78% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	eres V Mit
SB 242084	hydrochloride	Cat. No.: HY-13409A	SB 258719		Cat. No.: HY-U00443
Bioactivity:	SB 242084 hydrochloride is a 5-HT2C receptor antagonist(pKi=9.0) that displays 158- and 100-fc selectivity over 5-HT2A and 5-HT2B receptors res IC50 value: 9.0(pKi) [1] Target: 5-HT2C antagonist SB 242084 had over 100-fold selectivity over a ra	pectively. in vitro:	Bioactivity:	SB 258719 is a selective 5-HT₇ receptor a pK_i of 7.5.	antagonist with a
Purity: Clinical Data: Size:	98.58% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg		Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg	Contraction of the second
SB 271046 (SB 271046A)	Hydrochloride	Cat. No.: HY-14336A	SB-224289 (SB-224289A)	hydrochloride	Cat. No. : HY-101105A
Bioactivity:	SB271046 Hcl is a potent, selective and orally acti receptor antagonist with pKi of 8.9.		Bioactivity:	SB-224289 hydrochloride is a selective 5 - antagonist, with anxiolytic effect.	
Purity: Clinical Data: Size:	99.06% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

SB-269970		Cat. No.: HY-15370	SB-269970 (SB-269970A)	hydrochloride	Cat. No.: HY-15370
Bioactivity:	SB269970 is a 5-HT7 receptor antagonist with exhibits >50-fold selectivity against other recep		Bioactivity:	SB269970 hydrochloride is a hydrochloride sa SB-269970, which is a 5-HT7 receptor antag 8.3, exhibits >50-fold selectivity against other	onist with pKi of
Purity: Clinical Data: Size:	>98% No Development Reported 10 mg, 50 mg	O=S=O N	Purity: Clinical Data: Size:	99.41% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	O-+-CI
SB-399885	hydrochloride	Cat. No.: HY-103099	SB-616234	A	Cat. No. : HY-1947
Bioactivity:	SB-399885 hydrochloride is a 5-HT₆ receptor a		Bioactivity:	SB-616234A is a selective and orally bioavaila receptor antagonist, with anxiolytic and antic activity.	ble 5-HT1B
Purity: Clinical Data: Size:	98.93% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	а офно о, том н-о	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	I H H H H H H H H H H H H H H H H H H H
Scopolamir (Hyoscine; Sco	ne opine (-)-tropate; Scopine tropate)	Cat. No. : HY-N0296		ne hydrobromide ((-)-Scopolamine hydr robromide; Scopine hydrobromide)	obromide; Cat. No.: HY-N0296
Bioactivity:	Scopolamine is a high affinity (nM) muscarinic 5-HT ₃ receptor-responses are reversibly inhibit Scopolamine with an IC ₅₀ of 2.09 μ M.		Bioactivity:	Scopolamine hydrobromide is a high affinity antagonist. 5-HT₃ receptor-responses are rev inhibited by Scopolamine with an IC₅₀ of 2.09	versibly
Purity: Clinical Data: Size:	>98% Launched 100 mg	HO O HO	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	HO O HB/
	y drochloride ptamine hydrochloride; 5-HT hydrochloride)	Cat. No.: HY-B1473	Sertindole (Lu 23-174)		Cat. No.: HY-1454
Bioactivity: Purity: Clinical Data: Size:	Serotonin hydrochloride is a monoamine neuro CNS and an endogenous 5-HT receptor agoni hydrochloride is also a catechol O-methyltran COMT) inhibitor with a K _i of 44 μM. 99.97% No Development Reported 10mM x 1mL in DMSO, 50 mg, 100 mg	st. Serotonin	Bioactivity: Purity: Clinical Data: Size:	Sertindole, a neuroleptic, is one of the newer medications available. Target: Multi-target In showed that sertindole exerts a potent antage 5-HT2A, 5-HT2C, dopamine D2, and α I adren- Sertindole offers an alternative treatment opt 96.14% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	vitro studies onism at serotonin ergic receptors.
Setiptiline (Org-8282)		Cat. No.: HY-32329	Setiptiline	maleate	Cat. No.: HY-32329
Bioactivity:	Setiptiline(Org-8282) is a serotonin receptor an		Bioactivity:	Setiptiline is a serotonin receptor antagonist.	
Purity: Clinical Data: Size:	96.00% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg		Purity: Clinical Data: Size:	99.89% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg	É,

Sulamseroc (RS-100302)	t l	Cat. No.: HY-101668	T 82		Cat. No.: HY-U0002
Bioactivity:	Sulamserod is a 5-HT4 receptor antagonist, w antiarrhythmic activities.	ith	Bioactivity:	T 82 is a potent 5-HT3 antagonist an (AChE) inhibitor, used for treatment	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	as normalized
-	dihydrochloride hydrochloride))	Cat. No. : HY-A0008	Tandospiro (SM-3997)	ne	Cat. No.: HY-1455
Bioactivity:	Talipexole dihydrochloride (B-HT 920 dihydroc dopamine D2 receptor agonist, α2-adrenocept 5-HT3 receptor antagonist, which displays antil activity.	hloride) is a or agonist and	Bioactivity:	Tandospirone(SM-3997) is a potent a receptor partial agonist (Ki = 27 nM) selectivity over SR-2, SR-1C, α 1, α 2, C values ranging from 1300-41000 nM)	nd selective 5-HT1A that displays 91 and D2 receptors (Ki
Purity: Clinical Data: Size:	99.99% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	96.81% Launched 10 mg, 50 mg	$({\mathbb A}^{n,p}_{\mu,\mu} {\sim} {\sim} {\circ} {\circ}^{n,\mu}_{\mu}$
Tandospiro (SM-3997 citr		Cat. No.: HY-B0061		ine hydrobromide hydrobromide)	Cat. No.: HY-10175
Bioactivity: Purity: Clinical Data: Size:	Tandospirone citrate is a potent and selective 5 partial agonist (Ki = 27 nM) that displays select SR-2, SR-1C, α 1, α 2, D1 and D2 receptors (Ki va from 1300-41000 nM). IC50 Value: 27±5 nM(Ki 5-HT1A in vitro: Tandospirone is most potent a 98.87% Launched 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg	ivity over lues ranging) [1] Target:	Bioactivity: Purity: Clinical Data: Size:	Tedatioxetine hydrobromide acts as a and 5-HT_{2A}, 5-HT_{2C}, 5-HT₃ and α _{1A} antagonist. >98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Tegaserod (SDZ-HTF-919		Cat. No.: HY-14153A	Temanogre (APD791)	91	Cat. No.: HY-1056
Bioactivity:	Tegaserod maleate is a partial agonist of the 5- stimulates the peristaltic reflex and accelerates gastrointestinal transit.	HT4 receptor;	Bioactivity:	Temanogrel is a highly selective 5-H 1 with a K_i of 4.9 nM.	F_{2A} receptor antagonist
Purity: Clinical Data: Size:	99.80% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	C C C C C C	Purity: Clinical Data: Size:	98.14% Phase 1 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	
Tertatolol ((±)-Tertatolo	l; Racemic Tertatolol; dl-Tertatolol)	Cat. No.: HY-U00356	TG6-10-1		Cat. No.: HY-1697
Bioactivity:	Tertatolol is a potent antagonist of beta-adrer 5-HT receptor , with unique renal vasodilatator		Bioactivity:	TG6-10-1 is an EP2 antagonist, show: activity against only EP2, >300-fold s EP3, EP4, and IP receptors, 100-fold s receptors ^[1] .	electivity over human
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Cs OH H	Purity: Clinical Data: Size:	99.28% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	the second se

Bioactivity: Theridazine is an antipsychotic drug, used in the treatment of schizophenia and psycholis, shows D4 selectivity or sector in sectors and psycholis, shows D4 selectivity or sector in sectors. Bioactivity: Tameptine is a selective facilitator of 5-HT applies in with and degament gr230-30 LpM and has no effect on HT and in vivo. (SD Value IVA Target 5-HT Receptor Tameptine is a selective facilitator of 5-HT applies in with and degament gr230-30 LpM and has no effect on HT and in vivo. (SD Value IVA Target 5-HT Receptor Tameptine is a selective facilitator of 5-HT applies in with and the selective facilitator of 5-HT applies in with and in vivo. (SD Value Target 5-HT Receptor Tameptine in selective facilitator of 5-HT applies in with and in vivo. (SD Value Target 5-HT Receptor Tameptine in selective facilitator and psycholic diverses and the selective facilitator of 5-HT applies in with and in vivo. (SD Value Target 5-HT Receptor Tameptine in advance of the selective facilitator of 5-HT applies in with and in vivo. (SD Value Target 5-HT Receptor Tameptine in advance of the selective facilitator of 5-HT applies in with and in vivo. (SD Value Target 5-HT Receptor Tameptine in advance of the selective facilitator of 5-HT applies in with and in vivo. (SD Value Target 5-HT Receptor Tameptine in advance of the selective facilitator of 5-HT applies in with and in vivo. (SD Value Target 5-HT Receptor Target 5-HT Receptor Tameptine in advance of the selective facilitator of 5-HT applies in with and in vivo. (SD Value Target 5-HT Receptor Target	Thioridazin	e hydrochloride	Cat. No.: HY-B0965	Tianeptine		Cat. No.: HY-900
of xbitophrenia antigonics. and in vice. (SD Value, VIAT arget p1 Receptor Tangenia antigonics. winty: 993% Times Date: Soft Sign 20 and 20 systems. Winty: Date: Times Date: Soft Sign 20 and 20 systems. Sign: Date: Times Date: Soft Sign 20 and 20 systems. Sign: Date: Times Date: Soft Sign: Soft Sign: Soft Sign: Times Date: Soft Sign: Times Date: Soft Sign: Soft Sign: Soft Sign: Times Date: Soft Sign: Soft Sign: Soft Sign: Soft Sign: Soft Sign: Soft Sign: Soft Sign: Times Date: Soft Sign: Soft Sign: Soft Sign: Soft Sign: Soft Sign: Soft Sign: Soft Sign:						
unity: 99.83% ize: Dordk x ImL in DMSO, 100 mg. 500 mg unity: ize: Dordk x ImL in DMSO, 100 mg. 500 mg unity: ianeptine sodium salt Cat. No:: HY-9003A ianeptine sodium salt is a selective facilitator of 5+IT Trazodone (hydrochloride) update in vitro and in vito. ICSO Value: Target 5+IT Receptor: Trazodone (hydrochloride) including 5+F1 and coparmic update. Antidepressant. Bioschilty: unity: 99.89% Unitable base and into Vito. Disk A Tul. in DMSO, 100 mg. 500 mg unitable base and into Vito. unitable base and into Vito. Disk A Tul. in DMSO, 100 mg. 500 mg unitable base and into Vito. vito: Pillog Disk A Tul. in DMSO, 100 mg. 500 mg unitable base and into Vito. vito: Pillog Disk A Tul. in DMSO, 100 mg. 500 mg unitable base and the Vito A State and	lioactivity:	of schizophrenia and psychosis, shows D4 s		Bioactivity:	and in vivo. IC50 Value: N/A Target: 5 has no affinity for a wide range of rec and dopamine (IC50 > 10 μ M) and ha	-HT Receptor Tianeptine eptors, including 5-HT is no effect on
 Trained Date: Lanched Stee: Dom N sp. 100 mg. 500 mg Taneptine sodium salt Cat. No: HY 9003A Taneptine sodium salt is a selective fulfator of 5-HT gampion has no sufficient by the vide and in vio. ICO Volue: Target FHR Ceptor Targetine hild for a vide range of receptor and gampion has no sufficient by the vide and in vio. ICO Volue: Target FHR Ceptor Targetine hild for a vide range of receptor and gampion has no sufficient by the vide and in vio. ICO Volue: Target FHR Ceptor Targetine hild for a vide range of receptor and gampion has no sufficient by the vide and in vio. ICO Volue: Target FHR Ceptor Targetine hild for a vide range of receptor and gampion has no sufficient by the vide and in vio. ICO Volue: Target FHR Ceptor Targetine hild for a vide range of receptor and gampion has no sufficient by the vide and in vio. ICO Volue: Target FHR Ceptor Target FHR Ceptor Target FHR Ceptor and gampion has no sufficient by the vide and in vio. ICO Volue: Target FHR Ceptor Target FHR Ceptor Target FHR Ceptor Target FHR Ceptor And gampion has no sufficient by the vide and in vio. ICO Volue: Target FHR Ceptor And gampion has no sufficient by the vide and the vide of sufficient by the vide and the vide of sufficient by the vide and the vide of sufficient by the vide of	huritye	00 03%	\sim	Durity		itidepressant, analgesic and
izer 10mM x 1mL in DMSQ, 100 mg, 500 mg image 1 mg			ΥN.			a-000
100 mg. 500 mg S mg. 10 mg. 50 mg ianeptine sodium salt Cat. No: HY 90003 ianeptine sodium salt is a selective facilitator of 5+HT Cat. No: HY 900034 ianeptine sodium salt is a selective facilitator of 5+HT Selectivity: trazedone hydrochloride Cat. No: HY 900034 effect on noadersalin or dopamine uptake. Antidepressant, selective facilitator of selective selective and selective facilitator of selective selective and selective facilitator of selective selective and selective facilitator of selective selecti			ANAS.			HN
Cat. No: HY-9003A (AF-1161) Cat. No: HY- Image base in vitro and invito a selective facilitator of 5-HT Transpite has no affinity for a wide range of neeptors, including 5-HT and opposition stand in reuptake inhibitors for treatment of anxiety disorders. urity: Bisactivity: Transpite has no affinity for a wide range of neeptors. urity: Bisactivity: Transpite has no affinity for a wide range of neeptors. urity: Bisactivity: Transpite has no affinity for a wide range of neeptors. urity: Bisactivity: Transpite has no affinity for a wide range of neeptors. urity: Bisactivity: Transpite has no affinity for a wide range of neeptors. urity: Bisactivity: Transpite has no affinity for a wide range of neeptors. inicid Data: Cat. No: HY-B123 cat. No: HY-B123 Topisetron respectively. See: urity: Bisactivity: Tropisetron Hydrochloride See: 100 mg s 100 mg urity: Bisactivity: Tropisetron Hydrochloride (SDZ-KCS-300) for a selective S-HT3 receptor ranspoints with an CSO of 701 t = 09 M or S-HT3 receptor ranspoints with an CSO of 701 t = 09 m or chicon is repetor anagonist and a number of an anagemetor in witro: Topisetron Hydrochloride (SDZ-KCS-300) for a selective S-HT3 receptor ranspoints with an CSO of 701 t = 0.9 M or S-		100 mg, 500 mg	↓ _s ↓↓ ⊢-ci		5 mg, 10 mg, 50 mg	
Cat. No: HY-8003A (AF-1161) Cat. No: HY- Cat. No: HY- (AF-1161) Cat. No: HY- Cat. No: HY- Solution (SD Value: Targets F-HT Receptor Targetpice has no affinity for a wide range of memory of Solution (SD Value: Targets F-HT Receptor Targetpice has no affinity for a wide range of memory of Solution (SD Value: Targets F-HT Receptor Targetpice has no affinity for a wide range of memory of Solution (SD Value: Targets F-HT Receptor Targetpice has no affinity for a wide range of memory of Solution (SD Value: Targets F-HT Receptor Targetpice has no affinity for a wide range of memory of Solution (SD Value: Targets F-HT Receptor Targetpice has no affinity for a wide range of memory of Solution (SD Value: Targets F-HT Receptor Targetpice has no affinity for a wide range of memory of Solution (SD Value: Targets F-HT Receptor Targetpice has no affinity for a wide range of memory of Solution (SD Value: Targets F-HT Receptor Targetpice has no affinity for a wide range of Solution (SD Value: Targets F-HT Receptor Targetpice has Targetpice has Solution (SD Value: Targets	ianeptine	sodium salt		Trazodone	hydrochloride	
uptake in vitro and in vivo. ICS0 Value: Target: 5-HT Receptor Transitional Date: urity: 92.83% including 5-HT and dopamine (ICS0 > 10 µM) and has no effect on norderealin or dopamine uptake. Antidepressant 92.83% including 5-HT and dopamine uptake. Antidepressant 92.83% including 5-HT and dopamine (ICS0 > 10 µM) and has no effect on norderealin or dopamine uptake. Antidepressant 92.83% initial Date: Lonched 10 mg, 50 mg, 100 mg of 6.39, 8.10, 4.66 for 5-HT 10, 5-HT 2 and 5-HT 1A/r respectively. urity: 98.0% 100 mg 5-HT 3 cecptor (ICS0 value: 70.1 ± 100 mg 5-HT 3 cecptor (ICS0 value: 70.1 ± 98.0% 100 mg 100 mg 5-HT 3 cecptor (ICS0 value: 70.1 ± 100 mg 5-HT 3 cecptor (ICS0 value: 70.1 ± 100 mg 50 mg (ICS -S-930) cat. No: HY-80020 5 cat. No: HY-80020 <			Cat. No.: HY-90003A		,	Cat. No.: HY-B04
 urity: 99.88% 10 mg.50 mg.100 mg 10 mg.50 mg 11 mipramine maleate Cat. No: HY-81213 12 cat. No: HY-81213 13 cat. No: HY-81213 14 cat. No: HY-81213 15 cat. No: HY-81213 15 cat. No: HY-81213 16 cat. No: HY-81213 16 cat. No: HY-81213 17 cat. No: HY-81213 10 cat. No: HY-81214 10 cat. No: HY-81244 10 cat. No: HY-81244 <li< td=""><td>ioactivity:</td><td>uptake in vitro and in vivo. IC50 Value: Tarc Tianeptine has no affinity for a wide range including 5-HT and dopamine (IC50 > 10 μ</td><td>get: 5-HT Receptor of receptors, IM) and has no</td><td>Bioactivity:</td><td>belonging to the class of serotonin re</td><td>ceptor antagonists and</td></li<>	ioactivity:	uptake in vitro and in vivo. IC50 Value: Tarc Tianeptine has no affinity for a wide range including 5-HT and dopamine (IC50 > 10 μ	get: 5-HT Receptor of receptors, IM) and has no	Bioactivity:	belonging to the class of serotonin re	ceptor antagonists and
Inicid Date:LaunchedCircle Date:Launchedizee:10 mg. 50 mg. 100 mg \checkmark \checkmark iming provide the pr	urity		e. Antidepressant,	Purity	99 95%	
 Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg Size: 10mM x 1mL in DMSO, 100 mg, 50 mg. 100 mg Size: 10mM x 1mL in DMSO, 100 mg, 50 mg Size: 10mM x 1mL in DMSO, 100 mg, 50 mg Size: 10mM x 1mL in DMSO, 100 mg Size: 10mK x 1mL in DMSO, 10mM x 1mL in DMSO, 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 10mM x 1mL 1m DMSO, Size: 10mM x 1mL in DMSO, Size:			a-000			
Intrinspramine maleateCat. No: HY-B1213Bioactivity: Tripisetron (SDZ-ICS-930 (free base))Cat. No: HY-B0213O 90 M (II) Target: 5-HT3 ceeptor antagonist and a 7-intrium creeptor antagonist and a 7-intrium in zero			HŃ			° 🖉
Cat. No:: HY-B1213 (5DZ-1CS-930 (free base)) Cat. No:: HY-B1213 Bloactivity: Trimipramine maleate is a 5-HT receptor antagonist, with pK 5 of 6.39, 8.10, 4.66 for 5-HT 1_C 5-HT 2 and 5-HT 1_A' Purity: 98.0%		10 mg, 50 mg, 100 mg	or Net		100 mg, 500 mg	на 🦉
 Jioactivity: Trimipramine maleate is a 5-HT receptor antagonist, with pK is of 6.39, 8.10, 4.66 for 5-HT _{1/2}, 5-HT ₂ and 5-HT _{1/4}. Bioactivity: Trojestron (SDZ-ICS-930 free base) is a selective 5-HT3 receptor in vitro: Trojestron (SDZ-ICS-930 free base) is a selective 5-HT3 receptor in vitro: Trojestron Hydrochloride Size: 100 MX x 1mL in DMSO, 100 mg Cat. No: HY-80020 Cat. No: HY-80020	Trimiprami	ne maleate		Tropisetror	1	
of 6.39, 8.10, 4.66 for 5-HT $_{1c}$ 5-HT $_{2}$ and 5-HT $_{1A'}$ respectively. Purity: 98.0% Clinical Data: Launched Size: 10.MM x 1mL in DMSO, 100 mg Cat. No: HY-80020 Size: 10.MM x 1mL in DMSO, 100 mg Cat. No: HY-80020 Size: 10.MM x 1mL in DMSO, 100 mg Cat. No: HY-80020 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-80020 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-80020 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-80020 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-80020 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-80020 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-80020 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-80020 Size: 50 mg Cat. No: HY-800354 Size: 50 mg Cat. No: HY-803544 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-803544 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-803544 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg. 100 mg Cat. No: HY-803544 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg Cat. No: HY-803544 Size: 10.MM x 1mL in DMSO, 10 mg. 50 mg Cat. No: HY-803544 Size: 10.MM x 1mL in DMSO, Cat. No: HY-803544 Size: 10.MM x			Cat. No.: HY-B1213	(SDZ-ICS-930	(free base))	Cat. No.: HY-BOO
Purity: 98.0% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 100 mg Cat. No: HY-80020 Store Tropisetron Hydrochloride Subscription and L-2 98.0% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg Cat. No: HY-80020 Cat. No:	Bioactivity:	of 6.39, 8.10, 4.66 for 5-HT $_{\rm 1C^\prime}$ 5-HT $_{\rm 2}$ and 5		Bioactivity:	receptor antagonist and $\alpha7$ -nicotinic IC50 of 70.1 \pm 0.9 nM for 5-HT3 receptor	receptor agonist with an otor. IC50 value: 70.1 ±
Clinical Data: Size:Launched 100 mg \Box_{TL} 100 mg \Box_{TL}						
Size: $10 \text{mM} \times 1\text{mL in DMSO},$ 100 mg Size: $10 \text{mM} \times 1\text{mL in DMSO},$ 100 mg Size: $10 \text{mM} \times 1\text{mL in DMSO},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Size: $10 \text{mM} \times 1\text{mL in DMSO},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Size: $10 \text{mM} \times 1\text{mL in DMSO},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Size: $10 \text{mM} \times 1\text{mL in DMSO},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Size: $10 \text{mM} \times 1\text{mL in DMSO},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Size: $10 \text{mM} \times 1\text{mL in DMSO},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Size: $10 \text{mM} \times 1\text{mL in DMSO},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Size: $10 \text{mM} \times 1\text{mL in DMSO},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Size: $10 \text{mM} \times 1\text{mL in DMSO},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Size: $10 \text{mM} \times 1\text{mL in Water},$ 10 mg, 50 mg, 100 mg Size: $50 mg$ Chincal Data: Launched Size: $10 \text{mM} \times 1\text{mL in Water},$ $10 \text{ mg}, 50 \text{ mg}, 100 \text{ mg}$ Cat. No: HY-B0354A Bioactivity: Urapidil HCl is an $\alpha 1$ -adrenoceptor antagonist and 5-HT1A Bioactivity: Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C ($5 -\text{HT}_2c)$ receptor-selective agonist with an EC_{50} of 8 \text{ mM}. Purity: $> 98\%$ Clinical Data: Launched Size: $10 \text{ mg}, 50 \text{ mg}$ Size: $10 \text{ mM} \times 1\text{mL in DMSO},$ Size: $10 \text{ mg}, 50 \text{ mg}$ Size: $10 \text{ mM} \times 1\text{mL in DMSO},$ Size: $10 \text{ mM} \times 1\text{mL} \text{ m}$			α			×
100 mg 10 mg, 50 mg, 100 mg Tropisetron Hydrochloride (SDZ-ICS-930) Cat. No.: HY-B0020 Bioactivity: Tropisetron Hydrochloride (SDZ-ICS-930) is a selective 5-HT3 receptor antagonist and a 7-nicotinic receptor and gonist with an ICS 0 of 70.1 ± 0.9 nM for 5-HT3 receptor. TCS0 value: 70.1 ± 0.9 nM Target 5-HT3 receptor art. TCS0 value: 70.1 ± 0.9 nM Target 5-HT3 receptor art. Teceptor in vitro: Retinal ganglion cells(RGCs) pretreated with 100 nM 99.64% Bioactivity: Urapidil is an c1 adrenoreceptor antagonist and a 5-HT1A receptor agonist. Purity: 99.64% Org. 98.9% Clinical Data: Launched Size: Dimy, 50 mg. 100 mg Urapidil hydrochloride Cat. No: HY-B0354A Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C (5-HT2c) receptor-selective agonist with an EC50 of 8 nM. Purity: >98% Clinical Data: Size: 10 mg, 50 mg. 00 mg Purity: >98% Clinical Data: Cat. No: HY-B0354A			, N, M,			
(SDZ-ICS-930) Cat. No.: HY-80020 Bioactivity: Tropisetron Hydrochloride (SDZ-ICS-930) is a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist with an ICS0 of 70.1 ± 0.9 nM for 5-HT3 receptor. ICS0 value: 70.1 ± 0.9 nM for 5-HT3 receptor. ICS0 value: 70.1 ± 0.9 nM for 5-HT3 receptor. ICS0 value: 70.1 ± 0.9 nM for 5-HT3 receptor. ICS0 value: 70.1 ± 0.9 nM target. 5-HT3 receptor. ICS0 value. Target. ICS0 value. Target. ICS0 value. ICS0 valu	5120.		но о о	5126.		
(SDZ-ICS-930) Cat. No.: HY-80020 Bioactivity: Tropisetron Hydrochloride (SDZ-ICS-930) is a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist with an ICS0 of 70.1 ± 0.9 nM for 5-HT3 receptor. ICS0 value: 70.1 ± 0.9 nM for 5-HT3 receptor. ICS0 value: 70.1 ± 0.9 nM for 5-HT3 receptor. ICS0 value: 70.1 ± 0.9 nM for 5-HT3 receptor. ICS0 value: 70.1 ± 0.9 nM target. 5-HT3 receptor. ICS0 value. Target. ICS0 value. Target. ICS0 value. ICS0 valu	Tropisetror) Hydrochloride		Urapidil		
receptor antagonist and α ⁷ -nicotinic receptor agonist with an IC50 of 70.1 ± 0.9 nM for 5-HT3 receptor. IC50 value: 70.1 ± 0.9 nM for 5-HT3 receptor. IC50 value: 70.1 ± 0.9 nM for 5-HT3 receptor; α ⁷ -nicotinic receptor in vitro: Retinal ganglion cells(RGCs) pretreated with 100 nM Purity: 99.64% Clinical Data: Launched Size: 10mM x 1mL in Water, 10 mg, 500 mg $c_{a}^{++\alpha}$ Bioactivity: Urapidil Hydrochloride Cat. No:: HY-B0354A Purity: >98% Clinical Data: Launched Size: 100 mg, 500 mg $c_{a}^{-+\alpha}$ Purity: 99.89% Clinical Data: Launched Size: 50 mg $c_{a}^{-+\alpha}$ Purity: 99.89% Clinical Data: Launched Size: 50 mg $c_{a}^{-+\alpha}$ Purity: 99.89% Clinical Data: Launched Size: 50 mg $c_{a}^{-+\alpha}$		•	Cat. No.: HY-B0020			Cat. No.: HY-B07
Purity: 99.64% Clinical Data: Launched Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg Urapidil hydrochloride Cat. No.: HY-B0354A Bioactivity: Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist. Purity: 99.89% Clinical Data: No Development Reported Size: 50 mg Vabicaserin hydrochloride (SCA 136) Cat. No.: HY-1 Bioactivity: Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C (5-HT _{2C}) receptor-selective agonist with an EC ₅₀ of 8 nM. Purity: 98.99% Clinical Data: Launched Size: 100 mg, 500 mg Purity: 98.99% Clinical Data: No Development Reported Size: 100 mg, 500 mg	Bioactivity:	receptor antagonist and α 7-nicotinic receptor 0.9 nM for 5-HT3 receptor. If 0.9 nM Target: 5-HT3 receptor; α 7-nicotinic	tor agonist with an C50 value: 70.1 ± c receptor in vitro:	Bioactivity:		agonist and a 5-HT_{1A}
Clinical Data: Launched Size: 10 mM x 1mL in Water, 10 mg, 50 mg, 100 mg Image: Size: Urapidil hydrochloride Cat. No.: HY-B0354A Bioactivity: Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist. Purity: >98% Clinical Data: Launched Size: >98% Clinical Data: No Development Reported Size: Size: Size: Size: <tr< td=""><td>Duritar</td><td></td><td>h 100 nM</td><td>Durit:</td><td>00 80%</td><td></td></tr<>	Duritar		h 100 nM	Durit:	00 80%	
Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg Size: 50 mg Size: 50 mg Vabicaserin hydrochloride (SCA 136) Cat. No.: HY-1 Bioactivity: Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist. Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C (5-HT _{2C}) receptor-selective agonist with an EC ₅₀ of 8 nM. Purity: >98% Clinical Data: Launched Size: 100 mg, 500 mg						
Cat. No.: HY-B0354A (SCA 136) Cat. No.: HY-1 Bioactivity: Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist. Bioactivity: Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C (5-HT2c) receptor-selective agonist with an EC50 of 8 nM. Purity: >98% Purity: 98.99% Clinical Data: Launched Image: Size: No Development Reported Size: 100 mg, 500 mg Image: Size: 100 mX 1mL in DMSO,		10mM x 1mL in Water,	O H-CI			
Cat. No.: HY-B0354A (SCA 136) Cat. No.: HY-1 Bioactivity: Urapidil HCl is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist. Bioactivity: Vabicaserin hydrochloride is a 5-hydroxytryptamine 2C (5-HT2c) receptor-selective agonist with an EC50 of 8 nM. Purity: >98% Purity: 98.99% Clinical Data: Launched Clinical Data: No Development Reported J00 mg, 500 mg Tommy x 1mL in DMSO, H	Irapidil by	drochloride		Vabicaserir	bydrochloride	
Purity: >98% Clinical Data: Launched Size: 100 mg, 500 mg Purity: 98.99% Clinical Data: No Development Reported	erapian ny		Cat. No.: HY-B0354A		. injurocinoniue	Cat. No.: HY-1112
Clinical Data: Launched Size: 100 mg, 500 mg	Bioactivity:		nist and 5-HT1A	Bioactivity:	5	5 5 .
Clinical Data: Launched ize: 100 mg, 500 mg Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO,		000/		D. V	22.222/	
Size: 100 mg, 500 mg						, H
ы						⊂ C N
5 mg, 10 mg, 25 mg, 50 mg, 100 mg		J. J	на о			Ĥ ⊂ ∖_


Vilazodone (EMD 68843; S		Cat. No : HV 14262	Vilazodone	2 D8	Cat No . HV 142615
Bioactivity:	Vilazodone (EMD 68843; SB 659746A) is a com specific reuptake inhibitor (SSRI) and 5-HT1A r	receptor partial	Bioactivity:	Vilazodone D8 is the a deuterium labeled a combined serotonin specific reuptake in	
Purity: Clinical Data: Size:	agonist currently under clinical evaluation for 1 of major depression. 99.91% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	Sy-ofor	Purity: Clinical Data: Size:	5-HT1A receptor partial agonist. >98% No Development Reported 1 mg, 5 mg	
	Hydrochloride Hydrochloride); SB659746A (Hydrochloride))	Cat. No .: HY-14261	Volinanseri (MDL100907;		Cat. No. : HY-14940
Bioactivity:	Vilazodone Hydrochloride (EMD 68843 Hydrod Hydrochloride) is a serotonin transporter (SER 5-HT_{1A} receptor partial agonist.		Bioactivity:	Volinanserin is a potent and selective anta receptor , with a \mathbf{K}_{i} of 0.36 nM, and shows selectivity for 5-HT ₂ receptor over 5-HT ₁ D ₂ receptors. Volinanserin has antipsycho	s 300-fold _c , alpha-1 and DA
	99.94% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	g~~0 ⁰⁰⁻⁶ "	Purity: Clinical Data: Size:	99.71% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	rocaciiviiy.
Vortioxetin (Lu AA 21004)		Cat. No. : HY-15414		ne hydrobromide hydrobromide)	Cat. No.: HY-15414A
Bioactivity:	Vortioxetine is a inhibitor of 5-HT_{1A}, 5-HT_{1B}, 5-HT₇ receptor and SERT , with K ₁ values of 15 3.7 nM, 19 nM and 1.6 nM, respectively.		Bioactivity:	Vortioxetine hydrobromide is a multimod inhibits 5-HT_{1A}, 5-HT_{1B}, 5-HT_{3A}, 5-HT₇ SERT with K _i values of 15 nM, 33 nM, 3.7 nM, respectively.	receptor and
Purity: Clinical Data: Size:	98.81% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	S NH	Purity: Clinical Data: Size:	99.54% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	S N NH
WAY 16390	9	Cat. No. : HY-15401	WAY-1006	35	Cat. No.: HY-10349
Bioactivity:	WAY 163909 is a potent and selective 5-HT(2) agonist with a \mathbf{K}_{i} of 10.5±1.1 nM.		Bioactivity:	WAY-100635 is a potent and selective 5-h antagonist with a pIC $_{50}$ of 8.87, an appar	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	H NH	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg, 100 mg	
WAY-10063	35 Maleate	Cat. No .: HY-10349A	WAY-1006	35 maleate salt	Cat. No.: HY-13105
	WAY-100635 Maleate is a potent and selective antagonist with a pIC $_{50}$ of 8.87, an apparent p	10	Bioactivity:	WAY-100635 maleate salt is a potent and 5-hydroxytryptamine1A antagonist with a nM for 5-HT. IC50 Value: 0.95 nM Target: vitro: WAY 100635 has an IC50 of 1.35 nM selective for the 5-HT1A site relative to a	n IC50 of 0.95 ± 0.12 5-HT Receptor in 1 and is > 100-fold
	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.77% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	

Wf-516			Xanthotoxo		_
		Cat. No.: HY-19417A	(8-Hydroxyps	oralen)	Cat. No.: HY-30152
Bioactivity:	Wf-516 is an inhibitor of 5-HT reuptake , and of 5-HT1A and 5-HT2A receptors, with K _i of 5 for 5-HT1A receptor and 5-HT2A receptor in h respectively, and has potent antidepressant ac	5 nM and 40 nM numans,	Bioactivity:	Xanthotoxol is a biologically active line shows strong pharmacological activitie antioxidant, 5-HT antagonistic, and ne	es as anti-inflammatory,
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Josefi	Purity: Clinical Data: Size:	99.15% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	о- о с С
YL0919		Cat. No. : HY-100769	YM348		C-4 No - 10/ 10022
Bioactivity:	YL0919, a novel antidepressant candidate with a 5-HT1A receptor agonist and a selective serv inhibitor,the IC50 values of YL-0919 inhibiting 5-HT into rat cerebral cortical synaptosomes a recombinant cells were 1.78±0.34 nM and 1.93	a dual activity as otonin reuptake the uptake of ind human	Bioactivity:	YM348 is a potent and orally active 5 - agonist, which shows a high affinity fo receptor (K _i : 0.89 nM).	20
Purity: Clinical Data: Size:	99.84% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	H _A N N CO
Zatosetron (LY 277359 m		Cat. No.: HY-U00234	Ziprasidono (CP-88059)	9	Cat. No. : HY-1454
Bioactivity:	Zatosetron maleate is a potent and selective 5 antagonist.	HT3 receptor	Bioactivity:	Ziprasidone(CP88059) is a combined 5 dopamine receptor antagonist which e antipsychotic activity.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	HO CON	Purity: Clinical Data: Size:	98.69% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	• ۲۵۴٬۰۵۰ و ج
Ziprasidone (CP-88059 D8		Cat. No. : HY-14542S	Ziprasidono (CP-88059 hy	e hydrochloride drochloride)	Cat. No. : HY-14542/
Bioactivity:	Ziprasidone D8 is deuterium labeled Ziprasido combined 5-HT (serotonin) and dopamine rec which exhibits potent effects of antipsychotic	eptor antagonist	Bioactivity:	Ziprasidone Hcl(CP-88059 Hcl) is a cor and dopamine receptor antagonist wh of antipsychotic activity.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	0.2.50 ⁰ 0.0.00 0.2.50 ⁰ 0.0.00 0.0.50	Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg	0.750°-104. No
-	e hydrochloride monohydrate rdrochloride monohydrate))	Cat. No.: HY-17407			
Bioactivity: Purity:	Ziprasidone hydrochloride monohydrate (CP 8 monohydrate) is a combined 5-HT (serotonin) receptor antagonist which exhibits potent effe antipsychotic activity. Target: 5-HT receptor; D receptor Ziprasidone hydrochloride monohydr 99.83% Launched	88059 hydrochloride and dopamine ects of popamine			



Adenosine Receptor

P1 receptor



examined.

Adenosine receptors (ARs) comprise a group of G protein-coupled receptors (GPCR) which mediate the physiological actions of adenosine. To date, four AR subtypes have been cloned and identified in different tissues. These receptors have distinct localization, signal transduction pathways and different means of regulation upon exposure to agonists. A key property of some of Adenosine receptors is their ability to serve as sensors of cellular oxidative stress, which is transmitted by transcription factors, such as NF-kB, to regulate the expression of ARs. The importance of Adenosine receptors in the regulation of normal and pathological processes such as sleep, the development of cancers and in protection against hearing loss will be

Adenosine Receptor Inhibitors & Modulators

5'-N-Ethylc (NECA)	arboxamidoadenosine Cat. No.:	HY-103173	A2A recept	or antagonist 1	Cat. No. : HY-102024
Bioactivity:	5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective adenosine receptor agonist.		Bioactivity:	A2A receptor antagonist 1 is an antagonist of the A_{2A} receptor and A_1 receptor with K_i s of 4 and respectively.	
Purity: Clinical Data: Size:	99.86% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg		Purity: Clinical Data: Size:	98.25% No Development Reported 10mM × 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	
A2AR-agor		. 11/ 19776	A2B recept	or antagonist 1	Cot No . UV 100221
Bioactivity:	A2AR-agonist-1 is a potent A2AR and ENT1 agonist with K 4.39 and 3.47 for A2AR and ENT1.	: HY-18776 i of	Bioactivity:	A2B receptor antagonist 1 is a potent A2B ade antagonist extracted from patent WO 2009157	
Purity: Clinical Data: Size:	99.96% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	species
AB-MECA	Cat. No.	: HY-19365	Acefylline (Theophylline	acetic acid; Theophylline-7-acetic acid)	Cat. No.: HY-B1505
Bioactivity:	AB-MECA is a high affinity A3 adenosine receptor agonist, high affinity for recombinant A1 and A3 receptors.	has	Bioactivity:	Acefylline is an adenosine receptor antagonist	t.
Purity: Clinical Data: Size:	99.10% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg		Purity: Clinical Data: Size:	99.87% No Development Reported 10mM x 1mL in DMSO, 100 mg	
Adenosine (5'-AMP mon	5'-monophosphate monohydrate ohydrate) Cat. No.: H	HY-A0181A	Adenosine	antagonist-1	Cat. No. : HY-100274
Bioactivity:	Adenosine 5'-monophosphate monohydrate is an adenosi receptor agonist.	ine A ₁	Bioactivity:	Adenosine antagonist-1 is an adenosine A3 re antagonist.	ceptor (AA3R)
Purity: Clinical Data: Size:	99.07% Phase 4 10mM x 1mL in Water, 1 g	NH2 HO-C-C-C-C-CH HO-C-C-C-CH HO-C-C-CH HO-C-C-CH HO-C-C-CH HO-C-C-CH HO-C-C-CH HO-C-C-CH HO-C-C-CH HO-C-C-C-CH HO-C-C-C-CH HO-C-C-C-C-CH HO-C-C-C-C-C-CH HO-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	N C N
APNEA (N6-[2-(4-Am	inophenyl)ethyl]adenosine) Cat. No.	: HY-18687	AZD4635 (HTL1071)		Cat. No.: HY-101980
Bioactivity:	APNEA is a potent, non-selective A3 adenosine receptor agonist.		Bioactivity:	AZD4635 is a novel $adenosine$ 2A receptor ($\textit{\textbf{A}}$ with a \textbf{K}_i of 1.7 nM.	A2AR) inhibitor
Purity: Clinical Data: Size:	97.19%	In Cont	Purity: Clinical Data: Size:	99.79% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	

BAY-545	Cat. No. : HY-111767	Capadenoson Cat. No.: HY-14917 (BAY 68-4986) Cat. No.: HY-14917
Bioactivity:	BAY-545 is a potent and selective A_{2B} adenosine receptor antagonist, with an IC₅₀ of 59 nM. BAY-545 also exhibits IC₅₀s of 66, 400, 280 nM for human, mouse, rat A _{2B} adenosine	Bioactivity: Capadenoson is a selective agonist of adenosine-A1 receptor .
Purity: Clinical Data: Size:	receptor in cells, respectively, and a \mathbf{K}_{i} of 97 nM for huma 97.06% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: 98.43% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
CGS 21680	Cat. No.: HY-13201	CGS 21680 Hydrochloride Cat. No.: HY-13201A
Bioactivity:	CGS 21680 is a selective adenosine A2A receptor agonist, with a K _i of 27 nM.	Bioactivity: CGS 21680 Hydrochloride is a selective adenosine A2A receptor agonist with a K _i of 27 nM.
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg, 100 mg	Purity: 99.70% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
CPI-444 (V81444; cifor	adenant) Cat. No.: HY-101978	Diphylline (Diprophylline) Cat. No.: HY-B0128
Bioactivity:	CPI-444 is a potent and selective inhibitor of A2A receptor (A2AR) induces antitumor responses.	Bioactivity: Dyphylline acts as an adenosine receptor antagonist and phosphodiesterase inhibitor, which is used in the treatment of respiratory disorders.
Purity: Clinical Data: Size:	99.94% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	Purity: 99.28% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 100 mg, 500 mg
Doxofylline	саt. No.: НҮ-В0004	GP531 Cat. No.: HY-U00116
Bioactivity:	Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV .	Bioactivity: GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.
Purity: Clinical Data: Size:	99.88% No Development Reported 10mM x 1mL in DMSO, 100 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg
GR79236	Cat. No.: HY-18978	Istradefylline (KW-6002) Cat. No.: HY-10888
Bioactivity:	GR79236 is a highly potent and selective adenosine A1 receptor agonist (Ki = 3.1 nM) that has analgesic and anti-inflammatory actions in humans and animals. IC50 value: 3.1 nM(Ki) Target: adenosine A1 receptor in vitro: GR79236 is a highly potent and selective A1-receptor agonist that is originally developed for	Bioactivity: Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with K _i of 2.2 nM in experimental models of Parkinson's disease. Durity: 00.429/
Purity: Clinical Data: Size:	99.98% " No Development Reported " 10mM x 1mL in Water, " 5 mg, 10 mg, 50 mg "℃H	Purity: 99.42% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

KF21213	Cat. No.: HY-U00180	KFM19 Cat. No.: HY-U0025
Bioactivity:	KF21213 is a highly selective ligand for mapping CNS adenosine A_{2A} receptors. KF21213 shows a high affinity for the	Bioactivity: KFM19 is a potent, selective Adenosine receptor (A1-receptor) antagonist, with an IC ₅₀ of 50 nM.
Purity: Clinical Data: Size:	adenosine A _{2A} receptors (K _i =3.0 nM). >98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg
LAS101057	Cat. No. : HY-14390	LUF6000 Cat. No.: HY-132
Bioactivity:	LAS101057 is a potent, selective, and orally efficacious A2B receptor antagonist.	Bioactivity: LUF6000 is an allosteric modulator of the human A3 adenosine receptor (AR).
Purity: Clinical Data: Size:	99.78% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg	Purity: 99.34% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
MRE3008F2	20 Cat. No.: HY-103178	MRS 1754 Cat. No.: HY-141
Bioactivity:	MRE3008F20 is a highly potent and selective antagonistic of adenosine A3 receptor (AA3R) , inhibits agonist-induced cAMP elevation in resting T lymphocytes with an IC₅₀ of 5 nM ^[1] .	Bioactivity: MRS 1754 is a selective antagonist radioligand for A _{2B} adenosine receptor with very low affinity for A ₁ and A ₃ receptors of both humans and rats ^[1] .
Purity: Clinical Data: Size:	99.0% No Development Reported 5 mg	Purity:98.31%Clinical Data:No Development ReportedSize:10mM x 1mL in DMSO,5 mg, 10 mg, 25 mg
MRS-1706	Cat. No.: HY-103186	MRS1177 Cat. No.: HY-1200
Bioactivity:	MRS-1706 is a potent and selective adenosine A_{2B} receptor inverse agonist. MRS-1706 has K_i values of 1.39, 112, 157, and 230 nM for human A _{2B'} A _{2A'} A ₁ and A ₃ receptors	Bioactivity: MRS1177 is a potent and selective human Adenosine A3 receptor (hA ₃ AR) antagonist, with a K _i of 0.3 nM.
Purity: Clinical Data: Size:	respectively ^[1] ^[2] . 98.06% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg
MRS1186	Cat. No. : HY-118678	N-0861 racemate Cat. No.: HY-U001
Bioactivity:	MRS1186 is a potent and selective human Adenosine A3 receptor (hA_3AR) antagonist, with a K_i of 7.66 nM.	Bioactivity: N-0861 racemate is the racemate of N-0861. N-0861 is a selective adenosine A1 receptor antagonist.
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg

N-[(4-Amir	ophenyl)methyl]adenosine	Cat. No.: HY-100130		nylethyl)adenosine /ladenosine; N6-Phenylethyladenosine)	Cat. No.: HY-10185
Bioactivity:	N-[(4-Aminophenyl)methyl]adenosine is a ac inhibitor, with Ki of 29 nM for Rat ecto-5'-Nu		Bioactivity:	N6-(2-Phenylethyl)adenosine is a selective A1 receptor agonist.	Ladenosine
Purity: Clinical Data: Size:	98.68% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	Not the second s	Purity: Clinical Data: Size:	98.0% No Development Reported 10 mg, 50 mg, 100 mg, 200 mg	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
N6-Cyclohe	exyladenosine	Cat. No. : HY-18939	N6-Cyclop (CPA; UK-808	entyladenosine 82)	Cat. No. : HY-10318
Bioactivity:	N6-Cyclohexyladenosine is a selective A1 rec		Bioactivity:	N6-Cyclopentyladenosine (CPA) is a selective	
·	(EC50 = 8.2 nM).			receptor agonist, with \mathbf{K}_{i} values of 2.3 nM, 79 for human A $_{1}$, A $_{2A}$ and A $_{3}$ receptors, respectively.	0 nM and 43 nM
Purity: Clinical Data: Size:	99.98% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg		Purity: Clinical Data: Size:	[2] >98% No Development Reported 10 mg, 50 mg	HU HO HO HO HO HO HO HO HO HO HO HO HO HO
N6-Ethylad	lenosine	Cat. No.: HY-111809	Namodenc (CF-102; 2-Cl		Cat. No.: HY-123
Bioactivity:	N6-Ethyladenosine is an adenosine derivativ Adenosine receptor agonist, with K_i s of 4.9 ₁ AR and hA ₃ AR, respectively ^[1] .		Bioactivity:	Namodenoson (CF-102) is a selective A3 ader agonist (Ki = 0.33 nM). Displays 2500- and 14 selectivity over A1 and A2A receptors respect	00-fold
Purity: Clinical Data: Size:	>98% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	NH NSTH HO-SOH	Purity: Clinical Data: Size:	99.71% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	
PD 117519 CI947)		Cat. No.: HY-100032	Piclidenoso (IB-MECA; CF		Cat. No.: HY-135
Bioactivity: Purity:	PD 117519 is an adenosine agonist. 99.94% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	NH NH NG NG NG NG	Bioactivity: Purity:	Piclidenoson (IB-MECA) is an agonist of the a receptor with EC50 values of 0.11 µM. IC50 va (EC50) [3] Target: adenosine A3 receptor in vi Piclidenoson has been shown to play importa proliferation and apoptosis in a variety of can 98.97% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	denosine A3 Ilue: 0.11 μM tro: nt roles in cell
Preladenan SCH-420814)		Cat. No.: HY-10889	Proxyphyll	ine	Cat. No.: HY-B174
Bioactivity:	Preladenant is a potent and competitive and human adenosine A2A receptor with a K _i of 1000-fold selectivity over other adenosine re	f 1.1 nM and has over	Bioactivity:	Proxyphylline is a methylxanthine derivative c cardiac stimulant, vasodilator and bronchodila	
Purity: Clinical Data: Size:	99.08% Phase 3 5 mg, 10 mg, 50 mg, 100 mg	ange-a-a-	Purity: Clinical Data: Size:	99.46% Launched 10mM x 1mL in DMSO,	N N N


Regadenos (CVT-3146)	on	Cat. No.: HY-A0168	SCH 58261		Cat. No.: HY-1953
· · ·					
Bioactivity:	Regadenoson is an A2A adenosine receptor age coronary vasodilator that is commonly used in p stress testing.		Bioactivity:	SCH 58261 is the adenosine A2A receptor com antagonist. Displays 323-, 53- and 100-fold sele A1, A2B and A3 receptors, respectively.	
Purity: Clinical Data: Size:	99.59% Launched 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg	MA MACON NECCON	Purity: Clinical Data: Size:	99.38% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	()-1(^N () ()-1(N-1) Ny Ny
Sch412348		Cat. No. : HY-U00189	ST3932		Cat. No. : HY-11284
Die erstinden	C-1 41 22 40 :		Die erstiniten		
Bioactivity:	Sch412348 is a potent competitive antagonist of adenosine A_{2A} receptor (K_i =0.6 nM) and has a selectivity over all other adenosine receptors.		Bioactivity:	ST3932 is a metabolite of ST1535, acts as an an adenosine A_{2A} receptor, with K_i s of 8 nM and and A ₁ receptors, respectively.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	0-ttg-~0,0.	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	
ST4206		Cat. No.: HY-U00341	Taminaden	ant	Cat. No.: HY-10913
Bioactivity:	ST4206 is a potent adenosine A2A antagonist, and 197 nM for adenosine A2A receptor and ad receptor, respectively.	with K_i s of 12 nM	Bioactivity:	Taminadenant is an antagonist of adenosine r	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg		Purity: Clinical Data: Size:	99.13% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
Tecadenoso (CVT-510)	on	Cat. No. : HY-19661	Theobromi (3,7-Dimethyl		Cat. No.: HY-N013
Bioactivity:	Tecadenoson (CVT-510) is a selective A1 adeno agonist.	osine receptor	Bioactivity:	Theobromine is a methylxanthine found in caca inhibit adenosine receptor A1 (AR1) signaling	
Purity: Clinical Data: Size:	99.64% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	HN N N HO HO HO	Purity: Clinical Data: Size:	99.65% Phase 3 10mM x 1mL in DMSO, 100 mg	స్తు
Theophyllir (1,3-Dimethyl	1e xanthine; Theo-24)	Cat. No.: HY-B0809	Ticlopidine	hydrochloride	Cat. No.: HY-B0153
	Theophylline is a nonselective phosphodiester inhibitor, adenosine receptor blocker, and hist (HDAC) activator.	ase (PDE)	Bioactivity:	Ticlopidine hydrochloride is an adenosine diph receptor inhibitor against platelet aggregation $\sim 2 \ \mu$ M. Target: Adenosine diphosphate (ADP) T name Ticlig) is an antiplatelet drug in the thien family. Ticlopidine hydrochloride inhibits platel	osphate (ADP) with IC50 of 'iclopidine (trade opyridine
Purity: Clinical Data: Size:	99.94% Launched 10mM x 1mL in DMSO, 5 g		Purity: Clinical Data: Size:	family. Ticlopidine hydrochloride inhibits platel 99.99% Launched 10mM x 1mL in DMSO, 1 g, 5 g	

Tozadenan	t		UP202-56		
(SYN115)		Cat. No.: HY-10995			Cat. No.: HY-U00226
Bioactivity:	Tozadenant is an adenosine A_{2A} receptor anta of 11.5 nM on human A _{2A} and 6 nM on rhesus	· ·	Bioactivity:	UP202-56 is an adenosine analogue, which i agonist.	s an adenosinergic
Purity: Clinical Data: Size:	98.06% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Vipadenan			ZM241385		C + N - UV 10522
(BIIB-014; CEB Bioactivity:	Vipadenant (BIIB-014; CEB-4520) is an adenosin antagonist, with K _i s of 1.3 nM and 68 nM for A respectively.		Bioactivity:	ZM 241385 is a selective and high affinity A 2 receptor antagonist.	Cat. No.: HY-19532 2A adenosine
Purity: Clinical Data:	98.02% No Development Reported 10mM x 1mL in DMSO,	NN-SV-N-NNS	Purity: Clinical Data: Size:	98.55% No Development Reported 10mM x 1mL in DMSO,	Q-MAYANO



Adenylate Cyclase

Adenylyl cyclase



cAMP is produced by adenylatecyclase (AC), a 12-transmembrane-spanning enzyme that catalyzes the conversion of ATP to 3',5'-cAMP and pyrophosphate.

In neuronal and neuroendocrine cells, a variety of ligands, such as neurotransmitters and hormones, signal via activation of G protein coupled receptors (GPCRs) coupled to $G_S \alpha$. These receptors activate

adenylatecyclases (ACs), the family of enzymes that generate cAMP. cAMP is synthesized by adenylatecyclases (ACs) and degraded by phosphodiesterases (PDEs). Local cAMP signaling is achieved by targeting of signaling components to subcellular compartments and assembly of signaling complexes. Primary cilia also host several

cAMP-signaling components: the somatostatin 3 receptor (SSTR3), various adenylatecyclases (AC3, AC4, AC6, AC8), PKA, and Epac2 (exchange protein directly activated by cAMP).


Adenylate Cyclase Inhibitors & Modulators

CB-792122	0 Cat. No.: HY-101862	Forskolin (Coleonol; Colforsin) Cat. No.: HY-1
Bioactivity:	CB-7921220 is an adenylate cyclase inhibitor.	Bioactivity: Forskolin is a potent adenylate cyclase activator, with IC ₅₀ and EC ₅₀ of 41 nM and 0.5 μM for type I adenylyl cyclase, respectively.
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	Purity: 98.52% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg
LRE1	Cat. No.: HY-100524	Small Cardioactive Peptide B SCPB
Bioactivity:	LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase.	Bioactivity: Small Cardioactive Peptide B (SCP _B), a neurally active peptide, stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues with EC ₅₀ s of 0.1 and 1.0 μM, respectively.
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg
SQ22536	Cat. No. : HY-100396	ST034307 Cat. No.: HY-10
Bioactivity:	SQ22536 is an effective adenylate cyclase (AC) inhibitor.	Bioactivity: ST034307 is a potent and selective adenylyl cyclase 1 (AC1) inhibitor, with IC $_{50}$ of 2.3 μ M.
Purity: Clinical Data: Size:	98.43% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg	Purity: 98.11% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
TIP 39, Tuk	peroinfundibular Neuropeptide Cat. No.: HY-P1852	α-Melanocyte-Stimulating Hormone (MSH), amide Cat. No.: HY-P
Bioactivity:	TIP 39, Tuberoinfundibular Neuropeptide is a neuropeptide and parathyroid hormone 2 receptor (PTH2R) agonist. TIP 39 is highly conserved among species. TIP39 from all species activates adenylyl cyclase and elevates intracellular calcium levels through parathyroid hormone 2 receptor (PTH2R) ^[1] .	Bioactivity: α-Melanocyte-Stimulating Hormone (MSH), amide stimulates melanocortin 1 receptor that results in the activation of adenylyl cyclase.
Purity: Clinical Data:	>98% No Development Reported	Purity: 98.55% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg



Adiponectin Receptor

AdipoRs



HDAC (Histone deacetylase)

Adiponectin is a protein which in humans is encoded by the ADIPOQ gene. It is involved in regulating glucose levels as well as fatty acid breakdown. The hormone plays a role in the suppression of the metabolic derangements that may result intype 2 diabetes, obesity, atherosclerosis, non-alcoholic fatty liver disease and an independent risk factor for metabolic syndrome. Adiponectin binds to a number of receptors. Two receptors have been identified with homology to G protein-coupled receptors, and one receptor similar to the cadherin family: adiponectin receptor 1 and adiponectin receptor 2.

Adiponectin Receptor Inhibitors & Modulators

50 mg


AdipoRon		AdipoRon	hydrochloride	
	Cat. No.: HY-15848			Cat. No.: HY-110164
Bioactivity:	AdipoRon is an orally active adiponectin receptor (AdipoR) agonist, binding to AdipoR1 and AdipoR2 with K_ds of 1.8 and	Bioactivity:	AdipoRon hydrochloride is an orally active a agonist, binding to AdipoR1 and AdipoR2, w	
	3.1 μM, respectively.		3.1 μM, respectively.	
Purity: Clinical Data: Size:	99.76% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	orost.oo
Gramine (Donaxine)	Cat. No.: HY-N0166			
Bioactivity:	Gramine (Donaxine) is a natural alkaloid isolated from giant reed ^[2] , acts as an active adiponectin receptor (AdipoR) agonist, with IC₅₀s of 3.2 and 4.2 μ M for AdipoR2 and AdipoR1,			
	respectively ^[1] . Gramine is also a human and mo			
Purity: Clinical Data: Size:	99.45% No Development Reported 10mM x 1mL in DMSO,			

, T -Ņ



Adrenergic Receptor

Beta Receptor



HDAC (Histone deacetylase)

Adrenergic receptors are a class of G protein-coupled receptors that are targets of the catecholamines, especially norepinephrine and epinephrine. Many cells possess these receptors, and the binding of a catecholamine to the receptor will generally stimulate the sympathetic nervous system. The sympathetic nervous system is responsible for the fight-or-flight response, which includes widening the pupils of the eye, mobilizing energy, and diverting blood flow from non-essential organs to skeletal muscle. There are two main groups of adrenergic receptors, α and β , with several subtypes. α receptors have the subtypes $\alpha 1$ and $\alpha 2$. β receptors have the subtypes β 1, β 2 and β 3. All three are linked to Gs proteins, which in

turn are linked to adenylate cyclase. Agonist binding thus causes a rise in the intracellular concentration of the second messenger cAMP. Downstream effectors of cAMP include cAMP-dependent protein kinase (PKA), which mediates some of the intracellular events following hormone binding.

Adrenergic Receptor Inhibitors & Modulators

(+)-Penbut		(4E)-SUN9	
((R)-Penbutol Bioactivity:	ol; (+)-Isopenbutolol)Cat. No.: HY-116790A(+)-Penbutolol is a β -adrenoceptor antagonist, with an IC $_{50}$ of 0.74 μ M $^{[1]}$. (+)-Penbutolol is an optical isomer ofI-penbutolol with Na $^+$ channel-blocking action $^{[2]}$.	Bioactivity:	Cat. No.: HY-U00367 (4E)-SUN9221 is a potent antagonist of α1-adrenergic receptor and 5-HT2 receptor, with antihypertensive and anti-platelet aggregation activities.
Purity: Clinical Data: Size:	95.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	>98% : No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
(R)-(-)-Phe (Phenylephrir			enylephrine hydrochloride ne hydrochloride) Cat. No.: HY-B0471
Bioactivity:	(R)-(-)-Phenylephrine is a selective α_1 -adrenoceptor agonist primarily used as a decongestant.	Bioactivity:	(R)-(-)-Phenylephrine hydrochloride is a selective α_1 -adrenoceptor agonist with pK_is of 5.86, 4.87 and 4.70 for $\alpha_{1D'} \alpha_{1B}$ and α_{1A} receptors respectively.
Purity: Clinical Data: Size:	>98% Launched 200 mg	Purity: Clinical Data Size:	98.10% : Launched 10mM x 1mL in DMSO, 100 mg, 500 mg
(RS)-Butyry	ltimolol Cat. No.: HY-102032A	(S)-Timolo (L-714,465 (M	I Maleate Maleate); MK 950) Cat. No.: HY-17380
Bioactivity: Purity: Clinical Data: Size:	(RS)-Butyryltimolol is the racemate of Butyryltimolol. Butyryltimolol is the butyryl ester of Timolol. Timolol is in the non-selective β blocker family of medication. 98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Bioactivity: Purity: Clinical Data Size:	 (S)-Timolol maleate, is a potent non-selective β-adrenergic receptor antagonist (Ki values are 1.97 and 2.0 nM for β1 and β2 receptor subtypes respectively). IC50 Value: 1.97 nM(Ki for β1): 2.0 nM(Ki for β2) Target: β-adrenergic receptor (S)-Timolol, 50% bioavailability following oral 99.87% Launched 10mM x 1mL in DMSO, 100 mg, 200 mg
(±)-Befuno	lol Cat. No.: HY-101752		olol (hemifumarate) emifumarate salt) Cat. No.: HY-B0076
Bioactivity:	(\pm) -Befunolol is a β-adrenoceptor blocking agent.	Bioactivity:	Bisoprolol is a selective type $\beta 1$ adrenergic receptor blocker.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg	Purity: Clinical Data Size:	98.41% : Launched 10mM x 1mL in Water, 100 mg, 200 mg, 500 mg
3-Hydroxy	4-methoxycinnamic acid d) Cat. No.: HY-N0761	5-HT2 anta	agonist 1 Cat. No.: HY-U00365
Bioactivity:	3-Hydroxy-4-methoxycinnamic acid (Isoferulic acid) is a cinnamic acid derivative that has antidiabetic activity. 3-Hydroxy-4-methoxycinnamic acid binds to and activates α1-adrenergic receptors (IC ₅₀ =1.4 µM) to enhance secret	Bioactivity:	5-HT2 antagonist 1 is a potent antagonist of 5-HT2 receptor , with weak $\alpha 1$ adrenoceptor blocking activity.
Purity: Clinical Data: Size:	99.82% No Development Reported 10mM x 1mL in DMSO, 100 mg	Purity: Clinical Data: Size:	>98% : No Development Reported 1 mg, 5 mg, 10 mg, 20 mg

Acebutolol	hydrochloride	Cat. No .: HY-17497A	Adrenalone	e hydrochloride	Cat. No.: HY-B13
Bioactivity:	Acebutolol Hydrochloride is a β -adrenergic antagonist used in the treatment of hyperte pectoris and cardiac arrhythmias.		Bioactivity:	Adrenalone hydrochloride is a selective agonist, used as a topical vasoconstrict used to prolong the action of local and	tor and hemostatic,
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in Water, 100 mg, 5 g, 10 g	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data: Size:	98.0% Launched 100 mg	HO HO H-CI
AGN 19283	36		Alfuzosin		
Bioactivity:	AGN 192836 is a potent and selective $\alpha 2$ ad with EC ₅₀ s of 8.7, 41 and 6.6 nM for $\alpha 2A$, $\alpha 2$ receptor, respectively.		(SL 77499) Bioactivity:	Alfuzosin is an α1 adrenergic receptor treat benign prostatic hyperplasia (BPH	•
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	99.81% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	
Alfuzosin h (SL 77499-10)	ydrochloride	Cat. No.: HY-B0192A		n methylsulfate netilsulfate; Lu-1631)	Cat. No.: HY-A02
Bioactivity:	Alfuzosin hydrochloride is an $\alpha 1$ adrenergic antagonist used to treat benign prostatic hy		Bioactivity:	Amezinium metilsulfate has multiple m stimulation of alpha and beta-1 recept ofnoradrenaline and tyramine uptake.	-
Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg	on on on on on on on on on on	Purity: Clinical Data: Size:	99.51% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g	H,N -000
Amibegron (SR 58611A)	hydrochloride	Cat. No.: HY-103207	Amitraz (BTS-27419)		Cat. No.: HY-B11
Bioactivity:	Amibegron hydrochloride is a selective β3-a agonist, with an EC ₅₀ of 3.5 nM for β-adren colon; Amibegron hydrochloride has anxioly antidepressant activity.	oceptor in rat	Bioactivity:	Amitraz is a non-systemic acaricide and alpha-adrenergic agonist activity, inter receptors of the central nervous system monoamine oxidases and prostagland	action with octopamine n and inhibition of
Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in DMSO, 5 mg	" O Et Oo " In Ho	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 100 mg	Winput
Ancarolol		Cat. No.: HY-100141	AR-08		Cat. No.: HY-U003
Bioactivity:	Ancarolol is a beta-adrenergic blocking age		Bioactivity:	AR-08 is an agonist of $\alpha 2$ -adrenergic treatment of attention deficit hyperact	receptor, used for the
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	C, o HN C	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	

Asenapine		Atenolol
(Org 5222)	Cat. No.: HY-10121	((RS)-Atenolol) Cat. No.: HY-174
Bioactivity: Purity: Clinical Data: Size:	Asenapine(Org 5222) inhibits adrenergic receptor (α1, α2A, α2B, α2C) with Ki of 0.25-1.2 nM and also inhibits 5-HT receptor (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) with Ki of 0.03-4.0 nM. IC50 Value: 0.25-1.2 nM(Ki for adrenergic receptor); 0.03-4.0 nM(Ki for 5-HT receptor) Target: 5-HT Receptor, > 98% Launched IOMM x 1mL in DMSO,	Bioactivity: Atenolol is a selective β1 receptor antagonist. Purity: 98.0% Clinical Data: Launched Size: 10mM x 1mL in DMSO,
5120.	10 mg, 50 mg, 100 mg	1 g, 5 g
Atipamezo		Atipamezole hydrochloride
(MPV 1248)	Cat. No.: HY-12380A	(MPV-1248 hydrochloride) Cat. No.: HY-123
Bioactivity:	Atipamezole is a synthetic $\boldsymbol{\alpha}_2\text{-}adrenoceptor}$ antagonist with a \boldsymbol{K}_i of 1.6 nM.	Bioactivity: Atipamezole hydrochloride is a synthetic $α_2$ -adrenoceptor antagonist with a K_i of 1.6 nM.
Purity: Clinical Data: Size:	99.07% Phase 1 10mM x 1mL in DMSO, 10 mg, 50 mg	Purity: 99.96% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg H-CI
Bambutero (KWD-2183; (l ±)-Bambuterol) Cat. No.: HY-17501	Bambuterol hydrochloride (KWD-2183 hydrochloride; (±)-Bambuterol hydrochloride) Cat. No.: HY-1750:
Bioactivity: Purity: Clinical Data: Size:	Bambuterol is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. IC50 value: Target: beta-adrenoceptor agonist Bambuterol is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people >98% Launched 10 mg, 50 mg, 100 mg	 Bioactivity: Bambuterol Hcl is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. IC50 value: Target: beta-adrenoceptor agonist Bambuterol is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people Purity: 99.57% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
Batefentero (GSK961081;		Benzquinamide (P2647; BZQ; Benzoquinamide) Cat. No.: HY-U0024
Bioactivity:	Batefenterol (GSK961081;TD-5959) is a novel muscarinic receptor antagonist and β_2-adrenoceptor agonist; displays high affinity for hM2, hM3 muscarinic and h β_2 -adrenoceptor with K_i values of 1.4, 1.3 and 3.7 nM, respectively.	$\begin{array}{llllllllllllllllllllllllllllllllllll$
Purity: Clinical Data: Size:	98.30% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg
Betaxolol	Cat. No.: HY-B0381	Betaxolol hydrochloride (SL75212) Cat. No.: HY-B0382
Bioactivity:	Betaxolol is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma.	Bioactivity: Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma.
Purity: Clinical Data: Size:	96.95% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity: 98.94% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

Bometolol	Hydrochloride	Cat. No. : HY-U00386	Brimonidin (UK 14304; A		Cat. No.: HY-B0659
Bioactivity:	Bometolol Hydrochloride is a beta-adrene used for the research of cardiovascular dise		Bioactivity:	Brimonidine (UK 14304) is a full α2-ad (α2-AR) agonist.	renergic receptor
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	and meridian	Purity: Clinical Data: Size:	99.65% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
Brimonidin (UK 14304 (ta	e tartrate rtrate); AGN190342 (tartrate))	Cat. No. : HY-B0659A	Carbazochi (AC-17)	rome sodium sulfonate	Cat. No. : HY-B04914
Bioactivity:	Brimonidine tartrate (UK 14304 tartrate) is α 2-adrenergic receptor (α 2-AR) agonist.	a full	Bioactivity:	Carbazochrome (sodium sulfonate) (A agent. Target: Others Carbazochrome agent that will cease blood flow by car and adhesion of platelets in the blood plug, ceasing blood flow from an oper	is an antihemorrhagic using the aggregation to form a platelet
Purity: Clinical Data: Size:	99,90% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	HO T HO OH	Purity: Clinical Data: Size:	99.51% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	NA, 3 , 5 , 5 , 5 , 5 , 5 , 5 , 5 , 5 , 5
Carteolol h (OPC-1085 hy	ydrochloride ^r drochloride)	Cat. No .: HY-17495A	Carvedilol (BM 14190)		Cat. No.: HY-B0006
Bioactivity: Purity: Clinical Data: Size:	Carteolol HCl is a non-selective beta blocke glaucoma. Target: Beta adrenergic Recepto beta-adrenergic antagonist used as an anti an anti-angina agent, an antihypertensive a antiglaucoma agent. Carteolol hydrochlorid 98.0% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	r Carteolol HCl is a -arrhythmia agent, agent, and an	Bioactivity: Purity: Clinical Data: Size:	Carvedilol(BM14190) is a non-selective blocker with an IC50 of 3.8 μM for inh oxidation. IC50 Value: 3.8 μM (inhibiti Target: beta Adrenergic Receptor Carv nonselective-blocking agent and is use 99.93% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	ibition of LDL on of LDL oxidation) redilol is a
	phosphate hemihydrate hosphate hemihydrate))	Cat. No. : HY-B0006A	Centanafac (EB-1020)	line	Cat. No.: HY-16736
Bioactivity:	Carvedilol (phosphate hemihydrate) (BM 14 hemihydrate)) is a non-selective beta block with an IC $_{\rm 50}$ of 3.8 $\mu \rm M$ for inhibition of LDI	er/alpha-1 blocker	Bioactivity:	Centanafadine is dual norepinephrin transporter inhibitor, also inhibits sero with IC₅₀s of 6 nM, 38 nM and 83 nM serotonin transporter , respectively.	tonin transporter,
Purity: Clinical Data: Size:	>98% Launched 100 mg, 500 mg		Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	NH
Centanafac (EB-1020 (hyc	line hydrochloride Irochloride))	Cat. No .: HY-16736A	Cicloprolol	hydrochloride	Cat. No .: HY-U00066
Bioactivity:	Centanafadine (hydrochloride) is dual nore (NE)/ dopamine (DA) transporter inhibitor serotonin transporter, with IC ₅₀ s of 6 nM, 3 human NE, DA and serotonin transporter ,	, also inhibits 38 nM and 83 nM for	Bioactivity:	Cicloprolol is a partial β 1-adrenocep	tor agonist .
Purity:	>98%		Purity:	>98%	

Clonidine h	ydrochloride Cat. No.: HY-B0409A	Clorprenaline hydrochloride Cat. No.: HY-B1347
Bioactivity:	Clonidine hydrochloride is an agonist of α 2-adrenoceptor and potent antihypertensive agent.	Bioactivity: Clorprenaline hydrochloride is a β_2 -adrenergic receptor agonist.
Purity: Clinical Data: Size:	99.95% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg HCI	Purity: 99.89% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 50 mg H-cl
D2343	Cat. No.: HY-U00206	Dapiprazole hydrochloride
Bioactivity:	D2343 is a β2-adrenoceptor agonist and also is an α1- adrenoceptor inhibitor.	Bioactivity: Dapiprazole hydrochloride is a potent α-adrenergic blocking drug, which is used to reverse mydriasis after eye examination.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: 99.97% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Image: Clinical Data
Deriglidole (SL 86-0715)	Cat. No. : HY-101683	Detomidine Cat. No.: HY-B0163
Bioactivity:	Deriglidole is a peripheral adrenoceptor antagonist with a high affinity for α_2 -adrenoceptors.	Bioactivity: Detomidine produce dose-dependent sedative and analgesic effects, is a nonnarcotic, synthetic α2-adrenergic agonist
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: >98% Clinical Data: Launched Size: 10 mg, 50 mg, 100 mg
Detomidine	e hydrochloride Cat. No.: HY-B0163A	Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride) Cat. No.: HY-17034A
Bioactivity: Purity: Clinical Data: Size:	Detomidine hydrochloride produce dose-dependent sedative and analgesic effects, is a nonnarcotic, synthetic α2-adrenergic agonist 99.80% No Development Reported 10mM x 1mL in DMSO,	Bioactivity: Dexmedetomidine Hydrochloride is an agonist of adrenergic alpha-2 receptor, which is used in veterinary medicine for its analgesic and sedative properties. Target: Adrenergic alpha-2 Receptor Dexmedetomidine, acting at alpha(2A) adrenoceptors, must be present during the encoding process to decrease Purity: 98.0% Clinical Data: Launched Size: 10mM x 1mL in Water,
DL-Epineph	10 mg, 50 mg, 100 mg HCI	5 mg, 10 mg, 50 mg Dobutamine hydrochloride
((±)-Epinephr Bioactivity:	ine; (±)-Adrenaline; DL-Adrenali) Cat. No.: HY-B0447 DL-Epinephrine is the racemate of epinephrine. L-Epinephrine is a hormone secreted by the medulla of the adrenal glands. L-Epinephrine is an α-adrenergic and β-adrenergic receptor agonist.	Cat. No.: HY-15746 Bioactivity: Dobutamine Hcl(Dobutrex) is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Its primary mechanism is direct stimulation of β1 receptors of the sympathetic nervous system.
Purity: Clinical Data: Size:	99.0% No Development Reported 1 g, 5 g	Purity: 99.78% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 100 mg

Dopexamin (FPL60278AR)	e hydrochloride Cat. No.: HY-U00205	Doxazosin (UK 33274)	Cat. No.: HY-B0098
Bioactivity:	Dopexamine hydrochloride is a $\boldsymbol{\beta}2$ adrenergic receptor agonist.	Bioactivity:	Doxazosin(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α 1-adrenergic receptors.
Purity: Clinical Data: Size:	>98% Launched 1 mg	Purity: Clinical Data: Size:	>98% Launched 100 mg, 500 mg భిరోధిక
Doxazosin (UK 33274 me	-	Ecastolol	Cat. No.: HY-101693
Bioactivity:	Doxazosin mesylate(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α 1-adrenergic receptors. Target: α 1-adrenergic receptor Doxazosin (mesylate) is the mesylate salt form of doxazosin, which is a long-lasting inhibitor of α 1-adreneceptors that is widely used to treat	Bioactivity:	Ecastolol is a beta adrenergic receptor antagonist, with antianginal activities.
Purity: Clinical Data: Size:	98.60%	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
Epanolol (Visacor; ICI14	1292) Cat. No.: HY-U00183	Esmolol hy	drochloride Cat. No.: HY-B1393
Bioactivity: Purity: Clinical Data: Size:	Epanolol (Visacor; ICI141292) is a potent β-adrenoceptor partial agonist with a greater affinity for β1 - than β2-adrenoceptors. >98% No Development Reported 1 mg	Bioactivity: Purity: Clinical Data: Size:	Esmolol Hydrochloride is a beta adrenergic receptor blocker. Target: Adrenergic receptor Esmolol Hydrochloride is the hydrochloride salt form of Esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid of intrinsic sympathomimetic 99.77% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
Falintolol, (Z)- Cat. No.: HY-U00283	Fenmetozo	ole Tosylate Cat. No.: HY-U00402
Bioactivity:	Falintolol, (Z)-, a new β -adrenergic antagonist, is characterized by the presence of an oxime function.	Bioactivity:	Fenmetozole Tosylate is an antagonist of the actions of ethanol, also antagonizes $\alpha 2$ -adrenergic receptor, and acts as an antidepressant drug.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
Fenspiride	Hydrochloride Cat. No.: HY-A0027	Fiduxosin	Cat. No. : HY-U00399
Bioactivity:	Fenspiride Hcl is an α adrenergic and H1 histamine receptor antagonist.	Bioactivity:	Fiduxosin is a potent α1-adrenoceptor antagonist, with K _i of 0.160 nM, 24.9 nM, and 0.920 nM for α 1a-, α 1b-, and α 1d-adrenoceptors, respectively.
Purity: Clinical Data: Size:	99.03% Launched 10mM x 1mL in DMSO, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg

Gramine (Donaxine)	Cat.	No.: HY-N0166	Guanabenz (BR-750; Wy8		Cat. No.: HY-B0566
Bioactivity:	Gramine (Donaxine) is a natural alkaloid isolated from reed ^[2] , acts as an active adiponectin receptor (Adip agonist, with IC_{50} s of 3.2 and 4.2 µM for AdipoR2 and	oR)	Bioactivity:	Guanabenz (Acetate) (BR-750) is an alpha-2 sel adrenergic agonist used as an antihypertensive	
Purity: Clinical Data: Size:	respectively ^[1] . Gramine is also a human and mo 99.45% No Development Reported 10mM x 1mL in DMSO, 50 mg	The second secon	Purity: Clinical Data: Size:	98.88% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg	CI NH CI NH OH
Guanfacine			Guanfacine	hydrochloride	
Bioactivity: Purity:	Cat. I Guanfacine is a selective α 2A receptor agonist. Target: Receptor Guanfacine is a sympatholytic. It is a selective receptor agonist. These receptors are concentrated he the prefrontal cortex and the locus coeruleus, with the potential to improve attention resulting from interactive >98%	e α2A eavily in e	Bioactivity: Purity:	Guanfacine Hcl, an anti-hypertensive agent, is a α 2A-adrenoceptor agonist with Kd of 31 nM ar selectivity over α 2B-adrenoceptors. IC50 Value: Target: Adrenergic Receptor Guanfacine is a sy is a selective α 2A receptor agonist. These recep 99.96%	nd displays 60-fold 31 nM(Kd) mpatholytic. It
Clinical Data: Size:		$\bigcup_{CI}^{CI} \bigcup_{H}^{NH} \bigcup_{NH_2}^{NH}$	Clinical Data: Size:		CI NH NH2 H-CI
Guanoxabe (Hydroxyguar		No.: HY-U00123	HOKU-81 (4-Hydroxytul	lobuterol)	Cat. No. : HY-50291
Bioactivity:	Guanoxabenz is an $\boldsymbol{\alpha}2$ adrenergic receptor agonist.		Bioactivity:	HOKU-81, a new bronchodilator, is one of the r tulobuterol.	netabolites of
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	HO, H, N, N, C	Purity: Clinical Data: Size:	95.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 25 mg	HOCH
-	sone 17-butyrate utyrate; Hydrocortisone butyrate) Cat.	. No.: HY-B0983	ICI 118,551 (ICI 118551 hy	hydrochloride _y drochloride)	Cat. No.: HY-13951
Bioactivity:	Hydrocortisone 17-butyrate is an adrenocortico hormo	one.	Bioactivity:	ICI 118,551 (hydrochloride) is a highly selective adrenergic receptor antagonist, with \mathbf{K}_{i} s of 0.7 nM for β 2, β 1 and β 3 receptors, respectively.	
Purity: Clinical Data: Size:	99.93% Launched 10mM x 1mL in DMSO, 200 mg		Purity: Clinical Data: Size:	98.50% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	H-CI H-CI H-CI
Imoxiterol (RP 58802B)	Cat. I	No.: HY-101585	Indacaterol	l	Cat. No.: HY-14299
Bioactivity:	Imoxiterol is a β-adrenergic agonist.		Bioactivity:	Indacaterol(Onbrez; Arcapta) is an ultra-long-a β-adrenoceptor agonist.	cting
Purity: Clinical Data: Size:	98.0% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	م. رئىمىتىرى	Purity: Clinical Data: Size:	96.17% Launched 100 mg, 500 mg	A Contraction of the second se

Indacaterol (QAB149)	l maleate	Cat. No.: HY-14299A	Indanidine		Cat. No.: HY-101717
Bioactivity:	Indacaterol (QAB149) maleate is an ultra-long- β -adrenoceptor agonist.	acting	Bioactivity:	Indanidine is an alpha-adrenergic agonist.	
Purity: Clinical Data: Size:	99.92% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	jor ^{ne} ce.	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Indoramin (Indoramine I	D5 D5; Wy-21901 D5)	Cat. No. : HY-12760S		e hydrochloride I hydrochloride)	Cat. No.: HY-B0468
Bioactivity:	Indoramin D5 is deuterium labeled Indoramin, piperidine antiadrenergic agent.	which is a	Bioactivity:	Isoprenaline hydrochloride is a non-selectiv receptor agonist with potent peripheral va bronchodilator, and cardiac stimulating act	sodilator,
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg		Purity: Clinical Data: Size:	99.0% Phase 3 10mM x 1mL in DMSO, 200 mg, 1 g	HO, HO HCI
Ivabradine	D3 Hydrochloride	Cat. No. : HY-B0162AS1	Ivabradine	D6 hydrochloride	Cat. No.: HY-B0162AS
Bioactivity:	Ivabradine D3 Hydrochloride is the deuterium Ivabradine hydrochloride. Ivabradine hydrochloride. Ivabradine hydrochloride. $_{\rm f}$ inhibitor with IC $_{\rm 50}$ of 2.9 μ M, and used as a prate lowering agent.	oride is a new I	Bioactivity:	Ivabradine D6 hydrochloride is the deuteriu Ivabradine hydrochloride. Ivabradine hydroc $_{\rm f}$ inhibitor with IC $_{50}$ of 2.9 μ M, and used as rate lowering agent.	chloride is a new I
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	\$000 1000 **	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	
Ivabradine	hydrochloride	Cat. No. : HY-B0162A	JP1302 dih	ydrochloride	Cat. No. : HY-103213
Bioactivity:	Ivabradine is an orally bioavailable, hyperpolarization-activated, cyclic nucleotide- channel blocker.	gated (HCN)	Bioactivity:	JP1302 dihydrochloride is a selective, high a antagonist of the alpha2C-adrenoceptor (with a K_b value (antagonist activity) of 16 n (binding affinity) value of 28 nM ^[1] ^[2] .	α _{2C} -adrenoceptor),
Purity: Clinical Data: Size:	98.39% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg	Jampan	Purity: Clinical Data: Size:	>98% No Development Reported	N C C C C C C C C C C C C C C C C C C C
Ko-3290		Cat. No. : HY-101721	L-(-)-α-Me (MK-351; Met		Cat. No .: HY-B0225
Bioactivity:	Ko-3290 is an antagonist of β-adrenoceptor , cardioselectivity and antilipolytic effects in anir		Bioactivity:	Methyldopa is an alpha-adrenergic agonist α2-adrenergic receptors) psychoactive drug sympatholytic or antihypertensive. Target: agonist Methyldopa is an alpha-adrenergic for α2-adrenergic receptors) psychoactive of	g used as a Ilpha-adrenergic agonist (selective
Purity:	>98% No Development Reported		Purity: Clinical Data:	>98%	anay used as a

.,	t <mark>hyldopa hydrate</mark> rate; Methyldopa hydrate) Cat	No.: HY-B0225B		thyldopa hydrochloride rochloride; Methyldopa hydrochloride)	Cat. No.: HY-B0225A
Bioactivity: Purity: Clinical Data: Size:	L-(-)- α -Methyldopa hydrate is an alpha-adrenergic a (selective for α 2-adrenergic receptors) psychoactive as a sympatholytic or antihypertensive. Target: alpha-adrenergic agonist Methyldopa is an alpha-ac agonist (selective for α 2-adrenergic receptors) psych 98.93% Launched 10mM x 1mL in DMSO, 1 g	drug used Irenergic	Bioactivity: Purity: Clinical Data: Size:	L-(-)- α -Methyldopa hydrochloride is an alpha-a agonist (selective for α 2-adrenergic receptors) p drug used as a sympatholytic or antihypertensiv alpha-adrenergic agonist Methyldopa is an alph agonist (selective for α 2-adrenergic receptors) p >98% Launched 1 g	osychoactive e. Target: a-adrenergic
L-765314	Cat	t. No .: HY-101385	L-771688		Cat. No.: HY-U00237
Bioactivity:	L-765314 is a potent and selective α 1b adrenergic is antagonist with K_i s of 5.4 nM and 2.0 nM for rat and adrenergic receptor, respectively.	receptor	Bioactivity:	L-771688 is a highly selective α 1A-Adrenocept with a K_i of 0.43±0.02 nM.	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	a ^{on} tita.
L-Epinephr ((-)-Epinephri		. No.: HY-B0447B		ine Bitartrate ((-)-Epinephrine (+)-bitartrate line (+)-bitartrate salt)	Cat. No.: HY-B0447A
Bioactivity:	L-Epinephrine is a hormone secreted by the medulla adrenal glands. L-Epinephrine is an α -adrenergic ar β -adrenergic receptor agonist.		Bioactivity:	L-Epinephrine bitartrate is an α -adrenergic and receptor agonist. L-Epinephrine is a hormone se medulla of the adrenal glands.	
Purity: Clinical Data: Size:	99.0% Launched 1 g, 5 g, 25 g	HO HO	Purity: Clinical Data: Size:	99.0% Launched 10mM x 1mL in DMSO, 1 g, 5 g	HO HO HO U U U U U U U U U U U U U U U U
L755507	Ca	at. No.: HY-19334		ydrochloride Irochloride; Sch-15719W)	Cat. No.: HY-B1108
Bioactivity:	L755507 is a potent, selective agonist of $\boldsymbol{\beta_3}\text{-}AR$ with of 35 nM.	an IC ₅₀	Bioactivity:	Labetalol hydrochloride is a mixed alpha/beta a antagonist that is used to treat high blood press	9
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	~~~h0 ⁴ 0~nc.0"	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg	C R C R S
-	e dihydrochloride hydrochloride) Ca	at. No.: HY-14537	Levalbutero (Levosalbutar		Cat. No.: HY-17457
Bioactivity:	Latrepirdine dihydrochloride is a neuroactive compo- antagonist activity at histaminergic, α -adrenergic, ar serotonergic receptors. Latrepirdine stimulates amyl precursor protein (APP) catabolism and amyloid- β (nd oid	Bioactivity:	Levosalbutamol tartrate(levalbuterol) is the R-er the short-acting β 2-adrenergic receptor agonist	
Purity: Clinical Data: Size:	secretion. 99.75% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg		Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg	۳۵ ^۲ ۲۴ ۳۵۵ «بابا»

	olol hydrochloride hydrochloride; AL-1577A)	Cat. No.: HY-B0381B	Lidanserin (ZK-33839)		Cat. No.: HY-10181
Bioactivity:	Levobetaxolol hydrochloride is a beta-adre inhibitor (beta blocker), used to lower the p eye in treating conditions such as glaucom	pressure in the	Bioactivity:	Lidanserin is a drug which acts as a combined α_1 -adrenergic receptor antagonist.	ined 5-HT_{2A} and
Purity: Clinical Data: Size:	98.11% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	A. a. Dogati Ho	Purity: Clinical Data: Size:	98.0% No Development Reported 1 mg, 5 mg, 10 mg	.∞ ₀₀ ,
Lofexidine		Cat. No .: HY-B1052A	Lofexidine (Baq-168; MD	hydrochloride NL-14042)	Cat. No.: HY-B1053
Bioactivity:	Lofexidine is a selective α 2-receptor agoni to alleviate the physical symptoms of heroi of opioid withdrawal ^[1] ^[2] .	-	Bioactivity:	Lofexidine (hydrochloride) is a selective α agonist, commonly used to alleviate the p heroin and other types of opioid withdraw	physical symptoms of
Purity: Clinical Data: Size:	99.08% Launched 10mM x 1mL in DMSO, 50 mg		Purity: Clinical Data: Size:	>98% Launched 50 mg	
Lusaperido (R107474)	ne	Cat. No. : HY-U00117	Medetomic	dine	Cat. No.: HY-17034
Bioactivity:	Lusaperidone (R107474) is an $\alpha 2$ adrenerg with K _i s of 0.13 and 0.15 nM for $\alpha 2A$ and o		Bioactivity:	Medetomidine(Domtor) is a potent, highl α2-adrenoceptor agonist (Ki values are 1. α2- and α1-adrenoceptors respectively).	
Purity: Clinical Data: Size:	97.74% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	99.88% Launched 5 mg, 10 mg, 50 mg	NH
Medetomic (MPV785)	line hydrochloride	Cat. No. : HY-17034B	Metipranol	ol hydrochloride	Cat. No.: HY-1631
Bioactivity:	Medetomidine Hydrochloride is an agonist receptor, which is used in veterinary medic analgesic and sedative properties. Target: A Receptor Medetomidine, acting at alpha(2) be present during the encoding process to	ine for its Adrenergic alpha-2 A) adrenoceptors, must	Bioactivity:	Metipranolol is a non-selective β adrener blocking agent.	rgic receptor
Purity: Clinical Data: Size:	99.49% No Development Reported 10mM x 1mL in Water, 10 mg, 50 mg	HN N HCI	Purity: Clinical Data: Size:	99.94% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Contraction of the second seco
Metoprolol	1	Cat. No. : HY-17503	Metoprolo	Succinate	Cat. No.: HY-17503/
Bioactivity:	Metoprolol (Toprol) is a selective β 1 recept treatment of several diseases of the cardiou especially hypertension. IC50 value: Target:	vascular system,	Bioactivity:	Metoprolol Succinate (Toprol XL) is a sele blocker used in treatment of several disea cardiovascular system, especially hyperter Target: β1 receptor	ises of the
Purity: Clinical Data: Size:	>98% Launched 100 mg	,	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg	بر میں

Metoprolo	Tartrate	Cat. No.: HY-17503B	MG 1		Cat. No.: HY-U00110
Bioactivity:	Metoprolol is a cardioselective β 1-adrenergic b	blocking agent.	Bioactivity:	MG 1 is an α 1 adrenergic receptor antagonis	st.
Purity:	>98%		Purity:	>98%	
Clinical Data: Size:	Launched 100 mg	as to the of the	Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	NN CHON
Midaglizol	e hydrochloride		Mirabegro	n	
((±)-DG5128;	DG5128)	Cat. No.: HY-U00165	(YM178)		Cat. No.: HY-1477
Bioactivity:	Midaglizole hydrochloride (DG5128) is a prefer α 2-adrenoceptor antagonist. Midaglizole hyd (DG5128) exhibits 7.4 times higher affinity (pK α 2-adrenoceptor than α 1-adrenoceptor.	rochloride	Bioactivity:	Mirabegron is a selective $\boldsymbol{\beta_3}\text{-adrenoceptor}$ as $\boldsymbol{\text{EC}_{50}}$ of 22.4 nM.	gonist with
Descritere			Duritur	00.089/	
Purity: Clinical Data:	>98% No Development Reported		Purity: Clinical Data:		₽* H
Size:	1 mg, 5 mg, 10 mg, 20 mg	2 HCI	Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	O th O _{th} ur
	hydrochloride e hydrochloride)	Cat. No.: HY-B1435	Nadolol D9 (SQ-11725 D9		Cat. No.: HY-B0804
Bioactivity:	Moxisylyte (hydrochloride) is (alpha 1-blocker) can vasodilates cerebral vessels without reduci pressure. It is also used locally in the eye to rev mydriasis caused by phenylephrine and other s	ng blood verse the	Bioactivity:	Nadolol D9 is the deuterium labeled Nadolol(is a non-selective beta blocker.	SQ-11725), which
Purity: Clinical Data: Size:	agents. [1][2] 99.96% Launched 10mM x 1mL in DMSO, 100 mg, 1 g	Lotter M.	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	
Naftopidil (KT-611; BM-	15275)	Cat. No.: HY-B0391	Naphazolir	ne hydrochloride	Cat. No.: HY-B044
Bioactivity:	Naftopidil (Flivas), a selective α1-adrenergic rea antagonist or alpha blocker, is an antihyperten	ceptor	Bioactivity:	Naphazoline HCl is an ocular vasoconstrictor a derivative sympathomimetic amine.	
Purity: Clinical Data: Size:	98.83% Launched 10mM x 1mL in DMSO, 5 g, 10 g		Purity: Clinical Data: Size:	96.55% Launched 10mM x 1mL in DMSO, 1 g, 5 g, 10 g	NH N HCI
Nebivolol (R 065824)		Cat. No.: HY-B0203	Nebivolol ł (R 065824 hyd	nydrochloride drochloride)	Cat. No.: HY-B0203/
Bioactivity:	Nebivolol selectively inhibits β 1- adrenergic red IC50 of 0.8 nM.	ceptor with	Bioactivity:	Nebivolol hydrochloride selectively inhibits β 1 receptor with IC50 of 0.8 nM.	- adrenergic
Purity: Clinical Data: Size:	>98% Launched 5 mg, 10 mg, 50 mg	,ct ^{ir.tZi} oa,	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	o ^{sta} tion,

Nefazodon (BMY-13754;	e hydrochloride MJ-13754-1)	Cat. No.: HY-B1396	Nicergoline	e Cat. No.: HY-B0702
Bioactivity: Purity: Clinical Data: Size:	Nefazodone hydrochloride is an antidepress 99.71% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	ant drug.	Bioactivity: Purity: Clinical Data: Size:	Nicergoline is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Target: Alpha-1A adrenergic receptor Nicergoline acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of 99.06% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg
Norepinepl (Levarterenol;	hrine L-Noradrenaline)	Cat. No .: HY-13715		hrine bitartrate monohydrate (Levarterenol onohydrate);) Cat. No.: HY-13715E
Bioactivity:	Norepinephrine (Levarterenol; L-Noradrenali β_1 -selective adrenergic receptor agonist wi μ M.	-	Bioactivity:	Norepinephrine bitartrate monohydrate (Levarterenol bitartrate monohydrate; L-Noradrenaline bitartrate monohydrate) is a β_1 -selective adrenergic receptor agonist with EC ₅₀ of 5.37 μ M.
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg	HO I NH2 OH	Purity: Clinical Data: Size:	99.75% Launched 10mM x 1mL in DMSO, 500 mg, 1 g, 5 g
	hrine hydrochloride (Levarterenol (hyd ine (hydrochloride))	rochloride); Cat. No.: HY-13715A	NRA-0160	Cat. No. : HY-101641
Bioactivity:	Norepinephrine hydrochloride (Levarterenol L-Noradrenaline hydrochloride) is a β_1 -selec receptor agonist with EC ₅₀ of 5.37 μ M.		Bioactivity:	NRA-0160 is a selective dopamine D4 receptor antagonist, with a K _i value of 0.48 nM and with negligible affinity for dopamine D2 receptor (K _i : >10000 nM), D3 receptor (K _i : 39 nM), rat 5-HT2A receptor (K _i : 180 nM) and rat
Purity: Clinical Data: Size:	>98% Launched 500 mg, 1 g, 5 g	HO, HO, NH ₂ HO	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
	e hydrochloride amine hydrochlorid)	Cat. No.: HY-B0528A	OPC-28326	Cat. No .: HY-101610
Bioactivity:	Octopamine Hydrochloride is an endogenou is closely related to norepinephrine, and has adrenergic and dopaminergic systems.		Bioactivity:	OPC-28326 is a selective peripheral vasodilator and an angatonist of α 2-adrenergic receptor, with K_i of 2040, 285, and 55nM for α 2A-, α 2B- and α 2C-adrenoceptors, respectively.
Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in Water, 1 g, 5 g	HO HCI	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
Pamatolol		Cat. No. : HY-U00019	Pardoprun (SLV-308; DU	
Bioactivity:	Pamatolol is a cardioselective beta-adrenoc without sympathomimetic activity.	eptor antagonist	Bioactivity:	Pardoprunox(SLV-308) is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist; D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%); also binds to D4 (pKi = 7.8),
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	J. L. Congle	Purity: Clinical Data: Size:	>98% Phase 3 5 mg, 10 mg, 50 mg, 100 mg

-	ox hydrochloride rochloride; DU-126891 hydrochloride)	Cat. No.: HY-14958A	Pargolol hy (Ko 1400 hyd	/ drochloride rochloride)	Cat. No.: HY-101658
Bioactivity:	Pardoprunox hydrochloride is a novel partial D3 receptor agonist and serotonin 5-HT1A re (pKi = 8.1) and D3 receptor (pKi = 8.6) partial 5-HT1A receptor (pKi = 8.5) full agonist.	ceptor agonist, D2	Bioactivity:	Pargolol hydrochloride is a β adrenergi antagonist.	c receptor
Purity: Clinical Data: Size:	98.89% Phase 3 5 mg, 10 mg, 50 mg, 100 mg	$(\mathbf{y}_{N}^{I})_{N} = \mathbf{y}_{N}^{I}$	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	H-C
Penbutolol	sulfate		Perphenazi	ne	
((-)-Terbuclor	nine)	Cat. No.: HY-B1154			Cat. No.: HY-A007
Bioactivity:	Penbutolol sulfate is able to bind to both beta receptors and beta-2 adrenergic receptors (th thus making it a non-selective β blocker. Pend sympathomimetic drugused in the treatment pressure.	ne two subtypes), putolol is a	Bioactivity:	Perphenazine is a typical antipsychotic c 5-HT _{2A} receptor, Alpha-1A adrenergic receptor D2/D3, D2L receptor, and Hi with K _i values of 5.6, 10, 0.765/0.13, 3.4,	receptor, Dopamine stamine H1 receptor,
Purity: Clinical Data: Size:	99.62% Launched 10mM x 1mL in Water, 10 mg, 50 mg		Purity: Clinical Data: Size:	99.90% Launched 10mM x 1mL in DMSO, 1 g, 5 g	
Perphenazi	ne D8 Dihydrochloride	Cat. No. : HY-A0077AS	Phenoxybe	nzamine hydrochloride	Cat. No.: HY-B04314
Bioactivity:	Perphenazine D8 Dihydrochloride is the deute Perphenazine, which is a typical antipsychotic Dopamine receptor ligand).		Bioactivity:	Phenoxybenzamine hydrochloride is a solution both α -adrenoceptor and calmodulin for the treatment of hypertension, specipheochromocytoma.	that is commonly used
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	e ^{0,0} / _h , on ¹ 000 ¹ 000 ¹ 1000 ¹ 10000 ¹ 10000 ¹ 10000 ¹ 10000 ¹	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 200 mg, 500 mg, 1 g	
	ne mesylate e methanesulfonate)	Cat. No. : HY-B0362A	Pimozide (R6238)		Cat. No.: HY-12987
Bioactivity:	Phentolamine mesylate is a competitive, rever $\alpha\text{-}adrenoceptor$ antagonist with an IC_{50} betw		Bioactivity:	Pimozide is a dopamine receptor antag 1.4 nM, 2.5 nM and 588 nM for dopamin receptors, respectively, and also has affii α1-adrenoceptor , with a K _i of 39 nM; P	ne D2, D3 and D1 nity at
Purity: Clinical Data: Size:	99.83% Launched 10mM x 1mL in Water, 100 mg, 500 mg	Horis Horis	Purity: Clinical Data: Size:	99.88% Launched 10mM x 1mL in DMSO, 50 mg	
Pindolol (LB-46)		Cat. No.: HY-B0982	Piperoxan (Benodaine h	hydrochloride ydrochloride)	Cat. No. : HY-100850
Bioactivity:	Pindolol (LB-46) is a nonselective β-blocker w beta-adrenergic receptor agonist activity, also 5-HT1A receptor weak partial agonist / antag	o functions as a	Bioactivity:	Piperoxan hydrochloride is an α_2 adren	oceptor antagonist.
Purity: Clinical Data: Size:	99.84% Launched 10mM x 1mL in DMSO, 100 mg	HN N C O O HN N	Purity: Clinical Data: Size:	99.68% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 r	ng

Piribedil			Piribedil Da	3	
		Cat. No.: HY-12707	(ET-495 D8)		Cat. No.: HY-12707S
	Piribedil is a dopamine D_2 receptor (D_2R) ago which also displays antagonist property at $h\alpha_{1A}$ ($h\alpha_{1A}$ -AR).		Bioactivity:	Piribedil D8 is the deuterium labeled Piribedil, antiparkinsonian agent.	which is an
Purity: Clinical Data: Size:	99.90% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	
Prazosin			Prazosin hy	/drochloride	
		Cat. No.: HY-B0193			Cat. No.: HY-B0193A
Bioactivity: Purity: Clinical Data: Size:	Prazosin is an alpha-adrenergic blocker and is a drug used to treat high blood pressure and anxi panic disorder. > 98% Launched 10 mg		Bioactivity: Purity: Clinical Data: Size:	10mM x 1mL in DMSO,	xiety, PTSD, and azosin, is a ressure and
		NH ₂		100 mg, 200 mg, 500 mg	Nety
Pronethalo ((±)-Pronetha		Cat. No.: HY-B1238	Propranolo	l hydrochloride	Cat. No.: HY-B0573
Bioactivity:	Pronethalol is a non-selective beta-adrenergic b protect against and to reverse Digitalis-induced arrhythmias. Target: beta-adrenergic receptor		Bioactivity:	Propranolol hydrochloride is a nonselective β -a receptor (βAR) antagonist with an IC_{50} of 12 r	
Purity: Clinical Data: Size:	>98% No Development Reported 10 mg		Purity: Clinical Data: Size:	99.92% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g	HCI
QF0301B		Cat. No. : HY-101690		e hydrochloride (α-Yohimbine hydrochlor ne hydrochloride; Isoyohimbine hydrochloride)	
Bioactivity:	QF0301B is an α 1 adrenergic receptor antagon adrenoceptor, 5-HT2A, and histamine H1 recept	ist and a low α2	Bioactivity:	Rauwolscine hydrochloride is a potent and spe adrenergic receptor antagonist with a K _i of 12	cific α2
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	99.16% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	H-CI
Rotigotine	1221	Cat. No.: HY-75502		ydrochloride	Cot No. 11V 101226
(N-0437; N-09			(RS-17053)		Cat. No.: HY-101336
Bioactivity:	Rotigotine is a full agonist of dopamine recepte partial agonist of the 5-HT1A receptor , and an the α2B-adrenergic receptor , with K _i s of 0.71ni 83nM for the dopamine D3 receptor and D2, D5 and dopamine D1 receptor.	antagonist of M, 4-15nM, and	Bioactivity:	RS 17053 hydrochloride is a potent and selectii adrenoceptor antagonist, with a \mathbf{pK}_i value of \mathbf{S}_i cell membrane and a \mathbf{pA}_2 value of 9.8 in function	9.1 in native
Purity: Clinical Data: Size:	99.98%	COLOR S	Purity: Clinical Data: Size:	99.25% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	

Salbutamol		C + N - UV 01027		l hemisulfate	
(Albuterol; AF	נסככ-ו	Cat. No.: HY-B1037	(Albuterol (he	emisulfate); AH-3365 (hemisulfate))	Cat. No.: HY-B0436
Bioactivity:	Salbutamol is a short-acting β 2-adrenergic recept used for the relief of bronchospasm in condition asthma and chronic obstructive pulmonary diseases	s such as	Bioactivity:	Salbutamol Hemisulfate is a short-acting β2 ad receptor agonist Target: β2 Adrenergic Recept a short-acting, selective beta2-adrenergic rece used in the treatment of asthma and COPD. Al R,S-salbutamol on guinea-pig skeletal muscles	or Salbutamol is ptor agonist I the effects of
Purity:	>98%		Purity:	98.0%	
Clinical Data:			Clinical Data:		HO
Size:	10 mg, 50 mg, 100 mg	HO	Size:	10mM x 1mL in Water, 100 mg, 500 mg	HO 0.5H ₂ SO ₄
Salmeterol			Salmeterol	xinafoate	
(GR33343X)		Cat. No.: HY-14302	(GR 33343X x	inafoate)	Cat. No.: HY-17453
Bioactivity:	Salmeterol is a long-acting beta2-adrenergic rec 2AR) agonist used clinically to treat asthma.	eptor (beta	Bioactivity:	Salmeterol xinafoate is a long-acting beta-2 ac receptor (β_2AR) agonist, with K_i of 1.5 nM for and used for asthma treatment.	
Desident	00 000		Duritur	07 669/	
Purity: Clinical Data:	99.68% Launched		Purity: Clinical Data:	97.66% Launched	он сон
Size:	10mM x 1mL in DMSO,	-genno	Size:	10mM x 1mL in DMSO,	Handred Contraction
	5 mg, 10 mg, 50 mg, 100 mg	нс [.]		10 mg, 50 mg, 100 mg, 200 mg	CUC DH
Scopine			Scopine hy	drochloride	
(6,7-Epoxytro	pine)	Cat. No.: HY-B0459	(6,7-Epoxytro	pine hydrochloride)	Cat. No.: HY-B0459A
Bioactivity:	Scopine is the metabolite of anisodine, which is α 1-adrenergic receptor agonist and used in the acute circulatory shock.		Bioactivity:	Scopine Hcl salt is the metabolite of anisodine, α 1-adrenergic receptor agonist and used in the acute circulatory shock.	
Descriterer	>98%	χ.	Duritur	98.0%	
Purity: Clinical Data: Size:	No Development Reported 10 mg, 50 mg, 100 mg	H H H H H O H	Purity: Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	HO
Silodosin			Solabegror	1	
(KAD 3213; KM	MD 3213)	Cat. No.: HY-10122	(GW 427353)		Cat. No.: HY-19436
Bioactivity:	Silodosin (Rapaflo; KMD-3213) is an α1-adrenoc with high uroselectivity; In treatment of dysuria.	eptor antagonist	Bioactivity:	Solabegron (GW 427353) is a selective β_3 -adre	energic receptor
				ovary cells expressing the human β_3 -AR, with	
				of 22 nM ^[1] . Solabegron (GW 427353) is being	developed
Purity:	99.96%		Purity:	>98%	
Clinical Data:		0 Mt CH	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	No Development Reported	~ ~ ~
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Chippen and an and a second se	Size:	5 mg, 10 mg	Juria Car
Sotalol hyd	rochloride		Spirendolo		
(MJ-1999)		Cat. No.: HY-B0437	(Li 32-468; S 3	32-468; Substance 32468)	Cat. No.: HY-101817
Bioactivity:	Sotalol Hydrochloride is an adrenergic beta-anta used in the treatment of life-threatening arrhyth Adrenergic Receptor Sotalol is a non-selective co β -adrenergic receptor blocker that also exhibits antiarrhythmic properties by its inhibition of pot	mias. Target: ompetitive Class III	Bioactivity:	Spirendolol is a $\boldsymbol{\beta}$ adrenergic receptor antago	nist.
Purity:	99.77%		Purity:	>98%	
			1		

54 Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Synephrine (Oxedrine hyd	hydrochloride drochloride)	Cat. No.: HY-N0132A	-	dihydrochloride hydrochloride))	Cat. No.: HY-A0008
Bioactivity:	Synephrine Hcl(Oxedrine) is an alkaloid; syneph most of its biological effects by acting as an ago adrenergic receptors.		Bioactivity:	Talipexole dihydrochloride (B-HT 920 dihydroch dopamine D2 receptor agonist, α 2-adrenocepto 5-HT3 receptor antagonist, which displays antiF activity.	or agonist and
Purity: Clinical Data: Size:	99.83% No Development Reported 10mM x 1mL in DMSO, 100 mg, 500 mg	HCI HCI	Purity: Clinical Data: Size:	99.99% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	
TD-5471 hy	ydrochloride	Cat. No. : HY-19942A		ine hydrobromide hydrobromide)	Cat. No. : HY-101755
Bioactivity:	TD-5471 hydrochloride is a potent and selective of the human β_2 -adrenoceptor.		Bioactivity:	Tedatioxetine hydrobromide acts as a triple reu and 5-HT_{2A} , 5-HT_{2C} , 5-HT₃ and α_{1A} -adrenerg antagonist.	ptake inhibitor
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	ford with	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Teoprolol		Cat. No.: HY-U00016	Terazosin		Cat. No.: HY-B0371
Bioactivity:	Teoprolol is a $\pmb{\beta}\text{-adrenergic receptor}$ blocker.		Bioactivity:	Terazosin is a selective alpha1-antagonist used of symptoms of benign prostatic hyperplasia (B	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	>98% Launched 100 mg, 500 mg	
Terazosin ł	ydrochloride dihydrate	Cat. No.: HY-B0371A	Terbutaline		Cat. No.: HY-B0802
Bioactivity:	Terazosin Hydrochloride dihydrate is a selective alpha1-antagonist used for treatment of sympto prostatic hyperplasia (BPH).		Bioactivity:	Terbutaline sulfate is a β 2-adrenergic receptor a fast-acting bronchodilator and a tocolytic to de labor.	
Purity: Clinical Data: Size:	99.85% Launched 10mM x 1mL in DMSO, 100 mg		Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in Water, 1 g, 5 g	
Tertatolol ((±)-Tertatolo	l; Racemic Tertatolol; dl-Tertatolol)	Cat. No.: HY-U00356	-	vzoline hydrochloride Nydrochloride)	Cat. No.: HY-B0556A
Bioactivity:	Tertatolol is a potent antagonist of beta-adren 5-HT receptor , with unique renal vasodilatatory		Bioactivity:	Tetrahydrozoline (hydrochloride) is a α -adrenod	ceptor agonist.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Calor of the	Purity: Clinical Data: Size:	99.90% Launched 10mM x 1mL in DMSO, 1 g, 5 g	NNH HCI

Tiodazosin (BL-5111)	Cat. 1	No.: HY-100255	Tizanidine		Cat. No.: HY-B0194
Bioactivity:	Tiodazosin is a potent competitive postsynaptic alpha adrenergic receptor antagonist.	• E	Bioactivity:	Tizanidine is an α2-adrenergic receptor agonist neurotransmitter release from CNS noradrener	
	>98% No Development Reported 1 mg, 5 mg, 10 mg	China C	Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg, 100 mg	
Tizanidine l	nydrochloride		Folazoline Imidaline; NS	C35110)	Cat. No.: HY-A0066
Bioactivity:	Tizanidine hydrochloride is an α2-adrenergic receptor and inhibits neurotransmitter release from CNS norad neurons. Target: α2-adrenergic receptor Tizanidine is a that is used as a muscle relaxant. It is a centrally acting adrenergic agonist. It is used to treat the spasms, cran	agonist E renergic a drug g α2		Tolazoline(Imidaline) is a non-selective competi α-adrenergic receptor antagonist.	
Purity: Clinical Data: Size:	99.48%			>98% No Development Reported 1 g, 5 g	L L
	nydrochloride drochloride); NSC35110 (hydrochloride)) Cat. M		Tropodifen Tropaphen)	e	Cat. No.: HY-U00313
Bioactivity:	Tolazoline (hydrochloride)(Imidaline (hydrochloride)) H non-selective competitive α -adrenergic receptor antag IC50 value: Target: α -adrenoceptor antagonist Tolazol be synthesized by the heterocyclation of the ethyl est iminophenzylacetic acid with ethylene diamine, which	gonist. ine can er of	Bioactivity:	Tropodifene (Tropaphen) is an α-Adrenergic r e inhibitor.	eceptor
Purity: Clinical Data: Size:	99.0% Launched 10mM x 1mL in DMSO, 1 g, 5 g			>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	-0-;_2;
Tulobutero	l hydrochloride Cat. No	o.: HY-W011733	Urapidil		Cat. No.: HY-B071
Bioactivity:	Tulobuterol hydrochloride is a β2-adrenoceptor agor	nist. E	Bioactivity:	Urapidil is an α1 adrenoreceptor antagonist ar receptor agonist.	nd a 5-HT_{1A}
Purity: Clinical Data: Size:	99.82% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg		Purity: Clinical Data: Size:	99.89% No Development Reported 50 mg	CC-HC
Urapidil hy			Vanilpyruvi Vanylpyruvic		Cat. No.: HY-10141
Bioactivity:	Urapidil HCl is an α 1-adrenoceptor antagonist and 5-ł receptor agonist.	HT1A E		Vanilpyruvic acid is a catecholamine metabolite to vanillactic acid.	and precursor
Purity: Clinical Data: Size:	>98% Launched 100 mg, 500 mg	0.0	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 10 mg	HO


	hydrochloride rochloride; L-659066 hydrochloride)	Cat. No.: HY-19057A	Vilanterol (GW642444X;	; GW642444)	Cat. No.: HY-1430
Bioactivity:	Vatinoxan hydrochloride (MK-467 hydrochlor hydrochloride) is a peripheral a2 adrenergic antagonist.		Bioactivity:	Vilanterol is a long-acting β_2 -adrenoc agonist with 24 h activity. The pEC ₅₀ s and β_3 -AR is 10.37±0.05, 6.98±0.03 an	for β_2 -AR, β_1 -AR
Purity: Clinical Data: Size:	99.25% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg	O HOW OF NH	Purity: Clinical Data: Size:	respectively. 95.06% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	-Q ^{ti}
Vilanterol t			Xylazine		
(GW642444M		Cat. No.: HY-14300A	(BAY 1470)		Cat. No.: HY-B044
Bioactivity: Purity: Clinical Data: Size:	Vilanterol trifenatate is a long-acting β_2-adre $_2$ -AR) agonist with inherent 24-hour activity. T for β_2 -AR, β_1 -AR and β_3 -AR are 10.37, 6.98 respectively. 99.02% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	The pEC₅₀ s	Bioactivity: Purity: Clinical Data: Size:	Xylazine is α2 class of adrenergic recep >98% No Development Reported 100 mg, 500 mg	
Xylazine h y (BAY 1470 hy	rdrochloride drochloride)	Cat. No.: HY-B0443A	Xylometazo	oline hydrochloride	Cat. No.: HY-B043
Bioactivity:	Xylazine Hydrochloride is $\alpha 2$ class of adrener agonist.	gic receptor	Bioactivity:	Xylometazoline Hydrochloride is an α -commonly used as nasal decongestan	
Purity: Clinical Data: Size:	99.90% No Development Reported 10mM x 1mL in DMSO, 100 mg, 500 mg	HCI	Purity: Clinical Data: Size:	99.88% Launched 10mM x 1mL in DMSO, 1 g	
Yohimbine		Cat. No. : HY-12715	Yohimbine	Hydrochloride	Cat. No.: HY-N01.
Bioactivity: Purity: Clinical Data: Size:	Yohimbine is a potent and relatively nonselec 2-adrenergic receptor (AR) antagonist, with IG IC50 value: 0.6 uM [1] Target: alpha 2-adrene vitro: Yohimbine inhibits alpha2-receptor ant of 1.05 nM, 1.19 nM, and 1.19 nM for α 2A, α 2 > 98% Phase 4 1 g	tive alpha 550 of 0.6 μM. rgic receptor in agonist with Ki	Bioactivity: Purity: Clinical Data: Size:	Yohimbine hydrochloride is an alpha 2 antagonist, blocking the pre- and post adrenoreceptors and causing an increa noradrenaline and dopamine. ICSO val vivo: Yohimbine hydrochloride (0.2 mg 99.85% Phase 4 10mM x 1mL in DMSO, 1 g	P-adrenoreceptor synaptic alpha-2 ased release of ue: Target: In vitro: In
ZK-90055 ł	nydrochloride		α1 adrenoc	ceptor-MO-1	
Bioactivity:	ZK-90055 hydrochloride is a $\boldsymbol{\beta}2$ adrenergic r	Cat. No.: HY-U00293 eceptor agonist.	Bioactivity:	α 1 adrenoceptor-MO-1, an S enantion adrenergic receptor , shows alphalytic analgesic action; more active than R en	activity, and possesses

β3-AR ago	nist 2 Cat. No.: HY-U00391
Bioactivity:	β AR agonist 2 is a potent and selective $\beta_3\text{-}adrenergic$ receptor ($\beta_3\text{-}AR$) agonist with an EC_{50} of 8 nM.
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg



Angiotensin Receptor





HDAC (Histone deacetylase)

Angiotensin receptors are a class of G protein-coupled receptors with angiotensin II as their ligands. They are important in the renin-angiotensin system: they are responsible for the signal transduction of the vasoconstricting stimulus of the main effector hormone, angiotensin II. The AT1 and AT2 receptors have a similar affinity for angiotensin II, which is their main ligand. The AT1 receptor is the best elucidated angiotensin receptor. AT2 receptors are more plentiful in the fetus and neonate. Other poorly characterized subtypes include the AT3 and AT4 receptors.

Angiotensin Receptor Inhibitors & Modulators

A 779		Cat. No.: HY-P0216	A81988 (Abbott81988	3)	Cat. No.: HY-U00188
Bioactivity:	A 779 is a specific antagonist of G-protein c (Mas receptor), which is an Ang1-7 recepto the classical AngII.		Bioactivity:	A81988 is a potent, competitive, non-pe angiotensin AT ₁ receptors.	ptidic antagonist of
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in Water, 1 mg, 5 mg	277 274 E.	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Angiotensi		C-4 No - UV 12402	Angiotensi	n II (1-4), human	Cet Ne - UV D170
(Angiotensin-	(1-7); Ang-(1-7))	Cat. No.: HY-12403			Cat. No.: HY-P179
Bioactivity:	Angiotensin (1-7) inhibits purified canine an converting enzyme (ACE) activity with an IC		Bioactivity:	Angiotensin II (1-4), human is an endoge from AT I by angiotensin-converting-en: II binds the AT II type 1 (AT1) receptor, s vascular smooth muscle cells and increa ²⁺ levels. Angiotensin II also acts at the	zyme (ACE). Angiotensin timulating GPCRs in sing intracellular Ca
Purity: Clinical Data: Size:	99.61% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg		Purity: Clinical Data: Size:	>98% No Development Reported	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Angiotensi	n II (3-8), human	Cat. No.: HY-P1515	Angiotensi	n II (3-8), human TFA	Cat. No. : HY-P1515
Bioactivity:	Angiotensin II (3-8), human is a less effective angiotensin AT_1 receptor.	e agonist at the	Bioactivity:	Angiotensin II (3-8), human (TFA) is a les at the angiotensin AT₁ receptor .	s effective agonist
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg		Purity: Clinical Data: Size:	98.99% No Development Reported 5 mg, 10 mg, 25 mg	
Angiotensi	n II (5-8), human	Cat. No.: HY-P1769	-	n II 5-valine tensin II; 5-L-Valine angiotensin II)	Cat. No. : HY-P010
Bioactivity:	Angiotensin II (5-8), human is an endogenor fragment of the peptide vasoconstrictor ang Angiotensin II binds the AT II type 1 (ATI) re stimulating GPCRs in vascular smooth musc	jiotensin II ^[1] . eceptor,	Bioactivity:	Angiotensin II 5-valine is an agonist of a	ngiotensin receptor.
Purity: Clinical Data: Size:	>98% No Development Reported	$\sim \sum_{n=1}^{n} \sum_{j=1}^{n} \sum_$	Purity: Clinical Data: Size:	95.90% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg	ٷؿڔؿٷٚڹؿ
Angiotensii (Angiotensin 1	n II human II; Hypertensin II; Ang II; DRVYIHPF)	Cat. No.: HY-13948	Angiotensi	n III	Cat. No. : HY-11303
Bioactivity:	Angiotensin II human is a vasoconstrictor th AT1 and the AT2 receptor.	at acts on the	Bioactivity:	Angiotensin III is an angiotensin 1 (ATI agonist.	l) and AT2 receptor
Purity: Clinical Data:	99.96% No Development Reported		Purity: Clinical Data:	>98% No Development Reported	Angiotensin

Angiotensin III TFA Cat. No.: HY-113035A	Angiotensin III, human, mouse Cat. No.: HY-P1540
Bioactivity: Angiotensin III (TFA) is an angiotensin 1 (AT1) and AT2 receptor agonist.	Bioactivity: Angiotensin III, human, mouse is a heptapeptide, acts as an endogenous angiotensin type 2 receptor (AT2R) agonist, with IC50 s of 0.648 nM and 21.1 nM for AT 2R and AT 1R,
Purity: >98% Clinical Data: No Development Reported Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg	respectively. Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg
AVE 0991 Cat. No.: HY-15778	AVE 0991 sodium salt Cat. No.: HY-15778A
Bioactivity: AVE 0991 is a nonpeptide and orally active angiotensin-(1-7) receptor agonist with an IC ₅₀ of 21 nM.	Bioactivity: AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [¹²⁵]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC ₅₀ of 21±35 nM.
Purity: 99.92% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: 99.32% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Azilsartan (TAK-536) Cat. No.: HY-14914	Azilsartan D5 (TAK-536 D5) Cat. No.: HY-14914S
Bioactivity: Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC50 of 2.6 nM.	Bioactivity: Azilsartan D5 is the deuterium labeled Azilsartan(TAK-536), which is a specific and potent angiotensin II type 1 receptor antagonist.
Purity: 99.58% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg
Azilsartan medoxomil (TAK-491) Cat. No.: HY-14736	Azilsartan medoxomil monopotassium (Azilsartan kamedoxomil; TAK 491 monopotassium) Cat. No.: HY-17458
Bioactivity: Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.	Bioactivity: Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.
Purity: >98% Clinical Data: Launched Size: 5 mg, 10 mg, 50 mg	Purity:95.35%Clinical Data:LaunchedSize:10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
BIBS 39 Cat. No.: HY-19732	C-Type Natriuretic Peptide (1-53), human Cat. No.: HY-P1815
Bioactivity: BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.	Bioactivity: C-Type Natriuretic Peptide (1-53), human is the 1-53 fragment of C-Type Natriuretic Peptide. C-Type Natriuretic Peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone [1] 0.000
Purity: 99.70% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	Purity: >98% Clinical Data: No Development Reported Size:

C-Type Nat	triuretic Peptide (CNP) (1-22), human Cat. No: HY-P1237	Candesarta (CV 11974)	an Cat. No.: HY-B0205
Bioactivity:	C-Type Natriuretic Peptide (CNP) (1-22), human is the 1-22 fragment of C-Type Natriuretic Peptide. C-type natriuretic peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular	Bioactivity:	Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
Purity: Clinical Data: Size:	tone. 96.25% No Development Reported 10mM x 1mL in Water, 500u g, 1 mg, 5 mg	Purity: Clinical Data: Size:	98.34% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg
Candesarta	n Cilexetil	Candesarta	an D4
(TCV-116)	Cat. No.: HY-17505	(CV-11974 D	4) Cat. No.: HY-B0205
Bioactivity:	Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	Bioactivity:	Candesartan D4 is the deuterium labeled Candesartan, which is an angiotensin II receptor antagonist.
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 500 mg, 1 g	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg
CGP-42112 (CGP42112A)		CGP48369	Cat. No.: HY-10170
Bioactivity:	CGP-42112(CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist. IC50 value: Target: AT2 R agonist in vitro: CGP42112 (>==1 nM) significantly inhibited cGMP production from the basal value. CGP42112 (>==1 nM) significantly inhibited TH-enzyme activity from the basal	Bioactivity:	CGP48369 is a nonpeptidic angiotensin II receptor antagonist, used for anti-hypertensive research.
Purity: Clinical Data: Size:	98.82% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
Elisartan (HN 65021)	Cat. No. : HY-19214	Eprosartan (SKF-108566.	•
Bioactivity:	Elisartan is an orally active non-peptide pro-drug of angiotensin II AT1 receptor antagonist HN-12206, and shows anti-hypertension activities.	Bioactivity:	Eprosartan is a nonpeptide angiotensin II receptor antagonist with IC50 of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	99.94% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
Fimasartan (BR-A-657)	Cat. No .: HY-B0780	H-Val-Pro-	. Рго-ОН Саt. No.: HY-11416
Bioactivity:	Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.	Bioactivity:	H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC ₅₀ of 9 μ M.
Purity: Clinical Data: Size:	98.77% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg

H-Val-Pro-	Pro-OH TFA	Cat. No.: HY-114161A	Irbesartan (SR-47436; BN	MS-186295)	Cat. No.: HY-B0202
Bioactivity:	H-Val-Pro-Pro-OH (TFA), a milk-derived proderivative, is an inhibitor of Angiotensin I co (ACE), with an IC ₅₀ of 9 μ M.		Bioactivity:	Irbesartan is a highly potent and specific ar 1 (AT1) receptor antagonist with IC50 of 1.3	
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg	and the second s	Purity: Clinical Data: Size:	99.79% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	
Irbesartan (SR-47436 D4	D4 ; BMS-186295 D4)	Cat. No .: HY-B0202S	L-159282 (MK 996)		Cat. No.: HY-19193
Bioactivity:	Irbesartan D4 is the deuterium labeled Irbe highly potent and specific angiotensin II typ receptor antagonist.		Bioactivity:	L-159282 is a highly potent, orally active, n angiotensin II receptor antagonist, with a activity.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	C L H VO
L162389		Cat. No .: HY-101618	L162441		Cat. No.: HY-U0024
Bioactivity:	L162389 is a potent antagonist of angioter with \mathbf{K}_{i} of 28 nM.	nsin AT1 receptor	Bioactivity:	L162441 is an Angiotensin type 1 recepto	r antagonist.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
LCZ696 (Sacubitril mi	xture with Valsartan)	Cat. No.: HY-18204A	Losartan (DuP-753)		Cat. No.: HY-1751
Bioactivity:	LCZ696 is a dual angiotensin II receptor ar inhibitor.	nd neprilysin	Bioactivity:	Losartan is an angiotensin II receptor anta with the binding of angiotensin II to AT1 re of 20 nM.	5 1 5
Purity: Clinical Data: Size:	99.99% Launched 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg		Purity: Clinical Data: Size:	99.24% Launched 10mM x 1mL in DMSO, 1 g, 5 g	
Losartan D (DuP-753 D4)		Cat. No. : HY-17512S	Losartan D4 (E-3174 D4; E	4 Carboxylic Acid XP-3174 D4)	Cat. No.: HY-127655
Bioactivity:	Losartan D4 is the deuterium labeled Losar angiotensin II receptor antagonist, compe of angiotensin II to AT1 receptors with IC ₅₀	eting with the binding	Bioactivity:	Losartan D4 Carboxylic Acid is the deuteriu Losartan(EXP-3174), which is an angiotensi antagonist.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	a - N - P

Losartan po (DuP-753 pot		Cat. No. : HY-17512A	LY285434		Cat. No.: HY-U0020
Bioactivity:	Losartan (potassium) is an angiotensin (AT1) antagonist, competing with the bi II to AT1 with an IC ₅₀ of 20 nM.		Bioactivity:	LY285434 is a suitable angiotensin II	receptor antagonist.
Purity: Clinical Data: Size:	99.91% Launched 10mM x 1mL in DMSO, 1 g, 5 g		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Olmesartar (RNH 6270; C		Cat. No .: HY-17004	Olmesartar (RNH-6270 D	n D4 4; CS-088 D4)	Cat. No. : HY-17004
Bioactivity:	Olmesartan is an angiotensin II recepto used to treat high blood pressure.	or (AT1R) antagonist	Bioactivity:	Olmesartan D4 is the deuterium labele is an angiotensin II receptor (AT1R) high blood pressure.	
Purity: Clinical Data: Size:	99.01% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	N ^N N N OH	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	ⁿ ^H n (n.
Olmesartar (CS 866)	n medoxomil	Cat. No. : HY-17005	Olodanriga (EMA401; PD		Cat. No.: HY-1310
Bioactivity:	Olmesartan medoxomil is a potent and a receptor inhibitor with IC_{50} of 66.2 $\mu\text{M}.$	selective angiotensin AT1	Bioactivity:	Olodanrigan (EMA401), a highly select inhibition of augmented AngII/AT2R ir MAPK activation, and hence inhibition hyperexcitability and sprouting of DRC	nduced p38 and p42/p44 of DRG neuron
Purity: Clinical Data: Size:	99.03% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	ؿ ڹڔڮڔڮؿ	Purity: Clinical Data: Size:	99.29% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg	
PD 123319 ((S)-(+)-PD 12	23319)	Cat. No .: HY-10259	PD 123319	ditrifluoroacetate	Cat. No.: HY-10259
Bioactivity:	PD 123319 (ditrifluoroacetate) is a poter angiotensin II receptor antagonist with		Bioactivity:	PD 123319 (ditrifluoroacetate) is a pot angiotensin II receptor antagonist wi	
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg	****** ******	Purity: Clinical Data: Size:	99.76% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg	
Pratosartar (FW 7203; KD	ו 3-671; KT 3671)	Cat. No.: HY-101574	SL910102		Cat. No.: HY-10029
Bioactivity:	Pratosartan is a selective angiotensin II	receptor antagonist.	Bioactivity:	SL910102 is a nonpeptide angiotensi	n AT₁ receptor antagonist.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	


Sparsentan (RE-021; DAR		Cat. No.: HY-17621	Tasosartan (WAY-ANA 7		Cat. No.: HY-A025
Bioactivity:	Sparsentan (RE-021; BMS-346567; PS433540; potent dual angiotensin II and endothelin A with $\mathbf{K}_{i}\mathbf{s}$ of 0.8 and 9.3 nM, respectively.		Bioactivity:	Tasosartan is a long-acting angiotensin antagonist.	ll (Angll) receptor
Purity: Clinical Data: Size:	99.08% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	>98% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	
TD-0212		Cat. No. : HY-114412	Telmisartar (BIBR 277)	1	Cat. No. : HY-1395
Bioactivity:	TD-0212 (compound 35) is an orally active du angiotensin II type 1 receptor (AT_1) antago (NEP) inhibitor, with a pK _i of 8.9 for AT ₁ and	al pharmacology nist and neprilysin	Bioactivity:	Telmisartan is a potent, long lasting anta II type 1 receptor (AT1), selectively inh of ¹²⁵ I-AngII to AT1 receptors with IC ₅₀	agonist of angiotensin ibiting the binding
Purity: Clinical Data: Size:	9.2 for NEP ^[1] . >98% No Development Reported 500 mg, 100 mg, 250 mg	or the form	Purity: Clinical Data: Size:	99.96% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g	and the second se
Tranilast (MK 341; SB 2	:52218)	Cat. No.: HY-B0195	Tranilast So (Sodium Tran	o <mark>dium</mark> ilast; MK 341 Sodium; SB 252218 Sodiur	n) Cat. No.: HY-B0195
Bioactivity: Purity: Clinical Data: Size:	Tranilast is an antiallergic agent. Target: Angio Receptor Tranilast has been approved in Japa since 1982, for the treatment of bronchial astl indications for keloids and hypertrophic scar a Tranilast is also used to treat asthma, autoimn 99.60% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	n and South Korea, nma, with added in 1993.	Bioactivity: Purity: Clinical Data: Size:	Tranilast is an antiallergic agent. Target: Receptor Tranilast has been approved ir since 1982, for the treatment of bronchi indications for keloids and hypertrophic Tranilast is also used to treat asthma, au >98% Launched 10 mg, 50 mg	a Japan and South Korea, al asthma, with scar added in 1993.
Tranilast tra (trans-Tranila		Cat. No .: HY-18706	Valsartan (CGP 48933)		Cat. No.: HY-1820
Bioactivity:	Trans-Tranilast is an antiallergic drug, used to bronchial asthma, allergic rhinitis and atopic of		Bioactivity:	Valsartan (CGP-48933) is an angiotensi for the treatment of high blood pressure	
Purity: Clinical Data: Size:	99.66% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg		Purity: Clinical Data: Size:	99.35% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	
Valsartan D (CGP-48933 D		Cat. No. : HY-18204S	ZD 7155(hy	ydrochloride)	Cat. No.: HY-10209
Bioactivity:	Valsartan D9 (CGP-48933 D9) is deuterium lat Valsartan is an angiotensin II receptor antage of high blood pressure and heart failure.		Bioactivity:	ZD 7155 hydrochloride is an angiotensir AT1 receptor) antagonist.	II receptor type 1 (
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg		Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	

[Sar1, Ile8]-Angiotensin II Cat. No.: HY-P1564						
Bioactivity:	[Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction normal arteries and hypertrophy or hyperplasia of cultur cells or diseased vessels.					
Purity: Clinical Data: Size:	>98% No Development Reported 10 mg, 50 mg					



Bombesin Receptor





Bombesin, a peptide of 14 amino acids, is an amphibian homolog to the mammalian gastrin-releasing peptide (GRP), that has been extensively studied as a targeting ligand for diagnosis and therapy of GRP positive tumors, such as breast, pancreas, lungs and prostate cancers. Bombesin binds to and activates G-protein coupled receptors, known as gastrin releasing peptide receptor (GRPR).

Bombesin, a tetradecapeptide isolated from the skin of the frog Bombina bombina, have shown broad spectrum of biological activities. The BBS activates three G protein-coupled receptors: bombesin receptor 1 (BB₁), bombesin receptor 2 (BB₂), and bombesin

receptor 3 (BB₂). BBS-like peptides-Neuromedin B (NB) and gastrin

releasing peptide (GRP) are natural ligand of the BB1 and BB2 receptors, respectively.

In mammals, BBS receptors and BBS-like peptides are distributed in the Central Nervous System (CNS) including regions involved in the cardiorespiratory control.

The mammalian bombesin G-protein-coupled receptor subfamily comprises three structurally related members, the receptors for neuromedin B (NMBR or BB1), gastrin-releasing peptide (GRPR or BB2), and bombesin receptor subtype-3 (BRS-3 or BB3).

Bombesin receptor subtype-3 (BRS-3) is an orphan G protein-coupled receptor implicated in the regulation of energy homeostasis.


Bombesin Receptor Inhibitors & Modulators

Bombesin		MK-5046		
	Cat. No.: HY-P0195		Cat. No.: HY-14342	
Bioactivity:	Bombesin is a tetradecapeptide originally isolated from frog skin; plays an important role in the release of gastrin and the activation of G-protein receptors.	Bioactivity:	MK-5046 is a novel BRS-3 agonist, binds to BRS-3 with high affinity (mouse Ki = 1.6 nM, human Ki = 25 nM).	
Purity: Clinical Data: Size:	99.69% Phase 2 1 mg, 5 mg, 10 mg, 25 mg	Purity: Clinical Data: Size:	99.67% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
ML-18	Cat. No. : HY-101844	PD176252	Cat. No.: HY-103286	
Bioactivity:	ML-18 is a non-peptide bombesin receptor subtype-3 (BRS-3) antagonist with an IC_{50} of 4.8 μ M.	Bioactivity:	PD176252 is a potent antagonist of neuromedin-B preferring (${f BB_1}$) and gastrin-releasing peptide-preferring (${f BB_2}$)	
			receptor with K _i s of 0.17 nM and 1 nM for human BB $_1$ and BB	
			$_2$ receptors, and 0.66 nM, 16 nM for Rat BB $_1$ and BB $_2$	
Purity: Clinical Data: Size:	98.04% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.0% No Development Reported 2 mg, 5 mg	



Bradykinin Receptor





HDAC (Histone deacetylase)

cancer cell invasion and migration.

Bradykinin is a potent vasodilator peptide that exerts its vasodilatory action through stimulation of specific endothelial B_2 receptors,

thereby causing the release of prostacyclin, NO, and EDHF. Bradykinin (BK) has been reported to be involved in the progression of many types of cancer. Two bradykinin receptors, bradykinin B1 receptor (B1R) and bradykinin B2 receptor (B2R), are significantly expressed in all the tested colorectal cancer cells. Repression of B2R, but not B1R, attenuates the BK-mediated invasion and migration, and inhibits ERK1/2 activation and IL-6 production. Moreover, blocking of the ERK pathway decreases the BK-mediated IL-6 production. In addition, IL-6 repression suppresses the effects of BK on colorectal

Bradykinin, the enzymatic product of kallikrein-kinin system (KKS), is a major modulator of Ang II actions on blood volume, vascular reactivity and salt sensitivity.

Bradykinin Receptor Inhibitors & Modulators

	•		
Bradykinin	Cat. No.: HY-P0206	Bradykinin	1-3 Cat. No.: HY-P1497
Bioactivity:	Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.	Bioactivity:	Bradykinin (1-3) is a 3-amino acid residue peptide. Bradykinin (1-3) is an amino-truncated Bradykinin peptide, cleaved by Prolyl endopeptidase.
Purity: Clinical Data: Size:	98.97% Phase 2 5 mg, 10 mg, 25 mg, 50 mg, 100 mg RPPGFSPFR	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg
Bradykinin		Bradykinin	
	Cat. No.: HY-P1488		Cat. No.: HY-P1469
Bioactivity:	Bradykinin (1-5) is a major stable metabolite of Bradykinin, formed by the proteolytic action of angiotensin-converting enzyme (ACE).	Bioactivity:	Bradykinin (1-6) is an amino-truncated Bradykinin peptide. Bradykinin (1-6) is a stable metabolite of Bradykinin, cleaved by carboxypeptidase Y (CPY).
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg
Bradykinin (Bradykinin Fr		Bradykinin (Des-Arg1-br	
Bioactivity:	Bradykinin (1-7) is an amino-truncated Bradykinin peptide. Bradykinin (1-7) is a metabolite of Bradykinin, cleaved by endopeptidase.	Bioactivity:	Bradykinin (2-9) is an amino-truncated Bradykinin peptide. Bradykinin (2-9) is a metabolite of Bradykinin, cleaved by Aminopeptidase P.
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% No Development Reported
ELN-44195	8 Cat. No.: HY-15043	FR167344	free base Cat. No.: HY-100301
Bioactivity:	ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ -opioid receptor.	Bioactivity:	FR167344 free base is an orally active, nonpeptide bradykinin receptor B2 antagonist. FR167344 free base shows a high affinity binding to the B2 receptor with an IC ₅₀ value of 65 nM and no binding affinity for the B1 receptor.
Purity: Clinical Data: Size:	98.94% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg
Icatibant (HOE 140)	Cat. No. : HY-17446	SSR240612	2 Cat. No.: HY-15039
Bioactivity: Purity:	Icatibant (HOE-140) is a selective and specific antagonist of bradykinin B2 receptor with IC ₅₀ and K _i of 1.07 nM and 0.798 nM respectively. 97.19%	Bioactivity:	SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with K ₁ s of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells 99.19%
Clinical Data: Size:			99.19% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg


[Des-Arg9]	[Des-Arg9]-Bradykinin Cat. No.: HY-P0298		[Des-Arg9]-Bradykinin acetate Cat. N		
Bioactivity:	[Des-Arg9]-Bradykinin is a Bradykinin (B_1) receptor that displays selectivity for B $_1$ over B $_2$ receptors.	r agonist	Bioactivity:	[Des-Arg9]-Bradykinin acetate is a Bradykinin B_1 recept agonist that displays selectivity for B_1 over B_2 receptors.	or
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg		Purity: Clinical Data: Size:	99.06% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg	

Cat. No.: HY-P0298A



Cannabinoid Receptor

Cannabinoid Receptor



Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.

Cannabinoid Receptor Inhibitors & Modulators

(±)-Ibipina ((±)-SLV319; (2-Arachido	onoylglycerol Cat. No.: HY-W011051
Bioactivity:	 (±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC₅₀ of 22 nM. 	Bioactivity:	2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
Purity: Clinical Data: Size:	99.49% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	97.0% No Development Reported 1 mg
A-836339	Cat. No. : HY-12761	AM251	Cat. No.: HY-15443
Bioactivity:	A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.	Bioactivity:	AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC ₅₀ of 8 nM, also acts as a potent GPR55 agonist with an EC₅₀ of 39 nM.
Purity: Clinical Data: Size:	99.61% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	99.92% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
AM9405	Cat. No. : HY-112707	Anandami	de Cat. No.: HY-10863
Bioactivity:	AM9405 is a novel peripherally active cannabinoid type 1 (CB1) and serotonin type 3 receptor agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC₅₀s of 45.71 and 0.076 nM, respectively.	Bioactivity:	Anandamide is an immune modulator in the central nervous system acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18 / GPR55).
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg	Purity: Clinical Data: Size:	99.0% No Development Reported 5 mg, 10 mg
Bay 59-307	4 Cat. No.: HY-100488	BML-190 (Indomethac	in morpholinylamide; IMMA) Cat. No.: HY-15420
Bioactivity:	Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively . Orally active CB1 agonist in vivo.	Bioactivity:	BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).
Purity: Clinical Data: Size:	98.01% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.34% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
CB1 antago	onist 1 Cat. No.: HY-U00397	CB1-IN-1	Cat. No.: HY-12790
Bioactivity:	CB1 antagonist 1 is an antagonist of CB1 receptor , used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.	Bioactivity:	CB1-IN-1 is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

CB2R-IN-1	Cat. No. : HY-100328	GW842166X	Cat. No. : HY-14167
Bioactivity:	CB2R-IN-1 is a potent cannabinoid CB₂ receptor inverse agonist with a K _i of 0.9 nM.		s a potent and selective cannabinoid receptor 2 with IC_{50} values of 63 and 91 nM for human and
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: 99.97% Clinical Data: No Developm Size: 10mM x 1mL 2 mg, 5 mg, 1	in DMSO,
JD-5037	Cat. No.: HY-18697	LY2828360	Cat. No. : HY-16642/
Bioactivity:	JD-5037 is a novel, peripherally restricted CB₁R antagonist with an IC₅₀ of 1.5 nM.	-	a slowly acting but efficacious G protein-biased CB ₂) agonist, inhibiting cAMP accumulation and
Purity: Clinical Data: Size:	98.05% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity:98.99%Clinical Data:No DevelopmSize:10mM x 1mL5 mg, 10 mg,	
MDA 19	Cat. No.: HY-15451	N-Oleoyl glycine	Cat. No.: HY-113204
Bioactivity:	MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM.	adipogenesis	ine is a lipoamino acid, which stimulates associated with activation of CB1 receptor and pathway in 3T3-L1 adipocyte.
Purity: Clinical Data: Size:	99.56% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity:>98%Clinical Data:Size:10 mg	yU
Olivetol	Cat. No.: HY-W008364	Olorinab (APD 371)	Cat. No.: HY-11111
Bioactivity:	Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2 ^[3] . Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC ₅₀ s of 1	efficacious car	2 371) is a highly potent, selective and fully anabinoid receptor type 2 (CB₂) agonist, with a nM for hCB ₂ .
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 100 mg	Purity:>98%Clinical Data:No DevelopmSize:500 mg, 250 r	
Org 27569	Cat. No. : HY-13288	Otenabant (CP-945598)	Cat. No.: HY-1087:
Bioactivity:	Org 27569 is a potent CB1 receptor allosteric modulator, which increases agonist binding, yet blocks agonist-induced CB1 signaling.	antagonist wit	a potent and selective cannabinoid receptor CB1 th K_i of 0.7 nM, exhibits 10,000-fold greater inst human CB2 receptor.
Purity: Clinical Data: Size:	98.91% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	Purity: 99.65% Clinical Data: No Developm Size: 10mM x 1mL 5 mg, 10 mg,	in DMSO,

74 Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Otenabant (CP 945598 H	Hydrochloride ydrochloride)	Cat. No.: HY-10871A	Pregnenolo (Arthenolone	one ; 3β-Hydroxy-5-pregnen-20-one)	Cat. No.: HY-B0151
Bioactivity:	Otenabant Hydrochloride is a potent and sele receptor CB1 antagonist with K_i of 0.7 nM, ex 10,000-fold greater selectivity against human	hibits	Bioactivity:	Pregnenolone acts as a signaling-specific inhibit cannabinoid CB1 receptor, reduces several effe tetrahydrocannabinol (THC).	
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg		Purity: Clinical Data: Size:	98.0% Phase 4 10mM x 1mL in DMSO, 1 g, 5 g	
-	one monosulfate		Rimonabar	nt	
	20-on-3β-yl sulfuric acid)	Cat. No.: HY-B1739	(SR141716)		Cat. No.: HY-14136
Bioactivity:	Pregnenolone monosulfate acts as a signaling inhibitor of cannabinoid CB1 receptor , reduce of tetrahydrocannabinol (THC).		Bioactivity:	Rimonabant (SR141716) is a highly potent and s cannabinoid receptor (CB1) antagonist with a Rimonabant (SR141716) also inhibits Mycobact protein Large 3 (MMPL3).	K_i of 1.8 nM.
Purity: Clinical Data: Size:	>98% No Development Reported 50 mg		Purity: Clinical Data: Size:	>98%	and a state of the second
Rimonaban (SR 141716A;	t Hydrochloride SR 151716A)	Cat. No. : HY-14137	SR144528		Cat. No.: HY-13439
Bioactivity:	Rimonabant hydrochloride is a highly potent a central cannabinoid receptor (CB1) antagon 1.8 nM. Rimonabant hydrochloride also inhibi Mycobacterial membrane protein Large 3 (ist with an K_i of ts	Bioactivity:	SR144528 is a potent and selective CB2 recepto with a \mathbf{K}_{i} of 0.6 nM.	or antagonist
Purity: Clinical Data: Size:	99.08%		Purity: Clinical Data: Size:	99.61% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	t t t t t t t t t t t t t t t t t t t
Taranabant (MK-0364)	:	Cat. No. : HY-10013		t ((1R,2R)stereoisomer) 2R)stereoisomer)	Cat. No.: HY-10013B
Bioactivity:	Taranabant is a highly potent and selective ca CB1) receptor inverse agonist that inhibits the functional activity of various agonists, with a b 0.13 nM for the human CB1R in vitro.	binding and	Bioactivity:	Taranabant (1R,2R)stereoisomer is the R-enantic Taranabant. Taranabant is a highly potent and so cannabinoid 1 (CB1) receptor inverse agonist.	
Purity: Clinical Data: Size:	99.28%	zartiza.	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg	
Taranabant (MK-0364 rac		Cat. No. : HY-10013A	WIN 55,212 ((R)-(+)-WIN	2-2 Mesylate 55212)	Cat. No.: HY-13291
Bioactivity:	Taranabant racemate is an antagonist and/or the Cannabinoid-1 (CB1) receptor extracted 2004048317 A1.	-	Bioactivity:	WIN 55,212-2 Mesylate is a potent aminoalkylin (CB) receptor agonist with K _i s of 62.3 and 3.3 n recombinant CB1 and CB2 receptors, respectivel	M for human
Purity: Clinical Data: Size:	99.74% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	99.01% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	0.428 to

Yangonin	Cat. No.: HY-N0919		r llene ((-)-trans-Caryophyllene; ıyllene; (-)-(E)-Caryophyllene)
Bioactivity:	Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC_{50} and a K_i of 1.79 ± 0.53 μ M and 0.72±0.21 μ M, respectively.	Bioactivity:	β -Caryophyllene is a CB2 receptor agonist.
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg		94.40% No Development Reported 500 mg


Cat. No.: HY-N1415

 \square



CaSR

Calcium-sensing receptor



CaSR (calcium-sensing receptor) is a Class C G-protein coupled receptor which senses extracellular levels of calcium ion. In theparathyroid gland, the calcium-sensing receptor controls calcium homeostasis by regulating the release of parathyroid hormone (PTH). The release of PTH is inhibited in response to elevations in plasma calcium concentrations and activation of the calcium receptor. Increased calcium binding on the extracellular side gives a conformational change in the receptor, which, on the intracellular side, initiates the phospholipase C pathway, presumably through a Gq α type of G protein, which ultimately increases intracellular concentration of calcium, which inhibits vesicle fusion and exocytosis


of parathyroid hormone. It also inhibits the cAMP dependent pathway.

CaSR Inhibitors & Modulators

Calcium-Se	nsing Receptor Antagonists I Cat. No.: HY-50713	Cinacalcet (AMG 073)	Cat. No.: HY-70037
Bioactivity:	Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.	Bioactivity:	Cinacalcet (AMG 073) is an orally active, allosteric agonist of Ca receptor (CaR) , used for cardiovascular disease treatment.
Purity: Clinical Data: Size:	99.02% No Development Reported 10mM x 1mL in DMSO, 10 mg, 100 mg	Purity: Clinical Data: Size:	99.65% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg
Cinacalcet (AMG-073 (hy	hydrochloride /drochloride)) Cat. No.: HY-70037A	Evocalcet (KHK7580)	Cat. No.: HY-17613
Bioactivity:	Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of Ca receptor (CaR) , used for cardiovascular disease treatment.	Bioactivity:	Evocalcet has an activating effect on calcium sensing receptor (CaSR) extracted from patent WO 2017061621 A1, compound A.
Purity: Clinical Data: Size:	99.98% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.52% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
GSK300477	'4 Cat. No.: HY-107773	Ligustrofla (Nuezhenosi	
Bioactivity:	GSK3004774 is a potent, nonabsorbable agonist of CaSR , with an pEC ₅₀ of 7.3, 6.6 and 6.5 for human, mouse and rat CaSR, respectively. GSK3004774 shows an EC ₅₀ of 50 nM for human CaSR ^[1] .	Bioactivity:	Ligustroflavone, extracted from Ligustrum lucidum, is a potential candidate as calcium-sensing receptor (CaSR) antagonist. Ligustroflavone exhibits protective effects against diabetic osteoporosis in mice ^[1] .
Purity: Clinical Data: Size:	>98% No Development Reported 100 mg, 250 mg, 500 mg	Purity: Clinical Data: Size:	>98% "Signature No Development Reported "Signature Signa
NPS-2143 (SB 262470A)	Cat. No .: HY-10007	NPS-2143	hydrochloride Cat. No.: HY-10171
Bioactivity: Purity:	NPS-2143 is a selective antagonist of calcium-sensing receptor (CaSR) with an IC ₅₀ of 43 nM. 99.42% No Development Reported	Bioactivity: Purity:	NPS-2143 hydrochloride is a selective potent calcium ion-sensing receptor antagonist with IC50 of 43 and 41 nM for cytoplasmic Ca2+ concentrations and parathyroid hormone secretion, respectively. IC50 value: 43 nM(for Ca2+ receptor) [1] Target: CaSR in vitro: NPS-2143, even when tested at much 99.96% No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
SB-423562	Cat. No.: HY-15105	Strontium (Distrontium	Ranelate renelate; \$12911) Cat. No.: HY-17397
Bioactivity:	SB-423562 is a short-acting calcium-sensing receptor (CaR) antagonist.	Bioactivity:	Strontium ranelate(S12911) stimulates the calcium sensing receptors (CaSR) and leads to the differentiation of pre-osteoblast to osteoblast which increases the bone formation.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	99.16% Launched 100 mg, 500 mg



CCR CC chemokine receptor



HDAC (Histone deacetylase)

CCR (Chemokine receptors) are cytokine receptors found on the surface of certain cells that interact with a type of cytokine called achemokine. There have been 19 distinct chemokine receptors described in mammals. Each has a 7-transmembrane (7TM) structure and couples to G-protein for signal transduction within a cell, making them members of a large protein family of G protein-coupled receptors. Following interaction with their specific chemokine ligands, chemokine receptors trigger a flux in intracellular calcium (Ca²⁺) ions (calcium signaling). This causes cell responses, including the onset of a process known as chemotaxis that traffics the cell to a desired location within the organism. Chemokine receptors are divided into

different families, CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors and XC chemokine receptors that correspond to the 4 distinct subfamilies of chemokines they bind. Specific chemokine receptors provide the portals for HIV to get into cells, and others contribute to inflammatory diseases and cancer.

CCR Inhibitors & Modulators

Aplaviroc (AK 602; GSK	873140; GW 873140) Cat.	No .: HY-17450	AZ084		Cat. No.: HY-119217
Bioactivity:	Aplaviroc, a SDP derivative, is a CCR5 antagonist, with I of 0.1-0.4 nM for HIV-1 $_{\rm Ba-L^\prime}$ HIV-1 $_{\rm JRFL}$ and HIV-1 $_{\rm MOKV}$	30	Bioactivity:	AZ084 is a potent, selective, allosteric and or antagonist, with a \mathbf{K}_{i} of 0.9 nM. Has potential [1]	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	್ಷನ್ನು ಕ್ಷೇ	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	sooro
AZD2098	Cat N	o.: HY-U00064	BMS-81316	50	Cat. No .: HY-109593
Bioactivity:	AZD2098 is a potent and selective CC-chemokine rece (CCR4) inhibitor with pIC₅₀ s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthr research ^[1] ^[2] .	eptor 4	Bioactivity:	BMS-813160 is the first dual CCR2/CCR5 ant clinical development for cardiovascular.	
Purity: Clinical Data: Size:	99.85% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	99.81% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg	
BX471 (ZK-811752)	Cat.	No.: HY-12080	BX471 hyd (ZK-811752 (ł	r ochloride nydrochloride))	Cat. No.: HY-12080/
Bioactivity:	BX471 (ZK-811752) is a potent and selective non-pepti antagonist with a \mathbf{K}_{i} of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.	de CCR1	Bioactivity:	BX471 hydrochloride (ZK-811752 hydrochlori selective non-peptide CCR1 antagonist with human CCR1, and exhibits 250-fold selectivit CCR2, CCR5 and CXCR4.	K _i of 1 nM for
Purity: Clinical Data: Size:	95.64% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg		Purity: Clinical Data: Size:	98.00% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	на на на
CCR1 antag		o.: HY-U00350	CCR1 antag	jonist 6	Cat. No. : HY-11419
Bioactivity:	CCR1 antagonist 1 is an antagonist of CCR1 , with anti-inflammatory activity.		Bioactivity:	CCR1 antagonist 6 (compound 16q) is a cher (CCR1) antagonist, with an IC_{50} of 3 nM ^[1] .	nokine receptor 1
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	>98% No Development Reported 100 mg, 500 mg, 250 mg	نې مېرې کې
CCR1 antag		lo.: HY-114194	CCR1 antag	jonist 8	Cat. No. : HY-12058
Bioactivity:	CCR1 antagonist 7 (compound 16r) is a chemokine red (CCR1) antagonist, with an IC_{50} of 4 nM ^[1] .	ceptor 1	Bioactivity:	CCR1 antagonist 8 (compound 19n), a third a compound, is a CCR1 antagonist clinical cand IC_{50} of 1.8 nM in Ca ²⁺ flux assay ^[1] .	zaindazole series
Purity: Clinical Data: Size:	>98% No Development Reported 100 mg, 250 mg, 500 mg	~0.57.68#	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	

CCR2 antagonist 1	CCR2-RA-[R]
Cat. No.: HY-112792 Bioactivity: CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist with a K of 24 pM	Cat. No.: HY-50081 Bioactivity: CCR2-RA-[R] is an allosteric antagonist of the C-C chemokine recenter type 2 (CCP2) with an IC of 102 nM
CCR2 antagonist, with a K _i of 2.4 nM. Purity: >98% Clinical Data: No Development Reported Size: 500 mg, 250 mg	Purity: 99.36% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
CCR3 antagonist 1	CCR5 antagonist 1
Cat. No. : HY-U00331	Cat. No. : HY-100261
Bioactivity: CCR3 antagonist 1 is a potent antagonist of CCR3 , used for the research of immunologic and inflammatory diseases.	Bioactivity: CCR5 antagonist 1 is a CCR5 antagonist which can inhibit HIV replication extracted from WO 2004054974 A2.
Purity: >98% Clinical Data: No Development Reported Size: 20 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg
CCR6 inhibitor 1 Cat. No.: HY-112701	Cenicriviroc (TAK-652; TBR-652) Cat. No.: HY-14882
Bioactivity: CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC ₅₀ s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC ₅₀ , > 30000 nM), and CCR7 (IC ₅₀ , 9400 nM). CCR6 inhibitor 1 marke	Bioactivity: Cenicriviroc is an orally active, dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.
Purity: 99.82% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: 97.09% Clinical Data: Phase 3 Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Cenicriviroc Mesylate	DAPTA
(TAK-652 Mesylate; TBR-652 Mesylate) Cat. No.: HY-14882A	(D-Ala-peptide T-amide; Adaptavir) Cat. No.: HY-P1034
Bioactivity: Cenicriviroc is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.	Bioactivity: DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5 , and shows potent anti-HIV activities.
Purity: 98.23% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg	Purity:98.73%Clinical Data:No Development ReportedSize:1 mg, 5 mg, 10 mg, 25 mg
GSK2239633A Cat. No.: HY-100183	GW 766994 (GW 994) Cat. No.: HY-107051
Bioactivity: GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [¹²⁵ I]-TARC to human CCR4 with a pIC₅₀ of 7.96±0.11.	Bioactivity: GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis.
Purity: 98.05% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	Purity:99.53%Clinical Data:No Development ReportedSize:10mM x 1mL in DMSO,5 mg, 10 mg, 25 mg, 50 mg, 100 mg

INCB 3284			INCB 3284	dimesylate	
		Cat. No.: HY-15450A			Cat. No.: HY-1545
Bioactivity:	INCB 3284 is a potent, selective and orally bioas CCR2 antagonist, inhibiting monocyte chemoat protein-1 binding to hCCR2, with an IC ₅₀ of 3.7	tractant	Bioactivity:	INCB 3284 dimesylate is a potent, selective bioavailable human CCR2 antagonist, inhil chemoattractant protein-1 binding to hCC	biting monocyte
Develter	can be used in the research of acute liver failure 99.30%	<u>.</u>	Durita	3.7 nM. INCB 3284 dimesylate can be used acute liver failure.	l in the research of
Purity: Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	20140-0.04	Purity: Clinical Data: Size:	98.0% No Development Reported 10 mg, 50 mg	SOLOOC Fa Fa
INCB3344		Cat. No. : HY-50674	Maraviroc (UK-427857)		Cat. No. : HY-1300
Bioactivity:	INCB3344 is a potent, selective and orally bioav	ailable CCR2	Bioactivity:	Maraviroc is a selective CCR5 antagonist w	
	antagonist with IC ₅₀ values of 5.1 nM (hCCR2) a (mCCR2) in binding antagonism and 3.8 nM (hC (mCCR2) in antagonism of chemotaxis activity.			against human HIV .	
Purity: Clinical Data: Size:	99.76% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	ordely and	Purity: Clinical Data: Size:	99,71% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
MK-0812		Cat. No. : HY-50669	MK-0812 S	uccinate	Cat. No. : HY-50669
Bioactivity:	MK-0812 is a potent and selective CCR2 antago affinity for CCR2.		Bioactivity:	MK-0812 Succinate is a potent and selective with high affinity at CCR2.	
Purity: Clinical Data: Size:	99.75% Phase 2 5 mg, 10 mg		Purity: Clinical Data: Size:	99.57% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	ૼૢૺૡૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢૢ
PF-4136309 (INCB8761)	9	Cat. No .: HY-13245	RS 504393		Cat. No. : HY-1541
Bioactivity:	PF-4136309 is a potent, selective, and orally bio CCR2 antagonist, with IC₅₀ s of 5.2 nM, 17 nM a human, mouse and rat CCR2.		Bioactivity:	RS 504393 is a selective CCR2 chemokine IC_{50} values are 89 nM and > 100 μ M for ir recombinant CCR2 and CCR1 receptors res	hibition of human
Purity: Clinical Data: Size:	99.59% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg		Purity: Clinical Data: Size:	99.02% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
RS102895		Cat. No.: HY-18611A	RS102895 I	nydrochloride	Cat. No. : HY-1861
Bioactivity:	RS102895 is a potent CCR2 antagonist, with an and shows no effect on CCR1.	IC₅₀ of 360 nM,	Bioactivity:	RS102895 hydrochloride is a potent CCR2 IC ₅₀ of 360 nM, and shows no effect on CC	
Purity: Clinical Data: Size:	>98% No Development Reported 10 mg, 50 mg		Purity: Clinical Data: Size:	98.98% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	r,† r ⊬α


SB297006		ТАК-220		
	Cat. 1	No.: HY-103361		Cat. No.: HY-19974
Bioactivity:	SB297006 is a CCR3 antagonist, which significantly inh proliferation and neurosphere formation in CCL11-trea neural progenitor cells.		TAK-220 is a selective and orally bioavailable C antagonist, with IC ₅₀ s of 3.5 nM and 1.4 nM for the binding of RANTES and MIP-1 α to CCR5, rn shows no effect on the binding to CCR1, CCR2	r inhibition on espectively, but
Purity: Clinical Data: Size:	99.77% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.95% : No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	ist.org
TAK-779 (Takeda 779)	Cat.	No.: HY-13406	pound 1	Cat. No.: HY-10832
Bioactivity:	TAK-779 is a potent and selective nonpeptide antagon CCR5 and CXCR3 , with a K_i of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1 , with EC ₅₀		Teijin compound 1 is a specific CCR 2 antagon of 24 and 180 nM in chemotaxis and binding a respectively.	
Purity: Clinical Data: Size:	99.73% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	Purity: Clinical Data Size:	99.89% : No Development Reported 10mM x 1mL in DMSO, 5 mg	20juija
Vercirnon (GSK-160578	6; CCX282-B; Traficet-EN) Cat.	No.: HY-15724 (SCH-417690	maleate) (maleate); SCH-D (maleate))	Cat. No.: HY-1737
Bioactivity:	Vercirnon is an orally bioavailable, selective, and poter antagonist of CCR9 , with an IC₅₀ of 10 nM, used in the research of inflammatory bowel diseases.		Vicriviroc maleate is a potent, selective, oral biand CNS penetrated antagonist of CCR5 , with and also inhibits HIV-1 in PBMC cells, with IC ₉ (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nl	a K_i of 2.5 nM, os of 3.3 nM
Purity: Clinical Data: Size:	98.04% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	$ \begin{array}{c} & & \\ & & $	99.41% : Phase 3 10mM x 1mL in DMSO, 5 mg	h to the total tot
ZK756326	dihydrochloride Cat. No	o .: HY-101038A		
Bioactivity:	ZK756326 dihydrochloride is a nonpeptide chemokine			

	Purity:	99.53%	
l	Clinical Data:	No Development Reported	orona
l	Size:	10mM x 1mL in DMSO,	H0 H0
		5 mg, 10 mg, 25 mg, 50 mg, 100 mg	



CGRP Receptor

Calcitonin gene-related peptide receptor



HDAC (Histone deacetylase)

CGRP receptor is a heterotrimer: a large peptide with 7 transmembrane domains, named calcitonin receptor-like receptor (CLR or CRLR), is supplemented by a small single transmembrane peptide, named receptor activity-modifying protein (RAMP1) that forms the CGRP-specific ligand binding site. CGRP receptors are expressed by multiple different cell types within the nervous, cardiovascular and immune systems that are thought to play important roles in migraine pathology: on cerebral vascular smooth muscle, where they cause vasodilation, on dural mast cells triggering their degranulation, at the central terminals of the trigeminal nerve, where CGRP is a neuromodulator at second-order nociceptive

neurons in the spinal trigeminal nucleus caudalis and in the dorsal horn of the spinal cord, where CGRP has a similar role in inducing central sensitisation to tactile stimuli. CGRP is produced in both peripheral and central neurons. It is a potent peptide vasodilator and can function in the transmission of pain.

CGRP Receptor Inhibitors & Modulators


Adrenome	dullin (1-50), rat Cat. No.: HY-P1534	Adrenomedullin (11-50), rat Cat. No.: HY-P1766
Bioactivity:	Adrenomedullin (1-50), rat is a 50 amino acid peptide, which induces a selective arterial vasodilation via activation of CGRP1 receptor .	Bioactivity: Adrenomedullin (11-50), rat is the C-terminal fragment (11-50) of rat adrenomedullin. Rat adrenomedullin induces a selective arterial vasodilation via CGRP1 receptors ^[1] .
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	Purity: >98% Clinical Data: No Development Reported Size:
Adrenome	dullin (16-31), human	Adrenomedullin (AM) (22-52), human
Bioactivity:	Cat. No.: HY-P1770 Adrenomedullin (16-31), human is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human possesse pressor activity in the systemic vascular bed of the rat, but not the cat ^[1] .	(22-52-Adrenomedullin (human)) Cat. No.: HY-P1471 Bioactivity: Adrenomedullin (AM) (22-52), human is an adrenomedullin receptor antagonist, and also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat.
Purity: Clinical Data: Size:	>98% No Development Reported	Purity: >98% Clinical Data: No Development Reported Size: 500u g, 1 mg, 5 mg
Calcitonin	Gene Related Peptide (CGRP) (83-119), rat Cat. No.: HY-P1462	Calcitonin Gene Related Peptide (CGRP) (83-119), rat TFA Cat. No.: HY-P1462A
Bioactivity:	Calcitonin Gene Related Peptide (CGRP) (83-119), rat is a 37 amino acid calcitonin family of neuropeptide, acts through calcitonin receptor-like receptor (CRLR).	Bioactivity: Calcitonin Gene Related Peptide (CGRP) (83-119), rat (TFA) is a 37 amino acid calcitonin family of neuropeptide, acts through calcitonin receptor-like receptor (CRLR).
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	Purity: 96.21% Clinical Data: No Development Reported Size: 500u g, 1 mg, 5 mg
CGRP anta	gonist 1 Cat. No.: HY-112262	HCGRP-(8-37) (Human α-CGRP (8-37)) Cat. No.: HY-P1014
Bioactivity:	CGRP antagonist 1 is a highly potent CGRP receptor antagonist with a ${\rm K_i}$ and ${\rm IC_{50}}$ of 35 and 57 nM, respectively.	Bioactivity: HCGRP-(8-37) is a human calcitonin gene-related peptide (hCGRP) fragment and also an antagonist of CGRP receptor.
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: 98.28% Clinical Data: No Development Reported Size: 500u g, 1 mg, 5 mg
MK-3207	Cat. No .: HY-10301	MK-3207 Hydrochloride Cat. No.: HY-10302
Bioactivity:	MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki value= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3. IC50 Value: 0.024 nM (Ki, Human CGRP) [1] In common with other CGRP receptor antagonists, MK-3207 displays lower affinity for	Bioactivity: MK-3207 (Hydrochloride) is a potent and orally bioavailable CGRP receptor antagonist with IC ₅₀ of 0.12 nM and K ₁ of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3.
Purity: Clinical Data: Size:	98.76%	Purity: 98.07% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Olcegepan (BIBN-4096; E		Cat. No. : HY-10095	5.	t hydrochloride ydrochloride; BIBN4096BS hydrochloride)	Cat. No.: HY-100954
Bioactivity:	Olcegepant is a potent and selective non-peptid the calcitonin gene-related peptide 1 (CGRP) IC ₅₀ of 0.03 nM and K _i of 14.4 pM for human C	1) receptor with	Bioactivity:	Olcegepant hydrochloride is the first potent an non-peptide antagonist of the calcitonin gen (CGRP1) receptor with IC ₅₀ of 0.03 nM and w pM for human CGRP.	e-related peptide 1
Purity: Clinical Data: Size:	99.32% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg	aronter	Purity: Clinical Data: Size:	99.31% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg	
Rat CGRP-((8-37)	Cat. No.: HY-P0209	Rimegepar (BMS-927711		Cat. No.: HY-1549
Bioactivity:	Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVP highly selective CGRP receptor antagonist.	PTNVGSEAF) is a	Bioactivity:	Rimegepant (BMS-927711) is a highly potent, gene-related peptide (CGRP) receptor antago value of 0.027 nM.	
Purity: Clinical Data: Size:	98.29% No Development Reported 500u g, 1 mg, 5 mg	vality to the second	Purity: Clinical Data: Size:	99.08% Phase 3 5 mg, 10 mg, 50 mg, 100 mg	ня () ())
Telcagepar (MK-0974)	nt	Cat. No.: HY-32709	Ubrogepar (MK-1602)	nt	Cat. No.: HY-1236
Bioactivity:	Telcagepant (MK-0974) is a calcitonin gene-re (CGRP) receptor antagonist with K ₁ s of 0.77 nN human and rhesus CGRP receptors, respectively	A and 1.2 nM for	Bioactivity:	Ubrogepant (MK-1602) is a novel oral calciton peptide receptor (CGRP) antagonist in develo treatment of migraine ^[1] .	
Purity: Clinical Data: Size:	99.07% Phase 3 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	
5120.					
β-CGRP, hι	ıman iRP; CGRP-II (Human))	Cat. No.: HY-P1548	<mark>β-CGRP, hι</mark> (Human β-CG	uman TFA iRP (TFA); CGRP-II (Human) (TFA))	Cat. No.: HY-P1548
β-CGRP, hι		cts via the RLR) and			les, acts via the .RLR) and



Cholecystokinin Receptor

CCK Receptor



Cholecystokinin (CCK) is a neuropeptide that affects growth rate in chickens by regulating appetite. CCK peptides exert their function by binding to two identified receptors, CCKAR and CCKBR in the GI tract and the brain, respectively, as well as in other organs. In mammals, CCK/CCKAR interactions affect a number of immunological parameters, including regulation of lymphocytes and functioning of monocytes.

CCK, also known as pancreozymin, is synthesized and secreted by enteroendocrine cells in the duodenum. The main function of CCK is to cause the release of digestive enzymes and bile from the pancreas and gallbladder, respectively. It also induces drug tolerance to opioids

HDAC (Histone deacetylase) ——

like morphine and heroin. Cholecystokinin (CCK) has strong bioactivity in the regulation of a number of cell activities.

Cholecystokinin Receptor Inhibitors & Modulators


CCK-A rece	ptor inhibitor 1	Cat. No.: HY-U00387	CCK-B Rece	eptor Antagonist 1	Cat. No.: HY-U00360
Bioactivity:	CCK-A receptor inhibitor 1 is a cholecystok receptor inhibitor with a binging IC₅₀ of 34		Bioactivity:	CCK-B Receptor Antagonist 1 is an antag cholecystokinin B (CCK-B) receptor, and reducing the secretion of gastric acid.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	~~~~ ° °	Purity: Clinical Data: Size:	99.04% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg	
Ceruletide			CHEMBL33	3994	
	erulein; FI-6934)	Cat. No.: HY-A0190	(FK-480)		Cat. No.: HY-U00363
Bioactivity:	Ceruletide, a biologically active decapeptide the skin of the Australian frog Hyla caerulea cholecystokinetic agent, and acts as a chole receptor agonist.	, is a potent	Bioactivity:	CHEMBL333994 is a potent and orally eff A (CCK-A) antagonist, with an IC ₅₀ of 0.6	
Purity: Clinical Data: Size:	99.96% No Development Reported 1 mg, 5 mg, 10 mg	aggigg. 487	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Gastrin-1, I	numan	Cat. No.: HY-P1097	Gastrin/CC	K antagonist 1	Cat. No.: HY-U00375
Bioactivity:	Gastrin-1, human is the endogenous peptid stomach, and increases gastric acid secretio cholecystokinin 2 (CCK2) receptor.	e produced in the	Bioactivity:	Gastrin/CCK antagonist 1 is an antagonis for the research of gastrointestinal disord	-
Purity: Clinical Data: Size:	98.41% No Development Reported 1 mg, 5 mg, 10 mg	DE OPVLEEEEAVONNDFAN,	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	
GI 181771		Cat. No.: HY-11076	Lorglumide (CR-1409 (soc	e sodium salt lium salt))	Cat. No. : HY-B1439F
Bioactivity:	GI 181771 is a cholecystokinin 1 receptor a for the treatment of obesity.	agonist investigated	Bioactivity:	Lorglumide sodium salt (CR-1409 sodium cholecystokinin (CCK) receptor antago	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg		Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	
Loxiglumid (CR-1505)	e	Cat. No.: HY-B2154	Mini Gastri	n I, human	Cat. No.: HY-P1593
Bioactivity:	Loxiglumide is a cholecystokinin (CCK-1) re antagonist.	eceptor	Bioactivity:	Mini Gastrin I, human is a shorter version consists of amino acids 5-17 of the paren with the CCK2i4svR .	
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	ч Ч Ч Ч Ч	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	LEEEEEAYGWMDF-NH

Nastorazep	bide		Proglumid	2	
(Z-360)		Cat. No.: HY-17617	J		Cat. No.: HY-B1330
Bioactivity:	Nastorazepide (Z-360) is a selective, oral 1,5-benzodiazepine-derivative gastrin/ch (CCK-2) receptor antagonist with potent activity.	nolecystokinin 2	Bioactivity:	Proglumide is a known cholecystokinin (CCK) antagonist.
Purity: Clinical Data: Size:	99.89% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.74% Launched 10mM x 1mL in DMSO, 100 mg	Г пусон С
Sograzepid	le		SR 146131		
(Netazepide; '	YF 476; YM-220)	Cat. No.: HY-14850			Cat. No.: HY-11077
Bioactivity:	Sograzepide (Netazepide;YF476) is a gas receptor (CCK2) antagonist.	trin/cholecystokinin 2	Bioactivity:	SR 146131 is a potent, orally available, and nonpeptide (cholecystokinin 1) receptor	
Purity: Clinical Data: Size:	98.01% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Contraction of the second seco	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	
Tarazepide					
Bioactivity:	Tarazepide is a potent and specific CCK - antagonist.	Cat. No.: HY-U00062			
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg				



CRFR

Corticotropin-releasing Factor Receptor



HDAC (Histone deacetylase)

CRFR (Corticotropin-releasing Factor Receptor), also known as corticotropin-releasing hormone receptor (CRHR), belongs to the G protein-coupled receptor family. There are 3 types of this recetpor, $CRF_{1'}$, CRF_{2} and CRF_{3} receptor. CRF_{1} receptor (CRF_{1} or $CRF_{1\alpha}$) is functionally coupled to adenylate cyclase and it belongs to the secretin-like, family B of GPCRs. CRF1 receptor has several splice variants (CRF_{1c} - CRF_{1m}) including $CRF_{1\beta}$. CRF_{2} receptor is a 411-amino acid protein with approximately 70% identity to the known $\ensuremath{\mathsf{CRF}}_1$ and it is functionally coupled to adenylate cyclase. The CRF_2 receptor has been shown to be expressed as three functional splice variants, the

 $CRF_{2\alpha}$ (411-413 amino acids), the $CRF_{2\beta}$ (431-438 amino acids) and the $CRF_{2\nu}$ (397 amino acids). CRF_{3} receptor is a 428-amino acid protein, which binds CRF with a 5-fold higher affinity than URO and SVG and is expressed in the pituitary gland, urophysis, and brain.

CRFR subserves central functions related to stress physiology, and also exerts peripheral actions relevant to cardiovascular, muscular, gastrointestinal, pancreatic, inflammatory, and neoplastic diseases.

CRFR Inhibitors & Modulators


CP 316311		Cat. No. : HY-14129	CP 376395		Cat. No. : HY-14130
Bioactivity:	CP 316311 is a potent and selective CRF1 rec with an IC₅₀ value of 6.8 nM.		Bioactivity:	CP 376395 is a potent and selective Cortice factor 1 (CRF1) receptor antagonist.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	99.53% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	HH N N
CRF, bovin (Corticotropi	e n Releasing Factor bovine)	Cat. No.: HY-P1533	CRF, bovin (Corticotropii	e TFA n Releasing Factor bovine (TFA))	Cat. No. : HY-P1533A
Bioactivity:	CRF, bovine is a potent agonist of CRF recep displaces [¹²⁵ I-Tyr]ovine CRF with a K _i of 3.5		Bioactivity:	CRF, bovine (TFA) is a potent agonist of CR displaces [¹²⁵ I-Tyr]ovine CRF with a K _i of 3	
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg		Purity: Clinical Data: Size:	96.50% No Development Reported 10mM x 1mL in Water, 500u g, 1 mg, 5 mg	$w_{\gamma_{s}^{\prime}},$
Emicerfont (GW876008)	· · · · · · · · · · · · · · · · · · ·	Cat. No.: HY-14367	NVS-CRF38	8	Cat. No.: HY-12339
Bioactivity:	Emicerfont is a corticotropin-releasing factor ${\bf CRF_1}$ receptor antagonist with an ${\bf IC_{50}}$ of 66		Bioactivity:	NVS-CRF38 is a novel corticotropin-releasi (CRF1) antagonist with low water solubility Target: CRF1 antagonist	· ·
Purity: Clinical Data: Size:	>98% Phase 2 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg, 100 mg	N N O N N O O
Pexacerfor (BMS-562086		Cat. No.: HY-12127	R121919 (NBI30775)		Cat. No.: HY-14127
Bioactivity:	Pexacerfont is a selective corticotropin-releas CRF_1 receptor antagonist with IC_{50} of 6.1±0 CRF $_1$ receptor.		Bioactivity:	R121919 is a potent small-molecule CRF1 with a \mathbf{K}_i of 2 to 5 nM for the CRF1 receptor 1000-fold weaker activity at the CRF2 receptor protein, or 70 other receptor types.	r and over
Purity: Clinical Data: Size:	>98% Phase 3 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	99.46% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg	
Urocortin I	I, human	Cat. No.: HY-P1752	Urocortin I	II, mouse	Cat. No. : HY-P1858
Bioactivity:	Urocortin II (human) is a selective endogenou of type-2 corticotropin-releasing factor (C For investigating the role of the CRF (2) recepting stive behavior ^[1] .	RF2) receptor.	Bioactivity:	Urocortin III, mouse is a corticotropin-relea CRF)-related peptide. Urocortin III preferen activates CRF-R2 ^[1] .	
Purity:	>98%		Purity:	>98%	

	human (Urocortin (human); Human uroco Iuman urocortin I)	rtin; Human Cat. No.: HY-P1295	Urocortin, (Urocortin (R	rat attus norvegicus); Rat urocortin;)	Cat. No.: HY-P1296
Bioactivity:	Urocortin, human, a 40-aa neuropeptide, act agonist of endogenous CRF_2 receptor, with and 0.5 nM for hCRF $_{1'}$ rCRF $_{2\alpha}$ and mCRF $_{2\beta}$	K _i s of 0.4, 0.3,	Bioactivity:	Urocortin, rat is a selective agonist of CRF \mathbf{K}_{js} of 0.32, 2.2, and 0.62 nM for hCRF $_{1'}$, rC $_{2\beta'}$ respectively.	
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg		Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	
Urotensin I (Catostomus		Cat. No.: HY-P1542	Verucerfor (GSK561679)		Cat. No.: HY-14875
Bioactivity:	Urotensin I is, 41-aa neuropeptide, acts as ar receptor with PEC_{50} s of 11.46, 9.36 and 9.89 ₁ , human CRF ₂ and rat CRF _{2α} receptors in C K ₁ s of 0.4, 1.8, and 5.7 nM for hCRF ₁ , rCRF ₂	5 for human CRF CHO cells, and	Bioactivity:	Verucerfont is a corticotropin-releasing f CRF1) antagonist with IC₅₀s of ~6.1, >100 for CRF1, CRF2, and CRF-BP, respectively.	
Purity: Clinical Data:	>98% No Development Reported 500u g, 1 mg, 5 mg	carreat resonances and resonances	Purity: Clinical Data: Size:	99.94% Phase 2 10mM x 1mL in DMSO,	



CXCR

CXC chemokine receptors;C-X-C motif chemokine receptors



CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as CXCL12 (or SDF-1)

and, as with CCR5, is utilized by HIV-1 to gain entry into target cells. The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.

CXCR Inhibitors & Modulators

ALX 40-4C	Cat. No.: HY-P7061	ALX 40-4C	Trifluoroacetate Cat. No.: HY-P7061A
Bioactivity: Purity: Clinical Data: Size:	ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4 , inhibits SDF-1 from binding CXCR4 with a K _i of 1 µM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagon >98% No Development Reported 1 mg, 5 mg	Bioactivity: Purity: Clinical Data Size:	ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4 , inhibits SDF-1 from binding CXCR4 with a K _i of 1 µM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as 98.15% No Development Reported 1 mg, 5 mg
AMD 3465			i hexahydrobromide
(GENZ-644494 Bioactivity:	4) Cat. No.: HY-15971A AMD 3465 is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12 ^{AF647} to CXCR4, with IC ₅₀ s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC ₅₀ : 1-10 nM), but has	Bioactivity:	94 hexahydrobromide) Cat. No.: HY-15971 AMD 3465 hexahydrobromide is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12 AF647 to CXCR4, with IC ₅₀ of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC ₅₀
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	98.79% : No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg
AMG 487	Cat. No. : HY-15319	ATI-2341	Cat. No.: HY-P0172
Bioactivity:	AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC ₅₀ s of 8.0 and 8.2 nM, respectively.	Bioactivity:	ATI-2341 is a CXCR4 agonist, induces CXCR4-dependent calcium flux, with an EC₅₀ of 194 nM in CCRF-CEM cells. ATI-2341 is also a potent and efficacious mobilizer of bone marrow hematopoietic cells ^[1] . >98%
Purity: Clinical Data: Size:	99.65% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	296% : No Development Reported 1 mg, 5 mg, 10 mg
AZD-5069	Cat. No. : HY-19855	AZD8797	Cat. No.: HY-13848
Bioactivity:	AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.	Bioactivity:	AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with K ₁ s of 3.9 and 2800 nM, respectively.
Purity: Clinical Data: Size:	99.92% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.22% : Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Baohuoside (Icariin-II; Icar		Burixafor l (TG-0054 hyd	hydrobromide drobromide) Cat. No.: HY-19867A
Bioactivity:	Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4 , downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.	Bioactivity:	Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well water soluble anti-angiogenic drug that is of potential value in treating choroid neovascularization ^[1] . Burixafor
Purity: Clinical Data: Size:	98.96% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	Purity: Clinical Data Size:	hydrobromide (TG-0054 hydrobromide) mobilizes mesenchymal సరిగిని. : No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

CXCR2-IN-	1 Cat. No.: HY-101022	CXCR7 mo	dulator 2 Cat. No.: HY-112154
Bioactivity:	CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonists with a pIC₅₀ of 9.3.	Bioactivity:	CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (CXCR7), with a K _i of 13 nM.
Purity: Clinical Data: Size:	98.81% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
Danirixin (GSK1325756)	Cat. No. : HY-19768	E6130	Cat. No. : HY-107456
Bioactivity:	Danirixin is a selective, and reversible CXCR2 antagonist, with IC₅₀of12.5 nM for CXCL8.	Bioactivity:	E6130 is an orally available and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.
Purity: Clinical Data: Size:	98.21% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
IT1t	Cat. No.: HY-101458	IT1t dihydr	rochloride Cat. No.: HY-101458A
Bioactivity:	IT1t is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC_{50} of 2.1 nM.	Bioactivity:	IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC_{50} of 2.1 nM.
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.09% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
JMS-17-2	Cat. No.: HY-123918	LIT-927	Cat. No. : HY-112709
Bioactivity:	JMS-17-2 is a potent and selective $\textbf{CX3CR1}$ antagonist with an $\textbf{IC}_{\textbf{50}}$ of 0.32 nM $^{[1]}.$	Bioactivity:	LIT-927 is a locally and orally active CXCL12 neutraligand with anti-inflammatory effect, with a K _i of 267 nM for CXCL12 binding to its specific receptor CXCR4 ^[1] .
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg	Purity: Clinical Data: Size:	99.66% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
LY2510924	Cat. No.: HY-12488	Mavorixafo (AMD-070)	or Cat. No.: HY-50101
Bioactivity:	LY2510924 is a potent and selective CXCR4 antagonist that blocks SDF-1 binding to CXCR4 with an IC₅₀ of 0.079 nM.	Bioactivity:	Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC ₅₀ value of 13 nM against CXCR4 ¹²⁵ I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells
Purity: Clinical Data: Size:	99.91% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98%


	r trihydrochloride ihydrochloride))	Cat. No.: HY-50101A	Motixaforti (BKT140 (4-flu	ide uorobenzoyl); BL-8040; TF14016)	Cat. No.: HY-P0173	
Bioactivity:	Mavorixafor trihydrochloride (AMD-070 trihy potent, selective and orally available CXCR4 an IC₅₀ value of 13 nM against CXCR4 ¹²⁵ I-S inhibits the replication of T-tropic HIV-1 (NL-	antagonist, with DF binding, and also	Bioactivity:	Motixafortide (BKT140 4-fluorobenzoyl) is a nove antagonist with an \mathbf{IC}_{50} vakue of 1 nM.	el CXCR4	
Purity: Clinical Data: Size:	99.14% Phase 1 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg	H-a H-a	Purity: Clinical Data: Size:	99.19% Phase 3 1 mg, 5 mg, 10 mg, 25 mg	e boorden to possive a constante de co Desente may constante a constante de co	
MSX-122		Cat. No.: HY-13696	Navarixin (SCH 527123;	MK-7123)	Cat. No.: HY-1019	
Bioactivity:	MSX-122 is a partial antagonist of CXCR4 , ir CXCR4/CXCL12 actions, with an IC₅₀ of 10 r anti-inflammatory and anti-metastatic activit	hibiting nM; MSX-122 has	Bioactivity:	Navarixin is a potent, allosteric antagonist of bot and CXCR2 , with K _d values of 41 nM for cynomo 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cy	h CXCR1 Igus CXCR1 and	
Purity: Clinical Data: Size:	98.29%		Purity: Clinical Data: Size:	CXCR2, respectivelly. 98.62%		
NBI-74330		Cat. No.: HY-15320	Nicotinami	de N-oxide	Cat. No.: HY-10140	
Bioactivity:	NBI-74330 is a potent antagonist for CXCR3 potent inhibition of (125 I)CXCL10 and (125 I) binding with K _i of 1.5 and 3.2 nM, respective	, and exhibits CXCL11 specific	Bioactivity:			
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.45% No Development Reported 10mM x 1mL in DMSO, 100 mg	"D _f u	
Plerixafor (AMD 3100; J	M3100; SID791)	Cat. No.: HY-10046		octahydrochloride (AMD3100 (octahydroch hydrochloride); SID791 (octahydrochloride))	loride); Cat. No.: HY-5091	
Bioactivity:	Plerixafor (AMD 3100) is a selective CXCR4 a IC₅₀ of 44 nM.	intagonist with an	Bioactivity:	Plerixafor octahydrochloride (AMD3100 octahyd selective CXCR4 antagonist with an IC ₅₀ of 44 nl		
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in Ethanol, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg		
Reparixin (Repertaxin; E	DF 1681Y)	Cat. No.: HY-15251	Reparixin L (Repertaxin L-	•	Cat. No.: HY-15252	
Bioactivity:	Reparixin is a non-competitive allosteric inhi chemokine receptors CXCR1 and CXCR2 act 1 and 100 nM, respectively.		Bioactivity:	Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.		
Purity: Clinical Data: Size:	99.98% Phase 3 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 2	200 mg	Purity: Clinical Data: Size:	99.97% Phase 3 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg		

SB225002			SCH 54673	8	
		Cat. No.: HY-16711			Cat. No.: HY-1001
Bioactivity:	SB225002 is a potent and selective CXCR2 anta IC ₅₀ of 22 nM.	igonist with an	Bioactivity:	SCH 546738 is a novel, potent and non-co antagonist, the affinity constant (${\rm K_i}$) of SC	H 546738 binding
				to human CXCR3 receptor is determined to experiments.	o be 0.4 nM in multiple
Purity:	99.58%		Purity:	99.20%	
Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg	o ^{NU} CU ^{OH} b ^{BC}	Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	ng transformer and the second se
SCH 56370	5		SRT3109		
		Cat. No.: HY-10011			Cat. No.: HY-1546
Bioactivity:	SCH 563705 is a potent and orally available CX antagonist, with $\rm IC_{50}$ s of 1.3 nM, 7.3 nM and $\rm K_{1}$ nM, respectively.		Bioactivity:	SRT3109 is an antagonist of CXCR2 , with a used in the research of chemokine mediat	**
Purity: Clinical Data: Size:	95.34% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	99.82% No Development Reported 10mM x 1mL in DMSO, 5 mg	
SRT3190			TAK-779		
		Cat. No.: HY-13021	(Takeda 779)		Cat. No.: HY-1340
Bioactivity:	SRT3190 is an antagonist of CXCR2 , used in the research of chemokine mediated diseases.		Bioactivity:	TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3 , with a K_i of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1 , with EC ₅₀	
Purity: Clinical Data:	99.61% No Development Reported	\$ \$\$	Purity: Clinical Data:	99.73% No Development Reported	~ ^{aQ} .
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg	HO CH H O NO	Size:	10mM x 1mL in DMSO, 5 mg, 10 mg	a f
UNBS5162			USL311		
		Cat. No.: HY-16509			Cat. No.: HY-11424
Bioactivity:	UNBS5162 is a pan-antagonist of CXCL chemo with anti-tumor activity.	kine expression,	Bioactivity:	USL311 is a selective CXCR4 antagonist, w activity. USL311 prevents the binding of st factor-1 (SDF-1 or CXCL12) to CXCR4 $^{[1]}$.	
Purity:	99.75%	`N_	Purity:	99.97%	
	No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	O NH2		No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg)-O-Q _Q işt
WZ811		C + N - UV 15470			
Bioactivity:	WZ811 is a potent CXCR4 antagonist, effective TN14003 binding to CXCR4 , with an EC₅₀ of 0.				
Purity: Clinical Data: Size:	99.74% No Development Reported 10mM x 1mL in DMSO,	Control of the			



Dopamine Receptor

HDAC Inhibitor: Vorinostat (SAHA)



HDAC (Histone deacetylase)

Dopamine Receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). The neurotransmitter dopamine is the primary endogenous ligand for dopamine receptors. Dopamine receptors are implicated in many neurological processes, including motivation, pleasure, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling. Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. Thus, dopamine receptors are common neurologic drug targets; antipsychotics are often dopamine receptor antagonists while psychostimulants are typically indirect agonists of

dopamine receptors. There are at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5. The D1 and D5 receptors are members of the D1-like family of dopamine receptors, whereas the D2, D3 and D4receptors are members of the D2-like family.

Dopamine Receptor Inhibitors & Modulators

(+)-Dihydre (DAR-0100 hy	exidine hydrochloride drochloride)	Cat. No.: HY-101299	(+)-PD 128	907 hydrochloride Cat. No.: HY-	11000
Bioactivity: Purity: Clinical Data: Size:	(+)-Dihydrexidine hydrochloride is a dopamir agonist with an EC ₅₀ of 72± 21 nM. >98% No Development Reported 250 mg, 500 mg	The D1 receptor	Bioactivity: Purity: Clinical Data: Size:	(+)-PD 128907 hydrochloride is a selective dopamine D_2/D_3 receptor agonist, with K_1 s of 1.7, 0.84 nM for human and rat D $_3$ receptors, 179, 770 n M for human and rat D $_3$ receptors, respectively. 98.83% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	
(±)-Methot	rimeprazine (D6)		5-HT6/7 ar	itagonist 1	
(dl-Methotrin	eprazine D6)	Cat. No.: HY-19489S		Cat. No.: HY-	10162
Bioactivity:	(±)-Methotrimeprazine (D6) is the deuterium Methotrimeprazine, which is a D3 dopamine a receptor antagonist.		Bioactivity:	5-HT6/7 antagonist 1 is a multifunctional ligand that antagonizes 5-HT6/7/2A and D2 receptors, without interacting with M1 receptors and hERG channels.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg		Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	° F F
A-381393		Cat. No .: HY-116941	A-437203 (Lu201640; A	37203) Cat. No.: HY-U	U0018
Bioactivity:	A-381393 is a potent, selective, brain penetral D_4 receptor antagonist, with K_1 s of 1.5, 1.9 ar human dopamine $D_{4,4'} D_{4,2'}$ and $D_{4,7}$ recept respectively, >2700-fold selectivity over $D_{1'} D_{4'}$	nd 1.6 nM for tor,	Bioactivity:	A-437203 is a selective D_3 receptor antagonist with K_i of 71, 1.6, and 6220 nM for D $_2$, D $_3$, and D $_4$ receptors, respectively.	
Purity: Clinical Data: Size:	99.96% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg	
Abaperidor	ne	Cat. No. : HY-101619	ABT-670	Cat. No.: HY	/-1948
Bioactivity:	Abaperidone is a potent antagonist of 5-HT_{2/} dopamine D₂ receptor with IC₅₀s of 6.2 and		Bioactivity:	ABT-670 is a selective, oral bioavailable agonist of dopamine D₄ receptor , with EC_{50} of 89 nM, 160 nM, and 93 nM for humanD ₄ , ferretD ₄ , and ratD ₄ , respectively.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	-ota-roje	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	n''Q v ^M
Adoprazine (SLV313)		Cat. No.: HY-14782	Alizapride	hydrochloride Cat. No.: HY-4	A0125
Bioactivity:	Adoprazine, a potential atypical antipsychotic D2 receptor antagonist and 5-HT1A receptor		Bioactivity:	Alizapride hydrochloride is a dopamine receptor antagonist with prokinetic and antiemetic effects which can also be used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.	
Purity: Clinical Data: Size:	98.13% Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg		Purity: Clinical Data: Size:	99.95% No Development Reported 10mM x 1mL in DMSO, 50 mg, 100 mg	

Amisulprid (DAN 2163)	Cat. No.: HY-14545		le hydrochloride ydrochloride) Cat. No.: HY-14545A
Bioactivity:	Amisulpride is a dopamine D_2/D_3 receptor antagonist with K_i s of 2.8 and 3.2 nM for human dopamine D_2 and D_3 , respectively.	Bioactivity:	Amisulpride hydrochloride is a dopamine D_2/D_3 receptor antagonist with K_i s of 2.8 and 3.2 nM for human dopamine D_2 and D_3 , respectively.
Purity: Clinical Data: Size:	98.0% Launched 100 mg, 200 mg, 500 mg	Purity: Clinical Data: Size:	>98% Launched 100 mg, 200 mg, 500 mg
Asenapine	nydrochloride	Azaperone	
	Cat. No.: HY-16567	(R-1929)	Cat. No.: HY-B1470
Bioactivity: Purity:	Asenapine maleate, an antipsychotic, is a 5-HT (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and Dopamine (D ₂ , D ₃ , D ₄) receptor antagonist with K ₁ values of 0.03-4.0 nM for 5-HT and 1.3, 0.42, 1.1 nM for Dopamine receptor, respectively. 99.39%	Bioactivity: Purity:	Azaperone (R-1929) acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic drug with sedative and antiemetic effects, which is used mainly as a tranquilizer in veterinary medicine. 99.58%
Clinical Data: Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Clinical Data: Size:	10mM x 1mL in DMSO, 100 mg, 500 mg
Benzamide	Derivative 1 Cat. No.: HY-U00415	Blonanseri (AD-5423)	n Cat. No.: HY-13575
Bioactivity:	Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be useful in treatment of gastrointestinal disorders.	Bioactivity:	Blonanserin(AD-5423) is a D2/5-HT2 receptor antagonist, atypical antipsychotic. Target: D2 receptor; 5-HT2 receptor Blonanserin(AD-5423) is a relatively new atypical antipsychotic for the treatment of schizophrenia. Blonanserin belongs to a series of 4-phenyl-2-(1-piperazinyl)pyridines and
Purity: Clinical Data: Size:	>98% No Development Reported	Purity: Clinical Data: Size:	99.77%
BP 897	Cat. No.: HY-106660	Brexpipraz (OPC-34712)	
Bioactivity:	BP 897 is a potent and selective dopamine D3 receptor agonist, and a weak dopamine D2 receptor antagonist, with K ₁ s of 0.92 nM and 61 nM for D3 and D2 receptors, and shows	Bioactivity:	Brexpiprazole is a partial agonist of human 5-HT1A and dopamine receptor with K _i s of 0.12 nM and 0.3 nM,
	low affinities at D1 and D4 receptors (K _i s, 3 and 0.3		respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K _i of 0.47 nM.
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Size:	99.38% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg
Bromocript (CB-154)	ine mesylate Cat. No.: HY-12705A	Bromoprid	le Cat. No.: HY-B1164
Bioactivity:	Bromocriptine mesylate is a potent dopamine D2/D3 receptor agonist, which binds D2 dopamine receptor with pK _i of 8.05±0.2.	Bioactivity:	Bromopride is a dopamine antagonist with prokinetic properties widely used as an antiemetic.
Purity: Clinical Data: Size:	99.98% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg	Purity: Clinical Data: Size:	>98% Launched 5 mg, 10 mg, 50 mg

Cabergolin (FCE-21336)	e	Cat. No. : HY-15296	Cariprazine (RGH-188)	2	Cat. No. : HY-1476
Bioactivity:	Cabergoline is an ergot derived-dopamine agonist that has high affinity for D_2 , D_3 , ar receptors (K_1 =0.7, 1.5, and 1.2, respectively	D ₂ -like receptor Id 5-HT_{2B}	Bioactivity:	Cariprazine is a novel antipsychotic drug exhibits high affinity for the D_3 (K_i =0.08 K_i =0.49 nM) receptors, and moderate affi	candidate that 5 nM) and D₂ (
Purity: Clinical Data: Size:	99.90%	of the second se	Purity: Clinical Data: Size:	receptor (K_i= 2.6 nM). 99.35% Launched 5 mg, 10 mg, 50 mg, 100 mg	And
•	e hydrochloride		CGP 25454	A	
(RGH188 hyd Bioactivity:	Cariprazine hydrochloride is a novel antips candidate that exhibits high affinity for the nM) and \mathbf{D}_2 (\mathbf{K}_i =0.49 nM) receptors, and r	D ₃ (K _i =0.085	Bioactivity:	CGP 25454A is a novel and selective pres- autoreceptor antagonist.	Cat. No.: HY-10045 /naptic dopamine
Purity: Clinical Data: Size:	for the 5-HT_{1A} receptor (K _i =2.6 nM). 99.89% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	م م بالم سر	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg	
Chlorprom	azine D6 hydrochloride	Cat. No. : HY-B0407AS	Chlorprom	azine hydrochloride	Cat. No.: HY-B0407
Bioactivity:	Chlorpromazine D6 hydrochloride is the de Chlorpromazine. Chlorpromazine is an inhi receptor, 5-HT receptor, potassium channe	euterium labeled bitor of dopamine	Bioactivity:	Chlorpromazine Hydrochloride is an anta dopamine D2, 5HT2A, potassium chann channel. Chlorpromazine binds with D2 a nM and 8.3 nM, respectively.	gonist of the rel and sodium
Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	D D D D D D D D D D D D D D D D D D D	Purity: Clinical Data: Size:	99.83% Launched 1 g, 5 g	
Chlorproth	ixene	Cat. No. : HY-B0274	Clebopride	emalate	Cat. No.: HY-B1613
Bioactivity:	Chlorprothixene has strong binding affiniti histamine receptors, such as D1, D2, D3, D and 5-HT7, with Ki of 18 nM, 2.96 nM, 4.56 9.4 nM, 3 nM and 5.6 nM, respectively.	es to dopamine and 5, H1, 5-HT2, 5-HT6	Bioactivity:	Clebopride malate is a dopamine antagor antiemetic and prokinetic properties used gastrointestinal disorders.	nist drug with
Purity: Clinical Data: Size:	99.52% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg	C S C I	Purity: Clinical Data: Size:	99.46% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	a g f y y y y y y y y y y y y y y y y y y
Clocapram	ine ne; 3-Chlorocarpipramine)	Cat. No. : HY-B2073		ine hydrochloride hydrate	Cat. No.: HY-B2073.
Bioactivity:	Clocapramine is an antagonist of the D ₂ , 5 receptors.		Bioactivity:	Clocapramine hydrochloride hydrate is ar D_2 and 5-HT _{2A} receptors.	
Purity: Clinical Data:	>98% Launched		Purity: Clinical Data:	>98% No Development Reported	apa

Clomipram	ine hydrochloride	Cat. No.: HY-B0457	Clozapine (HF 1854)	с	at. No.: HY-145
Bioactivity:	Clomipramine HCl is a serotonin transporter (S norepinephrine transporter (NET) dopamine tra blocker with Ki of 0.14, 54 and 3 nM, respective 5-HT Receptor Clomipramine hydrochloride (A	ERT), ansporter (DAT) ely. Target: nafranil) is a	Bioactivity:	Clozapine (HF 1854) is an antipsychotic used to trea schizophrenia. Clozapine is a potent antagonist of d and a number of other receptors, with a K_i of 9.5 nN receptor.	t opamine
Purity: Clinical Data: Size:	hydrochloride salt of clomipramine which is a s 99.72% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg		Purity: Clinical Data: Size:	99.97% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg, 5 g	
Dexpramip	exole		Dexpramip	exole dihydrochloride ((R)-Pramipexole	
((R)-Pramipex	ole; R-(+)-Pramipexole; KNS-760704)	Cat. No.: HY-17355B	(dihydrochlor	ide);) Cat	t. No.: HY-1735
Bioactivity:	Dexpramipexole(KNS-760704), also known as f is a neuroprotective agent and weak non-ergo agonist. IC50 Value:		Bioactivity:	Dexpramipexole dihydrochloride, also known as R-(+)-Pramipexole, is a neuroprotective agent and v non-ergoline dopamine agonist. IC50 Value: Target: Receptor Dexpramipexole has been found to have n effects and is being investigated for treatment of an	Dopamine europrotective
Purity: Clinical Data: Size:	>98% Phase 3 10 mg, 50 mg	∼~ ^{tt} S_wes	Purity: Clinical Data: Size:	98.01% Phase 3 10mM x 1mL in DMSO, 10 mg, 50 mg	H,ci H,c
Dicarbine		Cat. No.: HY-127086	Domperido (R33812)		at. No.: HY-B04
Bioactivity:	Dicarbine blocks dopamine receptors in vario and prevents the depression of the conditioner reflexes caused by stimulation of the mesencer the reticular formation. Dicarbine could be use patients with schizophrenia and alcoholic psycl	d defence phalic portion of d to treat	Bioactivity:	Domperidone is a dopamine blocker and an antidop reagent.	paminergic
Purity: Clinical Data: Size:	>98% No Development Reported		Purity: Clinical Data: Size:	99.52% Launched 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg	mg
Dopamine ASL279)	hydrochloride	Cat. No.: HY-B0451A	Dopamine	serotonin antagonist-1	at. No.: HY-421
Bioactivity:	Dopamine HCl is a catecholamine neurotransm wide variety of animals,And a dopamine D1-5 Target: Dopamine Receptor Dopamine (or 3,4-dihydroxyphenethylamine) is a neuroendod	nitter present in a receptors agonist.	Bioactivity:	Dopamine serotonin antagonist-1 is a dual dopami serotonin receptor antagonist with K _i s of 200, 2500 84, 40 nM for dopamine D1, D2,D4, and serotonin S respectively.	ne and , 420, 39,
Purity: Clinical Data: Size:	in the catecholamine and phenethylamine fam 98.0% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	ilies that plays a	Purity: Clinical Data: Size:	99.79% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	
Droperidol			Fenoldopa	n	
Dehydrobenz	zperidol)	Cat. No.: HY-B1240	(SKF 82526)	C	at. No.: HY-B07
3ioactivity:	Droperidol is a Dopamine-2 Receptor Antagon	iist.	Bioactivity:	Fenoldopam(SKF 82526) is a drug and synthetic ben derivative which acts as a selective D1 receptor part agonist.	
Purity: Clinical Data: Size:	99.29% Launched 10mM x 1mL in DMSO,	ja.	Purity: Clinical Data: Size:	>98% Launched 10 mg	HO

Fenoldopai (Fenoldopam	n mesylate methanesulfonate; SKF-82526 mesylate)	Cat. No.: HY-B0735A	Fluphenazi	ne dihydrochloride	Cat. No.: HY-A008
Bioactivity:	Fenoldopam(SKF 82526) mesylate is a drug an benzazepine derivative which acts as a selectiv partial agonist.		Bioactivity:	Fluphenazine dihydrochloride is a phenothiazir D2DR inhibitor; used to deliver Fluphenazine to systems in studies probing the effects and met this commonly used dopamine antagonist.	biological
Purity: Clinical Data: Size:	99.85% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	но но но 	Purity: Clinical Data: Size:	99.96% Launched 100 mg	#8
Foscarbido (Carbidopa 4'	pa -monophosphate)	Cat. No. : HY-109131	Foslevodor (Dopa 4-Phos	Da phate; 3-Hydroxy-O-phosphono-L-tyrosine)	Cat. No.: HY-109133
Bioactivity:	Foscarbidopa (Carbidopa 4'-monophosphate) Carbidopa, acts as a dopamine receptor agor	is a prodrug of	Bioactivity:	Foslevodopa is a dopamine receptor agonist	
Purity: Clinical Data: Size:	>98% No Development Reported		Purity: Clinical Data: Size:	>98% No Development Reported	H0, ^R 0, NH2
GSK163090)	Cat. No. : HY-14348	GSK598809)	Cat. No.: HY-19654
Bioactivity:	GSK163090 is a potent, selective, and orally ac receptor antagonist with pKi of 9.4/8.5/9.7, an 5-HT1A/B/D, and dopamine D2/D3, respective	ctive 5-HT1A/B/D id 6.3/6.7 for	Bioactivity:	GSK598809 is a potent and selective dopamine (DRD3) antagonist, with a pK _i of 8.9.	
Purity: Clinical Data: Size:	99.95% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.73% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	the start
Haloperido	I	Cat. No.: HY-14538	Haloperido	I D4	Cat. No. : HY-14538
Bioactivity:	Haloperidol is a potent dopamine D2 recepto widely used as an antipsychotic.	or antagonist,	Bioactivity:	Haloperidol D4 is deuterium labeled haloperido latter is a potent dopamine D2 receptor antag	
Purity: Clinical Data: Size:	99.72% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	, 0 ² ~0 ⁰	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	يلو محمد تي
Haloperido	I D4'	Cat. No. : HY-1453851	Haloperido	l hydrochloride	Cat. No.: HY-14538/
Bioactivity:	Haloperidol D4' is deuterium labeled haloperid latter is a potent dopamine D2 receptor anta	dol, and the	Bioactivity:	Haloperidol hydrochloride is a potent dopami n antagonist, widely used as an antipsychotic.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg		Purity: Clinical Data: Size:	>98% Launched 100 mg, 500 mg	, C ² ~ C ² w

Iloperidone (HP 873)	. Cat. No. : HY-17410	Iloperidone (HP 873 hydr	e hydrochloride ochloride) Cat. No.: HY-174104
Bioactivity:	Iloperidone(HP 873) is a D2/5-HT2 receptor antagonist, which is an atypical antipsychotic for the treatment of schizophrenia symptoms.	Bioactivity:	Iloperidone (hydrochloride) is a D(2)/5-HT(2) receptor antagonistis, which is an atypical antipsychotic for the treatment of schizophrenia symptoms.
Purity: Clinical Data: Size:	99.93% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg, 100 mg
L-DOPA		Levosulpiri	
(Levodopa; 3,	4-Dihydroxyphenylalanine) Cat. No.: HY-N0304	(RV-12309; S-	-(-)-Sulpiride) Cat. No.: HY-B1059
Bioactivity:	L-DOPA is a natural form of DOPA used in the treatment of Parkinson's disease. L-DOPA is the precursor of dopamine and product of tyrosine hydroxylase. Target: Dopamine Receptor L-DOPA (L-3,4-dihydroxyphenylalanine) is a chemical that is made and used as part of the normal biology of humans, some	Bioactivity:	Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic drug of the benzamide class.
Purity: Clinical Data: Size:	>98% Launched 200 mg, 1 g	Purity: Clinical Data: Size:	99.99% Launched 10mM x 1mL in DMSO, 100 mg
lumatepero (ITI-007)	one Tosylate Cat. No.: HY-19733	Lurasidone (SM-13496)	Cat. No. : HY-B00324
Bioactivity: Purity: Clinical Data: Size:	Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM). IC50 value: 0.54 nM (Ki, for 5-HT2A receptor) Target: 5-HT2A receptor Lumateperone also possesses 99.21% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Bioactivity: Purity: Clinical Data: Size:	Lurasidone (SM-13496) is an antagonist of both dopamine D_2 and 5 -HT ₇ with IC_{50} s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5 -HT _{1A} receptor with an IC_{50} of 6.75 nM. 99.33% Launched 10 mg, 50 mg, 100 mg
	Hydrochloride ydrochloride)) Cat. No.: HY-B0032	Metoclopra	amide Cat. No.: HY-1738
Bioactivity: Purity: Clinical Data: Size:	Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an antagonist of both dopamine D₂ and 5-HT₇ with IC₅₀ s of 1.68 and 0.495 nM, respectively. Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is also a partial agonist 99.87% Launched 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	Bioactivity: Purity: Clinical Data: Size:	10mM x 1mL in DMSO,
	amide hydrochloride hydrate nide monohydrochloride monohydrate) Cat. No.: HY-17382A	Molindone (EN-1733A)	100 mg, 500 mg • hydrochloride Cat. No.: HY-B1017
Bioactivity: Purity:	Metoclopramide hydrochloride hydrate is a dopamine D2 antagonist that is used as an antiemetic. IC50 Value: Target: D2 Receptor Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In 99.94%	Bioactivity: Purity:	Molindone is a therapeutic antipsychotic, used in the treatment of schizophrenia, works by blocking the effects of dopamine in the brain, leading to diminished psychoses. 99.92%
Clinical Data: Size:		Clinical Data: Size:	H

NEO 376 (SPI-376)	Cat. No. : HY-101583	Neuromed (Neuromedin	in N N (rat, mouse, porcine, canine))	Cat. No.: HY-P007
Bioactivity:	NEO 376 is a selective modulator of 5-HT1 receptor , GABA receptor and dopamine receptor , with anti-psychotic actively.	Bioactivity:	Neuromedin N is a potent modulator of dop agonist binding in rat neostriatal membranes	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	99.91% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg	
NMI 8739	Crt. No. (1)/ 101740	Nomifensir		Cot No - UV D111
	Cat. No.: HY-101540	((±)-Nomifen		Cat. No.: HY-B111
Bioactivity:	NMI 8739 is a dopamine D₂ autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine.	Bioactivity:	Nomifensine is a norepinephrine-dopamine r increases the amount of synaptic norepineph available to receptors by blocking the dopam norepinephrine reuptake transporters.	rine and dopamine
Purity: Clinical Data: Size:	>98% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg	Purity: Clinical Data: Size:	99.24% No Development Reported 10mM x 1mL in DMSO, 50 mg, 100 mg	NH2 N
Nomifensir		NRA-0160		
((±)-Nomifens				Cat. No.: HY-10164
Bioactivity: Purity: Clinical Data: Size:	Nomifensine maleate is a selective inhibitor of dopamine uptake, used in adult attention deficit disorder. 98.14% No Development Reported 10mM x 1mL in DMSO, 50 mg, 100 mg	Bioactivity: Purity: Clinical Data: Size:	NRA-0160 is a selective dopamine D4 recep with a K_i value of 0.48 nM and with negligible dopamine D2 receptor (K_i : >10000 nM), D3 K_i : 39 nM), rat 5-HT2A receptor (K_i : 180 nM >98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	e affinity for 3 receptor (
Nuciferine	Cat. No.: HY-N0049	Ocaperidor (R79598)	ne	Cat. No.: HY-10109
Bioactivity: Purity: Clinical Data: Size:	Nuciferine is an antagonist at 5-HT_{2A} (IC_{50} =478 nM), 5-HT_{2C} (IC_{50} =131 nM), and 5-HT_{2B} (IC_{50} =1 μ M), an inverse agonist at 5-HT₇ (IC_{50} =150 nM), a partial agonist at D₂ (EC₅₀ =64 nM), D₅ (EC₅₀ =2.6 μ M) and 5-HT₆ (EC₅₀ = 99.66% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	Bioactivity: Purity:	Ocaperidone is an effective antipsychotic age potent 5-HT ₂ and dopamine D_2 antagonist, agonist, with K _i s of 0.14 nM, 0.46 nM, 0.75 nM nM for 5-HT ₂ , a ₁ -adrenergic receptor, dopa 98.55% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	ent, acting as a and a 5-HT_{1A} M, 1.6 nM and 5.4
Org-10490	Cat. No.: HY-U00077		ne hydrobromide opamine hydrobromide; 6-OHDA hydrobrom	ide)Cat. No. : HY-B1081
Bioactivity:	Org-10490 is an antagonist of dopamine D1 receptor and Bioactivity : Oxidopamine (hydrobromine D2 receptor , used for the treatment for neurotransmitter dopam		Oxidopamine (hydrobromide), an antagonist neurotransmitter dopamine, is a widely use that selectively destroys dopaminergic neuro	ed neurotoxin
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g	HO, OH HO H-Br

Paliperidon (9-hydroxyrisp		Cat. No.: HY-A0019	Pardoprun (SLV-308; DU		Cat. No.: HY-14958
Bioactivity: Purity: Clinical Data: Size:	Paliperidone (9-hydroxyrisperidone is a dopan the atypical antipsychotic class of medications 99.09% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg		Bioactivity: Purity: Clinical Data: Size:	Pardoprunox(SLV-308) is a novel partial dop receptor agonist and serotonin 5-HT1A rece (pKi = 8.1) and D3 receptor (pKi = 8.6) parti 50% and 67%, respectively) and 5-HT1A rec full agonist (IA = 100%); also binds to D4 (p >98% Phase 3 5 mg, 10 mg, 50 mg, 100 mg	ptor agonist; D2 al agonist (IA = eptor (pKi = 8.5)
	ox hydrochloride rochloride; DU-126891 hydrochloride)	Cat. No.: HY-14958A	PD-168077	maleate	Cat. No. : HY-21098A
Bioactivity:	Pardoprunox hydrochloride is a novel partial d D3 receptor agonist and serotonin 5-HT1A rec (pKi = 8.1) and D3 receptor (pKi = 8.6) partial a 5-HT1A receptor (pKi = 8.5) full agonist.	opamine D2 and eptor agonist, D2	Bioactivity:	PD-168077 maleate is a selective dopamine agonist, with a K_i of 9 nM.	
Purity: Clinical Data: Size:	98.89% Phase 3 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	98.44% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	w _{ol} onia
Pentiapine (CGS 10746)		Cat. No.: HY-100143	Pergolide r (Pergolide me	nesylate ethanesulfonate; LY127809)	Cat. No. : HY-13720A
Bioactivity: Purity: Clinical Data: Size:	Pentiapine is a novel dopamine release inhibi >98% No Development Reported 1 mg, 5 mg, 10 mg		Bioactivity: Purity: Clinical Data: Size:	Pergolide Mesylate is an antiparkinsonian at functions as a dopaminergic agonist. Target Pergolide mesylate (trade name Permax) is a dopamine receptor agonist used in some co treatment of Parkinson's disease. Pergolide 99.93% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	Dopamine Receptor an ergoline-based ountries for the
Perphenazi	ne	Cat. No. : HY-A0077	Perphenazi	ne D8 Dihydrochloride	Cat. No. : HY-A0077AS
Bioactivity:	Perphenazine is a typical antipsychotic drug, ir 5-HT_{2A}receptor, Alpha-1A adrenergic recep receptor D2/D3, D2L receptor , and Histamir with K ₁ values of 5.6, 10, 0.765/0.13, 3.4, and 8	otor, Dopamine ne H1 receptor,	Bioactivity:	Perphenazine D8 Dihydrochloride is the deu Perphenazine, which is a typical antipsychot Dopamine receptor ligand).	
Purity: Clinical Data: Size:	99.90% Launched 10mM x 1mL in DMSO, 1 g, 5 g	^{یو} ۔ رکان محمی م	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	
PF-592379		Cat. No.: HY-U00400	Pimethixen (Pimetixene)	e	Cat. No.: HY-B1101
	PF-592379 is a potent dopamine D₃ receptor an EC₅₀ of 21 nM.	agonist with	Bioactivity:	Pimethixene is antihistamine and antiseroto acts as an antimigraine agent. Pimethixene i antagonist of 5-HT $_{1A'}$ 5-HT $_{2A'}$ 5-HT $_{2B'}$ 5-H histamine H $_1$, dopamine D $_2$ and D $_{4.4}$ as w	s a highly potent IT _{2C'}
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	HNN N N	Purity: Clinical Data: Size:	>98% Launched 10 mg	

Pimethixen (Pimetixene m		Cat. No.: HY-B1101A	Pimozide (R6238)	(Cat. No.: HY-12987
Bioactivity:	Pimethixene maleate is antihistamine and an compound, acts as an antimigraine agent. Pir is a highly potent antagonist of 5-HT $_{1A}$, 5-H 5-HT $_{2C}$, histamine H $_1$, dopamine D $_2$ and D	methixene maleate T _{2A} , 5-HT _{2B} ,	Bioactivity:	Pimozide is a dopamine receptor antagonist, with 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 a receptors, respectively, and also has affinity at α 1-adrenoceptor, with a K _i of 39 nM; Pimozide also	nd D1
Purity: Clinical Data: Size:	>98% No Development Reported 10 mg		Purity: Clinical Data: Size:	99.88% Launched 10mM x 1mL in DMSO, 50 mg	
Piperidine-	MO-1	Cat. No .: HY-19845A	Piribedil	(Cat. No.: HY-1270
Bioactivity:	Piperidine-MO-1 is a modulator of dopamin extracted from patent WO/2005/121087A1, o exhibits an ED₅₀ of 68 µmol/kg on increase o rat striatum.	ompound example 2;	Bioactivity:	Piribedil is a dopamine D_2 receptor (D_2R) agons which also displays antagonist property at $h\alpha_{1A}$ -ac ($h\alpha_{1A}$ -AR).	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	~~~~ [€] 0 ⁰ ⁰ #0	Purity: Clinical Data: Size:	99.90% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	
Piribedil D8 (ET-495 D8)	3	Cat. No .: HY-12707S	Pramipexo		C at. No.: HY-B041
Bioactivity:	Piribedil D8 is the deuterium labeled Piribedi antiparkinsonian agent.	l, which is an	Bioactivity:	Pramipexole is a dopamine agonist of the non-ergonic indicated for treating Parkinson's disease (PD) and legs syndrome (RLS).	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	>98% Launched 50 mg, 100 mg	
Pramipexol	le dihydrochloride	Cat. No. : HY-17355	Pridopidine (ACR16; ASP2		Cat. No.: HY-10684
Bioactivity: Purity:	Pramipexole 2Hcl is a partial/full D2S, D2L, D agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM fo D3, D4 receptor, respectively. IC50 Value: 3.9 nM(D2L); 0.5 nM(D3); 5.1 nM(D4) Target: Dop Pramipexole dihydrochloride is a dopamine r 98.0%	n D2S, D2L, nM(D2S); 2.2 pamine Receptor	Bioactivity: Purity:	Pridopidine, a dopamine (DA) stabilizer, acts as a affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 re (S1R) with K _i between 70 and 80 nM, which is ~10 than its affinity toward D2R. 99.76%	ceptor
Clinical Data: Size:	Launched 10mM x 1mL in Water, 10 mg, 50 mg	, сі н.сі	Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	°;•°
Prochlorpe	razine D8	Cat. No.: HY-B0807S	Prochlorpe	razine D8 dimeleate Cat	:. No.: HY-B0807S1
Bioactivity:	Prochlorperazine D8 is the deuterium labeled which is a dopamine (D2) receptor antagonis		Bioactivity:	Prochlorperazine D8 dimeleate is the deuterium lat Prochlorperazine, which is a dopamine (D2) recepto antagonist.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg	

Promazine	hydrochloride	Cat. No.: HY-B1225	Quetiapine	D4 fumarate	Cat. No. : HY-B00315
Bioactivity:	Promazine (hydrochloride) is a D2 dopamine antagonist, belongs to the phenothiazine cla antipsychotics, used to treat schizophrenia.	receptor	Bioactivity:	Quetiapine D4 fumarate is the deuterium l which is an atypical antipsychotic.	
Purity: Clinical Data: Size:	99.72% Launched 10mM x 1mL in Water, 100 mg	C) S H-CI	Purity: Clinical Data: Size:	98.0% No Development Reported 1 mg, 5 mg, 10 mg	CCC magnation magnation
Quetiapine	fumarate	Cat. No.: HY-B0031	Quinagolid (CV205-502 h	e hydrochloride ydrochloride)	Cat. No. : HY-137364
Bioactivity: Purity: Clinical Data: Size:	Quetiapine fumarate is an atypical antipsych treatment of schizophrenia, bipolar I mania, I depression, bipolar I depression. 99.54 Launched 10mM x 1mL in DMSO, 1 g, 5 g		Bioactivity: Purity: Clinical Data: Size:	Quinagolide hydrochloride is a selective de agonist, also is a prolactin inhibitor. Target receptor, prolactin Quinagolide is a selectiv agonist (or prolactin-release inhibitor) that treatment of elevated levels of prolactin. Q 99.96% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	: dopamine D2 ve, D2 receptor is used for the
Quinpirole ((-)-LY 171555	Hydrochloride	Cat. No.: HY-B1752A	rac-Rotigo	tine Hydrochloride	Cat. No.: HY-15394
Bioactivity:	Quinpirole (Hydrochloride) is a high-affinity a dopamine D2/D3 receptor.	agonist	Bioactivity:	rac-Rotigotine Hcl is a high potency and so for D-2 receptor with Ki of 0.69 nM.	electivity agonist
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg		Purity: Clinical Data: Size:	97.76% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	S H-CI
Raclopride		Cat. No.: HY-103414	Risperidon (R 64 766)	e	Cat. No.: HY-11018
Bioactivity: Purity: Clinical Data: Size:	Raclopride is a dopamine D_2/D_3 receptor a which binds to D_2 and D_3 receptors with dis constants (K_i s) of 1.8 nM and 3.5 nM, respec very low affinity for D_1 and D_4 receptors wit >98% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	sociation tively, but has a	Bioactivity: Purity: Clinical Data: Size:	Risperidone is a serotonin 5-HT₂ receptor P-Glycoprotein inhibitor and potent dopa antagonist, with K₁s of 4.8, 5.9 nM for 5-HT D ₂ receptor, respectively. 99.16% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	amine D ₂ receptor
Risperidone (R 64 766 hyd	e hydrochloride rochloride)	Cat. No. : HY-11018A	Risperidon (R 64 766 me	•	Cat. No. : HY-11018E
Bioactivity:	Risperidone hydrochloride is a serotonin 5-H blocker and a potent dopamine D_2 receptor with K _i s of 0.16, 1.4 nM for 5-HT ₂ and D ₂ re respectively.	IT ₂ receptor antagonist,	Bioactivity:	Risperidone mesylate(R 64 766 mesylate) i receptor blocker(Ki= 0.16 nM) and a poter receptor antagonist(Ki= 1.4 nM).	
Purity: Clinical Data: Size:	>98%	- Otomin	Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg, 100 mg	

Ro 10-5824 dihydrochloride Cat. No.: HY-101384A		Cat. No.: HY-101384A		hydrochloride ₁ ydrochloride)	Cat. No.: HY-B0623
Bioactivity:	Ro 10-5824 dihydrochloride is a selective dopa receptor partial agonist, with \mathbf{K}_{i} of 5.2 nM.	mine D4	Bioactivity:	Ropinirole hydrochloride(SKF101468 hydr dopamine D2 receptor inhibitor with IC50	
Purity: Clinical Data: Size:	98.89% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.93% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg	HILD HO
Rotigotine (N-0437; N-09	923)	Cat. No. : HY-75502		D7 Hydrochloride ydrochloride)	Cat. No.: HY-A0007
Bioactivity:	Rotigotine is a full agonist of dopamine recept partial agonist of the 5-HT1A receptor , and an the $\alpha 2B$ -adrenergic receptor, with K_i s of 0.71r	antagonist of nM, 4-15nM, and	Bioactivity:	Rotigotine D7 Hydrochloride is the deuter Rotigotine(N-0923), which is a dopamine agonist.	
Purity: Clinical Data: Size:	83nM for the dopamine D3 receptor and D2, D2 and dopamine D1 receptor. 99.98% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	5, D4 receptors,	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	
Rotundine ((-)-Tetrahydr	opalmatine; L-Tetrahydropalmatine)	Cat. No.: HY-N0096	SB-277011 (SB-277011A)		Cat. No.: HY-1084
Bioactivity:	Rotundine is an antagonist of dopamine D1 , D receptors with IC ₅₀ s of 166 nM, 1.4 µM and 3.3 respectively. Rotundine is also an antagonist of an IC ₅₀ of 370 nM.	3 μM,	Bioactivity:	SB-277011 is a potent and delective dopa antagonist (pKi values are 8.0, 6.0, 5.0 and D2, 5-HT1D and 5-HT1B respectively); bra	l <5.2 for D3,
Purity: Clinical Data: Size:	99.88%		Purity: Clinical Data: Size:	>98% No Development Reported 10 mg, 50 mg	
	dihydrochloride dihydrochloride)	Cat. No.: HY-10847A	SB269652		Cat. No.: HY-123.
Bioactivity:	SB-277011 dihydrochloride (SB-277011A dihyd potent, selective, orally bioavailable and brain p dopamine D ₃ receptor antagonist, with pK ₁ s o <5.2 and 5.9 for D ₃ , D ₂ , 5-HT _{1B} , and 5-HT _{1D}	penetrate	Bioactivity:	SB269652 is the first drug-like allosteric m dopamine D2 receptor (D2R); a new chem differentiate D2R monomers from dimers on the observed pharmacology.	ical probe that can
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg		Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg, 100 mg	
	hydrochloride 390 hydrochloride)	Cat. No.: HY-19545A	Sertindole (Lu 23-174)		Cat. No.: HY-145
Bioactivity:	SCH 23390 hydrochloride is a potent dopamin antagonist with \mathbf{K}_{i} values of 0.2 and 0.3 nM for		Bioactivity:	Sertindole, a neuroleptic, is one of the new medications available. Target: Multi-targe showed that sertindole exerts a potent an 5-HT2A, 5-HT2C, dopamine D2, and α I ad Sertindole offers an alternative treatment	t In vitro studies tagonism at serotonin renergic receptors.
Purity: Clinical Data: Size:	99.31% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	HO I N-	Purity: Clinical Data: Size:	96.14%	* CT

	nydrochloride 3 hydrochloride; SKF-38393A) Cat. No.: HY-12	SKF 82958 ((±)-SKF 829	58; Chloro-AP) Cat. No.: HY-10435
Bioactivity:	SKF 38393 hydrochloride is a selective agonist of the dopamine D1 receptor (D1DR) with an IC₅₀ of 110 nM ^[1] .	Bioactivity:	SKF 82958 is a D1/D5 receptor full agonist. IC50 value: Target: D1/D5 receptor in vitro: Neuropeptide and immediate early gene expression in striatonigral neurons of the normosensitive striatum is induced by mixed D1 receptor SKF-82958, which induces behavioral activity and
Purity: Clinical Data: Size:	>98% No Development Reported 50 mg, 100 mg, 200 mg, 500 mg	Purity: Clinical Data: Size:	No Development Reported 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
	hydrobromide 8 hydrobromide; Chloro-APB hydrobromide) Cat. No.: HY-10	ST-836	Cat. No.: HY-15238
Bioactivity:	SKF-82958 hydrobromide is a D1/D5 receptor full agonist. IC50 value: Target: D1/D5 receptor in vitro: Neuropeptide and immediate early gene expression in striatonigral neurons of the normosensitive striatum is induced by mixed D1 receptor SKF-82958, which induces behavioral activity and	Bioactivity:	ST-836 is a dopamine receptor ligand; Antiparkinsonian agent.
Purity: Clinical Data: Size:	99.95% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% : No Development Reported 5 mg, 10 mg, 50 mg
ST-836 hyd	rochloride Cat. No.: HY-1	Sulpiride	Cat. No. : HY-B1019
Bioactivity:	ST-836 Hcl is a dopamine receptor ligand; Antiparkinsonian agent.	Bioactivity:	Sulpiride is a D2 receptor a antagonist, an atypical antipsychotic drug of the benzamide class, used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression.
Purity: Clinical Data: Size:	98.01% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	99.99%
Sultopride (LIN-1418)	Cat. No.: HY		hydrochloride /drochloride) Cat. No.: HY-42849A
Bioactivity:	Sultopride is a selective antagonist of dopamine D2 receptor.	Bioactivity:	Sultopride hydrochloride is a selective antagonist of dopamine D2 receptor .
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg, 50 mg	Purity: Clinical Data: Size:	99.96% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg
Sumanirole (U-95666E; PI		Talipexole (B-HT 920)	Cat. No. : HY-A0040
Bioactivity: Purity: Clinical Data: Size:	Sumanirole maleate(PNU 95666E; U95666E) is a highly selective D2 receptor full agonist with an ED50 of about 46 nM. IC50 value: 46 nM (EC50) Target: D2 receptor Sumanirole was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for 98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	Talipexole (B-HT920) is a dopamine agonist that has been proposed as an antiparkinsonian agent. Target: Dopamine Receptor B-HT920 is a selective alpha 2-adrenoceptor agonist. The effects of B-HT920 have been specified using the alpha-adrenergic antagonists yohimbine and prazosin and the >98% : Launched 5 mg, 10 mg, 50 mg, 100 mg

110 Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com


-	dihydrochloride nydrochloride))	Cat. No.: HY-A0008	Tetrahydro (Canadine)	berberine Cat. No.: HY-N0925
Bioactivity: Purity: Clinical Data: Size:	Talipexole dihydrochloride (B-HT 920 dihydroc dopamine D2 receptor agonist, α2-adrenocep 5-HT3 receptor antagonist, which displays anti activity. 99.99% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	tor agonist and	Bioactivity: Purity: Clinical Data: Size:	Tetrahydroberberine is an isoquinoline alkaloid isolated from corydalis tuber; has micromolar affinity for dopamine D(2) (pK(i) = 6.08) and 5-HT(1A) (pK(i) = 5.38) receptors but moderate to no affinity for other relevant serotonin receptors (5-HT(1B), 5-HT(1D), 5-HT(3), and 5-HT(4); pK(i) < 5.00). 99.70% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg
Tetrahydro (DL-Tetrahydr		Cat. No.: HY-N0300	Thioridazin	e hydrochloride Cat. No.: HY-B0965
Bioactivity:	Tetrahydropalmatine, an active component isc corydalis, acts through inhibition of amygdalo dopamine to inhibit an epileptic attack in rats	lated from id release of	Bioactivity:	Thioridazine is an antipsychotic drug, used in the treatment of schizophrenia and psychosis, shows D4 selectivity or serotonin antagonism.
Purity: Clinical Data: Size:	99.07% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg		Purity: Clinical Data: Size:	99.93% Phase 4 10mM x 1mL in DMSO, 100 mg, 500 mg
Tiapride hy	drochloride	Cat. No.: HY-B1196	Trifluopera (TFP; SKF5019	zine dihydrochloride 3) Cat. No.: HY-B0532A
Bioactivity:	Tiapride hydrochloride is a drug that selectivel and D3 dopamine receptors in the brain. It is u variety of neurological and psychiatric disorde dyskinesia, alcohol withdrawal syndrome.	ised to treat a	Bioactivity:	Trifluoperazine Dihydrochloride is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic. Target: Dopamine D2 Receptor Trifluoperazine Dihydrochloride is a potent dopamine D2 receptor inhibitor used as an
Purity: Clinical Data: Size:	99.82% Launched 100 mg	K J J J J J J J J J J J J J J J J J J J	Purity: Clinical Data: Size:	antipsychotic and an antiemetic. Trifluoperazine inhibited in 99.0% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg
Trifluproma	azine hydrochloride	Cat. No.: HY-B0909	Trimethobe (Ro 2-9578)	enzamide hydrochloride Cat. No.: HY-127514
Bioactivity:	Triflupromazine hydrochloride is an antipsycho which are Dopamine D1/D2 receptor antagoni		Bioactivity:	Trimethobenzamide hydrochloride is a blocker of the D ₂ receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.
Purity: Clinical Data: Size:	99.94% Launched 10mM x 1mL in DMSO, 100 mg	H-QI	Purity: Clinical Data: Size:	99.70% Launched 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg
U91356		Cat. No.: HY-U00227	Veralipride ((±)-Veraliprid	
Bioactivity:	U91356 is a dopamine receptor agonist.		Bioactivity:	Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	99.12% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Ziprasidon (CP-88059)	e	Cat. No .: HY-14542	Ziprasidon (CP-88059 D8		Cat. No. : HY-14542S
Bioactivity:	Ziprasidone(CP88059) is a combined 5- dopamine receptor antagonist which ex antipsychotic activity.		Bioactivity:	Ziprasidone D8 is deuterium labeled 2 combined 5-HT (serotonin) and dopa which exhibits potent effects of antips	mine receptor antagonist
Purity: Clinical Data: Size:	98.69% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	je state	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	
Ziprasidon	e hydrochloride		Ziprasidon	e hydrochloride monohydrate	
(CP-88059 hy	drochloride)	Cat. No.: HY-14542A	(CP 88059 (hy	/drochloride monohydrate))	Cat. No.: HY-17407
Bioactivity: Purity: Clinical Data: Size:	Ziprasidone Hcl(CP-88059 Hcl) is a com and dopamine receptor antagonist whi of antipsychotic activity. >98% Launched 10 mg, 50 mg		Bioactivity: Purity: Clinical Data: Size:	Ziprasidone hydrochloride monohydr monohydrate) is a combined 5-HT (se receptor antagonist which exhibits po antipsychotic activity. Target: 5-HT rec receptor Ziprasidone hydrochloride m 99.83% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	rotonin) and dopamine tent effects of ceptor; Dopamine
Zuclopenth	nixol				
((Z)-Clopenth	ixol)	Cat. No.: HY-A0163			
Bioactivity:	Zuclopenthixol is a thioxanthene deriva mixed dopamine D1/D2 receptor anta				
Purity: Clinical Data: Size:	98.80% No Development Reported 10mM x 1mL in DMSO, 50 mg	A CHANNEL CONTRACT			



EBI2/GPR183





The Epstein-Barr virus (EBV) induced receptor 2 (EBI2; also known as GPR183) is an orphan member of the 7TM receptor family A. EBI2 is a constitutively active seven-transmembrane receptor. EBI2 has been placed in varying 7TM receptor subgroups by different phylogenetic analyses as being a target of peptide or lipid ligands. EBI2 constitutively activates extracellular signal-regulated kinase (ERK) in a pertussis toxin-insensitive manner. EBI2 is up-regulated up to 200-fold in B cells following EBV infection.

EBI2 activation stimulates immune cell migration and has been genetically linked to autoimmune diseases including type 1 diabetes. Small molecule modulators of EBI2 can be useful for probing the

HDAC (Histone deacetylase)

function of the receptor and its relevance to human diseases.


EBI2/GPR183 Inhibitors & Modulators

GSK682753	3A	NIBR189	
	Cat. No.: HY-101192		Cat. No.: HY-1233
Bioactivity:	GSK682753A is a selective and highly potent inverse agonist of the epstein-barr virus-induced receptor 2 (${\rm EBI2}$) with an ${\rm IC}_{\rm 50}$ of 53.6 nM.	Bioactivity:	NIBR189 is a small molecule antagonist of the Epstein-Barr virus-induced gene 2 (EBI2; GPR183) receptor with IC50 of 16 nM(Binding) and 11 nM (Functional).
Purity: Clinical Data: Size:	98.47% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.24% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Endothelin Receptor





HDAC (Histone deacetylase)

Endothelin receptors are G protein-coupled receptors whose activation results in elevation of intracellular-free calcium. There are at least four type known, ETA, ETB1, ETB2 and ETC. ETA is a subtype for vasoconstriction. These receptors are found in the smooth muscle tissue of blood vessels, and binding of endothelin to ETA increases vasoconstriction (contraction of the blood vessel walls) and the retention of sodium, leading to increased blood pressure. ETB1 mediates vasodilation, when endothelin binds to ETB1 receptors, this leads to the release of nitric oxide (also called endothelium-derived relaxing factor), natriuresis and diuresis (the production and elimination of urine) and mechanisms that lower blood pressure. ETB2

mediates vasoconstriction. ETC has yet no clearly defined function. ET receptors are also found in the nervous system where they may mediate neurotransmission and vascular functions.

Endothelin Receptor Inhibitors & Modulators

Ambrisenta	In	Aminaftor	le
(BSF 208075;			; Aminaphthone) Cat. No.: HY-1989
Bioactivity:	Ambrisentan is a selective ET type A receptor (ETAR) antagonist.	Bioactivity:	Aminaftone, a derivative of 4-aminobenzoic acid, downregulates endothelin-1 (ET-1) production in vitro by interfering with the transcription of the pre-pro-ET-1 gene.
Purity: Clinical Data: Size:	99.86% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	>98% : No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
Aprocitenta	an	Atrasentar	1
(ACT-132577)	Cat. No.: HY-15	395 (ABT-627; (+)-A 127722; A-147627) Cat. No.: HY-1540
Bioactivity:	Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of macitentan, which is dual ETA/ETB antagonist designed for tissue targeting.	Bioactivity:	Atrasentan is an $endothelin receptor$ antagonist with $\rm IC_{50}$ of 0.0551 nM for ET $_{\rm A}.$
Purity: Clinical Data: Size:	98.13% Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	>98% : Phase 3 5 mg, 10 mg, 50 mg
	hydrochloride (ABT-627 (hydrochloride); (+)-A ochloride); A-147627 (hydrochloride)) Cat. No.: HY-154		iuretic Peptide (ANP) (1-28), human, porcine Cat. No.: HY-P123
Bioactivity: Purity: Clinical Data: Size:	Atrasentan (hydrochloride) is an endothelin receptor antagonist with IC ₅₀ of 0.0551 nM for ET _A . 99.80% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Bioactivity: Purity: Clinical Data Size:	Atrial Natriuretic Peptide (ANP) (1-28), human, porcine is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. ANP (1-28) inhibits endothelin-1 secretion in a dose-dependent way. >98% : No Development Reported 500u g, 1 mg, 5 mg
Atrial Natri	uretic Peptide (ANP) (1-28), human, porcine Acetate Cat. No.: HY-P12		iuretic Peptide (ANP) (1-28), rat retic factor (1-28) (rat)) Cat. No.: HY-P123
Bioactivity:	Atrial Natriuretic Peptide (ANP) (1-28), human, porcine is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. ANP (1-28) inhibits endothelin-1 secretion in a dose-dependent way.	Bioactivity:	Atrial Natriuretic Peptide (ANP) (1-28), rat is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
Purity: Clinical Data: Size:	No Development Reported 10mM x 1mL in Water, 2 500u g, 1 mg, 5 mg	Purity: Clinical Data Size:	95.52% : No Development Reported 500u g, 1 mg, 5 mg
	uretic Peptide (ANP) (1-28), rat TFA etic factor (1-28) (rat) (TFA)) Cat. No.: HY-P12	Avosentar (Ro 67-0565)	•
Bioactivity:	Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.	Bioactivity:	Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist.
Purity: Clinical Data: Size:	98.74% No Development Reported 500u g, 1 mg, 5 mg	Purity: Clinical Data Size:	98.85% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

Bosentan		Bosentan h	-
	Cat. No.: HY-A0013		Cat. No.: HY-A0013A
Bioactivity:	Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ET _A and ET _B receptors with K _i of 4.7 nM and 95 nM in human SMC, respectively.	Bioactivity:	Bosentan hydrate is a competitive and dual antagonist of endothelin-1 (ET) for the ET _A and ET _B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.
Purity: Clinical Data: Size:	99.69% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg	Purity: Clinical Data: Size:	99.94% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 5 g
BQ-123	Cat No. 11/ 10070	BQ-788	Cre No. 11V 179044
Bioactivity:	Cat. No.: HY-12378 BQ-123 is an ETA endothelin receptor antagonist (Ki values are 1.4 and 1500 nM at ETA and ETB receptors respectively) . 1)	Bioactivity:	Cat. No.: HY-15894A BQ-788 is a potent, selective ETB receptor antagonist with IC ₅₀ of 1.2 nM for inhibition of ET-1 binding to human Girardi
	Reduces ischemia-induced ventricular arrhythmias in a rat model. 2) BQ-123 prevents LPS-induced preterm birth in mice via the induction of uterine and placental IL-10. 3) The		heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC₅₀ of 1
Purity: Clinical Data: Size:	95.43% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% Phase 1 1 mg, 5 mg, 10 mg
BQ-788 soc	lium salt Cat. No.: HY-15894	Endothelin	1 swine, human Cat. No.: HY-P0202
Bioactivity:	BQ-788 (sodium salt) is a potent and selective ETB receptor antagonist, inhibiting ET-1 binding to ETB receptors with an IC₅₀ of 1.2 nM in human Girrardi heart cells.	Bioactivity:	Endothelin 1 (swine, human) is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 acts through two types of receptors ETA and ETB.
Purity: Clinical Data: Size:	98.03% Phase 1 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	96.85% No Development Reported 500u g, 1 mg, 5 mg, 10 mg
Endothelin	Mordulator 1 Cat. No.: HY-106182	IRL-1620	Cat. No.: HY-16465
Bioactivity:	Endothelin Mordulator 1 is a endothelin receptor modulator, used for the research of endothelin-mediated disorders.	Bioactivity:	IRL-1620 is a potent and selective endothelin receptor type B (ETB) agonist with a K _i of 16 pM.
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg
Macitentan (ACT-064992)		Macitentar	n n-butyl analogue Cat. No.: HY-14184A
Bioactivity:	Macitentan is an orally active, non-peptide endothelin receptor antagonist for the treatment of idiopathic pulmonary fibrosis and pulmonary arterial hypertension.	Bioactivity:	Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary actorial by portagoing (PAH)
Purity: Clinical Data: Size:	99.93% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	pulmonary arterial hypertension (PAH). 97.90% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg


PD-159020			Ro 46-2005	5	
		Cat. No.: HY-101598			Cat. No.: HY-1952
Bioactivity:	PD-159020 is a non-selective ETA/ETB antagon of 30 and 50 nM for hETA and hETB, respectively		Bioactivity:	Ro 46-2005 is a novel synthetic non-pr receptor antagonist, inhibits the specif 125I-ET-1 to human vascular smooth r with IC50 of 220 nM.	ic binding of
	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	>98% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	
Sitaxsentan (IPI 1040; TBC		Cat. No.: HY-76520	Sitaxsentar	n sodium lium); TBC11251 (sodium))	Cat. No. : HY-1110
· · · ·	Sitaxsentan (IPI 1040; TBC-11251) is a selective e (ETA) receptor antagonist. Antihypertensive. Sita used in treatment of chronic heart failure. IC50 v Target: ETA receptor	ixsentan is	Bioactivity:	Sitaxsentan sodium (IPI 1040 sodium; orally active, highly selective antagonis receptors.	
Purity: Clinical Data: Size:	>98% Phase 3 10 mg, 50 mg		Purity: Clinical Data: Size:	98.73% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
Sparsentan (RE-021; DAR/		Cat. No.: HY-17621	Sulfisoxazo (Sulfafurazole		Cat. No.: HY-B032
Bioactivity:	Sparsentan (RE-021; BMS-346567; PS433540; DA potent dual angiotensin II and endothelin A re with K _i s of 0.8 and 9.3 nM, respectively.	ARA-a) is a highly	Bioactivity:	Sulfisoxazole, an endothelin receptor a sulfonamide antibacterial with an oxaz	intagonist, is a
Purity: Clinical Data: Size:	99.08% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.96% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	HAH C S C
Tezosentan (RO 610612)	1	Cat. No. : HY-17351	ZD-1611		Cat. No.: HY-1927
	Tezosentan (RO 610612) is an endothelin (ET) r antagonist, with pA_2s of 9.5, 7.7 for ET _A and ET receptors, respectively.		Bioactivity:	ZD-1611 is a potent, orally active, selec antagonist, used for the research of iso	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Zibotentan (ZD4054)		Cat. No.: HY-10088			
Bioactivity: Purity: Clinical Data:	Zibotentan (ZD4054) is an orally administered, p specific ETA-receptor (endothelin A receptor) an = 21 nM). IC50 value: 21 nM Target: ETA receptor capable of inhibiting or reducing the multitude of that are evoked by ET-1 activation of the ETA re 98.13% Phase 3	itagonist (IC50 or Zibotentan is of effects			
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg				

118 Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com



GHSR

Growth hormone secretagogue receptor



HDAC (Histone deacetylase)

GHSR (Growth hormone secretagogue receptor) is a member of the G-protein coupled receptor family. GHSR may play a role in energy homeostasis and regulation of body weight. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. One of the important features of GHSR1a displays constitutive activity possessing basal activity in the absence of an agonist, resulting in a high degree of receptor internalization as well as of signaling activity. Inverse agonists for the ghrelin receptor could be particularly interesting for

the treatment of obesity. A range of selective ligands for the GHSR receptor are now available and are being developed for several clinical applications. GHSR agonists have appetite-stimulating and growth hormone-releasing effects, and are likely to be useful for the treatment of muscle wasting and frailty associated with old-age and degenerative diseases. On the other hand, GHSR antagonists have anorectic effects and are likely to be useful for the treatment of obesity.

GHSR Inhibitors & Modulators

Alexamore ((D-Mrp)-Ala-		Cat. No.: HY-P0166A	Anamorelir (RC-1291; ON		Cat. No.: HY-14734
Bioactivity:	Alexamorelin Met 1 is one of the metabolites of the heptapeptide Ala-His- $_{\rm D}$ -2-methyl-Trp-Ala $_{\rm D}$ -Phe-Lys-NH $_2$ (Alexamorelin) is a synthetic minhibits growth hormone secretagogue bindin	a-Trp- nolecule which	Bioactivity:	Anamorelin is a novel ghrelin receptor agonist value of 0.74 nM in the FLIPR assay.	with EC ₅₀
Purity: Clinical Data: Size:	99.82% No Development Reported 1 mg, 5 mg, 10 mg	(D-Mrp)-Ala-Trp-(D-Pho)	Purity: Clinical Data: Size:	99.91% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	MAS HAS SANA MAS
Anamorelir (ONO-7643 F	n Fumarate umarate; RC1291 Fumarate)	Cat. No.: HY-14734B		n hydrochloride Irochloride; ONO-7643 hydrochloride)	Cat. No.: HY-14734A
Bioactivity:	Anamorelin Fumarate is a novel ghrelin recep $\mathbf{EC_{50}}$ value of 0.74 nM in the FLIPR assay.	vtor agonist with	Bioactivity:	Anamorelin hydrochloride is a novel ghrelin re with \mathbf{EC}_{50} value of 0.74 nM in the FLIPR assay.	ceptor agonist
Purity: Clinical Data: Size:	>98% Phase 3 5 mg, 10 mg, 50 mg, 100 mg	$\begin{array}{c} u_{M} \overset{H}{\longrightarrow} \overset{H}{\underset{0}{\overset{\circ}{\longrightarrow}}} \overset{H}{\longrightarrow} \overset{H}{\underset{0}{\overset{\circ}{\longrightarrow}}} \overset{H}{\underset{0}{\overset{H}{\longrightarrow}}} \overset{H}{\underset{0}{\overset{H}{\overset{H}{\longrightarrow}}} \overset{H}{\underset{0}{\overset{H}{\overset{H}{\longrightarrow}}} \overset{H}{\underset{0}{\overset{H}{\overset{H}{\longrightarrow}}} \overset{H}{\underset{0}{\overset{H}{\overset{H}{\overset{H}{\overset{H}{\overset{H}{\overset{H}{\longrightarrow}}}} \overset{H}{\underset{0}{\overset{H}{\overset{H}{\overset{H}{\overset{H}{\overset{H}{\overset{H}{\overset{H}{\overset$	Purity: Clinical Data: Size:	99.80% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	₩Ċ\$ĬijŶĊſŶ ^Ĭ . ₩Ċ ĸa
AZP-531		Cat. No.: HY-P0231	Capromore (CP 424391-1	elin Tartrate 8)	Cat. No.: HY-15243
Bioactivity:	AZP-531 is an analogue of unacylated ghrelin improve glycaemic control and reduce weight	-	Bioactivity:	Capromorelin Tartrate is an orally active, potent hormone secretagogue receptor (GHSR) ago for hGHS-R1a.	-
Purity: Clinical Data: Size:	96.61% Phase 1 1 mg, 5 mg, 10 mg	Cydo (RVQSPEHQ)	Purity: Clinical Data: Size:	98.01% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg	
Ibutamorer (MK-677; MK-	•	Cat. No.: HY-50844	JMV 2959		Cat. No.: HY-U00433
Bioactivity:	Ibutamoren (Mesylate) is a potent, non-peptid hormone secretagogue receptor (GHSR) ag		Bioactivity:	JMV 2959 is a growth hormone secretagogue re GHS-R _{1a}) antagonist with an IC ₅₀ of 32 nM.	eceptor type 1a (
Purity: Clinical Data: Size:	96.13% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg	and the second	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg	
JMV 2959 ł	nydrochloride	Cat. No.: HY-U00433A	ONC212		Cat. No.: HY-111343
Bioactivity:	JMV 2959 hydrochloride is a growth hormone receptor type 1a ($GHS-R_{1a}$) antagonist with a nM in LLC-PK ₁ cells.	secretagogue	Bioactivity:	ONC212, a fluorinated-ONC201 analogue, is a anti-cancer drug and also a selective agonist of	oromising
Purity: Clinical Data: Size:	98.02% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg		Purity: Clinical Data: Size:	99.20% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	aqtot

	Cat.	No.: HY-12584
Bioactivity:	PF-5190457 is a potent and selective ghrelin receptor agonist with a \mathbf{pK}_i of 8.36.	inverse
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	₽° ¢ Ϣ

TM-N1324


	Cat. No.: HY-108699	
Bioactivity:	TM-N1324 is an agonist of G-Protein-Coupled Receptor 39 (GPR39) with EC₅₀ s of 9 nM/5 nM in the presence of Zn ²⁺ ,	
	and 280 nM/180 nM in the absence of Zn ²⁺ for human/murine GPR39.	
Purity: Clinical Data: Size:	98.91% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	

(GPR39-C3)		Cat. No.: HY-1030
Bioactivity:	TC-G-1008 (GPR39-C3) is a potent and oral agonist with EC₅₀ values of 0.4 and 0.8 nM	,
	receptors respectively.	
Purity:	99.71%	
Clinical Data:	No Development Reported	Strange H
Size:	10mM x 1mL in DMSO,	° ŚŚ
	5 mg, 10 mg, 25 mg, 50 mg, 100 mg	_МН



Glucagon Receptor

GCGR



Glucagon receptor is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Glucagon Receptor Inhibitors & Modulators

Adomegliv (LY2409021)	ant	Cat. No.: HY-19904	Avexitide (Exendin (9-3	9))	Cat. No.: HY-P0264
Bioactivity:	Adomeglivant is a potent and selective glucago antagonist that is used in clinical trial for type 2 mellitus.		Bioactivity:	Avexitide (Exendin (9-39)) is a specific and cc glucagon-like peptide-1 receptor antagoni	
Purity: Clinical Data: Size:	99.84% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Stock and	Purity: Clinical Data: Size:	96.69% Phase 4 10mM x 1mL in Water, 500u g, 1 mg, 5 mg	Dopperations
BETP		Cat. No. : HY-103546	Dulaglutide	2	Cat. No.: HY-P0120
Bioactivity:	BETP is an agonist of glucagon-like peptide-1 receptor, with EC_{50} s of 0.66 and 0.755 μ M for h GLP-1 receptor, respectively.		Bioactivity:	Dulaglutide (LY2189265) is a glucagon-like receptor agonist.	peptide-1 (GLP-1)
Purity: Clinical Data: Size:	99.28% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Contract.	Purity: Clinical Data: Size:	>98% Launched 1 mg, 5 mg, 10 mg	Dulaglutide
Exendin-4 (Exenatide)		Cat. No. : HY-13443	Exendin-4 (Exenatide ac		Cat. No.: HY-13443A
Bioactivity:	Exendin-4, a 39 amino acid peptide, is a long-ac glucagon-like peptide-1 receptor agonist with nM.		Bioactivity:	Exendin-4 Acetate, a 39 amino acid peptide, glucagon-like peptide-1 receptor agonist w nM.	
Purity: Clinical Data: Size:	98.96% Phase 4 1 mg, 5 mg, 10 mg, 25 mg		Purity: Clinical Data: Size:	98.69% Phase 4 1 mg, 5 mg, 10 mg, 25 mg	in the transmission of transmission of the transmission of transmissi
FTSDVSKQ	MEEEAVRLFIEWLKNGGPSSGAPPPS	Cat. No. : HY-P1229	GLP-1 moie	ety from Dulaglutide	Cat. No.: HY-P1348
Bioactivity:	FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS is peptide derivative.	an Exendin-4	Bioactivity:	GLP-1 moiety from Dulaglutide is a 31-amine Dulaglutide which is a glucagon-like peptide (GLP-1) agonist, extracted from patent US 20	1 receptor
Purity: Clinical Data: Size:	98.01% No Development Reported 1 mg, 5 mg, 10 mg	monatesententomon	Purity: Clinical Data: Size:	96.23% No Development Reported 1 mg, 5 mg	HOEST TEMPELEENVERNALHOOD
GLP-1 rece	ptor agonist 1	Cat. No.: HY-112185	GLP-1 rece	ptor agonist 2	Cat. No. : HY-112679
Bioactivity:	GLP-1 receptor agonist 1 is a glucagon-like pep receptor agonist extracted from patent WO2018 Compound 67.		Bioactivity:	GLP-1 receptor agonist 2 is a glucagon-like p (GLP-1R) agonist.	peptide-1 receptor
Purity: Clinical Data: Size:	99.42% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	A States	Purity: Clinical Data: Size:	99.15% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

GLP-1(7-36 (Human GLP-	i) Acetate 1-(7-36)-amide Acetate) Cat. No.: HY-P0054	GLP-1(7-37	7) Cat. No.: HY-P005
Bioactivity:	GLP-1(7-36) Acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.	Bioactivity:	GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
Purity: Clinical Data: Size:	98.42% Phase 2 500u g, 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	98.62% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg
GLP-1(7-37	') acetate Cat. No.: HY-P0055A	GLP-2(1-33 (GLP-2 (huma	8)(human) m); Glucagon-like peptide 2 (human)) Cat. No.: HY-P102
Bioactivity:	GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion ^[1] .	Bioactivity:	GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the GLP-2 receptor and stimulate the growth of intestinal epithelium.
Purity: Clinical Data: Size:	98.65% No Development Reported	Purity: Clinical Data: Size:	95.12% No Development Reported 500u g, 1 mg, 5 mg
Glucagon (Porcine gluca	agon) Cat. No.: HY-P0082	Glucagon	receptor antagonists-1 Cat. No.: HY-1003
Bioactivity:	Glucagon is a peptide hormone that helps regulate the blood sugar (glucose) levels in the body.	Bioactivity:	Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist.
Purity: Clinical Data: Size:	96.85% Launched 1 mg, 5 mg, 10 mg, 25 mg, 50 mg	Purity: Clinical Data: Size:	90.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
Glucagon r	eceptor antagonists-2 Cat. No.: HY-50158	Glucagon r	eceptor antagonists-3 Cat. No.: HY-5015
Bioactivity:	Glucagon receptor antagonists-2 is a highly potent glucagon receptor antagonist.	Bioactivity:	Glucagon receptor antagonists-3 is a highly potent glucagon receptor antagonist.
Purity: Clinical Data: Size:	97.78% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	Purity: Clinical Data: Size:	95.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg
-	ike Peptide (GLP) I (7-36), amide, human 1-(7-36)-amide) Cat. No.: HY-P0054A	Glucagon- (HuGLP-1)	ike peptide 1 (1-37), human Cat. No.: HY-P114
Bioactivity:	Glucagon-Like Peptide (GLP) I (7-36), amide, human is a physiological incretin hormone that stimulates insulin secretion.	Bioactivity:	Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor .
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg

GRA Ex-25		Cat. No .: HY-50675	GTFTSDVSI	KQMEEEAVRLFIEWLKNGGPSSGAPPPS	Cat. No.: HY-P1233
Bioactivity:	GRA Ex-25 is an inhibitor of glucagon receptor	, with IC₅₀ of	Bioactivity:	GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPP: peptide derivative.	
	56 and 55 nM for rat and human glucagon receprespectively.	ptors,		peptide derivative.	
Purity:	99.70%		Purity:	99.03%	
	No Development Reported	sontoine.		No Development Reported	OTTOMINATION DIM INCOMPOSICION
Size:	10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg	roitou	Size:	1 mg, 5 mg, 10 mg	un desenancemente beson der m
HAEGTFT			HAEGTFTS)	
		Cat. No.: HY-P1228			Cat. No.: HY-P1220
Bioactivity:	HAEGTFT is the first N-terminal 1-7 residues of (GLP-1 peptide.	Bioactivity:	HAEGTFTSD is the first N-terminal 1-9 residues peptide.	of GLP-1
Purity:	99.27%		Purity:	98.04%	
	No Development Reported	and the the		No Development Reported	myniklini
Size:	1 mg, 5 mg, 10 mg	prif.a.a.	Size:	1 mg, 5 mg, 10 mg	a style and style
HAEGTFTS	DVS		KQMEEEAV	/RLFIEWLKNGGPSSGAPPPS	
		Cat. No.: HY-P1224			Cat. No.: HY-P1223
Bioactivity:	HAEGTFTSDVS is the first N-terminal 1-11 residu peptide.	ues of GLP-1	Bioactivity:	KQMEEEAVRLFIEWLKNGGPSSGAPPPS is a Exerc derivative.	din-4 peptide
Purity:	98.31%		Purity:	97.75%	
Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg	HAEGTFTSDVS	Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg	HOMEESAARL/REMLANDOPSODAFPP
LGD-6972			Liraglutide		
		Cat. No.: HY-12525			Cat. No.: HY-P0014
Bioactivity:	LGD-6972 is a glucagon receptor antagonist.		Bioactivity:	Liraglutide is a glucagon-like peptide-1 (GLP - agonist used clinically to treat type 2 diabetes n	
Purity:	98.0%		Purity:	99.96%	
Clinical Data: Size:	Phase 2 10mM x 1mL in DMSO,	toyot	Clinical Data: Size:	Launched 1 mg, 5 mg, 10 mg	http://www.wainingit.cy.jub rest:E17750/r-6591_0.004/e774/art/1466.0
5120.	1 mg, 5 mg, 10 mg, 50 mg, 100 mg	0 ² 51 40	5126.	1 mg, 5 mg, 10 mg	
Lixisenatide	e		MK 0893		
		Cat. No.: HY-P0119			Cat. No.: HY-5066
Bioactivity:	Lixisenatide is a glucagon-like peptide-1 (GLP agonist that can be used in the treatment of typ mellitus (T2DM).		Bioactivity:	MK 0893 is a potent and selective glucagon re with an IC_{50} of 6.6 nM.	ceptor antagonist
Purity:	98.36%		Purity:	99.22% Phase 2	à
Clinical Data:	Launched 1 mg, 5 mg, 10 mg	10007703.302403.0427470.00720472947299888.9%	Clinical Data: Size:	Phase 2 10mM x 1mL in DMSO,	
Size:	ing, sing, iong				

		PF-062918	74	
	Cat. No.: HY-124622	(Glucagon re	ceptor antagonists-4)	Cat. No.: HY-1994
Bioactivity:	NNC-0640 is a potent human G-protein-coupled glucagon receptor (GCGR) negative allosteric modulator (NAM) with an IC₅₀ of 69.2 nM ^[1] .	Bioactivity:	PF-06291874 is a highly potent glucago It displays low in vivo clearance and exce bioavailability in both rats and dogs.	
Purity: Clinical Data: Size:	>98% : No Development Reported 5 mg	Purity: Clinical Data: Size:	99.70% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	
Semaglutic		Semaglutic	de TFA	
	Cat. No.: HY-114118			Cat. No.: HY-114118/
Bioactivity:	Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes.	Bioactivity:	Semaglutide TFA, a long-acting GLP-1 a glucagon-like peptide-1 (GLP-1) recept used in the treatment of type 2 diabetes	or agonist that can be
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg Semaglutide	Purity: Clinical Data: Size:	98.24% Launched 500u g, 1 mg, 5 mg	Semaglutide HO F F
Taspogluti		Tirzepatide	2	
(ITM077; R15	683; BIM51077) Cat. No.: HY-P0165	(LY3298176)		Cat. No.: HY-P173
Bioactivity:	Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC ₅₀ value of 0.06 nM. Sequence: His-{Aib} -Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-A la-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-{Aib}-Arg-NH2. 97.17%	Bioactivity: Purity: Clinical Data:	Tirzepatide (LY3298176) is a dual glucos insulinotropic polypeptide (GIP) and g (GLP-1) receptor agonist that is being of treatment of type 2 diabetes. Tirzepatide significantly better efficacy with regard the >98% No Development Reported	glucagon-like peptide-1 developed for the e (LY3298176) shows
Clinical Data:	: Phase 3 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg	Size:	1 mg, 5 mg	
Purity: Clinical Data: Size: VU045337	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg	Size:	1 mg, 5 mg	

VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of **glucagon-like peptide-1R (GLP-1R)** with an **EC**₅₀ of 1.3 μ M

Bioactivity:

Purity:

Size:

^[1]. >98%

Clinical Data: No Development Reported



Glucocorticoid Receptor



at (SAHA)

HDAC (Histone deacetylase)

Glucocorticoid Receptor (GR, or GCR) also known as NR3C1 (nuclear receptor subfamily 3, group C, member 1) is the receptor to which cortisol and other glucocorticoids bind. The GR is expressed in almost every cell in the body and regulates genes controlling the development, metabolism, and immune response. When the glucocorticoid receptor binds to glucocorticoids, its primary mechanism of action is the regulation of gene transcription. The unbound receptor resides in the cytosol of the cell. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex can take either of two paths. The activated GR complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses

the expression of pro-inflammatory proteins in the cytosol by preventing the translocation of other transcription factors from the cytosol into the nucleus. Dexamethasone is an agonist, and RU486 and cyproterone acetate are antagonists of the GR. Also, progesterone and DHEA have antagonist effects on the GR.

Glucocorticoid Receptor Inhibitors & Modulators

(20S)-Proto (20(S)-APPT; g	ppanaxatriol g-PPT) Cat. No.: HY-N08	(S)-Mapra ((S)-ZK-2451	Corat Cat. No.: HY-1. 86; (S)-BOL-303242X) Cat. No.: HY-1.
Bioactivity:	(20S)-Protopanaxatriol is a metabolite of ginsenoside, works through the glucocorticoid receptor (GR) and oestrogen receptor (ER) , and is also a LXR α inhibitor.	Bioactivity:	(S)-Mapracorat is a selective and less active glucocorticoid receptor agonist.
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	99.40% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg
AL 082D06 (D06; D-06)	Cat. No.: HY-157	9 (CL-34699)	le Cat. No.: HY-
Bioactivity:	AL 082D06 is a selective, nonsteroidal glucocorticoid receptor (${\rm GR})$ antagonist with ${\rm K_i}$ of 210 nM.	Bioactivity:	Amcinonide inhibit NO release from activated microglia with IC50 3.38 nM. Amcinonide has affinity for the glucocorticoid receptor.
Purity: Clinical Data: Size:	98.92% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	>98% : Launched 100 mg
Amebucort	: Cat. No.: HY-U002	AZD2906	Cat. No.: HY-1
Bioactivity:	Amebucort is a synthetic glucocorticoid corticosteroid, may used for the research of inflammatory disorders.	Bioactivity:	AZD2906 is a selective glucocorticoid receptor (GR) agonist, increases micronucleated immature erythrocytes in the bone marrow of rats. AZD2906 shows IC₅₀s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blo
Purity: Clinical Data: Size:	98.04% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data Size:	99.82% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
AZD5423	Cat. No .: HY-1082	AZD7594 (AZ13189620	D) Cat. No.: HY-1
Bioactivity:	AZD5423 is an inhaled, potent, selective, and non-steroidal glucocorticoid receptor (GR) modulator (SGRM) ^[1] . AZD5423 effectively reduces allergen-induced responses in subjects with mild allergic asthma ^[2] .	Bioactivity:	AZD7594 is a potent selective nonsteroidal glucocorticoid receptor modulator, with an IC₅₀ of 0.9 nM.
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data Size:	98.70% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
AZD9567	Cat. No .: HY-1200	2 (Beclometa	
Bioactivity:	AZD9567 (compound 15) is a potent, oral active, non-steroidal and selective glucocorticoid receptor modulator (SGRM) , with an IC₅₀ of 3.8 nM. Exhibits excellent efficacy in the streptococcal cell wall (SCW) reactivation model of jo	Bioactivity:	Beclometasone (Beclomethasone) is a prototype glucocorticoid receptor agonist.
Purity: Clinical Data: Size:	9.0% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg	Purity: Clinical Data Size:	92.92% : Launched 10mM x 1mL in DMSO, 25 mg, 50 mg, 100 mg

Beclometas	sone dipropionate		Betametha	sone	Cat. No. LIV 125
Bioactivity:	Beclometasone dipropionate is a potent	Cat. No.: HY-13571A glucocorticoid agonist;	Bioactivity:	Betamethasone is a glucocorticoid s	Cat. No.: HY-1357
	it is a prodrug of the free form, beclomet 0.2 nM (Inhibiting thymidine incorporatic glucocorticoid receptor in vitro: Cortisol a dipropionate were more potent than salt	asone. IC50 Value: nn) [1] Target: and beclomethasone		anti-inflammatory and immunosupp Glucocorticoid Receptor Betametha glucocorticoid steroid with anti-infla immunosuppressive properties. Unl	pressive properties. Target: sone is a potent ammatory and
Purity:	99.92%		Purity:	99.24%	но-_
Clinical Data: Size:	Launched 10mM x 1mL in DMSO,		Clinical Data: Size:	Launched 10mM x 1mL in DMSO,	HO. A
Size.	250 mg	o chain o	5120.	100 mg, 500 mg	A A A A A A A A A A A A A A A A A A A
Betametha	sone acibutate		Betametha	sone dipropionate	
		Cat. No.: HY-121062	(Betamethaso	ne 17,21-dipropionate)	Cat. No.: HY-135
Bioactivity:	Betamethasone acibutate, derives from B acetate ester. Betamethasone acibutate is [1]		Bioactivity:	Betamethasone dipropionate is a g anti-inflammatory and immunosup	
Purity:	>98%		Purity:	99.12%	
	No Development Reported	HOLERAN	Clinical Data:		но
Size:	100 mg, 250 mg, 500 mg	ort the the transformed to the	Size:	10mM x 1mL in DMSO, 250 mg, 1 g	
Betametha	sone hydrochloride		Budesonide	e	
		Cat. No.: HY-13570A			Cat. No.: HY-135
Bioactivity:	Betamethasone (hydrochloride) is a glucc anti-inflammatory and immunosuppressi Glucocorticoid Receptor Betamethasone hydrochloride of betamethasone, which i glucocorticoid steroid with anti-inflamma	ve properties. Target: (hydrochloride) is the s a potent	Bioactivity:	Budesonide is a glucocortical stere anti-inflammatory activity.	oid with potent
Purity:	>98%	H0	Purity:	98.0%	
Clinical Data: Size:	Launched 100 mg, 500 mg		Clinical Data: Size:	Launched 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg	
Ciclesonide	3		Clobetasol	propionate	
(RPR251526)		Cat. No.: HY-B0625			Cat. No.: HY-136
Bioactivity:	Ciclesonide(RPR251526) is a glucocortico obstructive airway diseases.	id used to treat	Bioactivity:	Clobetasol propionate is a anti-infla used to treat various skin disorders.	mmatory corticosteroid
Purity:	98.95%	_/	Purity:	98.0%	
Clinical Data:			Clinical Data:		HOULO
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg	C C C C C C C C C C C C C C C C C C C	Size:	10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg	
	one (17-Deoxycortisol;			(17-Hydroxy-11-dehydrocorticoster	
	roxyprogesterone; Kendall's compound E		compound E)	Cortisone is a 21-carbon steroid ho	Cat. No.: HY-174
Bioactivity:	Corticosterone is an adrenocortical steroi but significant activities as a mineralocor glucocorticoid.		Bioactivity:	the main hormones released by the stress. Target In chemical structure, closely related to cortisol. It is used ailments and can be administered in	adrenal gland in response to it is a corticosteroid to treat a variety of
Purity:	99.70%	о, рн	Purity: Clinical Data:	99.90%	о Ю
Clinical Data					
Clinical Data: Size:	10mM x 1mL in DMSO,		Size:	10mM x 1mL in DMSO,	

Cortisone a (Cortisone 21		Dagrocorat Cat. No.: HY-1671 (PF-00251802) Cat. No.: HY-1671
Bioactivity: Purity:	Cortisone acetate (17-hydroxy-11-dehydrocorticosterone), a 21-carbon steroid hormone, is one of the main hormones released by the adrenal gland in response to stress. IC50 Value: Target: Glucocorticoid Receptor in vitro: Cortisone suppressed this apoptosis at a concentration range of 1-10,000 99.42%	Bioactivity: Dagrocorat (PF-00251802) is a novel and dissociated glucocorticoid receptor agonist. Purity: >98%
Clinical Data: Size:		Clinical Data: No Development Reported Size: 250 mg, 500 mg
Deflazacor	: Cat. No. : HY-13609	Desisobutyryl-ciclesonide (CIC-AP; Ciclesonide active principle) Cat. No.: HY-11149
Bioactivity:	Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.	Bioactivity: Desisobutyryl-ciclesonide is the active metabolite of Ciclesonide. Desisobutyryl-ciclesonide has affinity for the glucocorticoid receptor.
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	Purity:99.53%Clinical Data:No Development ReportedSize:10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg
Desonide	Cat. No. : HY-B0248	Dexamethasone (Hexadecadrol; Prednisolone F) Cat. No.: HY-1464
Bioactivity:	Desonide is a nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.	Bioactivity: Dexamethasone is a glucocorticoid receptor agonist.
Purity: Clinical Data: Size:	99.81% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	Purity: 99.86% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 1 g, 5 g
	sone acetate one 21-acetate) Cat. No.: HY-14648A	Dexamethasone phosphate disodium (Dexamethasone 21-phosphate disodium salt) Cat. No.: HY-B1825
Bioactivity:	Dexamethasone acetate is a glucocorticoid receptor agonist.	Bioactivity: Dexamethasone phosphate disodium is a glucocorticoid receptor agonist.
Purity: Clinical Data: Size:	97.68% Launched 10mM x 1mL in DMSO, 1 g, 5 g	Purity: 99.68% Clinical Data: Launched Size: 10mM x 1mL in Water, 100 mg, 500 mg
Exicorilant (CORT 12528)	L) Cat. No.: HY-117880	Flunisolide Cat. No.: HY-B112
Bioactivity:	Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a K _i value of 7 nM ^[1] . Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia ^[2] .	Bioactivity: Flunisolide is a corticosteroid often used to treat allergic rhinitis. The principal mechanism of action of Flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action.
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg	Purity: 99.86% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 100 mg

Fluocinolor	ne Acetonide	Cat. No.: HY-B0415	Fluocinonio	de	Cat. No.: HY-B04
Bioactivity:	Fluocinolone Acetonide is a glucocorticoid c	lerivative used	Bioactivity:	Fluocinonide (Vanos) is a potent glucocortico	id steroid used
	topically in the treatment of various skin dise	orders.		topically as anti-inflammatory agent for the to disorders. Target: Glucocorticoid Receptor Flu potent glucocorticoid steroid used topically a anti-inflammatory agent for the treatment of	iocinonide is a s an
Purity:	98.58%	OH	Purity:	99.42%	>0
Clinical Data:		HONCH	Clinical Data:		H0 0=
Size:	10mM x 1mL in DMSO, 1 g, 5 g		Size:	10mM x 1mL in DMSO, 100 mg, 500 mg	
Fluticasone	propionate		Fosdagroco	orat	
		Cat. No.: HY-B0154	(PF-04171327	7)	Cat. No.: HY-167
Bioactivity:	Fluticasone propionate is a high affinity, sele (glucocorticoid receptor) agonist which is de fluticasone used to treat asthma and allergic Target: Glucocorticoid Receptor Fluticasone corticosteroid derived from fluticasone used	erived from : rhinitis. propionate is a	Bioactivity:	Fosdagrocorat (PF-04171327) is a dissociated receptor agonist.	glucocorticoid
Purity:	99.97%		Purity:	>98%	
Clinical Data: Size:	Launched 10mM x 1mL in DMSO, 10 mg, 50 mg		Clinical Data: Size:	No Development Reported 250 mg, 500 mg	HO P P P P P
Glucocortic	oid receptor agonist	Cat. No.: HY-14234	GW-87008	6	Cat. No. : HY-1036
Bioactivity:	Glucocorticoid receptor agonist is a potent or receptor agonist. IC50 value: Target:	Glucocorticoid	Bioactivity:	GW-870086 is a potent anti-inflammatory ag glucocorticoid receptor agonist, with a plC _g cells expressing NF-κB.	
Purity:	98.57%		Purity:	>98%	
	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	исти Руданно Руданска		No Development Reported 250 mg, 500 mg	
Hydrocortis (Cortisol)	sone	Cat. No.: HY-N0583	-	sone acetate one 21-acetate; Cortisol 21-acetate)	Cat. No.: HY-B11
			-		
Bioactivity:	Hydrocortisone is a steroid hormone or gluc by the adrenal cortex.	ocorticoid secreted	Bioactivity:	Hydrocortisone acetate is a corticosteroid, us swelling, itching, and pain that is caused by n irritations or by hemorrhoids.	
Purity:	99.66%		Purity:	99.23%	
Clinical Data:		HO, I CHPH	Clinical Data:		HOL ~ HO
Size:	10mM x 1mL in DMSO, 1 g, 5 g		Size:	10mM x 1mL in DMSO, 100 mg	
Hydrocorti	sone cypionate		-	sone phosphate	
		Cat. No.: HY-U00089	(Hydrocortiso	one 21-phosphate; Cortisol 21-phosphate)	Cat. No.: HY-B11
Bioactivity:	Hydrocortisone cypionate is a synthetic gluc corticosteroid and a corticosteroid ester.	ocorticoid	Bioactivity:	Hydrocortisone phosphate is the pharmaceut cortisol, which is a steroid hormone, in the gl class of hormones, increases blood sugar thro gluconeogenesis, to suppress the immune sy the metabolism of fat, protein, and carbohyd	ucocorticoid bugh stem, and to aid in
Purity:	>98%		Purity:	>98%	
Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO,		Clinical Data: Size:	Launched 50 mg	


Lotepredno	ol Etabonate Cat. No.: HY-17358	Mapracora (ZK-245186; F	t BOL-303242X) Cat. No.: HY-1486
Bioactivity:	Loteprednol Etabonate is an anti-inflammatory corticosteroid used in optometry and ophthalmology.	Bioactivity:	Mapracorat is a novel non-steroidal selective glucocorticoid receptor agonist.
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.40% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg
Meprednis	one Cat. No.: HY-B0243	Methylpred (U 7532)	
Bioactivity:	Meprednisone is a glucocorticoid and a methylated derivative of prednisone. Target: Glucocorticoid Receptor Meprednisone is a glucocorticoid and a methylated derivative of prednisone. The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in	Bioactivity:	Cat. No.: HY-B026 Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Target: Glucocorticoid Receptor Methylprednisolone is typically used for its anti-inflammatory effects. Common uses include arthritis therapy and short-term treatment of bronchial
Purity: Clinical Data: Size:	99.36%	Purity: Clinical Data: Size:	99.67%
	Inisolone succinate isolone hydrogen succinate) Cat. No.: HY-B1900	Mifepristor (RU486; RU 3	
Bioactivity:	Methylprednisolone succinate is a synthetic glucocorticoid and widely used as an anti-inflammatory agent.	Bioactivity:	Mifepristone is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay.
Purity: Clinical Data: Size:	99.14% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg	Purity: Clinical Data: Size:	98.17% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg
Mometaso (Sch32088)	ne furoate Cat. No.: HY-13693	ORIC-101	Cat. No. : HY-11271
Bioactivity:	Mometasone furoate, prodrug of the free form mometasone, is a agent with high affinity for the glucocorticoid receptor.	Bioactivity:	ORIC-101 is a highly potent and selective glucocorticoid receptor antagonist, with an EC ₅₀ of 5.6 nM. Anti-cancer activity.
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
Prednisolo	ne Cat. No.: HY-17463		ne disodium phosphate e 21-phosphate disodium) Cat. No.: HY-B064
Bioactivity:	Prednisolone is a glucocorticoid with the general properties of the corticosteroids.	Bioactivity:	Prednisolone disodium phosphate is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Target: Glucocorticoid Receptor Prednisolone irreversibly binds with glucocorticoid receptors (GR) alpha and beta for which they have a bind affinity. Prednicolone can activate and
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO,	Purity: Clinical Data: Size:	which they have a high affinity. Prednisolone can activate and 98.37% Launched 10mM x 1mL in Water,

	ne Tebutate	Cat. No.: HY-U00098	Prednisone (Dehydrocort	-	Cat. No.: HY-B021
Bioactivity:	Prednisolone tebutate is a synthetic gluc antiinflammatory and immunosuppressa		Bioactivity:	Prednisone (Adasone) is a synthetic is particularly effective as an immur Target: Others Prednisone is a synt that is particularly effective as an in It is used to treat certain inflammat	nosuppressant compound. hetic corticosteroid drug nmunosuppressant drug.
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg		Purity: Clinical Data: Size:	99.35%	
Prednisone	acetate		Triamcinol	one	
(Prednisone 2	1-acetate)	Cat. No.: HY-B1832			Cat. No.: HY-B032
Bioactivity: Purity: Clinical Data: Size:	10mM x 1mL in DMSO,	d receptor agonist	Bioactivity: Purity: Clinical Data: Size:	10mM x 1mL in DMSO,	methyl fumarate is an r multiple sclerosis s also being investigated
	1g			100 mg, 500 mg	0~ ~ ~
Triamcinolo	one acetonide		Triamcinol	one Benetonide	
Bioactivity:	Triamcinolone acetonide is a more poter		Bioactivity:	Triamcinolone benetonide is a synt	
Purity: Clinical Data: Size:	triamcinolone, being about 8 times as ef Target: Glucocorticoid Receptor Triamcin synthetic corticosteroid used to treat var conditions, to relieve the discomfort of n 99.08% Launched 10mM x 1mL in DMSO, 1 g, 5 g	iolone acetonide is a ious skin	Purity: Clinical Data: Size:	corticosteroid with anti-inflammato >98% No Development Reported 100 mg, 250 mg, 500 mg	ory activity. مرتبا المرتبي مرتبا المرتبي مرتبا المرتبي مرتبا المرتبي مرتبي مرتبي مرتبي مرتبي مرتبي مرتبي مرتبا المرتبي مرتبا



GNRH Receptor

Gonadotropin releasing hormone receptor; GNRHR



GNRH Receptor (Gonadotropin-releasing hormone receptor, GNRHR), also known as the luteinizing hormone releasing hormone receptor (LHRHR), is a member of the seven-transmembrane, G-protein coupled receptor (GPCR) family. It is expressed on the surface of pituitary gonadotrope cells as well as lymphocytes,breast, ovary, and prostate. GNRH Receptor is a 60 kDa G protein-coupled receptor and resides primarily in the pituitary and is responsible for eliciting the actions of LHRH after its release from the hypothalamus. Upon activation, GNRH Receptor stimulates tyrosine phosphatase and elicits the release of LH from the pituitary. Following binding of Gonadotropin releasing hormone (GNRH), GNRH Receptor associates

with G-proteins that activate a phosphatidylinositol (PtdIns)-calcium second messenger system. Activation of GNRHR ultimately causes the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH).

GNRH Receptor Inhibitors & Modulators


Abarelix (R3827; PPI 14	49) Cat. No.: HY-13534	Alarelin Ac	etate Cat. No.: HY-17405
Bioactivity:	Abarelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.	Bioactivity:	Alarelin acetate is a synthetic GnRH agonist.
Purity: Clinical Data: Size:	98.11% Launched 10mM x 1mL in DMSO, 25 mg, 10 mg, 25 mg, 50 mg	Purity: Clinical Data: Size:	99.61% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
Buserelin A		Cetrorelix A	
Bioactivity:	Cat. No.: HY-13581A Buserelin (INN) Acetate is a gonadotropin-releasing hormone agonist (GnRH agonist). target: GnRH In vivo: Buserelin treatment reduced the number of neurons along the entire gastrointestinal tract, with increased relative numbers of	Bioactivity:	ate; NS-75A) Cat. No.: HY-P0009A Cetrorelix Acetate is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC ₅₀ of 1.21 nM.
Purity: Clinical Data: Size:	CRF-immunoreactive submucosal and myenteric neurons in colon 99.98% Launched 2 mg, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.88% Launched 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg
Degarelix	Cat. No. : HY-16168A	Elagolix (NBI-56418)	Cat. No. : HY-14789
Bioactivity:	Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist.	Bioactivity:	Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).
Purity: Clinical Data: Size:	99.92% Launched 10mM x 1mL in Water, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.06% Phase 3 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
Elagolix so (NBI-56418 so		Gonadorel	in acetate Cat. No.: HY-12555
Bioactivity: Purity:	Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC₅₀ and K _i of 0.25 and 3.7 nM, respectively. 99.20%	Bioactivity: Purity:	Gonadorelin acetate is a man-made protein that is like a hormone in the body called gonadotropin-releasing hormone (GnRH). Target: GNRH Receptor Gonadorelin acetate is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle 99.97%
Clinical Data: Size:		Clinical Data: Size:	
Goserelin (ICI 118630)	Cat. No. : HY-13673	Goserelin a (ICI-118630 a	
Bioactivity: Purity: Clinical Data: Size:	Goserelin(ICI 118630) is an injectable gonadotropin releasing hormone superagonist (GnRH agonist). IC50 value: Target: GnRH agonist Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders >98% Launched 10 mg	Bioactivity: Purity: Clinical Data: Size:	Goserelin (ICI 118630) acetate is an injectable gonadotropin releasing hormone superagonist (GnRH agonist). IC50 value: Target: GnRH agonist Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and perimenopausal women) and prostate, and some benign 99meelological Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

Lecirelin	Cat. No.: HY	-P0051 (Leuprorelin a		Cat. No.: HY-13665
Bioactivity:	Lecirelin is a synthetic GnRH (gonadotropin releasing hormone analogue which shows a great efficacy in the treatment of bovine ovarian follicular cysts.) Bioactivity:	Leuprolide acetate is a potent gonadotro receptor agonist used for the treatment o endometriosis, uterine fibroids.	
Purity: Clinical Data: Size:		Purity: Clinical Data: VSYVLRP Size:	99.88% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
opigolix	Cat. No.: HY-U	J00289 (TAK-385)		Cat. No.: HY-16474
Bioactivity:	Opigolix is a Gonadotropin-releasing hormone (GnRH) recepter antagonist, used for the research of endometriosis and rheumatoid arthritis.	or Bioactivity:	Relugolix is a novel, non-peptide, orally a gonadotropin-releasing hormone (GnRH) 0.33 nM in the presence of 40% fetal bov possesses higher affinity and potent anta compared with TAK-013. tarqet: GnRH [1]	antagonist with IC50 of ine serum, TAK-385 gonistic activity
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	, Purity: Clinical Data: Size:	98.0%	



GPCR19

G-protein coupled receptor 19



HDAC (Histone deacetylase)

hormone receptor which increases metabolic rate.

GPCR19 (G-protein coupled receptor 19, GPBAR1) is a protein that in humans is encoded by the GPBAR1 gene. This gene encodes a member of the G protein-coupled receptor (GPCR) superfamily. GPCR19 functions as a cell surface receptor for bile acids. Treatment of cells expressing this GPCR with bile acids induces the production of intracellular cAMP, activation of a MAP kinase signaling pathway, and internalization of the receptor. The receptor is implicated in the suppression of macrophage functions and regulation of energy homeostasis by bile acids. One effect of this receptor is to activate deiodinases which convert the prohormone thyroxine (T4) to the active hormone triiodothyronine (T3). T3 in turn activates the thyroid

GPCR19 Inhibitors & Modulators


BAR501	Cat. No.: HY-101274	BAR502	Cat. No.: HY-101273
Bioactivity:	BAR501 is a potent and selective agonist of GPBAR1 with an EC_{50} of 1 μ M.	Bioactivity:	BAR502 is a dual FXR and GPBAR1 agonist with IC_{50} values of 2 μ M and 0.4 μ M, respectively.
Purity: Clinical Data: Size:	98.82% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
Deoxycholi		Deoxycholi (Sodium deox	ic acid sodium salt «ycholate) Cat. No.: HY-N0593A
Bioactivity:	id; Desoxycholic acid) Cat. No.: HY-N0593 Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.	Bioactivity:	Deoxycholic acid sodium salt is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.
Purity: Clinical Data: Size:	99.13% No Development Reported 10mM x 1mL in DMSO, 100 mg, 500 mg	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg
Hyodeoxyc (HDCA)	holic acid Cat. No.: HY-N0169	INT-767	Cat. No.: HY-12434
Bioactivity:	Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC_{50} of 31.6 μ M in CHO cells.	Bioactivity:	INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC₅₀ s of 30 and 630 nM, respectively ^[1] ^[2] .
Purity: Clinical Data: Size:	>98% No Development Reported 100 mg	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
INT-777 (S-EMCA)	Cat. No. : HY-15677	INT-777 R- (S-EMCA R er	enantiomer nantiomer) Cat. No.: HY-15677A
Bioactivity:	INT-777 is a potent TGR5 agonist with an EC_{50} of 0.82 μ M.	Bioactivity:	INT-777 (R-enantiomer) is the R-enantiomer of INT-777, with EC $_{50}$ of 4.79 μM for TGR5, and less potent than INT-777.
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg $\sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum_{j=1}$
SB756050	Cat. No. : HY-102016	SBI-115	Cat. No.: HY-111534
Bioactivity:	SB756050 is a selective TGR5 agonist currently in phase 1clinical trials for the treatment of type 2 diabetes.	Bioactivity:	SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 ^[1] .
Purity: Clinical Data: Size:	99.02% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.51% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TGR5 Rece	ptor Agonist Cat. No.: HY-14229
Bioactivity:	TGR5 Receptor Agonist, a potent TGR5(GPCR19) agonist, showed improved potency in the U2-OS cell assay (pEC50 = 6.8) and in melanophore cells (pEC50 = 7.5).
Purity: Clinical Data: Size:	99.86% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



GPR109A

HM74A;PUMA-G;HCA2;HCAR2



HDAC (Histone deacetylase)

GPR109A is a G-protein-coupled receptor for nicotinate but recognizes butyrate with low affinity. GPR109A is expressed in the lumen-facing apical membrane of colonic and intestinal epithelial cells and that the receptor recognizes butyrate as a ligand. The expression of GPR109A is silenced in colon cancer in humans, in a mouse model of intestinal/colon cancer, and in colon cancer cell lines. The tumor-associated silencing of GPR109A involves DNA methylation directly or indirectly. Reexpression of GPR109A in colon cancer cells induces apoptosis, but only in the presence of its ligands butyrate and nicotinate. Butyrate is an inhibitor of histone deacetylases, but apoptosis induced by activation of GPR109A with its

ligands in colon cancer cells does not involve inhibition of histone deacetylation. The primary changes in this apoptotic process include down-regulation of Bcl-2, Bcl-xL, and cyclin D1 and up-regulation of death receptor pathway. In addition, GPR109A/butyrate suppresses nuclear factor-kappaB activation in normal and cancer colon cell lines as well as in normal mouse colon. These studies show that GPR109A mediates the tumor-suppressive effects of the bacterial fermentation product butyrate in colon.


GPR109A Inhibitors & Modulators

MK-0354			MK-6892		
	Cat. No.: HY-13008			Cat. No.: HY-10680	
Bioactivity:	MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 $\mu\text{M},$ showed no		Bioactivity:	MK-6892 is a potent, selective, and full as affinity nicotinic acid (NA) receptor GPR1	5
	activation of GPR109b.		EC₅₀ of MK-6892 on the Human GPR109 respectively.	A is 4 nM and 16 nM,	
Purity: Clinical Data: Size:	98.03% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	HZ N N N N	Purity: Clinical Data: Size:	98.73% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	H0-(



GPR119

G protein coupled receptor 119



GPR119 (G protein-coupled receptor 119) is a G protein-coupled receptor that in humans is encoded by the GPR119 gene. GPR119, along with GPR55 and GPR18, have been implicated as novel cannabinoid receptors. GPR119 is expressed predominantly in the pancreas and gastrointestinal tract in rodents and humans, as well as in the brain in rodents. Activation of the receptor has been shown to cause a reduction in food intake and body weight gain in rats. GPR119 has also been shown to regulate incretin and insulin hormone secretion. As a result, new drugs acting on the receptor have been suggested as novel treatments forobesity and diabetes.

GPR119 Inhibitors & Modulators

PSN632408 is an optimized agonist of GPR119 receptors that shows similar potency to OEA at both recombinant mouse and human GPR119 receptors, exhibiting EC50 values of 5.6 and 7.9

Bioactivity:

Purity:

uM, respectively.

5 mg, 10 mg, 50 mg

99.91%

Clinical Data:No Development ReportedSize:10mM x 1mL in DMSO,


APD597		APD668	
(JNJ-3843105	5) Cat. No.: HY-15566		Cat. No.: HY-15565
Bioactivity:	APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119. IC50 value: 46 nM (EC50) [1] Target: hGPR119 The design and synthesis of a second generation GPR119-agonist clinical candidate for the	Bioactivity:	APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively.
Purity: Clinical Data: Size:	treatment of diabetes is described. APD597 was selected for 99.97% Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.16% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
AR 231453	Cat. No.: HY-15564	Firuglipel	Cat. No.: HY-109032
Bioactivity:	AR231453 is a potent, selective and orally available GPR119 agonist.	Bioactivity:	Firuglipel (DS-8500a) is an orally available, potent and selective GPR119 agonist.
Purity: Clinical Data: Size:	99.52% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
GSK129226	3 Cat. No.: HY-12066	MBX-2982	Cat. No.: HY-15291
Bioactivity:	GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. IC50 value: Target: GPR119 in vitro: GSK-1292263 is selected from 1538 compounds by using Hypo1, the Fit-Value and Estimate of GSK-1292263 that is aligned in Hypo1 are 8.8 and 7.7 (nM), respectively [1]. in	Bioactivity:	MBX-2982 is a selective, orally-available G protein-coupled receptor 119 (GPR119) agonist.
Purity: Clinical Data: Size:	99.71%	Purity: Clinical Data: Size:	99.39% Phase 2 10mM x 1mL in DMSO, 2000 5 mg, 10 mg, 50 mg
PSN632408	сат. No.: НҮ-16673		

N. Orlok



GPR120

G-protein coupled receptor 120



GPR120 (G-protein coupled receptor 120) is a protein that in humans is encoded by the GPR120 gene. GPR120 is a member of the rhodopsin family of G protein-coupled receptors (GPRs). GPR120 has also been shown to mediate the anti-inflammatory and insulin-sensitizing effects of omega 3 fatty acids. Lack of GPR120 is responsible for reduced fat metabolism, thereby leading to obesity.


GPR120 Inhibitors & Modulators

Ginsenosid	e Rb2		GPR120 Ag	onist 2	
(Ginsenoside	C)	Cat. No.: HY-N0040			Cat. No.: HY-111353
Bioactivity:	Ginsenoside Rb2 is one of the main bioac ginseng extracts. Rb2 can upregulate GPF		Bioactivity:	GPR120 Agonist 2 is a GPR120 agonist extra 20110313003 A1, example 209.	cted from patent US
Purity: Clinical Data: Size:	98.26% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg	States States	Purity: Clinical Data: Size:	98.12% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	HO_O C C C C
GPR120 mo	odulator 1		GPR120 mc	odulator 2	
		Cat. No.: HY-50162			Cat. No.: HY-50172
Bioactivity:	GPR120 modulator 1 is useful for modular receptor 120 (GPR120).	ting G protein-coupled	Bioactivity:	GPR120 modulator 2 is useful for modulating receptor 120 (GPR120).	g G protein-coupled
Purity: Clinical Data: Size:	98.62% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Contraction	Purity: Clinical Data: Size:	>98% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	dyn ^{eri}
GPR120-IN	-1		GSK137647	Ά	
Bioactivity:	GPR120-IN-1 is a selective Gpr120 agonis -7.62.	Cat. No.: HY-101492 st with a logEC ₅₀ of	(GSK 137647) Bioactivity:	GSK137647A is a selective FFA4 agonist, with 6.2, and 6.1 for human, Mouse and Rat FFA4,	
Purity: Clinical Data: Size:	98.01% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	ю-6-00-20- ⁴ 1	Purity: Clinical Data: Size:	99.98% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	L, s C o



GPR139

G Protein-Coupled Receptor 139



GPR139 (G protein-coupled receptor 139) is a protein that in humans is encoded by the GPR139 gene. GPR139 is an orphan G-protein-coupled receptor expressed in the central nervous system. The expression pattern of GPR139 has primarily been studied on the mRNA level and showed expression mainly in the central nervous system.

GPR139 is an orphan receptor identified from bioinformatics analysis of the human genome. GPR139 is thus a potential target for the treatment of Parkinson's disease, obesity, eating disorders, and/or diabetes.

HDAC (Histone deacetylase)

The GPR139 is expressed specifically in the brain in areas of relevance

for motor control. GPR139 function and signal transduction pathways are elusive, and results in the literature are even contradictory. GPR139 agonists dose-dependently protect primary dopaminergic (DA) neurons against MPP⁺ toxicity.

GPR139 Inhibitors & Modulators


r

JNJ-635330		TC-O 9311		
	Cat. No. : HY-19838			Cat. No.: HY-101777
Bioactivity:	JNJ-63533054 is a potent and selective agonist of hGPR139 with an EC50 = 16 nM.	Bioactivity:	TC-O 9311 is a potent orphan G protein (GPR139) agonist with an EC₅₀ of 39 nM	
Purity: Clinical Data: Size:	99.94% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg	Jan



GPR40

Free fatty acid receptor 1;FFAR1;FFA1;G-protein-coupled receptor 40



GPR40 (Free fatty acid receptor 1, FFA1) is a class A G-protein coupled receptor that in humans is encoded by the FFAR1 gene. It is strongly expressed in the cells of the pancreas and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis. GPR40 is activated by medium to long chain fatty acids. GPR40 is most strongly activated by eicosatrienoic acid, but has been found to be activated by fatty acids as small as 10 carbons long. For saturated fatty acids the level of activation is dependent on the length of the carbon chain, which is not true for unsaturated fatty acids. It has been found that three hydrophilic residues (arginine-183, asparagine-244, and arginine-258)

anchor the carboxylate group of a fatty acid, which activates GPR40.

GPR40 Inhibitors & Modulators


AM-1638		AM-4668		
Bioactivity:	$\label{eq:cat.No::HY-13467}$ AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an \textbf{EC}_{50} of 0.16 μ M.	Bioactivity:	AM-4668 is a GPR40 agonist for type 2 diabeter	50
			3.6 nM and 36 nM for GPR40 in A9 cells (GPR40 CHO cells (GPR40 aequorin assay), respectively [[]	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in DMSO, 5 mg	+0-700 ²¹
AMG 837	Cat. No.: HY-13967	AMG 837 d	alcium hydrate	Cat. No. : HY-13967B
Bioactivity:	AMG 837 is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.	Bioactivity:	AMG 837 calcium hydrate is a potent GPR40 ag with a superior pharmacokinetic profile and rob glucose-dependent stimulation of insulin secret	onist(EC50=13 nM) ust
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	98.01% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	No or of the second sec
AMG 837 s	odium salt Cat. No.: HY-13967A	AP5		Cat. No.: HY-112603
Bioactivity:	AMG 837 sodium salt is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. IC50 value: 13 nM (EC50) [1] Target: GPR40 agonist AMG 837	Bioactivity:	AP5 exhibits potent and selective agonism for the receptor with positive allosteric modulation of eligands (AgoPAM). AP5 demonstrates a rat hIP1 0.49±0.28 nM against the GPR40 receptor ^[1] .	endogenous
Purity: Clinical Data: Size:	displayed the expected two-fold increase in potency on GPR4 >98% No Development Reported 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	" and and a
DC260126	Cat. No.: HY-101906	FAA1 agor	iist-1	Cat. No.: HY-103083
Bioactivity:	DC260126, a small-molecule antagonist of GPR40 .	Bioactivity:	FAA1 agonist-1 is a potent free fatty acid recep FFA1/ GPR40) agonist with a PEC₅₀ of 7.54.	ptor 1 (
Purity: Clinical Data: Size:	99.70% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.97% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	C. Ojyo
Fasiglifam (TAK-875)	Cat. No.: HY-10480	GPR40 Act	ivator 1	Cat. No. : HY-13971
Bioactivity:	Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC₅₀ of 72 nM.	Bioactivity:	GPR40 Activator 1 is a potent GPR40 activator for type 2 diabetes.	or treatment of
Purity: Clinical Data: Size:	98.94% Phase 3 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg	ourole

GPR40 Acti		GPR40 ago	
	Cat. No. : HY-12647		Cat. No.: HY-11135
Bioactivity:	GPR40 Activator 2 is a potent GPR40 activator from patents WO 2012147516 A1, WO 2012046869A1 and WO 2011078371 A1.	Bioactivity:	GPR40 agonist 1 is a potent and novel GPR40 full agonist with an EC_{50} of 2 nM and 17 nM for hGPR40 and rGPR40, respectively.
Purity: Clinical Data: Size:	99.63% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
GPR40 Ago	onist 2 Cat. No.: HY-U00395	GPR40/FFA	R1 modulator 1 Cat. No.: HY-11176
Bioactivity:	GPR40 Agonist 2 is a GPR40 agonist that can be used in the research of diabetes, extracted from patent WO2009054479A1.	Bioactivity:	GPR40/FFAR1 modulator 1 is an agonist and an allosteric modulator for Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1) ^[1] .
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% No Development Reported 100 mg, 500 mg, 250 mg
GW-1100	Cat. No. : HY-50691	GW9508	Cat. No. : HY-1558
Bioactivity:	GW-1100 is a selective GPR40 antagonist with a pIC₅₀ of 6.9.	Bioactivity:	GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32, 100-fold selective against GPR120, stimulates insulin secretion in a glucose-sensitive manner.
Purity: Clinical Data: Size:	97.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	99.19% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
PBI-4050 so	odium salt (sodium salt)) Cat. No.: HY-100775	TUG-770	Cat. No.: HY-1569
Bioactivity:	PBI-4050 sodium salt acts as an agonist for GPR40 and as an antagonist or inverse agonist for GPR84 .	Bioactivity:	TUG-770 is a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist with EC50 of 6 nM for hFFA1. IC50 Value: 6 nM (hFFA1, EC50) [1] Target: GPR40 in vitro: TUG-770 (Compound 22) displayed excellent physicochemical and in vitro ADME properties, with good aqueous solubility, good chemical
Purity: Clinical Data: Size:	99.39% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



GPR55

G protein-coupled receptor 55



GPR55 (G protein-coupled receptor 55) is a G protein-coupled receptor that in humans is encoded by the GPR55 gene. GPR55, along with GPR119 and GPR18, have been implicated as novel cannabinoid receptors. GPR55 is activated by the plant cannabinoids 9-THC and cannabidiol, and the endocannabinoids anandamide, 2-AG, noladin ether in the low nanomolar range. Recent research suggests that lysophosphatidylinositol and its 2-arachidonoyl derivative may be the endogenous ligands for GPR55, and the receptor appears likely to be a possible target for treatment of inflammation and pain as with the other cannabinoid receptors. The physiological role of GPR55 is unclear. GPR55 has been proposed as a new potential drug target for

the treatment of diabetes, Parkinson's disease, neuropathic pain, and cancer.


GPR55 Inhibitors & Modulators

Anandamide		CID 16020046	
	Cat. No. : HY-10863		Cat. No.: HY-16697
Bioactivity:	Anandamide is an immune modulator in the central nervous system acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18 / GPR55).	Bioactivity:	CID 16020046 is a potent and selective GPR55(LPI receptor) antagonist; inhibitsGPR55 constitutive activity with IC50 of 0.15 uM.
Purity: Clinical Data: Size:	99.0% No Development Reported 5 mg, 10 mg	Purity: Clinical Data: Size:	99.92% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg



GPR84

G protein coupled receptor 84



HDAC (Histone deacetylase)

GPR84 is a G protein-coupled receptor for medium-chain fatty acids. GPR84 is a receptor for free fatty acids and can be potently activated by saturated medium-chain free fatty acids (MCFAs) like decanoic acid, undecanoic acid and lauric acid. GPR84, a receptor for medium-length free fatty acids is upregulated on protein level in LPS activated tolerant CD14⁺ monocytes and THP-1 cells.

GPR84 is activated by MCFAs with the hydroxyl group at the 2- or 3-position more effectively than nonhydroxylated MCFAs. GPR84 is now considered to be a member of FFA-sensing GPCRs. MCFAs with carbon chain lengths of 9-14 activate GPR84, coupling primarily to a pertussis toxin (PTX)-sensitive ${\rm G}^{}_{\rm i/o}$ pathway. GPR84 should be a

proinflammatory receptor and may be a novel, attractive target for treating chronic low grade inflammation associated-diseases.

GPR84 Inhibitors & Modulators

6-OAU (GTPL5846)	Cat. No.: HY-12764
Bioactivity:	6-OAU(GTPL5846; 6-n-octylaminouracil) is a surrogate agonist of GPR84; activates human GPR84 in the presence of Gqi5 chimera in HEK293 cells with an EC50 of 105 nM in the PI assay. IC50 value: 105 nM [1] Target: GPR84 agonist in vitro: 6-OAU increased [355]GTPγS incorporated in Sf9 cell membranes
Purity:	97.53%
Clinical Data:	No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

PBI-4050 sodium salt


(Setogepram	(sodium salt))	Cat. No.: HY-100775
Bioactivity:	PBI-4050 sodium salt acts as an agonist for GP antagonist or inverse agonist for GPR84 .	R40 and as an
Purity: Clinical Data: Size:	99.39% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

		Cat. No.: HY-11256
Bioactivity:	GPR84 antagonist 8 is a selective GPR84 antago	nist.
Purity:	99.96%	
Clinical Data:	No Development Reported	~~~~
Size:	10mM x 1mL in DMSO,	i topi
	5 mg, 10 mg, 25 mg, 50 mg, 100 mg	0



Guanylate Cyclase





and GCAP2).

Guanylylcyclase is often part of the G protein signaling cascade that is activated by low intracellular calcium levels and inhibited by high intracellular calcium levels. In response to calcium levels, guanylylcyclase synthesizes cGMP from GTP. cGMP keeps cGMP-gated channels open, allowing for the entry of calcium into the cell. The guanylylcyclase activity is modulated by the calcium-binding guanylylcyclase activating proteins (GCAP1 and GCAP2). A key mechanism by which Ca²⁺ modulates phototransduction in rods involves the synthesis of cGMP by guanylylcyclase (GC), regulated by a pair of Ca²⁺-binding GuanylylCyclase Activating Proteins (GCAP1

Guanylatecyclase (guanylylcyclase, GC) is a lyase enzyme.

The second messenger cyclic quanosine monophosphate (cGMP) is generated by the heterodimeric α/β -heme protein soluble guanylatecyclase (sGC) upon activation by its endogenous ligand nitric oxide (NO). NO binds to the reduced prosthetic heme group bound to the β subunit. cGMP is a key mediator of the cardiovascular system and its effects lead to vasodilation, inhibition of smooth muscle proliferation, blockade of leukocyte infiltration and inhibition of platelet aggregation. Impairment of the cytoprotective NO/sGC/cGMP-signalling pathway is associated with the development of serious cardiovascular diseases such as hypertension or heart failure.

Guanylate Cyclase Inhibitors & Modulators

(4-Acetami (BM121307)	docyclohexyl) nitrate	Cat. No.: HY-100295	BAY 41-22	72	Cat. No.: HY-1237
Bioactivity:	BM121307 is a guanylate cyclase activator the development for the treatment of ischaemic I The research has been discontinued.		Bioactivity:	BAY 41-2272 is a soluble guanylate cyclas	es (sGC) activator.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	99.93% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	
Cinaciguat (BAY 58-2667)	Cat. No. : HY-14181		hydrochloride / hydrochloride)	Cat. No. : HY-14181
Bioactivity:	Cinaciguat is an activator of guanylate cycla used for acute decompensated heart failure.	se (sGC), and	Bioactivity:	Cinaciguat hydrochloride is a potent solul GC) activator with EC ₅₀ of 15 nM in platel	
Purity: Clinical Data: Size:	99.40% Phase 2 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg	Cut to in	Purity: Clinical Data: Size:	98.0% Phase 2 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg	arichat
Lificiguat (YC-1)		Cat. No.: HY-14927	Linaclotide	,	Cat. No.: HY-1758
Bioactivity:	Lificiguat binds to the β subunit of soluble g (sGC) with \mathbf{K}_{d} of 0.6-1.1 μ M in the presence of		Bioactivity:	Linaclotide is a potent and selective guan agonist; developed for the treatment of constipation-predominant irritable bowel chronic constipation.	
Purity: Clinical Data: Size:	99.83% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg	K N N C O H	Purity: Clinical Data: Size:	98.46% Launched 10mM x 1mL in Water, 5 mg, 10 mg	
Nelociguat (BAY60-4552)		Cat. No. : HY-78237	Plecanatide	e acetate	Cat. No.: HY-108741
Bioactivity:	Nelociguat (BAY60-4552) is a nitric oxide sen guanylate cyclase stimulator.	sitive soluble	Bioactivity:	Plecanatide acetate is a guanylate cyclas agonist, with an EC₅₀ of 190 nM in T84 ce acetate shows anti-inflammatory activity i colitis ^[1] .	ells. Plecanatide
Purity: Clinical Data: Size:	99.73% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 m	g, 1 g	Purity: Clinical Data: Size:	99.26% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	
Praliciguat (IW-1973)		Cat. No. : HY-109039	Riociguat (BAY 632521)		Cat. No.: HY-1477
Bioactivity:	Praliciguat (IW-1973) is a potent and orally ac guanylate cyclase stimulator, enhances NO s vasodilator. Praliciguat (IW-1973) stimulates s cells with an EC₅₀ of 197 nM ^[1] .	signaling, acts as a	Bioactivity:	Riociguat is an oral stimulator of soluble g sGC) used in the treatment of pulmonary	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 100 mg, 500 mg		Purity: Clinical Data: Size:	99.58% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg	

Runcacigua	t Cat. No.: HY-109136	sGC activa	tor 1 Cat. No.: HY-111510
Bioactivity:	Runcaciguat is an orally active stimulator of soluble guanylate cyclase , and is used in the research of cardiovascular and renal diseases combined with selective partial adenosine A1 receptor agonists ^[1] .	Bioactivity:	sGC activator 1 (Compound (+)-23) is a soluble guanylate cyclase (sGC) activator with EC_{50} s of <5 nM, and 5 nM in CHO and GTM-3 E cells, respectively ^[1] .
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported です。 250 mg, 500 mg, 100 mg
Vericiguat (BAY1021189) Cat. No.: HY-16774		
Bioactivity:	Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.		

N N P N N P Han Ha

 Purity:
 98.0%

 Clinical Data:
 Phase 3


 Size:
 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com



Histamine Receptor

HDAC Inhibitor: Vorinostat (SAHA)



HDAC (Histone deacetylase)

Histamine Receptors are a class of G protein-coupled receptors with histamine as their endogenous ligand. There are four known histamine receptors: H1 receptor, H2 receptor, H3 receptor, H4 receptor. The H1 receptor is a histamine receptor belonging to the family of Rhodopsin-like G-protein-coupled receptors. This receptor, which is activated by the biogenic amine histamine, is expressed throughout the body, to be specific, in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. H2 receptors are positively coupled to adenylate cyclase via Gs. It is a potent stimulant of cAMP production, which leads to activation of Protein Kinase A. Histamine H3 receptors are expressed in the central

nervous system and to a lesser extent the peripheral nervous system, where they act asautoreceptors in presynaptic histaminergic neurons, and also control histamine turnover by feedback inhibition of histamine synthesis and release. The Histamine H4 receptor has been shown to be involved in mediating eosinophil shape change and mast cell chemotaxis.

Histamine Receptor Inhibitors & Modulators

(±)-Methot (dl-Methotrim	rimeprazine (D6) neprazine D6) Cat. No.: HY-19489S	(±)-Tazifylline Cat. No.: HY-U00018
Bioactivity:	(±)-Methotrimeprazine (D6) is the deuterium labeled Methotrimeprazine, which is a D3 dopamine and Histamine H1 receptor antagonist.	Bioactivity: (±)-Tazifylline is a potent, selective and long-acting histamine H1 receptor antagonist.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg $\begin{pmatrix} v \\ v \\ c \\ b \\ c \\ b \end{pmatrix}$	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg
ABT-239	Cat. No.: HY-12195	Acrivastine (BW825C) Cat. No.: HY-B1510
Bioactivity:	ABT-239 is a novel, highly efficacious, non-imidazole class of H3R antagonist and a transient receptor potential vanilloid type 1 (TRPV1) antagonist.	Bioactivity: Acrivastine (BW825C) is a short acting histamine 1 receptor antagonist for the treatment of allergic rhinitis.
Purity: Clinical Data: Size:	98.94% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	Purity: 98.00% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg Chine
Alcaftadine (R89674)	Cat. No .: HY-17039	Alimemazine D6 (Trimeprazine D6) Cat. No.: HY-12752S
Bioactivity:	Alcaftadine(R89674) is a H1 histamine receptor antagonist, which is used to prevent eye irritation brought on by allergic conjunctivitis.	Bioactivity: Alimemazine D6 is deuterium labeled Alimemazine, which is an antihistamine.
Purity: Clinical Data: Size:	97.17% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity:>98%Clinical Data:No Development ReportedSize:1 mg, 5 mg
	hydrochloride hydrochloride) Cat. No.: HY-B1067	Antihistamine-1 Cat. No.: HY-100238
Bioactivity: Purity:	Antazoline hydrochloride is a 1st generation antihistamine with also anticholinergic properties used to relieve nasal congestion and in eye drops. 99.36%	Bioactivity: Antihistamine-1 is a H1-antihistamine (K _i =6.9 nM) with acceptable blood-brain barrier penetration and also an inhibitor of CYP2D6 and hERG channel with IC ₅₀ s of 5.4 and 0.8 μM, respectively. Purity: >98%
Clinical Data: Size:		Clinical Data: No Development Reported
Astemizole (R 43512)	Cat. No. : HY-12532	Azatadine Cat. No.: HY-B0170
Bioactivity:	Astemizole, a second-generation antihistamine drug to diminish allergic symptoms with a long duration of action, is a histamine H1-receptor antagonist, with an IC ₅₀ of 4 nM. Astemizole also shows potent hERG K+ channel blocking activ >98%	Bioactivity: Azatadine is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. Target: Histamine Receptor Azatadine, a new antihistamine, was evaluated for its efficacy in 20 patients with chronic allergic rhinitis. Eighty percent of patients had symptomatic relief with a twice daily dosage Purity: >98%
Purity: Clinical Data: Size:	>98% No Development Reported	Purity: >98% Clinical Data: Launched Size: 10 mg, 50 mg, 100 mg

Azatadine o		Cat. No.: HY-B0170A	Azelastine		Cat. No.: HY-B0462A
Bioactivity:	Azatadine dimaleate is an histamine and chol with IC50 of 6.5 nM and 10 nM, respectively. Receptor Azatadine, a new antihistamine, was efficacy in 20 patients with chronic allergic rh	inergic inhibitor Target: Histamine s evaluated for its initis. Eighty	Bioactivity:	Azelastine is a potent, second-generation histamine antagonist.	
Purity: Clinical Data: Size:	percent of patients had symptomatic relief wi 99.85% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	ith a twice daily ۲۹۹۹ ۳۰۵۴ میل ۲۹۹۹ ویل ۲۹۹۹ میل ۲۹۹۹ میل ۲۹۹۹۹ میل ۲۹۹۹ میل ۲۹	Purity: Clinical Data: Size:	>98% Launched 100 mg, 200 mg	
Azelastine	hydrochloride	Cat. No.: HY-B0462	Bamirastine (TAK-427)	9	Cat. No. : HY-101601
Bioactivity:	Azelastine HCl is a potent, second-generation histamine antagonist.		Bioactivity:	Bamirastine inhibits ligand binding to rec histamine H $_1$ receptors (rhH_1R) with an nM.	ombinant human
Purity: Clinical Data: Size:	99.95% Launched 10mM x 1mL in DMSO, 100 mg, 200 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	0 ^{2,0~,65%}
Bavisant (JNJ-3100107	4)	Cat. No .: HY-14880	Bavisant di	hydrochloride	Cat. No .: HY-14880A
Bioactivity:	Bavisant (JNJ-31001074) is a highly selective, antagonist of the human H3 receptor with a r action, involving wakefulness and cognition, v a treatment for ADHD.	novel mechanism of	Bioactivity:	Bavisant Hcl (JNJ-31001074) is a highly se active antagonist of the human H3 recep mechanism of action, involving wakefulne potential as a treatment for ADHD.	tor with a novel
Purity: Clinical Data: Size:	>98% Phase 2 5 mg, 10 mg, 50 mg, 100 mg	a.d'a.	Purity: Clinical Data: Size:	>98% Phase 2 5 mg, 10 mg, 50 mg, 100 mg	℃ ¹ ℃ #a #a
Bavisant di (JNJ31001074	hydrochloride hydrate AAC)	Cat. No. : HY-14880B	Bepotastin	e Beslilate	Cat. No.: HY-A0015
Bioactivity:	Bavisant Hcl hydrate(JNJ-31001074) is a highl orally active antagonist of the human H3 rece mechanism of action, involving wakefulness a potential as a treatment for ADHD.	eptor with a novel	Bioactivity:	Bepotastine Beslilate (Bepreve) is a histar anatagonist.	nine H1 receptor
Purity: Clinical Data: Size:	99.77%	C, C, C, C, C, K, +a +a +a No	Purity: Clinical Data: Size:	99.36% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	\$antor
Betahistine	dihydrochloride	Cat. No.: HY-B0524A	Bilastine		Cat. No.: HY-14447
Bioactivity:	Betahistine Dihydrochloride is a histamine H3 inhibitor used as an antivertigo drug.	receptors	Bioactivity:	Bilastine is a selective histamine H1 recept for treatment of allergic rhinoconjunctivities	5
Purity: Clinical Data: Size:	99.88% Launched 10mM x 1mL in Water, 1 g, 5 g, 10 g	HCI HCI	Purity: Clinical Data: Size:	99.95% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	

160 Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

BMY-2527	1		Brompheni	ramine maleate	
		Cat. No.: HY-100191			Cat. No.: HY-B048
Bioactivity:	BMY-25271 is a histamine H2 receptor antag	gonist.	Bioactivity:	Brompheniramine maleate is a histam antagonist.	ine H1 receptors
Purity:	>98%		Purity:	99.95%	$\langle \rangle$
Clinical Data:	No Development Reported	N - MALIN	Clinical Data:	Launched	N N
Size:	1 mg, 5 mg, 10 mg	-N OLS N NSO	Size:	10mM x 1mL in DMSO,	Br Ni Ho-O S-oH
				50 mg, 100 mg	но-
Carbinoxar	nine maleate salt		Cetirizine		
		Cat. No.: HY-B1589A			Cat. No.: HY-1704
Bioactivity:	Carbinoxamine maleate salt is a histamine H I antagonist.	L receptor	Bioactivity:	Cetirizine, a second-generation antihis metabolite of hydroxyzine, and a race inverse agonist used in the treatment angioedema, and urticaria. IC50 value: receptor Cetirizine crosses the blood-l	mic selective H1 receptor of allergies, hay fever, Target: Histamine H1
Purity:	99.78%		Purity:	>98%	
Clinical Data: Size:	Launched 10mM x 1mL in Water,		Clinical Data: Size:	Launched 100 mg, 200 mg, 500 mg	
5120.	100 mg, 500 mg	HO-CO HO-CO HO-CO HO-CO	5128.	100 mg, 200 mg, 300 mg	and Chron
Cetirizine [04 dihydrochloride	Cat. No.: HY-17042AS	Cetirizine D	08 dihydrochloride	Cat. No. : HY-17042A
		Cal. NO HT-1/042A3			Cat. NO., HT-17042A
Bioactivity:	Cetirizine D4 2Hcl is deuterium labeled Cetiriz major metabolite of hydroxyzine, and a racem receptor inverse agonist.		Bioactivity:	Cetirizine D8 2Hcl is deuterium labelee major metabolite of hydroxyzine, and receptor inverse agonist.	
Purity:	>98%	~	Purity:	>98%	
· · · · · · · · · · · · · · · · · · ·	No Development Reported 1 mg, 5 mg			No Development Reported 1 mg, 5 mg	
Cetirizine c	lihydrochloride		Chlorcycliz	ine hydrochloride	
(P071)		Cat. No.: HY-17042A			Cat. No.: HY-11206
Bioactivity:	Cetirizine 2Hcl, a second-generation antihistar metabolite of hydroxyzine, and a racemic sele inverse agonist used in the treatment of allerg angioedema, and urticaria. IC50 value: Target: recenter Cetirizine crosses the blood-brain ba	ctive H1 receptor jies, hay fever, Histamine H1	Bioactivity:	Chlorcyclizine hydrochloride is a hista	mine H1 antagonist.
Purity:	receptor Cetirizine crosses the blood-brain ba 99.17%	inci oniy	Purity:	99.90%	~
Clinical Data:		Q	Clinical Data:		\bigcirc
Size:	10mM x 1mL in DMSO,	and Querran	Size:	10mM x 1mL in DMSO,	
	100 mg, 200 mg, 500 mg	на на С		100 mg, 200 mg, 500 mg	HCI
Chloropyra	mine hydrochloride		-	ramine maleate	
		Cat. No.: HY-B1305	(Chlorphenan	nine maleate)	Cat. No.: HY-B028
Bioactivity:	Chloropyramine hydrochloride is a histamine antagonist which can also inhibit the biochem VEGFR-3 and FAK .	•	Bioactivity:	Chlorpheniramine maleate is an histar antagonist with IC50 of 12 nM.	nine H1 receptor
Purity:	99.30%	Į.	Purity:	99.91%	r≈n rri ^{Ci}
	No Development Reported	~~~ ^N ~	Clinical Data:	Launched	
		A L			
Clinical Data: Size:	10mM x 1mL in DMSO, 50 mg		Size:	10mM x 1mL in DMSO, 1 g, 5 g	N HOLO

Chlorphene		CI-949	
	Cat. No.: HY		Cat. No.: HY-U0036
Bioactivity:	Chlorphenoxamine is an antihistamine and anticholinergic use as an antipruritic and antiparkinsonian agent.	d Bioactivity:	CI-949 is an allergic mediator release inhibitor, which inhibits histamine , leukotriene C_a/D_a (LTC _a /LTD _a), and
			thromboxane B₂ (TXB₂) release with IC₅₀s of 11.4 μ M, 0.5
			μ M and 0.1 μ M, respectively.
Denter	05.00%	Duritar	
Purity: Clinical Data:	95.09% c	Purity:	>98% No Development Reported
Size:	10mM x 1mL in DMSO,	Size:	1 mg, 5 mg, 10 mg, 20 mg
	50 mg	·o~~~N	~^
Cimetidine		Cinnarizine	2
(SKF-92334)	Cat. No.: HY		Cat. No.: HY-B109
Bioactivity:	Cimetidine is a histamine-2 (H2) receptor antagonist.	Bioactivity:	Cinnarizine is an antihistamine and a calcium channel blocker, promote cerebral blood flow, used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis.
Purity:	98.0%	Purity:	98.0%
Clinical Data:			
Size:	1 g, 5 g, 10 g	Size:	10mM x 1mL in DMSO,
Cipralisant		Ciproxifan	
(GT-2331)	Cat. No.: HY-		Cat. No.: HY-1456
Bioactivity:	Cipralisant is a potent and selective histamine H3 receptor antagonist in vivo, and an agonist in vitro, with a pK _i of 9.9 for histamine H3 receptor and a K _i of 0.47 nM for	Bioactivity:	Ciproxifan(FUB-359) is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.
	rat histamine H3 receptor; Cipralisant has entered in clinical trials for the treatment of attention-deficit hyperactivity >98%		
Purity:	>98% No Development Reported	Purity:	>98% No Development Reported
Size:	250 mg, 500 mg		S mg, 10 mg, 50 mg
Ciproxifan	maleate	Clemastine	e fumarate
(FUB 359 mal	eate) Cat. No.: HY	-15289 (HS-592 (fum	narate); Meclastine (fumarate)) Cat. No.: HY-B0298
Bioactivity:	Ciproxifan maleate(FUB-359 maleate) is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.	Bioactivity:	Clemastine (fumarate) (HS-592 (fumarate)) is a selective histamine H1 receptor antagonist with IC $_{50}$ of 3 nM.
Purity:	99.56%	Purity:	99.82%
Clinical Data:	No Development Reported	Clinical Data:	: Launched
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	^о Сон Size:	10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg
Clemizole	Cot No. (1)		hydrochloride
D	Cat. No.: HY		Cat. No.: HY-30234
Bioactivity:	Clemizole is an H1 histamine receptor antagonist, is found to substantially inhibit HCV replication. The IC ₅₀ of	Bioactivity:	Clemizole hydrochloride is an H1 histamine receptor antagonist, is found to substantially inhibit HCV
	Clemizole for RNA binding by NS4B is 24 ± 1 nM, whereas its		replication. The IC ₅₀ of Clemizole for RNA binding by NS4B is
	EC_{50} for viral replication is 8 μ M.		24±1 nM, whereas its EC_{50} for viral replication is 8 µM.
	>98%	Purity:	99.32%
Purity:			^
Purity: Clinical Data:	Launched	🚬 🖂 🚽 Clinical Data:	Launched
	Launched 5 mg, 10 mg, 50 mg	Clinical Data:	Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

CP-66948		Cat. No. : HY-19048	Cyprohepta	adine hydrochloride sesquihyd	rate Cat. No.: HY-B116
Bioactivity:	CP-66948 is a histamine H2-receptor antag gastric antisecretory activity and mucosal pro properties.	onist with	Bioactivity:	Cyproheptadine hydrochloride sesqui and is an antagonist of serotonin and	hydrate is an antihistamine
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	$\sim \int_{a}^{a} \int_{a}^{a} \frac{1}{2} \int_{a}^{a} \frac{1}{2$	Purity: Clinical Data: Size:	99.20% Launched 10mM x 1mL in DMSO, 100 mg	() +-0 1540
Decloxizine (UCB-1402; N		Cat. No. : HY-17582		e dihydrochloride hydrochloride)	Cat. No.: HY-A007
Bioactivity:	Decloxizine(UCB-1402; NSC289116) is a hista antagonist.		Bioactivity:	Decloxizine dihydrochloride(UCB-140) histamine 1 receptor antagonist.	
Purity: Clinical Data: Size:	>98% Launched 50 mg, 100 mg, 500 mg	C Constant	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg	0 0 100 100 100 100 100 100 100 100 100
Desloratad (Sch34117)	ine	Cat. No.: HY-B0539	-	neniramine maleate heniramine maleate salt)	Cat. No.: HY-B106
Bioactivity:	Desloratadine(Sch34117) is a potent antagon histamine H1 receptor used to treat allergies.		Bioactivity:	Dexchlorpheniramine maleate is an ar anticholinergic properties, used to tre	
Purity: Clinical Data: Size:	99.75% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg	G-CONN	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 200 mg	
Dimenhydr	inate	Cat. No.: HY-B1215	Diphenhyd	ramine hydrochloride	Cat. No.: HY-B0303
Bioactivity: Purity: Clinical Data: Size:	Dimenhydrinate is an anti-emetic and anti-hi available over-the-counter as a motion sickne 99.89% Launched 10mM x 1mL in DMSO, 100 mg		Bioactivity: Purity: Clinical Data: Size:	Diphenhydramine HCI (Benadryl), a hi as an antiemetic, antitussive, for derm for hypersensitivity reactions, as a hyp antiparkinson, and as an ingredient in preparations. Target: Histamine H1 re 99.75% Launched 10mM x 1mL in DMSO, 250 mg, 500 mg, 5 g	natoses and pruritus, onotic, an ocommon cold
	raline hydrochloride ethoxy-1-methylpiperidine hydrochloride)	Cat. No.: HY-B0970	Doxylamin	e D5 succinate	Cat. No.: HY-A0069
Bioactivity:	Diphenylpyraline Hcl is a first-generation anti anticholinergic effects, acts as a dopamine re inhibitor, shows to be useful in the treatment Parkinsonism.	uptake	Bioactivity:	Doxylamine D5 succinate is deuterium is a first generation antihistamine.	n labeled Doxylamine, which
Purity: Clinical Data: Size:	99.02% Launched 10mM x 1mL in Water,	N N	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	

Doxylamin		at. No.: HY-A0069	Ebastine (LAS-W 090; F	RP64305) Cat. 1	No.: HY-B0674
Bioactivity:	Doxylamine (succinate) is a first generation antihista can be used by itself as a short-term sedative and in combination with other drugs to provide night-time cold relief.	1	Bioactivity:	Ebastine(LAS-W 090;RP64305) is a long-acting and sele H1-histamine receptor antagonist. Target: Histamine H2 Receptor Ebastine is a H1 antihistamine with low poten causing drowsiness. Ebastine (10 mg orally) causes brai histamine H1-receptor occupation of approximately 10	1 tial for n
Purity: Clinical Data: Size:	99.77% Launched 10mM x 1mL in DMSO, 100 mg		Purity: Clinical Data: Size:	99.96%	yourout
Ebrotidine (FI3542)	c	at. No .: HY-15538	Epinastine (WAL801)	Cat.	No.: HY-B0640
Bioactivity:	Ebrotidine(FI 3542) is a competitive H2-receptor ant (Ki= 127.5 nM) with a potent antisecretory activity a evidenced gastroprotection.	agonist	Bioactivity:	Epinastine(WAL801) is an antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis.	
Purity: Clinical Data: Size:	97.78% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	"Of grand and and a start of the second and a start of the second and the second	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg	H ₂ N K N
Famotidine (MK-208)		at. No.: HY-B0377	Fenspiride	Hydrochloride Cat. I	No.: HY-A0027
Bioactivity:	Famotidine (MK-208) is a competitive histamine H2- antagonist. Its main pharmacodynamic effect is the of gastric secretion.		Bioactivity:	Fenspiride Hcl is an α adrenergic and H1 histamine rece antagonist.	eptor
Purity: Clinical Data: Size:	98.17% Launched 10mM x 1mL in DMSO, 1 g, 5 g	of g and a set of the	Purity: Clinical Data: Size:	99.03% Launched 10mM x 1mL in DMSO, 100 mg	C N N NH
Fexofenadi (MDL-16455 I		t. No. : HY-B0801S		ne hydrochloride (MDL-16455 hydrochloride; arboxylate hydrochloride) Cat. N	o.: HY-B0801A
Bioactivity:	Fexofenadine D6 is deuterium labeled is Fexofenadi an antihistamine pharmaceutical drug.	ne, which is	Bioactivity:	Fexofenadine hydrochloride (MDL-16455 hydrochloride Terfenidine carboxylate hydrochloride), a H1R antagon an anti-allergic agent used in seasonal allergic rhinitis a chronic idiopathic urticarial (person aged \geq 16 years) ^[1]	ist, is Ind
Purity: Clinical Data: Size:	98.0% No Development Reported 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	99.61% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	а Королори на Сулбан
FRG8701	Cat	t. No.: HY-U00238	GSK189254		No.: HY-14111
Bioactivity:	FRG-8701 is a new Histamine H₂-receptor antagor an IC_{50} of ranging from 0.25 to 0.43 μ M.	nist with	Bioactivity:	GSK189254A (GSK189254) is a novel, potent and select histamine H3 receptor antagonist with pK _i values of 9.9 and 8.51-9.17 for human and rat H3, respectively.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	a.u _{r~} 0.0	Purity: Clinical Data: Size:	98.58% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	<

H3 recepto	r antagonist 1 Cat. No.: HY-U00269	H3 recepto	or-MO-1 Cat. No.: HY-U00339
Bioactivity:	H3 receptor antagonist 1 is an antagonist of histamine H3 receptor, used in the research of neurological disease.	Bioactivity:	H3 receptor-MO-1 is a modulator of histamine H3 receptor .
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
H3R-IN-1 H	lydrochloride Cat. No.: HY-112219A	H4 Recept	or antagonist 1 Cat. No.: HY-114025
Bioactivity:	H3R-IN-1 Hydrochloride is a histamine receptor 3 (H3R) inverse agonist extracted from patent WO2013107336A1, compound example 2.	Bioactivity:	H4 Receptor antagonist 1 is a potent and selective histamine H4 receptor inverse agonist, with an IC₅₀ of 19 nM.
Purity: Clinical Data: Size:	95.52% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.70% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
H4R antago	onist 1 Cat. No.: HY-111501	Histamine (Ergamine)	Cat. No. : HY-B1204
Bioactivity:	H4R antagonist 1 is a potent and highly selective histamine H4 receptor (H4R) antagonist with an IC $_{50}$ of 27 nM. H4R antagonist 1 does not show any noticeable binding affinity	Bioactivity:	Histamine is an organic nitrogenous compound involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Size:	99.96% Launched 10mM x 1mL in Water, 100 mg
Histamine (Histamine di		Hydroxyzir	ne Cat. No.: HY-B0548
Bioactivity:	Histamine diphosphate is a potent agonist of histamine receptors and vasodilator. It can activate nitric oxide synthetase.	Bioactivity:	Hydroxyzine is a histamine H1-receptor antagonist.
Purity: Clinical Data: Size:	99.79% Launched HK Mater, Ho-F-on 1 g	Purity: Clinical Data: Size:	>98% Launched 100 mg, 500 mg
Hydroxyzin	e D4 dihydrochloride Cat. No.: HY-B0548AS	Hydroxyzir	ne dihydrochloride Cat. No.: HY-B0548A
Bioactivity:	Hydroxyzine D4 2Hcl is deuterium labeled Hydroxyzine, which is a histamine H1-receptor antagonist.	Bioactivity:	Hydroxyzine Dihydrochloride is a histamine H1-receptor antagonist. Target: Histamine H1-Receptor Hydroxyzine inhibits carbachol (10 μ M)-induced serotonin release by 34% at 10 μ M, by 25% 1 μ M and by 17% 0.1 μ M in pretreated bladder slices for
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	60 min [1]. Hydroxyzine (0.1 mM) treatment inhibits the 99.96% Launched 10mM x 1mL in Water, 100 mg, 500 mg

Hydroxyzin	ne pamoate Cat. No.: HY-B0895	JNJ-39758979	Cat. No. : HY-1011
	Cat. No.: H1-D0093		
Bioactivity:	Hydroxyzine pamoate is a histamine H1-receptor antagonist. Target: Histamine H1-Receptor Hydroxyzine inhibits carbachol (10 μ M)-induced serotonin release by 34% at 10 μ M, by 25% 1 μ M and by 17% 0.1 μ M in pretreated bladder slices for 60 min [1]. Hydroxyzine (0.1 mM) treatment inhibits the progression and		elective, high-affinity histamine H_4 with a K_i of 12.5 nM.
Purity:	>98%	Purity: 98.01%	
Clinical Data:	Launched	Clinical Data: No Development Re	ported H2N+- CN
Size:	100 mg	Size: 10mM x 1mL in DMS 1 mg, 5 mg, 10 mg, 5	
JNJ-520785	52	JNJ-7777120	
	Cat. No.: HY-12190		Cat. No.: HY-135
Bioactivity:	JNJ-5207852 is a selective and potent $\mathbf{histamine} \; \mathbf{H_3}$		ective H4R antagonist with Ki of 4 ± 1 nM,
	receptor (H $_3$ R) antagonist, with pK _i s of 8.9, 9.24 for rat and human H $_3$ R, respectively.	exhibits >1000-fold : receptors.	selectivity over the other histamin
Purity:	98.0%	Purity: 99.96%	
Clinical Data:	No Development Reported 10mM x 1mL in DMSO,	Clinical Data: No Development Re	
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Size: 10mM x 1mL in DMS 5 mg, 10 mg, 50 mg,	
Ketotifen fu		KP136	
(HC 20511 fur	marate) Cat. No.: HY-B0157A	(AL136)	Cat. No.: HY-U001
Bioactivity:	Ketotifen (fumarate) is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer, which is used to prevent asthma attacks.		fective antiallergic agent. The IC₅₀ is mine release and 63 ug/mL for
Purity:	99.92%	Purity: >98%	
Clinical Data: Size:	0	Clinical Data: No Development Re Size: 1 mg, 5 mg, 10 mg, 2	
	200 mg, 1 g		U
Lafutidine		Latrepirdine dihydrochloride	
(FRG-8813)	Cat. No.: HY-B0160	(Dimebolin dihydrochloride)	Cat. No.: HY-145
Bioactivity:	Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion.	antagonist activity at serotonergic recepto	chloride is a neuroactive compound with t histaminergic, α -adrenergic, and rs. Latrepirdine stimulates amyloid
		secretion.	PP) catabolism and amyloid-β (Αβ)
Purity:	97.86%	Purity: 99.75%	No N
Clinical Data: Size:	Launched C'Ca 10mM x 1mL in DMSO, A 2 2	Clinical Data: Launched Size: 10mM x 1mL in DMS	
nze.	10 mg, 50 mg		ьо, 50 mg, 100 mg, 200 mg
evodropro	ppizine	Lodoxamide	
DF-526; (S)-(-)-Dropropizine) Cat. No.: HY-B1895		Cat. No.: HY-142
Bioactivity:	Levodropropizine (DF-526) is a histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive drug.		tiallergic compound acting as a mast-cell Itment of asthma and allergic
Purity:	99.92%	Purity: 98.00%	
Clinical Data:		Clinical Data: Launched	
Size:	10mM x 1mL in DMSO, 50 mg, 100 mg	Size: 10mM x 1mL in DMS 5 mg, 10 mg, 50 mg,	
3126.			

Lodoxamid (U 42585 E)	e tromethamine	Cat. No.: HY-16289	Loratadine (SCH 29851; L	oratidine)	Cat. No.: HY-1704
(U 42585 E) Bioactivity:	Lodoxamide tromethamine (U 42585 E) is a me		Bioactivity:	Loratadine(SCH-29851) is a selective inverse p	
	treatment of prophylaxis of mast cell-mediated disease.			histamine H1-receptor agonist with an IC50 o value: 32 uM Target: H1-receptor Loratadine i antihistamine that inhibits histamine-induced IL-6 and IL-8 secretion in endothelial cells.	f >32 μM. IC50 s a non-sedative
Purity:	98.0%	Ν	Purity:	99.95%	ci (
Clinical Data:		ѩӷѯӄѺӈҲҹ	Clinical Data:		Ϋ́ν.
Size:	10mM x 1mL in DMSO, 1 mg, 5 mg		Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	of q
Mebhydrol	in		Mebhydrol	in napadisylate	
		Cat. No.: HY-B1303A	(Mebhydrolin	e 1,5-naphthalenedisulfonate salt)	Cat. No.: HY-B130
Bioactivity:	Mebhydrolin is a specific histamine H₁ recep t antagonist.	tor	Bioactivity:	Mebhydrolin napadisylate is a specific histam receptor antagonist.	ine H ₁
Purity:	99.46%		Purity:	99.53%	<u>م</u> م
Clinical Data:			Clinical Data:		0°0, 0°0
Size:	10mM x 1mL in DMSO, 100 mg		Size:	10mM x 1mL in DMSO, 100 mg	
	lihydrochloride		Mepyramir		
(Meclozine di	hydrochloride; NSC28728)	Cat. No.: HY-B0349	(Pyrilamine m		Cat. No.: HY-B12
Bioactivity:	Meclizine is a histamine H1 receptor antagonis nausea and motion sickness Target: Histamine Meclizine is a histamine H1 receptor antagonis	H1 Receptor	Bioactivity:	Mepyramine maleate, a first generation antihi antagonist of histamine H1 receptor , with K	<mark>d</mark> s of 0.8 nM,
	nausea and motion sickness, possesses antiche nervous system depressant, and local anesthet	olinergic, central		5200 nM and >3000 nM for H1, H2, and H3 respectively, and a $\mathbf{pK}_{\mathbf{d}}$ of 9.4 for H1 receptor	
Purity:	99.97%		Purity:	99.0%	~~n~
Clinical Data: Size:	10mM x 1mL in DMSO, 100 mg, 5 g		Size:	No Development Reported 10mM x 1mL in DMSO, 100 mg	HO CON
Mequitazin	e		Metiamide		
(LM-209)		Cat. No.: HY-B2168	(SK&F 92058)		Cat. No.: HY-1554
Bioactivity:	Mequitazine is a potent, nonsedative and long $\mathbf{H_1}$ antagonist.	-acting histamine	Bioactivity:	Metiamide (SK&F 92058) is a histamine H2-re antagonist developed from another H2 antag	
Purity:	99.93%		Purity:	97.31%	
Clinical Data: Size:	Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	N S	Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	N H S S S S S S S S S S S S S S S S S S
Mianserin				nydrochloride	
(Mianserine)		Cat. No.: HY-B0188	(Org GB 94)		Cat. No.: HY-B0188
Bioactivity:	Mianserin is a H1 receptor inverse agonist and psychoactive agent of the tetracyclic antidepre		Bioactivity:	Mianserin hydrochloride is a H1 receptor inve is a psychoactive agent of the tetracyclic antio Target: H1 receptor Mianserin is a psychoactiv tetracyclic antidepressant (TeCA) therapeutic classified as a noradrenergic and specific sero	lepressant. ve drug of the family. It is
Purity:	>98%	~_N′	Purity:	99.79%	/-N
Clinical Data: Size:	Launched 100 mg, 200 mg, 500 mg	N	Clinical Data: Size:	Launched 10mM x 1mL in DMSO,	

Mizolastine	Cat. No.: HY-B0164	Mizolastine	e dihydrochloride	Cat. No.: HY-B01644
Bioactivity:	Mizolastine is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.	Bioactivity:	Mizolastine dihydrochloride is a histamine H1-rec antagonist with IC50 of 47 nM used in the treatm fever (seasonal allergic rhinitis), hives and other a reactions.	eptor ent of hay
Purity: Clinical Data: Size:	99.33% Launched 100 mg, 200 mg, 500 mg	Purity: Clinical Data: Size:	>98% Launched 100 mg, 200 mg, 500 mg	
MK-0249	Cat. No. : HY-U00076	N-Acetylhi (N-Omega-ac		Cat. No.: HY-11217
Bioactivity:	MK-0249 is a potent histamine H3 receptor antagonist, with K_i of 1.7 nM for human H3.	Bioactivity:	N-Acetylhistamine is a histamine metabolite. N-a can be used as a potential biomarker of histidine for anaphylactoid reactions.	,
Purity: Clinical Data: Size:	>98% Phase 2 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	98.99% No Development Reported 10mM x 1mL in DMSO, 50 mg	
Nedocromi (FPL 59002)	il Cat. No.: HY-13448	Nedocrom (FPL 59002KP	il sodium ; Nedocromil disodium salt)	Cat. No.: HY-1634
Bioactivity:	Nedocromil suppresses the action or formation of multiple mediators, including histamine , leukotriene C_4 (LTC_4), and prostaglandin D_2 (PGD_2).	Bioactivity:	Nedocromil sodium suppresses the action or form multiple mediators, including histamine , leukotr LTC_4), and prostaglandin D_2 (PGD ₂).	
Purity: Clinical Data: Size:	95.66% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	~ijçir~
Niperotidin	1e Cat. No.: HY-15539	Nizatidine		Cat. No.: HY-B031
Bioactivity:	Niperotidine is a histamine H2-receptor antagonist.	Bioactivity:	Nizatidine is a histamine H2 receptor antagonist to toxicity that inhibits gastric acid secretion.	with low
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	99.49% Launched 10mM x 1mL in DMSO, 1 g, 5 g	-N-S
Olopatadin (ALO4943A; K	e hydrochloride (W4679) Cat. No.: HY-B0426A	Osthole (NSC 31868; 0	Osthol; Ostol)	Cat. No.: HY-N005
Bioactivity:	Olopatadine HCl is a histamine blocker used to treat allergic conjunctivitis.	Bioactivity:	Osthole is a natural antihistamine alternative. Ost a potential inhibitor of histamine H_1 receptor as	
Purity: Clinical Data: Size:	99.55% Launched 10mM x 1mL in DMSO,	Purity: Clinical Data: Size:	99.90% No Development Reported 10mM x 1mL in DMSO, 250 mg, 1 g, 5 g	

Pemirolast (TWT-8152; B	•	Cat. No.: HY-B0538A	Peptide 40	1	Cat. No.: HY-1253
Bioactivity: Purity: Clinical Data: Size:	Pemirolast Potassium (BMY 26517) is a hista and mast cell stabilizer that acts as an antial Target: Histamine H1 Receptor Pemirolast p is a new oral, nonbronchodilator antiallergy is being evaluated for the therapy of asthma 99.96% Launched 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg	llergic agent. botassium (BMY 26517) medication that	Bioactivity: Purity: Clinical Data: Size:	Peptide 401, a potent mast cell degranulating venom, suppresses the increased vascular per intradermal injection of various smooth musch histamine , and 5-HT). 98.29% No Development Reported 500u g, 1 mg, 5 mg	meability due to
Perphenazi	ne	Cat. No.: HY-A0077	Perphenazi	ne D8 Dihydrochloride	Cat. No.: HY-A0077A
Bioactivity:	Perphenazine is a typical antipsychotic drug 5-HT_{2A}receptor, Alpha-1A adrenergic rec receptor D2/D3, D2L receptor , and Histar with K ₁ values of 5.6, 10, 0.765/0.13, 3.4, and	ceptor, Dopamine nine H1 receptor,	Bioactivity:	Perphenazine D8 Dihydrochloride is the deute Perphenazine, which is a typical antipsychotic Dopamine receptor ligand).	
Purity: Clinical Data: Size:	99.90% Launched 10mM x 1mL in DMSO, 1 g, 5 g	How the state of t	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	
PF-3893787	7 hydrochloride	Cat. No. : HY-19705B	Pheniramin	ne Maleate	Cat. No. : HY-B097
Bioactivity:	PF-3893787 hydrochloride is a novel histan antagonist binding affinity (K_i =2.4 nM) and functional (K_i =1.56 nM) antagonist.		Bioactivity:	Pheniramine Maleate ia an antihistamine and	vasoconstrictor.
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	A N A HI N N H H H H H H H H H H H H H H H H H H	Purity: Clinical Data: Size:	99.88% Launched 10mM x 1mL in Water, 100 mg, 500 mg	CN HOCOLOH
Pimethixen (Pimetixene)	e	Cat. No. : HY-B1101	Pimethixen (Pimetixene n		Cat. No. : HY-B1101
Bioactivity:	Pimethixene is antihistamine and antiseroto acts as an antimigraine agent. Pimethixene antagonist of 5-HT $_{1A'}$ 5-HT $_{2A'}$ 5-HT $_{2B'}$ 5-H histamine H $_{1'}$ dopamine D $_2$ and D $_{4.4}$ as w	is a highly potent HT _{2C'}	Bioactivity:	Pimethixene maleate is antihistamine and anti compound, acts as an antimigraine agent. Pim is a highly potent antagonist of 5-HT $_{1A'}$ 5-HT 5-HT $_{2C'}$ histamine H $_1$, dopamine D $_2$ and D $_2$	ethixene maleate _{2A} , ^{5-HT} _{2B} ,
Purity: Clinical Data: Size:	>98% Launched 10 mg		Purity: Clinical Data: Size:	>98% No Development Reported 10 mg	HO ^L OH
Pirolate (CP-32387)		Cat. No.: HY-100280	Pitolisant (Tiprolisant)		Cat. No.: HY-1219
Bioactivity:	Pirolate is a histamine H1 receptor.		Bioactivity:	Pitolisant is a potent and selective nonimidate agonist at the recombinant human histamine \mathbf{K}_{i} =0.16 nM).	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	topic.	Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg	g


Pitolisant h (Ciproxidine;	ydrochloride BF 2649)	Cat. No.: HY-12199B	Pitolisant o (Tiprolisant o		Cat. No.: HY-12199A
Bioactivity:	Pitolisant hydrochloride is a potent and selectiv nonimidazole inverse agonist at the recombinar histamine H3 receptor (K _i =0.16 nM).		Bioactivity:	Pitolisant oxalate is a potent and selecti inverse agonist at the recombinant hum receptor (κ_i =0.16 nM).	
Purity: Clinical Data: Size:	99.22% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	Creation and a	Purity: Clinical Data: Size:	>98% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	Crimer and a second sec
Promethaz	ine hydrochloride	Cat. No .: HY-B0781	Quinotolas (FR71021)	t sodium	Cat. No.: HY-U00027
Bioactivity:	Promethazine Hcl(NSC-231688) is the first-gene antihistamine; strong antagonist of the H1 recep moderate mACh receptor antagonist, moderate 5-HT2A, 5-HT2C, D2 and α1-adrenergic receptor	otor and affinity for	Bioactivity:	Quinotolast sodium in the concentration inhibits histamine , LTC ₄ and PGD ₂ rele concentration-dependent manner.	
Purity: Clinical Data: Size:	99.82% Launched 1 g, 5 g	N S H-Cl	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	NA INV.N
Ranitidine	hydrochloride	Cat. No.: HY-B0281A		hydrochloride 9 hydrochloride)	Cat. No.: HY-101724
Bioactivity:	Ranitidine is a histamine H2-receptor antagonis stomach acid production.	t that inhibits	Bioactivity:	ReN 1869 hydrochloride is a novel, sele receptor antagonist, which demonstrat histamine H ₁ receptor (guinea pig brain $0.19\pm0.04 \mu$ M and the non-selective σ s	es affinity to the n) with K _i of
Purity: Clinical Data: Size:	99.48% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	()	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	СССО н-а Модан
Rocastine (AHR-11325)		Cat. No. : HY-101745	Roxatidine (HOE 760)	Acetate Hydrochloride	Cat. No.: HY-B0305A
Bioactivity:	Rocastine is a selective, nonsedating H1 antago as an antihistamine.	nist, acting	Bioactivity:	Roxatidine Acetate HCl is a specific and H2 receptor antagonist.	competitive histamin
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	98.87% Launched 10mM x 1mL in Water, 1 g, 5 g	jal ^g ~~Q~Q
S 38093		Cat. No.: HY-104003	SUN 1334H	I	Cat. No.: HY-U00084
Bioactivity:	S 38093 is a brain-penetrant antagonist of H3 r K_i of 8.8, 1.44 and 1.2 μ M for rat, mouse and hu receptors, respectively.		Bioactivity:	SUN 1334H is a potent, orally active, hig receptor antagonist, with $\mathbf{K}_{\mathbf{j}}$ of 9.7 nM.	
Purity: Clinical Data: Size:	99.02% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data: Size:	95.0% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	,000,000 ,000,000

Toreforant (JNJ-3851816	8) Cat. No.: HY-16	-	mine hydrochloride	Cat. No.: HY-17428
Bioactivity: Toreforant is a potent and selective histamine H $_4$ receptor (H4R) antagonist, with a \mathbf{K}_i at the human receptor of 8.4 nM.		Bioactivity:	Tripelennamine Hcl, a H1-receptor antagonist, is a psychoactive drug and member of the pyridine andethylenediamine classes that is used as an antipruritic and first-generation antihistamine. IC50 Value: Target: Histamine H1 receptor Tripelennamine can be used in the treatment of	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Or Size:	99.87% Launched 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg, 1 g, 5 g	H-CI
VUF10460		Wy 49051		
Bioactivity:	Cat. No.: HY-101- VUF10460 is a non-imidazole histamine H4 receptor agonist; binds to rat H4 receptor with a pK _i of 7.46.	Bioactivity:	Wy 49051 is a potent, orally active H1 receptor a with IC₅₀ of 44 nM.	Cat. No.: HY-101830 antagonist,
Purity: Clinical Data: Size:	98.37% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	245-05-0
Zaltidine (CP-57361)	Cat. No.: HY-15:	541		
Bioactivity:	Zaltidine(CP-57361) is a H2-receptor antagonist, which has the antisecretory action.			
Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg	94 NM-2		



Imidazoline Receptor





HDAC (Histone deacetylase)

Imidazoline receptors are the primary receptors on which clonidine and other imidazolines act. There are three classes of imidazoline receptors: I1 receptor - mediates the sympatho-inhibitory actions of imidazolines to lower blood pressure, (NISCH or IRAS, imidazoline receptor antisera selected), I2 receptor - an allosteric binding site of monoamine oxidase and is involved in pain modulation and neuroprotection, I3 receptor - regulates insulin secretion from pancreatic beta cells. Activated I1-imidazoline receptors trigger the hydrolysis of phosphatidylcholine into DAG. Elevated DAG levels in turn trigger the synthesis of second messengers arachidonic acid and downstreameicosanoids. In addition, the sodium-hydrogen antiporter

is inhibited, and enzymes of catecholamine synthesis are induced. The I1-imidazoline receptor may belong to the neurocytokine receptorfamily, since its signaling pathways are similar to those of interleukins.

Imidazoline Receptor Inhibitors & Modulators

Agmatine s	sulfate	Cat. No.: HY-101238	Allantoin (5-Ureidohyd	antoin)	Cat. No.: HY-N0543
Bioactivity:	Agmatine sulfate exerts modulatory action at r molecular targets, such as neurotransmitter sys channels and nitric oxide synthesis. It is an end agonist at imidazoline receptor and a NO syn inhibitor.	stems, ion logenous	Bioactivity:	Allantoin is a skin conditioning ager skin, stimulates new and healthy tiss	
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g	H ₂ N H ₂ N	Purity: Clinical Data: Size:	98.36% Launched 10mM x 1mL in DMSO, 100 mg	-741.
Moxonidin (BDF5895)	e	Cat. No. : HY-B0374	Moxonidin (BDF5895 hyd	e hydrochloride drochloride)	Cat. No.: HY-B0374A
Bioactivity:	Moxonidine is a selective agonist at the imidaz subtype 1, used as antihypertensive agent.	oline receptor	Bioactivity:	Moxonidine Hydrochloride is a select imidazoline receptor subtype 1, user agent.	5
Purity: Clinical Data: Size:	99.91% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	>98% Launched 10 mg, 50 mg, 100 mg	



Leukotriene Receptor



AHA)

HDAC (Histone deacetylase)

Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may

also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.

Leukotriene Receptor Inhibitors & Modulators

Amelubant (BIIL 284)	Cat. No.: HY-19304	AS-35	Cat. No. : HY-101946
Bioactivity: Purity:	Amelubant (BIIL 284) is a potent, oral and long acting LTB_4 receptor antagonist, negligibly binds to LTB $_4$ receptor, with K_i s of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a prodrug of active metabolites B >98%	Bioactivity: Purity:	AS-35 is an orally effective, potent and selective antagonist of leukotrienes , antagonizes LTC4-, LTD4 and LTE4-induced contractions of the ileum with IC ₅₀ values of 8 nM, 4 nM and 3 nM, respectively, and has antiallergic activities.
	No Development Reported 500 mg, 250 mg		No Development Reported 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
Bunaprolas (U66858)	t Cat. No.: HY-U00170	CI-949	Cat. No.: HY-U00364
Bioactivity:	Bunaprolast (U66858) is a potent inhibitor of LTB ₄ production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of lipoxygenase and TXB₂ release.	Bioactivity:	CI-949 is an allergic mediator release inhibitor, which inhibits histamine , leukotriene C_4/D_4 (LTC ₄ /LTD ₄), and thromboxane B_2 (TXB ₂) release with IC ₅₀ s of 11.4 µM, 0.5 µM and 0.1 µM, respectively.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
CP-105696 (Pfizer 10569)	5) Cat. No.: HY-19193	CP-96486	Cat. No. : HY-100316
Bioactivity:	CP-105696 is a potent and selective Leukotriene B ₄ Receptor antagonist, with an IC_{50} of 8.42 nM.	Bioactivity:	CP-96486 is a potent and orally active leukotriene D $_4$ (LTD $_4$)/platelet activating factor (PAF) receptor antagonist with K ₄ s of 20 and 24 nM, respectively.
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg
Darbufelon (CI-1004 mes	-	DW-1350	Cat. No. : HY-100173
Bioactivity:	Darbufelone mesylate is a dual inhibitor of cellular $PGF_{2\alpha}$ and LTB_4 production. Darbufelone potently inhibits PGHS-2 ($IC_{50} = 0.19 \mu$ M) but is much less potent with PGHS-1 ($IC_{50} = 20 \mu$ M).	Bioactivity:	DW-1350 is a LTB₄ receptor antagonist.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg
Gemilukast (ONO-6950)	Cat. No. : HY-16780	Iralukast (CGP 45715A)) Cat. No.: HY-101944
Bioactivity:	Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT ₁ and CysLT ₂) antagonist, with IC ₅₀ s of 1.7, 25 nM for human CysLT ₁ and CysLT ₂ , respectively.	Bioactivity:	Iralukast is a cysteinyl-leukotriene antagonist (${\rm CysLT}$) with a pK $_{\rm i}$ of 7.8 for ${\rm CysLT_1}$
Purity: Clinical Data: Size:	> 98% No Development Reported 250 mg, 100 mg, 500 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg

КР496	LM-1484
Cat. No.: HY-U00253	Cat. No.: HY-101686
Bioactivity: KP496 is a selective, dual antagonist for Leukotriene D4 receptor and Thromboxane A2 receptor.	Bioactivity: LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for ³ H-LTC4 sites.
Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg
LTD4 antagonist 1 Cat. No.: HY-U00359	LY210073 Cat. No.: HY-U00263
Bioactivity: LTD ₄ antagonist 1 is a potent, orally active antagonist of leukotriene D ₄ (LTD ₄) with a K _i of 0.57 nM.	Bioactivity: LY210073 is a Leukotriene B ₄ (LTB_4) receptor antagonist with an IC ₅₀ of 6.2 nM.
Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg
LY223982	MK-571 sodium salt
(CGS23131; SKF107324) Cat. No.: HY-112737	(L-660711 (sodium salt)) Cat. No.: HY-19989A
Bioactivity: LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC ₅₀ of 13.2 nM against [³ H]LTB4 binding to LTB4 receptor.	Bioactivity: MK-571 sodium salt is a selective, orally active leukotriene D4 receptor antagonist, with K _i s of 0.22 and 2.1 nM in guinea pig and human lung membranes.
Purity: 100.00% Clinical Data: No Development Reported Size: 1 mg, 5 mg	Purity: 99.24% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg
Montelukast sodium (MK0476) Cat. No.: HY-13315	Nedocromil (FPL 59002) Cat. No.: HY-13448
Bioactivity: Montelukast (sodium) (MK0476) is a potent, selective CysLT₁ receptor antagonist.	Bioactivity: Nedocromil suppresses the action or formation of multiple mediators, including histamine, leukotriene C ₄ (LTC ₄), and prostaglandin D ₂ (PGD ₂).
Purity: 99.82% Clinical Data: Launched Size: 10mM x 1mL in Water, 50 mg, 100 mg, 500 mg	Purity: 95.66% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 5 mg, 10 mg
Nedocromil sodium	ONO4057
(FPL 59002KP; Nedocromil disodium salt) Cat. No.: HY-16344	(ONO-LB457) Cat. No.: HY-U00252
Bioactivity: Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C ₄ (LTC ₄), and prostaglandin D ₂ (PGD ₂).	Bioactivity: ONO4057 is a Leukotriene $B^{}_4$ receptor antagonist, with an $\text{IC}^{}_{50}$ of 0.7 \pm 0.3 $\mu\text{M}.$
Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg


176 Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Pranlukast (ONO-1078)	Cat. No.: HY-B0290		hemihydrate hemihydrate)) Cat. No.: HY-B0290A
Bioactivity:	Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes . Pranlukast inhibits [3 H]LTE _{4'} [3 H]LTD _{4'} and [3 H]LTC ₄ bindings to lung membranes with K _i s of 0.63±0.11, 0.99±0.19, and 5640±680	Bioactivity:	Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotriene s. Pranlukast inhibits [3 H]LTE ₄ , [3 H]LTD ₄ , and [3 H]LTC ₄ bindings to lung membranes with K _i s of 0.63±0.11, 0.99±0.19,
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	Purity: Clinical Data: Size:	99.93% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg
Quinotolas (FR71021)	t sodium Cat. No.: HY-U00027	RG-12525 (NID 525)	Cat. No. : HY-101676
Bioactivity:	Quinotolast sodium in the concentration range of 1-100 μ g/mL inhibits histamine , LTC ₄ and PGD ₂ release in a concentration-dependent manner.	Bioactivity:	RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes , LTC4 , LTD4 and LTE4 , inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC₅₀ of 2.6 nM, 2.5 nM and 7 nM,
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	respectively; RG-12525 is also a peroxisome >98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
RS-601	Cat. No.: HY-U00072	Tipelukast (KCA 757; Mi	N 001) Cat. No.: HY-14938
Bioactivity:	RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.	Bioactivity:	Tipelukast (KCA 757) is a sulfidopeptide leukotriene receptor antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% Phase 2 1 mg
YM158 free (YM-57158)	e base Cat. No.: HY-U00355	Zafirlukast (ICI 204219)	Cat. No.: HY-17492
Bioactivity:	YM158 free base is a potent and selective LTD₄ and TXA₂ receptor antagonist with pA₂ values of about 8.87 and 8.81, respectively.	Bioactivity:	Zafirlukast is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist.
Purity:	>98% No Development Reported	Purity: Clinical Data:	99.10% Launched 10mM x 1mL in DMSO,



LPL Receptor

Lysophospholipid Receptor



LPL Receptor (Lysophospholipid Receptor) group are members of the G protein-coupled receptor family of integral membrane proteins that are important for lipid signaling. In humans, there are eight LPL receptors, each encoded by a separate gene. These LPL receptor genes are also sometimes referred to as "Edg". LPL receptor ligands bind to and activate their cognate receptors located in the cell membrane. Depending on which ligand, receptor, and cell type is involved, the activated receptor can have a range of effects on the cell. These include primary effects of inhibition of adenylyl cyclase and release of calcium from the endoplasmic reticulum, as well as secondary effects of preventingapoptosis and increasing cell

proliferation. Type: LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, LPAR6, S1PR1, S1PR2, S1PR3, S1PR4, S1PR5.

LPL Receptor Inhibitors & Modulators

Г

AM095			AM095 fre	e acid	
Bioactivity:	AM095 is a selective LPA₁ receptor antagonist AM095 antagonism of LPA-induced calcium flu LPA ₁ -transfected CHO cells is 0.025 and 0.023	ux of human or mouse	Bioactivity:	AM095 (free acid) is a potent LPA1 receptor at IC_{50} values of 0.98 and 0.73 μ M for recombina LPA1 respectively.	
Purity: Clinical Data: Size:	respectively. 98.14% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg		Purity: Clinical Data: Size:	99.28% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	And
AM966		Cat. No.: HY-15277	Amiselimo (MT-1303 hyd	d hydrochloride	Cat. No .: HY-16734A
Bioactivity:	AM966 is a high affinity, selective, oral LPA₁ -a inhibits LPA-stimulated intracellular calcium re	ntagonist,	Bioactivity:	Amiselimod hydrochloride is a novel sphingos receptor-1 (S1P1) modulator, designed to redu bradycardia effects associated with fingolimod	ine 1-phosphate uce the
Purity:	IC ₅₀ =17 nM). 98.75% No Development Reported	он о	Purity: Clinical Data:	receptor modulators. 99.02%	
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	л ² установ н-р н-р
AS2717638		Cat. No.: HY-114379	ASP-4058		Cat. No.: HY-111021
Bioactivity:	AS2717638 is an oral active lysophosphatidic (LPA5) antagonist in rodents. AS2717638 also improves PGE $_{2^{-7}}$, PGF $_{2\alpha^{-7}}$, and AMPA-induced	significantly	Bioactivity:	ASP-4058 is a next-generation, selective and o agonist for Sphingosine 1-Phosphate receptor and S1P₅), ameliorates rodent experimental a	s 1 and 5 (S1P₁ utoimmune
Purity: Clinical Data: Size:	>98% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg		Purity: Clinical Data: Size:	encephalomyelitis with a favorable safety profi >98% No Development Reported 250 mg, 500 mg	^r ∕~~~~~ ^t , t
ASP6432		Cat. No.: HY-120478	BMS-98602 (AM152)	20	Cat. No.: HY-100619
Bioactivity: Purity:	ASP6432 is a potent and selective type 1 lyso acid receptor (LPA1) antagonist with IC₅₀s of for human LPA1 and rat LPA1, respectively ^[1] . >98% No Development Reported		Bioactivity: Purity: Clinical Data:	BMS-986020 is an LPA1 antagonist. target: LPA in Phase 2 clinical development for treating idi pulmonary fibrosis. BMS-986020 selectively inl receptor, which is involved in binding of the si molecule lysophosphatidic acid, which in turn 99.53%	opathic hibits the LPA gnaling
Size:	500 mg, 250 mg		Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	Chord Hole
Cenerimod (ACT-334441)		Cat. No.: HY-17606	Ceralifimoo (ONO-4641)	d	Cat. No.: HY-12685
Bioactivity:	Cenerimod (ACT-334441) is a potent and orally sphingosine 1-phosphate 1 receptor (S1P1) at from patent WO 2016184939 A1 and WO 2011 with an EC₅₀ of 2.7 nM.	gonist extracted	Bioactivity:	Ceralifimod (ONO-4641) is selective, high pote sphingosine 1-phosphate receptors 1 and 5, w 27.3, 334 pM for human S1P receptor 1 and 5,	rith EC₅₀s of
Purity: Clinical Data: Size:	98.43% Phase 2 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	-ئىمەنىر

CYM-5541 (ML249)	Cat. No.: HY-1	01419 (APD334)	Cat. No.: HY-12789
Bioactivity:	CYM-5541 (ML249) is an selective and allosteric ${\rm S1P_3}$ receptor agonist with an ${\rm EC_{50}}$ between 72 and 132 nM.	Bioactivity:	Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 ($S1P_1$) receptor with an IC_{50} value of 1.88 nM in CHO cells.
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.64% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
Fingolimod (FTY720 free b			l hydrochloride Cat. No.: HY-12005
Bioactivity:	Fingolimod is a sphingosine 1-phosphate (S1P) antagonist with IC₅₀ of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator.	Bioactivity:	Fingolimod hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with an IC₅₀ of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride also is a pak1 activator.
Purity: Clinical Data: Size:	99.95% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg	Purity: Clinical Data: Size:	99.76% Launched 10mM x 1mL in DMSO, 100 mg, 200 mg, 1 g, 5 g
FTY720 (S)- ((S)-FTY720P;	Phosphate (S)-FTY720 phosphate) Cat. No.: HY-	GSK20186	32 Cat. No.: HY-19511
Bioactivity:	FTY720 (S)-Phosphate is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.	Bioactivity:	GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC ₅₀ s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO,	Purity: Clinical Data: Size:	98.23% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Ki16425 (Debio 0719)	Cat. No.: HY-	LPA1 antag	gonist 1 Cat. No.: HY-18076
Bioactivity:	Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with $K_{\rm JS}$ of 0.34 μ M and 0.93 μ M, respectively.	Bioactivity:	LPA1 antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 (LPA1) antagonist with an IC_{50} of 25 nM.
Purity: Clinical Data: Size:	98.67% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
LPA2 antag	onist 1 Cat. No.: HY-	ONO-7300	243 Cat. No.: HY-100882
Bioactivity:	LPA2 antagonist 1 is a LPA2 antagonist with an IC₅₀ of 17 nM.	Bioactivity:	ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC ₅₀ of 0.16 μM.
Purity: Clinical Data: Size:	98.85% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.04% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

Ozanimod (RPC-1063)	Cat. No.: HY-1		dihydrochloride Cat. No.: HY-13447/
Bioactivity:	Ozanimod is a potent and selective $S1P_1$ and $S1P_5$ receptor agonist with EC_{50} s of 410 ± 160 pM and 11 ± 4.3 nM in [³⁵ S]-GTPyS binding, respectively.	Bioactivity:	PF429242 dihydrochloride is a reversible and competitive ${\bf S1P}$ inhibitor with an ${\bf IC_{50}}$ of 175 nM.
Purity: Clinical Data: Size:	99.81% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.76% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Ponesimod (ACT-128800)	Cat. No.: HY-1	0569	ectin-1 Cat. No.: HY-11438
Bioactivity:	Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator.	Bioactivity:	Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA₂) , with an EC₅₀ value of 25 nM for murine LPA ₂ subtype ^[1] .
Purity: Clinical Data: Size:	99.53% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	ారా Purity: Clinical Data: Size:	99.44% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
S1p recepto	or agonist 1 Cat. No.: HY-10	S1P1 Agor	ist III Cat. No.: HY-1283
Bioactivity:	S1p receptor agonist 1 is an S1P receptor agonist extracted from patent WO 2015039587 A1, compound example 2.	Bioactivity:	S1P1 Agonist III is a potent and orally active S1P1 agonist with EC50 of 18 nM; no activity on S1P3.
Purity: Clinical Data: Size:	98.28% No Development Reported 10mM x 1mL in DMSO,	Purity: Clinical Data: Size:	99.83% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg
S1PR1 mod	ulator 1 Cat. No.: HY-12	S1PR1-MO	- 1 Cat. No.: HY-U0036
Bioactivity:	S1PR1 modulator 1 is a selective S1PR1 inhibitor, with a pIC₅₀ of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4 ^[1] .	Bioactivity:	S1PR-MO-1 is the modulator of sphingosine-1-phosphate receptor , used for research of hyperproliferative, inflammatory diseases.
Purity: Clinical Data: Size:	>98% No Development Reported 100 mg, 500 mg, 250 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
SAR-10084	2 Cat. No.: HY-10	Siponimod (BAF-312)	Cat. No.: HY-1235
Bioactivity:	SAR-100842 is a lysophaphatidic acid 1 (LPA1/ Edg-2) receptor inhibitor.	Bioactivity:	Siponimod (BAF-312) is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. It is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC₅₀s of 0.39, 0.98, >10,000, >1,000, and 750
Purity: Clinical Data: Size:	99.69% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	nM, respectively). Used to treat adult multiple sclerosis. 98.61% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g


TY-52156	Cat. No.: HY-19736
Bioactivity:	TY-52156 is a potent and selective ${\bf S1P_3}$ receptor antagonist with a ${\bf K_i}$ value of 110 nM $^{[1]}.$
Purity: Clinical Data: Size:	99.96% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

(W-146; W 14	6)	Cat. No.: HY-10139
Bioactivity:	W146 is a selective antagonist of sph receptor 1 ($\textbf{S1PR1}$) with an EC $_{50}$ value	
Purity: Clinical Data:	>98% No Development Reported 250 mg, 500 mg	



mAChR

Muscarinic acetylcholine receptor



mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or

antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia.

mAChR Inhibitors & Modulators

(+)-Cevime	line hydrochloride hemihydrate Cat. No.: HY-7		evime	line hydrochloride hemihydrate	Cat. No.: HY-76772B
Bioactivity: Purity: Clinical Data: Size:	Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other >98% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg	o∽ S Clinic Size:		Cevimeline hydrochloride hemihydrate, a nove receptor agonist, is a candidate therapeutic dr xerostomia in Sjogren's syndrome. IC50 value: The general pharmacol. properties of this drug gastrointestinal, urinary, and reproductive syst >98% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg	ug for Target: mAChR J on the
AC260584	Cat. No.: HY-1			Bromide LAS-W 330)	Cat. No. : HY-14144
Bioactivity:	AC260584 is an M1 muscarinic receptor allosteric agonist with a pEC₅₀ of 7.6.		tivity:	Aclidinium Bromide(LAS 34273; LAS-W 330) is inhaled muscarinic antagonist as a maintenanc chronic obstructive pulmonary disease (COPD)	a long-acting, ce treatment for
Purity: Clinical Data: Size:	98.02% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	。 Purity Clinic Size:		99.54% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
Alvameline (Lu 25-109)	Cat. No.: HY-1			um bromide	Cat. No.: HY-U00067
Bioactivity:	Alvameline (Lu25-109) is a partial M1 agonist and M2/M3 antagonist.	Bioac	tivity:	Ambutonium bromide is an acetylcholine anta	gonist.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg	Purity ^{N≥N} Clinic ^N Size:		>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Anisodami (6-Hydroxyhy			oline l	hydrobromide omide)	Cat. No.: HY-B0489
Bioactivity:	Anisodamine is an anticholinergic and α 1-adrenergic receptor antagonist used in the treatment of acute circulatory shock, is also a naturally occurring tropane alkaloid found in some plants of the Solanaceae family.	Bioac	tivity:	Arecoline Hydrobromide is a muscarinic acety agonist.	choline receptor
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg	Purity Clinic Size:		99.0% Launched 10mM x 1mL in DMSO, 500 mg, 1 g	, N, O, HBr
Atropine (Tropine trop	ate; DL-Hyoscyamine) Cat. No.: HY		•	nethyl bromide ine bromide)	Cat. No. : HY-112076
Bioactivity: Purity: Clinical Data:	Atropine is a medication used to treat certain types of nerve agent and pesticide poisonings, some types of slow heart rate, and to decrease saliva production during surgery. 99.55%	Purity		Atropine methyl bromide, a muscarinic recep antagonist, is a quaternary ammonium salt of mydriatic for dilation of the pupil during ophtl examination. It is introduced for relieving pylo infants for its highly polar nature. It penetrates 95.0%	atropine and a nalmic ric spasm in
Size:	10mM x 1mL in DMSO,	Size:	ur Data.	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Br OH

Atropine su (Sulfatropinol		Cat. No.: HY-B1205A	Atropine sulf	ulfate monohydrate rate hydrate)	Cat. No.: HY-B039
Bioactivity:	Atropine sulfate is a competitive muscarir receptor antagonist.	ic acetylcholine	Bioactivity:	Atropine sulfate monohydrate is a comp acetylcholine receptor antagonist. Targe naturally occurring tropane alkaloid ext nightshade (Atropa belladonna), Jimson stramonium), mandrake (Mandragora o	et: mAChR Atropine is a racted from deadly weed (Datura
Purity:	>98%		Purity:	99.62%	· .
Clinical Data:		- <u>N</u> -•	Clinical Data:		th Lott
Size:	100 mg	ОН 0.5H₂SO4	Size:	10mM x 1mL in DMSO, 100 mg	0.5H ₂ SO4 0.5H ₂ O
Batefentero	bl		Benzamide	Derivative 1	
(GSK961081;	TD-5959)	Cat. No.: HY-12980			Cat. No.: HY-U0041
Bioactivity:	Batefenterol (GSK961081;TD-5959) is a nc receptor antagonist and β_2 -adrenocepto high affinity for hM2, hM3 muscarinic and with K _i values of 1.4, 1.3 and 3.7 nM, resp	r agonist; displays l hβ ₂ -adrenoceptor	Bioactivity:	Benzamide Derivative 1 is a benzamide EP0213775A1, compound 18. Benzamid in treatment of gastrointestinal disorder	e Derivative 1 may be useful
Purity:	98.30%		Purity:	>98%	
Clinical Data:		č	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	No Development Reported	HN
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	fraze.	Size:	1 mg, 5 mg, 10 mg	and the second
Benzetimid (R4929)	e hydrochloride	Cat. No.: HY-B1547A		e mesylate (Benzatropine mesylate; ztropine methanesulfonate)	Benzotropine Cat. No.: HY-B0520
Bioactivity: Purity:	Benzetimide hydrochloride is a muscarinie receptor antagonist. 99.44%	c acetylcholine	Bioactivity: Purity:	Benzotropine is a centrally-acting, antin as an adjunct in the treatment of Parkin mAChR Benzotropine is a centrally-actir used as an adjunct in the treatment of F may also be used to treat extrapyramide 99.86%	son's disease. Target: ng, antimuscarinic agent 'arkinson's disease. It
	No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	of H CH-CH	Clinical Data: Size:		
Beperidium (SX 810)	iodide	Cat. No.: HY-100152	Bethanech (Carbamyl-β-	Dl methylcholine)	Cat. No.: HY-B040
Bioactivity:	Beperidium iodide shows a competitive a against acetylcholine receptor with a pA		Bioactivity:	Bethanechol is a parasympathomimetic selectively stimulates muscarinic recept on nicotinic receptors. Target: muscarin butylbromide concentration dependent	ors without any effect ic receptor Hyoscine
D 1:	000%			contractions, calcium mobilization, and	epithelial secretion
Purity: Clinical Data:	>98% No Development Reported	<u>∩</u> °N	Purity: Clinical Data:	>98% Launched	<u>^</u>
Size:	1 mg, 5 mg, 10 mg	Che On	Size:	1 g	
Bethanecho	ol chloride		Biperiden		
(Carbamyl-β-ι	methylcholine chloride)	Cat. No.: HY-B0406A	(KL 373)		Cat. No.: HY-13204
Bioactivity:	Bethanechol Chloride is a selective musca agonist without any effect on nicotinic rea		Bioactivity:	Biperiden(KL 373) is an antiparkinsoniar selective central M1 cholinoreceptors bl receptors Biperiden is an antiparkinsoni anticholinergic type. It is used for the ac of all forms of Parkinson's disease (post	ocker. Target: M1 an agent of the ljunctive treatment
Purity:	95.00%		Purity:	>98%	· · ·
Clinical Data: Size:	Launched 10mM x 1mL in Water,		Clinical Data: Size:	Launched 100 mg, 500 mg	COH N-

Biperiden H (KL 373 (Hydr	<mark>łydrochloride</mark> ochloride))	Cat. No.: HY-13204	BQCA		Cat. No.: HY-101858
Bioactivity:	Biperiden Hydrochloride (KL 373 Hydrochloride) is antiparkinsonian agent, which is the selective cent cholinoreceptors blocker. Target: M1 receptors Bip antiparkinsonian agent of the anticholinergic type.	ral M1 periden is an . It is used	Bioactivity:	BQCA a highly selective allosteric modulator of mAChR .	f the M1
Purity: Clinical Data: Size:	for the adjunctive treatment of all forms of Parkins 98.0% Launched 10mM x 1mL in Water, 100 mg, 500 mg		Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	N ON
BTM-1086	c	at. No.: HY-U00406	Camylofine		Cat. No.: HY-B1230
Bioactivity:	BTM-1086 is a potent anti-ulcer and gastric secret inhibiting agent.		Bioactivity:	Camylofin is an antimuscarinic, is a smooth mu	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	S S S S S S S S S S S S S S S S S S S	Purity: Clinical Data: Size:	>98% Launched 1 g	Ju~B_o~~
-	choline chloride arbamylcholine chloride)	Cat. No.: HY-B1208	CDD0102 (CDD0102A)		Cat. No.: HY-U00230
Bioactivity: Purity: Clinical Data: Size:	Carbamoylcholine chloride is used to study respon by nAChR and mAChR, including smooth muscle or motility, and neuronal signaling. IC50 value: 10 to (Ki) Target: nAChR, mAChR Carbamoylcholine is ar acetylcholine that activates acetylcholine receptors 98.0% Launched 10mM x 1mL in DMSO, 100 mg	ontraction, gut 10,000 nM n analog of	Bioactivity: Purity: Clinical Data: Size:	CDD0102 is a potent M₁ Muscarinic receptor >98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	agonist.
Cevimeline (AF-102B)		Cat. No. : HY-70020		hydrochloride rochloride; SNI-2011 hydrochloride)	Cat. No.: HY-70020B
Bioactivity:	Cevimeline (AF-102B) is a parasympathomimetic a agonist, with particular effect on M3 receptors; use treatment of dry mouth associated with sjogren's s	ed in the	Bioactivity:	Cevimeline (Evoxac) Hcl is a parasympathomin muscarinic agonist, with particular effect on M. used in the treatment of dry mouth associated syndrome.	3 receptors;
Purity: Clinical Data: Size:	90.0% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	N S	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg	o (N HCI
Cevimeline	hydrochloride hemihydrate	Cat. No. : HY-76772	CHF5407		Cat. No.: HY-U00302
Bioactivity:	Cevimeline hydrochloride hemihydrate, a novel mu receptor agonist, is a candidate therapeutic drug fo xerostomia in Sjogren's syndrome.		Bioactivity:	CHF5407 is a muscarinic M3-receptor antago from patent WO 2008012290 A2, formula Ic.	nist extracted
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in Water,	of the second se	Purity: Clinical Data: Size:	>98% No Development Reported 100 mg, 250 mg, 500 mg	j., a

(DA-3177)	m Bromide	Cat. No. : HY-U00106	Clidinium k (Ro 2-3773)	promide	Cat. No.: HY-B113
			, ,		
Bioactivity:	Cimetropium Bromide (DA-3177) is a mACh long-term treatment of irritable bowel syndr		Bioactivity:	Clidinium bromide is an anticholinergic (specific muscarinic antagonist) drug, may help symptom abdominal/stomach pain by decreasing stomach the intestines.	ns of cramping and
Purity:	95.34%	HO. A	Purity:	>98%	\bigcirc
Clinical Data:			Clinical Data:		
Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg	Br	Size:	100 mg	N ⁺ Br ⁺
Cyclodrine	hydrochloride		Darenzepir	ne	
		Cat. No.: HY-U00139			Cat. No.: HY-10015
Bioactivity:	Cyclodrine hydrochloride is a cholinergic (mu nicotinic) (mAChR and nAChR) receptor and		Bioactivity:	Darenzepine is a muscarinic receptor inhibitor from patent US 20170095465 A1.	extracted
Purity:	>98%	\diamond	Purity:	>98%	HN
Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg	V Co
5120.	1 mg, 5 mg, 16 mg, 25 mg	н-а	5120.	1 mg, 5 mg, 16 mg	$\langle \stackrel{N}{\gamma} \rangle$
Darifenacir	1		Darifenacir	n hydrobromide	
(UK-88525)		Cat. No.: HY-A0033	(UK-88525 (h	ydrobromide))	Cat. No.: HY-A001
Bioactivity: Purity: Clinical Data: Size:	Darifenacin(UK88525) is a selective M3 musc antagonist with pKi of 8.9. IC50 value: 8.9 (ph M3 receptor in vitro: Darifenacin exerts non- rightward displacement of the agonist curve significant depression of the maximum respo 97.38% Launched 10 mg	(i) [1] Target: parallel and also	Bioactivity: Purity: Clinical Data: Size:	Darifenacin hydrobromide is a selective M3 mus antagonist with pKi of 8.9. IC50 value: 8.9 (pKi) [M3 receptor in vitro: Darifenacin exerts non-par rightward displacement of the agonist curve and significant depression of the maximum response 95.14% Launched 10mM x 1mL in DMSO, 10 mg, 100 mg	1] Target: allel d also
Desfesoter		Cat. No. : HY-76569	-	hydrochloride drochloride)	Cat. No.: HY-A008
(PNU-200577	odine ; (R)-5-Hydroxymethyl Tolterodine) Desfesoterodine (PNU-200577; Desfesoterod selective muscarinic receptor antagonist with of 0.84 nM and 9.14, respectively.	line) is a potent and	Diphenidol (Difenidol hyd Bioactivity:	-	
(PNU-200577 Bioactivity:	: (R)-5-Hydroxymethyl Tolterodine) Desfesoterodine (PNU-200577; Desfesoteroc selective muscarinic receptor antagonist with	line) is a potent and	(Difenidol hyd	drochloride) Diphenidol hydrochloride is a muscarinic antago	
(PNU-200577 Bioactivity: Purity: Clinical Data:	 (R)-5-Hydroxymethyl Tolterodine) Desfesoterodine (PNU-200577; Desfesoterod selective muscarinic receptor antagonist with of 0.84 nM and 9.14, respectively. 99.66% No Development Reported 	line) is a potent and	(Difenidol hyd Bioactivity: Purity: Clinical Data:	drochloride) Diphenidol hydrochloride is a muscarinic antago as an antiemetic and as an antivertigo agent. 99.60% Launched	
(PNU-200577 Bioactivity: Purity: Clinical Data:	: (R)-5-Hydroxymethyl Tolterodine) Desfesoterodine (PNU-200577; Desfesoterod selective muscarinic receptor antagonist with of 0.84 nM and 9.14, respectively. 99.66%	line) is a potent and	(Difenidol hyd Bioactivity: Purity:	drochloride) Diphenidol hydrochloride is a muscarinic antago as an antiemetic and as an antivertigo agent. 99.60%	
(PNU-200577 Bioactivity: Purity: Clinical Data: Size: Diphenman	 (R)-5-Hydroxymethyl Tolterodine) Desfesoterodine (PNU-200577; Desfesoterod selective muscarinic receptor antagonist with of 0.84 nM and 9.14, respectively. 99.66% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg methylsulfate 	line) is a potent and a AKb and a pA2	(Difenidol hyd Bioactivity: Purity: Clinical Data:	drochloride) Diphenidol hydrochloride is a muscarinic antago as an antiemetic and as an antivertigo agent. 99.60% Launched 10mM x 1mL in DMSO, 100 mg	onist employed
(PNU-200577 Bioactivity: Purity: Clinical Data: Size: Diphenmai (Diphemanil I	 (R)-5-Hydroxymethyl Tolterodine) Desfesoterodine (PNU-200577; Desfesoterod selective muscarinic receptor antagonist with of 0.84 nM and 9.14, respectively. 99.66% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg methylsulfate nesylate) 	tine) is a potent and a a Kb and a pA2 $\downarrow_{H} \downarrow_{U} \downarrow_{U} \downarrow_{U}$ Cat. No.: HY-16171	(Difenidol hyd Bioactivity: Purity: Clinical Data: Size: DREADD ag	Diphenidol hydrochloride is a muscarinic antage as an antiemetic and as an antivertigo agent. 99.60% Launched 10mM x 1mL in DMSO, 100 mg gonist 21	Саt. No.: HY-10023
(PNU-200577 Bioactivity: Purity: Clinical Data: Size: Diphenmai (Diphemanil I	 (R)-5-Hydroxymethyl Tolterodine) Desfesoterodine (PNU-200577; Desfesoterod selective muscarinic receptor antagonist with of 0.84 nM and 9.14, respectively. 99.66% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg methylsulfate 	tine) is a potent and a Kb and a pA2 $\downarrow_{H} \downarrow_{I} \downarrow_{G} \downarrow_{GH}$ Cat. No.: HY-16171 monium ine receptors f stomach acids as nAChR Diphemanil	(Difenidol hyd Bioactivity: Purity: Clinical Data: Size:	drochloride) Diphenidol hydrochloride is a muscarinic antago as an antiemetic and as an antivertigo agent. 99.60% Launched 10mM x 1mL in DMSO, 100 mg	Cat. No.: HY-10023
(PNU-200577 Bioactivity: Purity: Clinical Data: Size: Diphenman (Diphemanil I Bioactivity: Purity:	 (R)-5-Hydroxymethyl Tolterodine) Desfesoterodine (PNU-200577; Desfesoterod selective muscarinic receptor antagonist with of 0.84 nM and 9.14, respectively. 99.66% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg hil methylsulfate nesylate) Diphemanil methylsulfate is a quaternary am anticholinergic. It binds muscarinic acetychol and thereby decreases secretory excretion of well as saliva and sweat. IC50 value: Target: r Methylsulfate exerts its action by primarily bi 99.83%	tine) is a potent and a Kb and a pA2 $\downarrow_{H} \downarrow_{I} \downarrow_{G} \downarrow_{GH}$ Cat. No.: HY-16171 monium ine receptors f stomach acids as nAChR Diphemanil	(Difenidol hyd Bioactivity: Purity: Clinical Data: Size: DREADD ag Bioactivity: Purity:	drochloride) Diphenidol hydrochloride is a muscarinic antage as an antiemetic and as an antivertigo agent. 99.60% Launched 10mM x 1mL in DMSO, 100 mg gonist 21 DREADD agonist 21 is a potent human muscarin M3 receptors (hM3Dq) agonist(EC ₅₀ =1.7 nM). 98.00%	Cat. No.: HY-10023
(PNU-200577 Bioactivity: Purity: Clinical Data: Size: Diphenman	 (R)-5-Hydroxymethyl Tolterodine) Desfesoterodine (PNU-200577; Desfesoterod selective muscarinic receptor antagonist with of 0.84 nM and 9.14, respectively. 99.66% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg hil methylsulfate nesylate) Diphemanil methylsulfate is a quaternary am anticholinergic. It binds muscarinic acetychol and thereby decreases secretory excretion of well as saliva and sweat. IC50 value: Target: r Methylsulfate exerts its action by primarily bi 99.83%	tine) is a potent and a Kb and a pA2 $\downarrow_{H} \downarrow_{I} \downarrow_{G} \downarrow_{GH}$ Cat. No.: HY-16171 monium ine receptors f stomach acids as nAChR Diphemanil	(Difenidol hyd Bioactivity: Purity: Clinical Data: Size: DREADD ag Bioactivity: Purity:	Diphenidol hydrochloride is a muscarinic antage as an antiemetic and as an antivertigo agent. 99.60% Launched 10mM x 1mL in DMSO, 100 mg gonist 21 DREADD agonist 21 is a potent human muscarir M3 receptors (hM3Dq) agonist(EC ₅₀ =1.7 nM).	Cat. No.: HY-10023

Dronedaro (SR 33589)	ne Cat. No.: HY-A0016	Elucaine	Cat. No.: HY-10174
(31 33363)			
Bioactivity:	Dronedarone (SR 33589) is a newer therapeutic agent with a structural resemblance to amiodarone and a better side effect profile; it is a multichannel blocker with antiadrenergic properties and has been evaluated in both rate and rhythm control strategies in the management of AF.	Bioactivity:	Elucaine is a muscarinic acetylcholine receptor antagonist with anti-ulcerative activity.
Purity:	99.49%	Purity:	>98%
Clinical Data:	Launched 3		No Development Reported
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg	Size:	1 mg, 5 mg, 10 mg, 20 mg
ENS-163 p	hosphate (ENS 213-163; Sandoz ENS 163 phosphate;	Fesoterodi	ne fumarate
Thiopilocarpi	ne phosphate) Cat. No.: HY-U00038		Cat. No.: HY-A003
Bioactivity:	ENS-163 phosphate is a selective muscarinic M1 receptor agonist.	Bioactivity:	Fesoterodine Fumarate is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. IC50 value: Target: mAChR Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic
Purity:	>98%	Purity:	99.52%
	No Development Reported	Clinical Data:	L T 1 mg.
Size:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg
Flavoxate ł (Rec-7-0040;	nydrochloride	Gallamine	Triethiodide
(Rec-7-0040,	DW61) Cat. No.: HY-B0549A		Cat. No.: HY-B04:
Bioactivity:	Flavoxate Hydrochloride(DW-61 Hydrochloride) is a muscarinic AChR antagonist used in various urinary syndromes and as an antispasmodic.	Bioactivity:	Gallamine Triethiodide is a synthetic nondepolarizing blocking drug.
Densite a	99.0%	Duritur	98.0%
Purity: Clinical Data:		Purity: Clinical Data:	
Size:	10mM x 1mL in Water, 100 mg, 1 g	Size:	10mM x 1mL in Water, 100 mg, 500 mg
Glycopyrro			ne Bromide
(Glycopyrrola	te bromide; Glycopyrronium bromide) Cat. No.: HY-17465	(Homatropin	e hydrobromide) Cat. No.: HY-B0547
Bioactivity:	Glycopyrrolate(Glycopyrronium Br) is a muscarinic competitive antagonist used as an antispasmodic.	Bioactivity:	Homatropine Bromide is muscarinic AChR antagonist that is an anticholinergic medication.
Purity:	98.0%	Purity:	99.0%
Clinical Data:	Vº"	Clinical Data: Size:	
	10mM x 1mL in Water,	Size.	10mM x 1mL in DMSO, 1 g, 5 g
Size:	10 mg, 30 mg, 100 mg Br		
	ine methylbromide	Imidafenac	
Homatropi	ine methylbromide e methobromide) Cat. No.: HY-B1388	Imidafenad (KRP-197; ON	
Homatropi	ine methylbromide		
Homatropi (Homatroping Bioactivity:	ine methylbromide e methobromide) Cat. No.: HY-B1388 Homatropine Methylbromide is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC50 of 162.5 nM and 170.3 nM,	(KRP-197; ON	IO-8025) Cat. No.: HY-B06 Imidafenacin(KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors with Kb of 0.317 nM; less potent for
Homatropi (Homatropine	ine methylbromide e methobromide) Homatropine Methylbromide is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC50 of 162.5 nM and 170.3 nM, respectively. 98.0%	(KRP-197; ON Bioactivity:	IO-8025) Cat. No.: HY-B06 Imidafenacin(KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors with Kb of 0.317 nM; less potent for M2 receptors(IC50=4.13 nM). 98.38%
Homatropin Homatropin Bioactivity: Purity:	ine methylbromide e methobromide) Homatropine Methylbromide is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC50 of 162.5 nM and 170.3 nM, respectively. 98.0%	(KRP-197; ON Bioactivity: Purity:	IO-8025) Cat. No.: HY-B06 Imidafenacin(KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors with Kb of 0.317 nM; less potent for M2 receptors(IC50=4.13 nM). 98.38%

Ipratropiun (Sch 1000)	n bromide	Cat. No.: HY-B0241	Irsogladine (Dicloguamin		Cat. No. : HY-B0327
(SCH 1000)		Cat. No.: HY-B0241	Dicioguamin		Cat. No.: HY-B0327
Bioactivity:	Ipratropium Bromide is a muscarinic antagonist, bronchodilator, N-Isopropyl salt of atropine.		Bioactivity:	Irsogladine is a PDE4 inhibitor and muscarinic ac receptor binder.	etylcholine
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg	B (N) (OH	Purity: Clinical Data: Size:	95.13% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	
Irsogladine		Cat. No.: HY-B0327A	L-Hyoscyar (Daturine)	nine	Cat. No.: HY-N0471
	Irsogladine is a PDE4 inhibitor and muscarinic act receptor binder.		Bioactivity:	L-Hyoscyamine is a chemical compound, a tropa the levo-isomer to atropine.	
Purity: Clinical Data: Size:	>98% Launched 100 mg, 500 mg	COCH	Purity: Clinical Data: Size:	99.08% No Development Reported 10mM x 1mL in DMSO, 100 mg, 500 mg	С С СССТАТИВИИ С
Levetiraceta (UCB L059)	am	Cat. No.: HY-B0106	LY2119620		Cat. No.: HY-15885
Bioactivity:	Levetiracetam (UCB L059) is a selective M2 musc acetylcholine receptors (mAChR) inhibitor ^[1] . Antiepileptic agent ^[1] .	arinic	Bioactivity:	LY2119620 is a high-affinity muscarinic M_2/M_4 r agonist.	eceptor
Purity: Clinical Data: Size:	99.99% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg	H ₂ N N 0	Purity: Clinical Data: Size:	99.74% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	rne solo-sol
mAChR-IN-	1	Cat. No. : HY-12426	mAChR-IN	-1 hydrochloride	Cat. No.: HY-12426A
Bioactivity:	mAChR-IN-1 is a potent muscarinic cholinergic re antagonist with IC50 of 17 nM.	eceptor(mAChR)	Bioactivity:	mAChR-IN-1 hydrochloride is a potent muscarin receptor (mAChR) antagonist, with an IC ₅₀ of 1	
Purity: Clinical Data: Size:	99.78% No Development Reported 5 mg, 10 mg, 50 mg	off 60	Purity: Clinical Data: Size:	99.94% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	of H oc
Methacholi (Acetyl-β-met	ne chloride hylcholine chloride)	Cat. No.: HY-A0083		lamine bromide ine methyl bromide; Hyoscine methyl bromide)	Cat. No.: HY-B0344
Bioactivity:	Methacholine chloride is a synthetic choline ester as a non-selective muscarinic receptor agonist in parasympathetic nervous system.	r that acts	Bioactivity:	Methscopolamine (Pamine) is a muscarinic acety receptor blocker. Target: mAChR Methylscopolar medication used along with other medications to ulcers by reducing stomach acid secretion. With proton pump inhibitors and antihistamine medic	Icholine nine is an oral o treat peptic the advent of
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg		Purity: Clinical Data: Size:	99.44% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	HO O Br

Methylbena	actyzium Bromide Cat. No.: HY-B2070	Metixene h	ydrochloride Cat. No.: HY-120083
Bioactivity:	Methylbenactyzium Bromide is a muscarinic acetylcholine receptor (mAChR) inhibitor.	Bioactivity:	Metixene hydrochloride is an anticholinergic antiparkinsonian agent, potently inhibits binding of quinuclidinyl benzilate (QNB) to the muscarinic receptor in rat brain cortical tissue, with an IC₅₀ of 55 nM and a K _d of 15 nM ^[1] .
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg	Purity: Clinical Data: Size:	>98% No Development Reported
Metixene h	ydrochloride hydrate Cat. No.: HY-120081A	MHP 133	Cat. No.: HY-1016
Bioactivity:	Metixene hydrochloride hydrate is an anticholinergic antiparkinsonian agent, potently inhibits binding of quinuclidinyl benzilate (QNB) to the muscarinic receptor in rat brain cortical tissue, with an IC ₅₀ of 55 nM and a K _d <	Bioactivity:	MHP 133 is a drug with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with \mathbf{K}_{i} of 69 μ M; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.
Purity: Clinical Data: Size:	99.85% Launched 10mM x 1mL in DMSO, 10 mg HG H ₂ O	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
MK-7622 (M1 receptor	modulator) Cat. No.: HY-15618	Nuvenzepi	ne Cat. No.: HY-U001:
Bioactivity: Purity: Clinical Data: Size:	MK-7622 is a muscarinic M1 receptor positive allosteric modulator. Target: M1 receptor MK-7622 is useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. 98.37% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Bioactivity: Purity: Clinical Data: Size:	Nuvenzepine is an mAChR antagonist previously in phase I clinical trials for the treatment of gastrospasm. 99.0% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg $\int_{-\infty}^{+\infty} \int_{-\infty}^{+\infty} \int_{-\infty$
Otilonium I (Octylonium b	promide promide; SP63) Cat. No.: HY-B0499A	Oxitropium	ו Bromide Cat. No.: HY-U001
Bioactivity:	Otilonium Bromide is an antimuscarinic used as a spasmolytic agent.	Bioactivity:	Oxitropium bromide is an mAChR antagonist used as an anticholinergic bronchodilator drug for the treatment of asthma and chronic obstructive pulmonary disease.
Purity: Clinical Data: Size:	95.07% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	Purity: Clinical Data: Size:	>98% Launched 5 mg
Oxybutynir	Cat. No.: HY-B0267	Oxybutynii	n chloride Cat. No.: HY-B0267
Bioactivity:	Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties.	Bioactivity:	Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties.
Purity: Clinical Data: Size:	98.96% Launched 10mM x 1mL in DMSO,	Purity: Clinical Data: Size:	98.24% Launched 10mM x 1mL in DMSO,

Pilocarpine	Hydrochloride Cat. No.: HY-B0726	Pilocarpine nitrate Cat. No.: HY-B100
Bioactivity:	Pilocarpine Hydrochloride is a selective M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.	Bioactivity: Pilocarpine nitrate is a selective M3-type muscarinic acetylcholine receptor (M3 muscarinic receptor) agonist.
Purity: Clinical Data: Size:	99.92% Launched 100 mg, 500 mg	Purity: >98% Clinical Data: Launched Size: 100 mg
Pimethixen (Pimetixene)	e Cat. No.: HY-B1101	Pimethixene maleate (Pimetixene maleate) Cat. No.: HY-B1101
Bioactivity:	Pimethixene is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene is a highly potent antagonist of 5-HT $_{1A'}$ 5-HT $_{2A'}$ 5-HT $_{2B'}$ 5-HT $_{2C'}$ histamine H $_1'$ dopamine D $_2$ and D $_{4,4}$ as well as muscari	Bioactivity: Pimethixene maleate is antihistamine and antiserotonergic compound, acts as an antimigraine agent. Pimethixene maleate is a highly potent antagonist of 5-HT 1A, 5-HT 2A, 5-HT 2B, 5-HT 2C, histamine H 1, dopamine D 2 and D 4, as well
Purity: Clinical Data: Size:	>98% Launched 10 mg	Purity: >98% Clinical Data: No Development Reported Size: 10 mg
Piperidolat	e Cat. No.: HY-B0962A	Piperidolate hydrochloride Cat. No.: HY-B09
Bioactivity:	Piperidolate is an antimuscarinic, inhibits intestinal cramp induced by acetylcholine (rats and dogs).	Bioactivity: Piperidolate hydrochloride is an antimuscarinic, inhibits intestinal cramp induced by acetylcholine (rats and dogs).
Purity: Clinical Data: Size:	99.09% Launched 10mM x 1mL in DMSO, 100 mg, 200 mg	Purity: 99.94% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 100 mg, 200 mg H-0
Pirenzepine	e dihydrochloride Cat. No.: HY-17037	Pirmenol hydrochloride (Cl-845; (±)-Pirmenol hydrochlorid) Cat. No.: HY-10079
Bioactivity:	Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.	Bioactivity: Pirmenol hydrochloride inhibits I _{K.ACh} by blocking muscarinic receptors. The IC ₅₀ of Pirmenol for inhibition of Carbachol-induced I _{K.ACh} is 0.1 μM.
Purity: Clinical Data: Size:	99.65% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	Purity: 97.20% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
Propanthel	ine bromide Cat. No.: HY-B1188	Rapacuronium bromide (Org 9487) Cat. No.: HY-164
Bioactivity:	Propantheline bromide is an antimuscarinic agent, used for the treatment of hyperhidrosis, cramps or spasms of the stomach, intestines or bladder, and enuresis.	Bioactivity: Rapacuronium bromide is an allosteric modulator of muscarinic acetylcholine receptor (mAChR).
Purity: Clinical Data: Size:	95.0% Launched 10mM x 1mL in DMSO, 100 mg	Purity: 98.0% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Revefenaci (TD-4208; GSI		Cat. No. : HY-15851	Rispenzepi	ne Cat. No.: HY-	U00030
Bioactivity:	Revefenacin (TD-4208; GSK1160724) is a pot antagonist; has a high affinity on M3 recepto 0.18 nM.		Bioactivity:	Rispenzepine is a novel antimuscarinic compound with a preferential action at ${\rm M}_{1'}$ and ${\rm M}_{3}$ receptor subtypes.	
Purity: Clinical Data: Size:	99.62% Phase 3 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg	braylaci.	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	
Scopolamir (Hyoscine; Sco	1e opine (-)-tropate; Scopine tropate)	Cat. No. : HY-N0296		ne butylbromide (Hyoscine butylbromide; ine butylbromide; Butylscopolamine bromide) Cat. No.: HY	-N0340
Bioactivity:	Scopolamine is a high affinity (nM) muscarir 5-HT₃ receptor-responses are reversibly inhi Scopolamine with an IC_{50} of 2.09 μ M.		Bioactivity:	Scopolamine butylbromide is a competitive antagonist of muscarinic acetylcholine receptor (mAChR) with an IC50 of 55 ± 4.3 nM. Target: mAChR Scopolamine (USAN), also known as levo-duboisine and hyoscine, sold as Scopoderm, is a tropane alkaloid drug with muscarinic antagonist effects. It is among	
Purity: Clinical Data: Size:	>98% Launched 100 mg		Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	Br
	ne hydrobromide ((-)-Scopolamine hydrobromide; Scopine hydrobromide)	robromide; Cat. No.: HY-N0296A		ne N-oxide hydrobromide oxide hydrobromide) Cat. No.: H	(-B2146
Bioactivity:	Scopolamine hydrobromide is a high affinity antagonist. 5-HT₃ receptor-responses are re inhibited by Scopolamine with an IC₅₀ of 2.0	versibly	Bioactivity:	Scopolamine N-oxide hydrobromide is an antagonist of the muscarinic acetylcholine .	
Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	HO V HB/	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 100 mg	Br
Solifenacin (YM905 (free	base))	Cat. No .: HY-A0034	Solifenacin (YM905 hydro	hydrochloride ochloride) Cat. No.: H	Y-I0230
Bioactivity:	Solifenacin (YM905 free base) is a novel mus receptor antagonist with pK _i s of 7.6, 6.9 and M ₂ and M ₃ receptors, respectively.		Bioactivity:	Solifenacin Hcl(YM905 Hcl; Vesicare Hcl) is a muscarinic receptor antagonist.	
Purity: Clinical Data: Size:	99.77% Launched 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg	C N L of A	Purity: Clinical Data: Size:	99.22% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
Solifenacin (YM905)	Succinate	Cat. No.: HY-A0002	TAK-071	Cat. No.: HY	-122190
Bioactivity:	Solifenacin Succinate(YM905; Vesicare) is a m receptor antagonist. IC50 value: Target: musc Solifenacin succinate (YM905; Vesicare) is a p medication used to treat certain bladder pro	carinic receptor prescription	Bioactivity:	TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC₅₀ of TAK-071 M1R agonist activities is 520 nM [1]	
Purity: Clinical Data: Size:	99.99% Launched 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	25°0

Tarafenacir (SVT-40776)	1	Cat. No.: HY-14825	Tarafenacir (SVT-40776 D	n D-tartrate	Cat. No.: HY-14825
. ,			-		
Bioactivity:	Tarafenacin(SVT-40776) is a highly selective receptor antagonist (Ki= 0.19 nM), ~200 fold M2 receptor.		Bioactivity:	Tarafenacin(SVT-40776) is a highly select receptor antagonist (Ki= 0.19 nM), ~200 M2 receptor.	
Purity:	>98%		Purity:	99.70%	
Clinical Data:			Clinical Data:		AND AND
Size:	10 mg, 50 mg, 100 mg	(N O O O O O O O O O O O O O O O O O O O	Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	HO,
ТВРВ			Tematropiu	ım	
		Cat. No.: HY-14562	(CDDD3602; I	HGP6)	Cat. No.: HY-U0020
Bioactivity:	TBPB is an allosteric M1 mAChR agonist(ECS regulates amyloid processing and produces activity in rats.		Bioactivity:	Tematropium (CDDD3602) is a soft antic	holinergics.
Purity:	99.92%		Purity:	>98%	(i) 0 (
	No Development Reported	HAN CHONG		No Development Reported	(N) O
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	HGR ~	Size:	1 mg, 5 mg, 10 mg, 20 mg	°0—§—0—
lemiverine	hydrochloride	Cat. No.: HY-U00055	Timepidiun (Sesden; SA50		Cat. No.: HY-U0018
Bioactivity:	Temiverine hydrochloride is a synthesized d expected to have anticholinergic action.	rug that is	Bioactivity:	Timepidium bromide (Sesden; SA504) is agent.	an anticholinergic
Purity: Clinical Data:	>98% No Development Reported		Purity: Clinical Data:	>98%	
Size:	1 mg, 5 mg, 10 mg, 20 mg	H-CI	Size:	1 mg, 5 mg, 10 mg, 20 mg	Br
Tiotropium	Bromide		Tiotropium	bromide hydrate	
(BA679 BR)		Cat. No.: HY-17360	(BA-679 BR h	ydrate)	Cat. No.: HY-B046
Bioactivity:	Tiotropium Bromide (BA679 BR) is a muscar receptor (mAChR) antagonist that blocks the acetylcholine ligand and subsequent openin ligand-gated ion channel.	e binding of the	Bioactivity:	Tiotropium Bromide hydrate is an antich bronchodilator and a muscarinic recepto mAChR Tiotropium bromide (Ba 679 BR) long-lasting muscarinic antagonist that h	r antagonist. Target: is a novel potent and
				the treatment of chronic obstructive airw	ays disease (COPD)
Purity: Clinical Data:	99.61%		Purity: Clinical Data:	>98%	Q-A
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Size:	5 mg, 10 mg, 50 mg	
	e ((R)-(+)-Tolterodine; (+)-Tolterodine;		Tolterodine		
(R)-Tolterodir	ne; PNU-200583)	Cat. No.: HY-A0024	(Kabi-2234; P		Cat. No.: HY-9001
Bioactivity:	Tolterodine(PNU-200583) is a potent musca antagonists that show selectivity for the urin salivary glands in vivo.		Bioactivity:	Tolterodine Tartrate(PNU-200583E; Kabi- muscarinic receptor antagonists that sho urinary bladder over salivary glands in vi Target: mAChR in vitro: Carbachol-induc isolated guinea pig bladder were effective	w selectivity for the vo. IC50 Value: ed contractions of
			Purity:	99.57%	- ,
Purity:	95.0%	~	· · · · · · · · · · · · · · · · · · ·		
Purity: Clinical Data: Size:		\bigcirc	Clinical Data: Size:		1 HO 1 HO.


Trihexyphe	nidyl hydrochloride	Cat. No.: HY-B1277	Tropicamid (Ro 1-7683)	le	Cat. No.: HY-B0321
Bioactivity:	Trihexyphenidyl hydrochloride is an antiparki the antimuscarinic class, binds to the M1 mus	3	Bioactivity:	Tropicamide is an anticholinergic and a muscari subtype M4-preferring antagonist .	nic receptor
Purity: Clinical Data: Size:	99.43% Launched 10mM x 1mL in DMSO, 1 g	ON OH H-CI	Purity: Clinical Data: Size:	99.06% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	
Trospium c	hloride	Cat. No.: HY-B0461	Umeclidinin (GSK573719A	um bromide	Cat. No.: HY-12100
Bioactivity:	Trospium Chloride is a competitive muscarini receptor antagonist.	c cholinergic	Bioactivity:	Umeclidinium bromide is a novel mAChR antag affinity (K _i) of Umeclidinium bromide for the cl M1-M5 mAChRs ranges from 0.05 to 0.16 nM.	
Purity: Clinical Data: Size:	99.14% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg	Grad Contraction of the second	Purity: Clinical Data: Size:	99.72% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
Vinconate (Chanodeseth	ylapovincamine)	Cat. No.: HY-U00316	VU 023842	9	Cat. No.: HY-12157
Bioactivity:	Vinconate is an indolonaphthyridine derivativ stimulate the muscariic acetylcholine recep		Bioactivity:	VU 0238429 is positive allosteric modulator of r acetylcholine receptor subtype 5 (mAChR5 or I EC_{50} of 1.16 μ M.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	99.96% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	stor of the
VU 036511	4	Cat. No.: HY-107651	VU0152100 (VU152100))	Cat. No.: HY-13340
Bioactivity:	VU 0365114 is a $\rm mAChR~M_5$ positive alloster with an $\rm EC_{50}$ of 2.7 $\mu M.$	ic modulator,	Bioactivity:	VU0152100 is a potent and selective allosteric p M4 mAChR with an EC50 of 380 \pm 93 nM.	otentiator of
Purity: Clinical Data: Size:	99.41% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	×°chio ⁰	Purity: Clinical Data: Size:	99.94% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	
VU0357017 (CID-2501077	7 hydrochloride ⁽⁵⁾	Cat. No .: HY-19752A	VU0467154	4	Cat. No.: HY-112209
Bioactivity: Purity: Clinical Data: Size:	VU0357017 hydrochloride is a highly selective appear to act at an allosteric site to activate t (EC50 = 477 \pm 172 nM; pEC50 = 6.37 \pm 0.15). 172 nM (EC50) [1] Target: M1 in vitro: VU0357 M1-selective agonists that appear to activate 99.95% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	he receptor IC50 value: 477 ± 7017 is a	Bioactivity: Purity: Clinical Data: Size:	VU0467154 is a positive allosteric modulator of muscarinic acetylcholine receptor (mAChR) , response to ACh with pEC₅₀ s of 7.75, 6.2 and 6 human and cynomolgus monkey M4 receptor, r 98.78% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	potentiating the for rat,

VU6005806 (AZN-000161		Cat. No.: HY-128584	Xanomelin (LY246708)	e oxalate	Cat. No.: HY-13410
Bioactivity:	VU6005806 (AZN-00016130) is a potent musc receptor subtype 4 (M ₄) positive allosteric mo with EC₅₀s of 94 nM, 28 nM, 87 nM and 68 nM dog and cyno M ₄ , respectively. Used in the re >98%	odulator (PÁM), 1 for human, rat,	Bioactivity: Purity:	Xanomeline oxalate (LY246708) is a sele receptor agonist. IC50 value: Target: M1 in vitro: Xanomeline had high affinity fo receptors in brain homogenates, but ha no affinity for a number of other neurot 98.87%	. muscarinic receptor r muscarinic d substantially less or
Clinical Data: Size:	No Development Reported 250 mg, 500 mg, 100 mg	$\overset{\delta - \bigcup_{m \neq k} m_{k}}{=} \overset{\delta - \bigcup_{m \neq k}}{=} \overset{\delta - \bigcup_{m \neq k} m_{k}}{=} \overset{\delta - \bigcup_{m \neq k}}{=} \overset{\delta - \bigcup_{m \neq k} m_{k}}{=} \overset{\delta - \bigcup_{m \to k} m_{k}}{=} $	Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	
YM-46303			YM-58790		
		Cat. No.: HY-U00104			Cat. No.: HY-101679
Bioactivity:	YM-46303 is an mAChR antagonist which exh affinities for M1 and M3 receptors, and selecti over M2 receptor.	3	Bioactivity:	YM-58790 is a potent antagonist of $\rm M3$ with $\rm K_i$ of 15 nM.	muscarinic receptor,
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	



MCHR1 (GPR24)

Melanin concentrating hormone receptor 1



MCHR1 (GPR24), also known as Melanin concentrating hormone receptor 1, belongs to a member of the G protein-coupled receptor family 1, is an integral plasma membrane protein which binds melanin-concentrating hormone, and is one of the melanin-concentrating hormone receptors found in all mammals. MCHR1 can inhibit cAMP accumulation and stimulate intracellular calcium flux, and is probably involved in the neuronal regulation of food consumption. Although structurally similar to somatostatin receptors, this protein does not seem to bind somatostatin. MCHR1 is thought to regulate appetite, and also functions in stress, anxiety and depression.


MCHR1 (GPR24) Inhibitors & Modulators

ALB-12715	8(a) Cat. No.: HY-111398	AZD1979	Cat. No.: HY-U00257
Bioactivity:	ALB-127158(a) is a potent and selective melanin concentrating hormone 1 (MCH_1) receptor antagonist.	Bioactivity:	AZD1979 is a Melanin-concentrating hormone receptor 1 ($MCHr1$) antagonist with an IC_{50} of ~12 nM.
Purity: Clinical Data: Size:	99.32% No Development Reported 10mM x 1mL in DMSO, ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data: Size:	>98% Phase 1 1 mg, 5 mg, 10 mg
BMS-81988	31 Cat. No.: HY-12433	MCH-1 ant	agonist 1 Cat. No.: HY-100331
Bioactivity:	BMS-819881 is a melaninconcentrating hormone receptor 1 (MCHR1) antagonist, which binds rat MCHR1 with a K _i of 7 nM. BMS-819881 also is selective and potent for CYP3A4 activity with an EC ₅₀ of 13 µM.	Bioactivity:	MCH-1 antagonist 1 is a potent melanin concentrating hormone (MCH-1) antagonist with a K_i of 2.6 nM. MCH-1 antagonist 1 also inhibits CYP3A4 with an IC₅₀ of 10 μ M.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg
MCHr1 ant	agonist 1 Cat. No.: HY-U00353	MCHr1 ant	agonist 2 Cat. No.: HY-100321
Bioactivity:	MCHr1 antagonist 1 is a selective antagonist of melanin concentrating hormone-1 (MCH1) receptor , with a K_b of 1 nM and a K_i of 4 nM at human MCH1, and may be used to reduce the body mass.	Bioactivity:	MCHr1 antagonist 2 is an antagonist of melanin concentrating hormone receptor 1 , with an IC ₅₀ of 65 nM; MCHr1 antagonist 2 also inhibits hERG , with an IC ₅₀ of 4.0 nM in IMR-32 cells.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg
Melanin Co (MCH (salmor	ncentrating Hormone, salmon	NGD-4715	Cat. No. : HY-100318
Bioactivity:	Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system.	Bioactivity:	NGD-4715 is a selective and orally active melanin-concentrating hormone receptor 1 (MCHR1) antagonist .
Purity: Clinical Data: Size:	Melanin-concentrating hormone is a ligand for an orphan G >98% No Development Reported 500u g, 1 mg, 5 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg
SB-568849	Cat. No. : HY-100308		
Bioactivity:	SB-568849 is a melanin-concentrating hormone receptor 1 (MCH R1) antagonist with a pK _i of 7.7.		
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg		



Melanocortin Receptor

MC Receptor



HDAC (Histone deacetylase)

Melanocortin receptors (MCRs) comprise a family of five, class A, G protein-coupled receptors designated MC1R-MC5R with diverse physiological roles. MCRs are found in chordates and are regarded as having evolved from a single ancestral receptor, possibly corresponding most closely to MC4R. Signaling by MCRs has primarily been observed as occurring through the stimulatory α unit Gs which activates adenylyl cyclase to produce cAMP.

The central nervous melanocortin system is involved in energy homeostasis, regulating food intake and energy expenditure. The brain melanocortin system is defined as the primary neurons that express neuropeptide ligands, and secondary neurons expressing the

predominant neural melanocortin receptors (MC3R, MC4R). Mutations in the gene encoding melanocortin receptor agonists, or the genes encoding MC3R or MC4R cause obesity. The other members of the melanocortin receptor family are primarily expressed in the periphery, and are involved in regulating pigmentation (MC1R), adrenal gland function (MC2R), immune function (MC1R/MC3R), and sebaceous gland activity (MC5R).

Melanocortin Receptor Inhibitors & Modulators


	•				
ACTH (1-17	7) TFA		ACTH 1-17		
(α1-17-ACTH	(TFA))	Cat. No.: HY-P1545A	(α1-17-ACTH)	Cat. No.: HY-P154
Bioactivity:	ACTH (1-17) TFA, an adrenocorticotropin anal human melanocortin 1 (MC1) receptor ago 0.21 nM.		Bioactivity:	ACTH (1-17), an adrenocorticotropin analo human melanocortin 1 (MC1) receptor a 0.21 nM.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	SYSMEHFRWGSPVCKR F F F CH	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	SYSMEHERWOKPVQ
Adrenocori (ACTH (1-39)	ticotropic Hormone (ACTH) (1-39), ra (mouse, rat))	t Cat. No.: HY-P1477		ticotropic Hormone (ACTH) (1-39), (mouse, rat) (TFA))	rat TFA Cat. No.: HY-P1477
Bioactivity:	Adrenocorticotropic Hormone (ACTH) (1-39), melanocortin 2 (MC2) receptor agonist.	rat is a potent	Bioactivity:	Adrenocorticotropic Hormone (ACTH) (1-3 potent melanocortin 2 (MC2) receptor a	
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg		Purity: Clinical Data: Size:	99.25% No Development Reported 10mM x 1mL in Water, 500u g, 1 mg, 5 mg	Z.
Bremelano (PT-141 Aceta	tide Acetate	Cat. No. : HY-18678A	JNJ-10229	570	Cat. No.: HY-1071:
Bioactivity: Purity: Clinical Data: Size:	Bremelanotide Acetate is a melanocortin agoi Target: melanocortin in vivo: Bremelanotide is candidate for the treatment of male and fema dysfunction. Bremelanotide has shown promi- treating erectile dysfunction (ED) without the 99.97% Phase 3 10mM x 1mL in DMSO, 10 mg, 50 mg	s a novel drug ale sexual se in effectively	Bioactivity: Purity: Clinical Data: Size:	JNJ-10229570 is an antagonist of melanor (MC1R) and melanocortin receptor 5 (M inhibits sebaceous gland differentiation ar sebum-specific lipids. JNJ-10229570 inhibi 125 I-NDP- α -MSH to cells expressing huma 98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	IC5R) , which id the production of ts the binding of
MC-4R Ago	onist 1	Cat. No.: HY-U00396		de-1 acetate salt ne-5 acetate salt)	Cat. No.: HY-P009
Bioactivity:	MC-4R Agonist 1 is an agonist of human mel receptor (MC-4R), used in the research of ob diabetes, and sexual dysfunction.		Bioactivity:	Nonapeptide-1 acetate salt, a peptide horr α -Melanocyte-stimulating hormone (α -M an IC ₅₀ of 11 nM. Reduces synthesis of me decrease skin pigmentation to a substantia	SH) antagonist, with elanin and helps
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	÷	Purity: Clinical Data: Size:	99.76% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	
PF-0044668	87	Cat. No. : HY-10622	Setmelano (RM-493; BIM	tide 1-22493; IRC-022493)	Cat. No.: HY-1983
Bioactivity:	PF-00446687 is a potent, selective melanoco (MC4R) agonist with EC50 of 12 ± 1 nM ^[1] . Pf brain penetrant ^[2] .	-	Bioactivity:	Setmelanotide (RM-493;BIM-22493;IRC-02 melanocortin 4 receptor (MC4R) agonist 0.27 nM for human MC4R.	,
Purity: Clinical Data:	>98% No Development Reported 250 mg, 500 mg	ى ئەت	Purity: Clinical Data: Size:	99.35% Launched 10mM x 1mL in Water,	

SNT-20770	17		SNT-20785	8	
		Cat. No.: HY-11029			Cat. No.: HY-11030
Bioactivity:	SNT-207707 is a selective, potent and o melanocortin MC-4 receptor antagoni: nM (binding) and 5 nM (function) on the	st with an IC₅₀ of 8	Bioactivity:	SNT-207858 is a selective and orally a MC-4 receptor antagonist with a 170 MC-3 and a 40-fold selectivity versus IC₅₀ of 8 nM (binding) and 5 nM (fun	-fold selectivity vs. MC-5. SNT-207858 has an
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	22 - 23 -	Purity: Clinical Data: Size:	receptor. >98% No Development Reported 250 mg, 500 mg	Church Ch
β-Melanoc	yte Stimulating Hormone (MSH)	, human	β-Melanoc	yte Stimulating Hormone (MS	H), human TFA
(Beta-MSH (1	-22) (human))	Cat. No.: HY-P1504	(Beta-MSH (1	-22) (human) (TFA))	Cat. No.: HY-P1504A
Bioactivity:	β -Melanocyte Stimulating Hormone (M: peptide, acts as an endogenous melano MC4-R) agonist ^[1] .		Bioactivity:	Bioactivity: β-Melanocyte Stimulating Hormone (MSH), human TFA, a 22-residue peptide, acts as an endogenous melanocortin receptor (MC4-R) agonist ^[1] .	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	лемосантякнятковнию	Purity: Clinical Data: Size:	99.95% No Development Reported 1 mg, 5 mg, 10 mg	$\operatorname{ADVECLOPVILLEHVOLUPY}_{\operatorname{P}} \operatorname{P}$
γ-1-Melano	ocyte Stimulating Hormone (MS	H), amide Cat. No.: HY-P1531			
Bioactivity:	γ -1-Melanocyte Stimulating Hormone (acid peptide. γ -1-Melanocyte Stimulatir regulates sodium (Na ⁺) balance and bl activation of the melanocortin recepto	MSH), amide is a 11-amino ng Hormone (MSH) ood pressure through			
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	YVMGHFRWDRF-NH2			



Melatonin Receptor





HDAC (Histone deacetylase)

Melatonin Receptor is a G protein-coupled receptor (GPCR) which binds melatonin. Three types of melatonin receptor have been cloned. The MT1 and MT2 receptor subtypes are present in humans and other mammals, while an additional melatonin receptor subtype MT3 has been identified in amphibia and birds. The MT1 subtype's expression in the pars tuberalis of the pituitary gland and suprachiamatic nuclei of the hypothalamus is indicative of melatonin's circadian and reproductive functional involvement. The MT2 subtype's expression in the retina is suggestive of melatonin's effect on the mammalian retina occurring through this receptor. Research suggests that melatonin acts to inhibit the Ca2+-dependent release of dopamine. Melatonin's

action in the retina is believed to affect several light-dependent functions, including phagocytosis and photopigment disc shedding.


Melatonin Receptor Inhibitors & Modulators

Melatonin (N-Acetyl-5-n	nethoxytryptamine)	Cat. No.: HY-B0075	Ramelteon (TAK-375)		Cat. No.: HY-A0014
Bioactivity:	Melatonin is a hormone made by the pine activates melatonin receptor . Melatonin p sleep and possesses important antioxidativ anti-inflammatory properties.	plays a role in	Bioactivity:	Ramelteon is a highly potent and selective receptor agonist with \mathbf{K}_{i} values of 14 and melatonin1 and melatonin2.	
Purity: Clinical Data: Size:	98.95% Launched 10mM x 1mL in DMSO, 1 g, 5 g	- CLH	Purity: Clinical Data: Size:	99.92% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg	J.
Ramelteon	metabolite M-II	Cat. No. : HY-103005	Tasimelteo (BMS-214778		Cat. No.: HY-14803
Bioactivity:	Ramelteon metabolite M-II is the major m Ramelteon, with IC $_{50}$ s of 208 pM, 1470 pM receptors (MT $_1$ or MT $_2$). Ramelteon is a su agonist.	/l for human melatonin	Bioactivity:	Tasimelteon is a melatonin MT1 and MT2	receptor agonist.
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	ji n S	Purity: Clinical Data: Size:	99.58% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	



mGluR

Metabotropic glutamate receptors



mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, amino acid that functions an as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of

mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity.

mGluR Inhibitors & Modulators

(1R,2S)-VU		lo .: HY-14417A	(R)-ADX-47	7273 Cat. No.: HY-130588
Bioactivity:	(1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a $\textbf{mGluR4}$ agonist with an $\textbf{EC}_{\textbf{50}}$ of 2.35 $\mu\text{M}.$	a partial	Bioactivity:	(R)-ADX-47273 is a potent $\rm mGluR5$ positive allosteric modulator, with an $\rm EC_{50}$ of 168 nM for potentiation .
Purity: Clinical Data: Size:	98.42% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	C C C C C C C C C C C C C C C C C C C	Purity: Clinical Data: Size:	99.25% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
(RS)-MCPG	Cet N		(S)-MCPG	Cat. No. 117, 100406
(alpha-MCPG) Bioactivity:	(RS)-MCPG is a non-selective group I/group II metabol glutamate receptor antagonist.	lo.: HY-100371 rropic	((+)-MCPG) Bioactivity:	Cat. No.: HY-100406 (S)-MCPG is the active isomer of (RS)-MCPG (Cat. No. HY-100371), non-selective group I/group II metabotropic glutamate receptor antagonist. In vivo: (S)-MCPG (20.8 µg)
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	HO TOH	Purity: Clinical Data: Size:	injected intraventricularly (i.c.v.) before testing impaired the performance of rats in the spatial version of the Morris 98.10% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg
ADX-47273		No .: HY-13058	ADX88178	Cat. No.: HY-18654
Bioactivity:	ADX-47273 is a positive allosteric modulator selective metabotropic glutamate receptor subtype mGluR5(EC IC50 value: 170 nM(EC50) [1] [2] Target: positive alloste modulator (PAM) of mGluR5 in vitro: ADX-47273 incre-	for the 50=170 nM). pric ased	Bioactivity:	ADX88178 is a potent positive allosteric modulator for metabotropic glutamate receptor 4 (mGluR4) with EC₅₀ of 4 nM for human mGluR4.
Purity: Clinical Data: Size:	(9-fold) the response to threshold concentration of glu 99.34% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	tamate , ن ^{وز} س ^{ری} کرد.	Purity: Clinical Data: Size:	98.59% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
AZD 9272	Cet 1	lo .: HY-110254	AZD-8529	Cat. No. : HY-107457
Bioactivity:	AZD 9272 is a brain penetrant mGluR5 antagonist.	W. . 111-110234	Bioactivity:	AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2 , with an EC ₅₀ of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg		Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
Basimglura (RG7090; CTEI		No .: HY-15446	BMT-14502	27 Cat. No.: HY-100728
Bioactivity:	Basimglurant (RG7090) is a potent, selective and orally available mGlu5 negative allosteric modulator with a k of 1.1 nM.		Bioactivity:	BMT-145027 is an mGluR5 positive allosteric modulator without inherent agonist activity, exhibits an EC₅₀ of 47 nM.
Purity: Clinical Data: Size:	99.56% Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	, Children Ch	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

CFMTI		СРРНА		
	Cat. N	o.: HY-100402		Cat. No.: HY-14612
Bioactivity:	CFMTI is a potent and selective metabotropic glutamat receptor (mGluR) 1 allosteric antagonist with IC50 of 2. The selectivity of CFMTI to mGluR1 over mGluR5 was >2000-fold. target : mGluR IC 50: 2.6 nM In vitro: The It	5 nM.	CPPHA is a selective positive allosteric modulator receptor.	r of mGluR5
Purity:	values of CFMTI against human mGluR5 were 5400 \pm 1 98.0%	Purity:	97.93%	
	No Development Reported		: No Development Reported	a da
Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg	Clinical Data Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	C CH C
СТЕР		DFMTI		
(RO 4956371;	mGluR5 inhibitor) Cat.	No.: HY-15445 (MK5435)		Cat. No.: HY-100404
Bioactivity:	CTEP (RO 4956371) is a novel, long-acting, orally bioav allosteric antagonist of mGlu5 receptor with IC_{50} of 2.2 nM, and shows > 1000-fold selectivity over other mGlu receptors.	ailable Bioactivity:	DFMTI can completely block the rmGlu1 L757V g response.	lutamate
Purity:	97.49%	Purity:	99.25%	
	No Development Reported	Clinitian Data	: No Development Reported	, °~~ .
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Size:	10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg)-N, L, L, L, N, N, L, L, P, P
Dipraglura	nt	E4CPG		
(ADX48621)	Cat.	No.: HY-14859		Cat. No.: HY-100372
Bioactivity:	Dipraglurant (ADX 48621) is a mGluR5 antagonists with 0.021 μ M.	IC50 of Bioactivity:	E4CPG is a novel group I/group II metabotropic or receptor antagonist, more potent than (RS)-MCP	
Purity: Clinical Data: Size:	99.99% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg	Purity: Clinical Data Size:	98.0% : No Development Reported 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	HOUT OH
Eglumegad (LY354740; Eg		FITM		Cat. No. : HY-101845
Bioactivity:	Eglumegad (LY354740) is a highly potent and selective II (mGlu2/3) receptor agonist with IC ₅₀ s of 5 and 24 r transfected human mGlu2 and mGlu3 receptors, respec	IM on	FITM is a negative allosteric modulator of $\mathbf{mGlu1}$ with a $\mathbf{K}_{\mathbf{i}}$ of 2.5 nM.	. receptor
	98.0%	Purity:	98.82%	
Purity: Clinical Data: Size:	No Development Reported 5 mg, 10 mg, 50 mg		: No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	$= \bigcirc \neg \overset{p}{\models} \overset{p}{\models} \overset{p}{\underset{N \searrow N}} \overset{q}{\underset{N \searrow N}} \overset{q}{\underset{N \searrow N}} \overset{q}{\underset{N \searrow N}}$
Clinical Data: Size: Foliglurax I	No Development Reported 5 mg, 10 mg, 50 mg nonohydrochloride	HO H HINT OH Size:	10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	
Clinical Data: Size: Foliglurax r (PXT002331 (No Development Reported 5 mg, 10 mg, 50 mg nonohydrochloride monohydrochloride)) Cat. No	но н	10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Cat. No.: HY-100382
Clinical Data: Size: Foliglurax I	No Development Reported 5 mg, 10 mg, 50 mg monohydrochloride monohydrochloride)) Cat. No Foliglurax monohydrochloride (PXT002331 monohydroc a highly selective and potent, brain-penetrant mGluR4 positive allosteric modulator (PAM), with an EC ₅₀ of 79	но на на сlinical Data Size: .: HY-108703A chloride) is	10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg FPTQ is mGluR1 antagonist with IC50 of 6 nM an human and mouse mGluR1 respectively. Inhibit [: target: mGluR1 IC 50: 6 nM [1] In vivo: FPTQ exhil	Cat. No.: HY-100382 d 1.4 nM for 3H] FTIDC bited
Clinical Data: Size: Foliglurax r (PXT002331 (No Development Reported 5 mg, 10 mg, 50 mg monohydrochloride monohydrochloride)) Cat. No Foliglurax monohydrochloride (PXT002331 monohydroc a highly selective and potent, brain-penetrant mGluR4	но на на сlinical Data Size: .: HY-108703A chloride) is	10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg FPTQ is mGluR1 antagonist with IC50 of 6 nM an human and mouse mGluR1 respectively. Inhibit [2	Cat. No.: HY-100382 d 1.4 nM for 3HJ FTIDC bited endent receptor
Clinical Data: Size: Foliglurax I (PXT002331 (Bioactivity: Purity:	No Development Reported 5 mg, 10 mg, 50 mg monohydrochloride monohydrochloride)) Cat. No Foliglurax monohydrochloride (PXT002331 monohydro a highly selective and potent, brain-penetrant mGluR4 positive allosteric modulator (PAM), with an EC ₅₀ of 79 nM ^[1] . Antiparkinsonian effect ^[1] . 98.93%	Linical Data Size: Clinical Data Size: FPTQ FPTQ ±19 Purity:	10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg FPTQ is mGluR1 antagonist with IC50 of 6 nM an human and mouse mGluR1 respectively. Inhibit [target: mGluR1 IC 50: 6 nM [1] In vivo: FPTQ exhil dose-dependent and plasma concentration- dep occupancy in the cerebellum and striatum. Comp 99.89%	Cat. No.: HY-100382 d 1.4 nM for 3HJ FTIDC bited endent receptor
Clinical Data: Size: Foliglurax I (PXT002331 (Bioactivity: Purity:	No Development Reported 5 mg, 10 mg, 50 mg monohydrochloride monohydrochloride)) Cat. No Foliglurax monohydrochloride (PXT002331 monohydro a highly selective and potent, brain-penetrant mGluR4 positive allosteric modulator (PAM), with an EC ₅₀ of 79 nM ^[1] . Antiparkinsonian effect ^[1] .	Linical Data Size: Clinical Data Size: FPTQ FPTQ ±19 Purity:	10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg FPTQ is mGluR1 antagonist with IC50 of 6 nM an human and mouse mGluR1 respectively. Inhibit [target: mGluR1 IC 50: 6 nM [1] In vivo: FPTQ exhil dose-dependent and plasma concentration- dep occupancy in the cerebellum and striatum. Comp	Cat. No.: HY-100382 d 1.4 nM for 3HJ FTIDC bited endent receptor

JNJ-404118	313	Cot No. 11V 15740	JNJ-42153	
(ADX-71149)		Cat. No.: HY-15748		Cat. No.: HY-181
Bioactivity:	JNJ-40411813 is a novel positive allosteric m metabotropic Glutamate 2 receptor (mGlu2F nM. IC50 value: 147 nM(EC50) Target: mGlu2 displayed an optimal interplay between pote favorable ADMET/PK and cardiovascular safe	R) with EC50 of 147 2R JNJ-40411813 ency, selectivity,	Bioactivity:	JNJ-42153605 is a positive allosteric modulator of the metabotropic glutamate 2 ($\rm mGlu2)$ receptor with an $\rm EC_{50}$ of 17 nM.
Purity: Clinical Data: Size:	99.69% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	de la companya de la comp	Purity: Clinical Data: Size:	98.10% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
JNJ-467782	212		JNJ162596	85
(VU 0409551)		Cat. No.: HY-19559		Cat. No.: HY-1004
Bioactivity:	JNJ-46778212 (VU 0409551) is an mGlu5 po modulator with an EC₅₀ of 260 nM.	sitive allosteric	Bioactivity:	JNJ16259685 is a selective antagonist of mGlu1 receptor , and inhibits the synaptic activation of mGlu1 in a concentration-dependent manner with IC₅₀ of 19 nM.
Purity: Clinical Data: Size:	99.24% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	10402-0	Purity: Clinical Data: Size:	98.85% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg
L-APB (L-AP 4)		Cat. No.: HY-100781A	L-Cysteines	sulfinic acid Cat. No.: HY-1008
Bioactivity:	L-APB is a potent and specific agonist for the mGluRs, with EC_{50} s of 0.13, 0.29, 1.0, 249 µN		Bioactivity:	L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluR s) with pEC sos of
	$_{4'}$ mGlu $_{8'}$ mGlu $_{6}$ and mGlu $_{7}$ receptors, resp			3.92±0.03, 4.6±0.2, 3.9±0.2, 2.7±0.2, 4.0±0.2, and 3.94±0.08 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively. >98%
Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg	HO' OH NH2	Purity: Clinical Data: Size:	>98%No Development Reported Ho 250 mg, 500 mgNH2
L-Glutamin			Lu AF21934	
(L-Glutamic a	cid 5-amide)	Cat. No.: HY-N0390		Cat. No.: HY-1003
Bioactivity:	L-Glutamine is a non-essential amino acid pu throughout the body and is involved in gast disorders. Target: mGluR Glutamine (abbrevi is one of the 20 amino acids encoded by the code. It is not recognized as an essential am	rointestinal iated as Gln or Q) e standard genetic	Bioactivity:	Lu AF21934 is a selective and brain-penetrant mGlu4 receptor positive allosteric modulator with an IC₅₀ of 500 nM for human mGlu4.
Purity: Clinical Data: Size:	98.0% Phase 4 10mM x 1mL in Water, 100 mg, 500 mg	${\rm spl}_{\lambda_{i}^{\rm loc}}$	Purity: Clinical Data: Size:	98.76% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
LY2794193		Cot No - UV 110242	LY2979165	
Bioactivity:	LY2794193 is a highly potent and selective n agonist (hmGlu3 K _i =0.927 nM EC ₅₀ =0.47 n K_i =412 nM EC ₅₀ =47.5 nM) ^[1] .		Bioactivity:	Cat. No.: HY-132. LY2979165 is a mGlu2 agonist, which is a novel potent agent that is used as anti-depressants.
Purity: Clinical Data: Size:	> 98% No Development Reported 500 mg, 250 mg	ися на <u>право со право со право Про страни и право со право со</u>	Purity: Clinical Data: Size:	98.0% Phase 1 10mM x 1mL in water, 1 mg, 5 mg, 10 mg, 50 mg

LY341495			LY404039		
		Cat. No.: HY-70059			Cat. No.: HY-5090
Bioactivity:	LY341495 is a metabotropic glutamate rece antagonist with IC₅₀s of 2.9 nM, 10 nM, 170 n mGluR-3, mGluR-8, respectively.		Bioactivity:	LY404039 is an inhibitor for mGluR1(K 92 nM), which can also inhibit dopami Value:149 nM(Ki for mGlu2); 92 nM(Ki mGluR1; mGluR2 Metabotropic glutan been shown to mediate a number of b	ne receptor. IC50 for mGlu3)[1] Target: nate (mGlu) receptors have
Purity:	99.11%	о‱он	Purity:	98.0%	0
	No Development Reported	H ₂ N ₄ OH	Clinical Data:		HO NHAH
Size:	10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg		Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	0% H
Mavoglura	nt		Mavoglura	nt racemate	
(AFQ056)		Cat. No.: HY-15257	(AFQ-056 rac	emate)	Cat. No.: HY-15257
Bioactivity:	Mavoglurant is a structurally novel, non-comp receptor antagonist, has an IC50 of 30 nM in a assay with human mGluR5.		Bioactivity:	Mavoglurant (racemate) is the racemat Mavoglurant is a novel, non-competiti antagonist.	-
Purity:	99.99%	Ŷ	Purity:	98.88%	ň
Clinical Data:	Phase 3	Ý		No Development Reported	н
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	HOL H HOL H	Size:	10mM x 1mL in DMSO, 2 mg, 5 mg	celative storeochamistry
Methoxy-P	EPy		MPEP		
		Cat. No.: HY-12510			Cat. No.: HY-14609
Bioactivity:	Methoxy-PEPy is a potent and highly selective antagonist with IC50 of 1 nM.	e mGlu5 receptor	Bioactivity:	MPEP is a potent and highly selective antagonist at the mGlu5 receptor subt positive allosteric modulator at mGlu4	ype (IC50 = 36 nM) and a
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	N N	Purity: Clinical Data: Size:	>98% No Development Reported 10 mg, 50 mg	
MPEP Hydr	rochloride		MSOP		
		Cat. No.: HY-14609			Cat. No.: HY-10122
Bioactivity:	MPEP hydrochloride is a potent and highly sel non-competitive antagonist at the mGlu5 rece IC50 of 36 nM.		Bioactivity:	MSOP is a selective group III metabo receptor antagonist with apparent K _D L-AP4-sensitive presynaptic mGluR.	
Purity: Clinical Data: Size:	99.57% No Development Reported 10mM × 1mL in Water, 10 mg, 50 mg	H-CI N-CI	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg	
MTEP hydr	ochloride	Cat. No. : HY-13206	O-Phospho (L-Serine O-p	D-L-serine hosphate; L-SOP)	Cat. No.: HY-1512
Bioactivity:	MTEP hydrochloride is a potent, selective and mGlu5 antagonist with IC50 and Ki of 5 nM ar respectively. IC50 Value: 5 nM [1] Target: mGlu occupied mGlu5 receptors in a dose-depende	non-competitive nd 16 nM, uR5 MTEP ent manner with	Bioactivity:	O-Phospho-L-serine is the immediate the serine synthesis pathway, and an a mGluR receptors (mGluR4, mGluR6, n O-Phospho-L-serine also acts as a wea	precursor to L-serine in gonist at the group III nGluR7, and mGluR8); ık antagonist for
		est dose tested		mGluR1 and a potent antagonist for n	nGluR2.
	essentially full receptor occupancy at the high		D 11	00.00/	
Purity: Clinical Data:	essentially full receptor occupancy at the high 99.73% No Development Reported	>N	Purity: Clinical Data:	98.0% No Development Reported	NH∘


PHCCC	Cat	No.: HY-100409	Ro 67-7476	5	Cat. No.: HY-10040
Bioactivity:	PHCCC is a Group I metabotropic glutamate receptor		Bioactivity:	Ro 67-7476 is a positive allosteric modulator	
·	with EC 50 of 6 uM and a positive allosteric modulato mGluR4. Also as a potent to antagonism for mGluR2			receptors. Displays no activity at human mGlu Potentiates glutamate-induced calcium releas 60.1 nM.	
Purity: Clinical Data: Size:	99.96% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	© ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	Purity: Clinical Data: Size:	98.58% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
TCN238	(m	t. No .: HY-14419	Topiramate (McN 4853; R		Cat. No.: HY-B012
Bioactivity:	TCN238 is a positive allosteric $mGlu4$ receptor modu with an EC_{50} of 1 $\mu M.$		Bioactivity:	Topiramate is an anticonvulsant that antagon receptors and acts as a positive allosteric mod receptor-mediated currents.	zes GluR5
Purity: Clinical Data: Size:	99.74% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	NNH2	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	$>^{\circ}_{\circ} \subset \overset{\circ}{\leftarrow} \overset{\circ}{\leftarrow} \overset{\circ}{\circ} \overset{\circ}{\leftarrow} \overset{\circ}{\circ}$
trans-ACPD (Trans-(±)-AC		t. No. : HY-19434	VU 035712	1	Cat. No.: HY-1539
Bioactivity:	trans-ACPD, a metabotropic receptor agonist, produc calcium mobilization and an inward current in culture cerebellar Purkinje neurons.	es	Bioactivity:	VU0357121 is a novel positive and highly sele modulator (PAM) of mGlu5R with EC50 of 33	ctive allosteric
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in Water, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	нр _{ил}	Purity: Clinical Data: Size:	99.85% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	~~~ ¹ ² ⁴
VU 036443		t. No. : HY-15476	VU0361737 (ML-128)	,	Cat. No.: HY-144
Bioactivity:	VU 0364439 is a mGlu4 positive allosteric modulator with EC50 of 19.8 nM.		Bioactivity:	VU 0361737 is a selective positive allosteric m for mGlu4 receptor with EC50 of 240 nM and rat receptors, respectively, displays weak activ and mGlu8 receptors, is inactive at mGlu1, mG	odulator (PAM) 110 nM at human and ity at mGlu5 6lu2, mGlu3, mGlu6
Purity: Clinical Data: Size:	98.01% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg		Purity: Clinical Data: Size:	and mGlu7 receptors. IC50 value: 110 nM (EC 99.83% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	ou, for rat), 240
VU0364770		No.: HY-100588	VU0424238	3	Cat. No.: HY-166:
Bioactivity:	VU0364770 is an allosteric of metabotropic glutamat 4 ($mGlu_4$) modulator, which exhibits a EC_{50} of 1.1±0 μ M at human mGlu $_4$.		Bioactivity:	VU0424238 is a novel and selective mGlu5 ar IC_{50} value of 11 nM (rat) and an IC_{50} value of VU0424238 has an acceptable CNS penetration	14 nM (human).
Purity: Clinical Data: Size:	99.54% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.40% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	

VU0650786		VU0652835	5
	Cat. No.: HY-108710		Cat. No. : HY-11994
Bioactivity:	VU0650786 is a potent and selective CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 (mGlu3) , with an IC₅₀ of 392 nM. VU0650786 has	Bioactivity:	VU0652835 is a metabotropic glutamate receptor subtype 5 (mGlu5) negative allosteric modulator with an IC₅₀ of 81 nM ^[1] .
	antidepressant and anxiolytic activity in rodents ^[1] .		
Purity: Clinical Data: Size:	>98% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	Purity: Clinical Data: Size:	>98% No Development Reported 100 mg, 250 mg, 500 mg
VU6001376	5	VU6005649	9
	Cat. No.: HY-112814		Cat. No .: HY-10798
Bioactivity:	VU6001376 is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4 PAM) with an EC_{50} of 50.1 nM ^[1] .	Bioactivity:	VU6005649 is a CNS penetrant $mGlu_{7/8}$ receptor agonist with EC_{50} s of 0.65 μ M and 2.6 μ M for $mGlu_7$ receptor and $mGlu_8$ receptor, respectively.
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 100 mg, 250 mg	Purity: Clinical Data: Size:	98.91% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
VU6012962	2	Xanthureni	ic acid
	Cat. No.: HY-114403		Cat. No.: HY-W01466
Bioactivity:	VU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (mGlu₇) negative	Bioactivity: Xanthurenic acid is a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory	
	allosteric modulator (NAM) with an $\mathbf{IC_{50}}$ of 347 nM $^{[1]}.$		transmission in the thalamus.
Purity: Clinical Data: Size:	99.92% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 100 mg



Motilin Receptor

MLNR



Motilin receptor is a G protein-coupled receptor that binds motilin. Motilin in turn is an intestinal peptide that stimulates contraction of gutsmooth muscle. The main function of motilin is to increase the migrating myoelectric complex component of gastrointestinal motility and stimulate the production of pepsin. Motilin is called "housekeeper of the gut" because it improves peristalsis in the small intestine and clears out the gut to prepare for the next meal. A high level of motilin secreted between meals into the blood stimulates the contraction of the fundus and antrum and accelerates gastric emptying. It then contracts the gallbladder and increases the squeeze pressure of the lower esophageal sphincter. Other functions of motilin

include increasing the release of pancreatic polypeptide and somatostatin.

Motilin Receptor Inhibitors & Modulators

hamster ovary cell line.

Purity:95.82%Clinical Data:No Development ReportedSize:500u g, 1 mg, 5 mg

Camicinal (GSK962040)	Cat. No.: HY-10922		hydrochloride (hydrochloride))	Cat. No.: HY-10922A
Bioactivity:	Camicinal (GSK962040) is a small molecule, selective motilin receptor agonist with pEC50 of 7.9.	Bioactivity:	Camicinal (GSK962040) hydrochloride is a small molecule, selective motilin receptor agonist with pEC50 of 7.9.	
Purity: Clinical Data: Size:	97.08% Phase 2 10mM x 1mL in DMSO,	Purity: Clinical Data Size:	>98% : Phase 2 5 mg, 10 mg, 50 mg, 100 mg	"0"0 <u>"0"</u>
Motilin (26	- 47), human, porcine Cat. No.: HY-P1037			
Bioactivity:	Motilin(human, porcine) is an endogenous motilin receptor ligand with $\mathbf{K_i}$ and $\mathbf{EC_{50}}$ of 2.3 nM and 0.3 nM in a Chinese	-		


FVPIFTYGELORMQEKERNKGQ

www.MedChemExpress.com



Neurokinin Receptor

NK receptor



There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the G α q-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP

HDAC (Histone deacetylase)

(cAMP) is stimulated by NK1R coupled to the $G\alpha$ s-protein. The neurokinin receptors are expressed on many cell types and tissues.

Neurokinin Receptor Inhibitors & Modulators

Aprepitant (MK-0869; MI	(-869; L-754030) Cat. No.: HY-10052	Befetupita (Ro67-5930)	nt Cat. No.: HY-19670
Bioactivity:	Aprepitant (MK-0869) is a selective and high-affinity neurokinin 1 receptor antagonist with a K_d of 86 pM.	Bioactivity:	Befetupitant is a high-affinity, nonpeptide, competitive tachykinin 1 receptor (NK1R) antagonist.
Purity: Clinical Data: Size:	99.93% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
Fezolinetar (ESN-364)	t Cat. No.: HY-19632	Fosaprepit (L-758298)	cat. No.: HY-14407
Bioactivity:	Fezolinetant is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes.	Bioactivity:	Fosaprepitant (L-758298) is a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Purity: Clinical Data: Size:	98.29% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% Launched 5 mg, 10 mg, 50 mg
Fosaprepita (MK-0517; L7	ant dimeglumine 85298) Cat. No.: HY-14407A	GR 159897	Cat. No .: HY-107691
Bioactivity: Purity: Clinical Data: Size:	Fosaprepitant dimeglumine(MK-0517) is a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. IC50 Value: Target: NK1 receptor in vitro: Fosaprepitant (also known as MK-0517 and L-758,298) is a water-soluble phosphoryl prodrug for aprepitant, which, when 99.0% Launched 5 mg, 10 mg, 50 mg	Bioactivity: Purity: Clinical Data: Size:	GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide antagonist at tachykinin NK₂ receptors , inhibits binding of [³ H]GR100679 to hNK ₂ -CHO cells and rat colon membranes with pK_i s of 9.51 and >98% No Development Reported $\qquad \qquad $
Hemokinin	1 mouse Cat. No.: HY-P1030	Ibodutant (MEN 15596)	Cat. No.: HY-14770
Bioactivity:	Hemokinin 1 (mouse) is a selective agonist of neurokinin-1 receptor, with K_i of 0.175 nM and 560 nM for human NK1 receptor and human NK2 receptor, respectively.	Bioactivity:	Ibodutant (MEN 15596) is a potent and selective tachykinin NK2 receptor antagonist with a $\mathbf{pK}_{\rm i}$ of 10.1.
Purity: Clinical Data: Size:	98.41% No Development Reported 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
Kassinin	Cat. No.: HY-P0250	Maropitan	t Cat. No.: HY-10053
Bioactivity: Purity: Clinical Data: Size:	Kassinin is a peptide derived from the Kassina frog. It belongs to tachykinin family of neuropeptides. It is secreted as a defense response, and is involved in neuropeptide signalling. >98% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	Bioactivity: Purity: Clinical Data: Size:	Maropitant is a neurokinin (NK1) receptor antagonist. IC50 value: Target: NK1 receptor Maropitant is the first NK1 receptor antagonist developed to treat and prevent emesis in dogs. Treatment with 1 mg/kg Maropitant citrate, significantly reduced the size of ulcerative dermatitis (UD) lesions in 99.00% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg

Men 10376			Men 10376		
(Neurokinin-2	ereceptor antagonist)	Cat. No.: HY-P1276	(Neurokinin-2	ereceptor antagonist (TFA))	Cat. No.: HY-P1276
Bioactivity:	Men 10376 is a selective $tachykinin$ NK-2 recovit with a ${\rm K}_i$ of 4.4 μM for rat small intestine NK-2		Bioactivity:	Men 10376 TFA is a selective tachykini antagonist, with a K_i of 4.4 μ M for rat s receptor ^[1] .	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	99.76% No Development Reported 1 mg, 5 mg, 10 mg	
MEN11467		Cat. No.: HY-U00207	Monohydro	oxy Netupitant D6	Cat. No.: HY-G0012
Bioactivity:	MEN11467 is a selective and orally- effective p tachykinin NK₁ receptor antagonist.	eptidomimetic	Bioactivity:	Monohydroxy Netupitant D6 is the deu Netupitant, which is a metabolite of Ne	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	04, 1970.	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	
Netupitant (CID 6451149)		Cat. No.: HY-16346	Netupitant (CID-6451149		Cat. No.: HY-16346
Bioactivity: Purity: Clinical Data: Size:	Netupitant (CID-6451149) is a highly potent an orally active neurokinin-1 receptor antagonist v nM. IC50 value: 0.95 nM (Ki) [1] Target: NK1 rec vitro: Netupitant also dose-dependently inhibit response as expected from an NK1 receptor an 99.78% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	with Ki of 0.95 ceptor in ced the SP	Bioactivity: Purity: Clinical Data: Size:	Netupitant D6 is the deuterium labeled Netupitant(CID-6451149), which is a hig selective, orally active neurokinin-1 reco >98% No Development Reported 1 mg, 5 mg, 10 mg	ghly potent and
Netupitant (Monohydrox	metabolite Monohydroxy Netupitant y Netupitant)	Cat. No.: HY-G0012	Neurokinin (α-Neurokinin	A n; Neuromedin L; Substance K)	Cat. No.: HY-P019
Bioactivity:	Monohydroxy Netupitant is the metabolite of f is a highly selective NK1 receptor antagonist.	Netupitant, which	Bioactivity:	Neurokinin A acts via neurokinin 2 (Ne	(- 2) receptor.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	10.0 .0 .0 .0 .0 .0 .0 .0 .0 .0	Purity: Clinical Data: Size:	98.92% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	HKTDSFVGLM-N
Neurokinin	A(4-10)	Cat. No.: HY-P0236	Neurokinin	A(4-10) TFA	Cat. No.: HY-P0236
Bioactivity:	Neurokinin A (4-10) is a tachykinin NK₂ recep	tor agonist.	Bioactivity:	Neurokinin A (4-10) TFA is a tachykinin [1]	n NK ₂ receptor agonist
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	www.wyf	Purity: Clinical Data: Size:	98.48% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	and the state of the

Neurokinin	antagonist 1		Neurokinin	В	
		Cat. No.: HY-U00320			Cat. No.: HY-P02
	Neurokinin antagonist 1 is a Neurokinin anta extracted from patent WO1998045262A1.	igonist	Bioactivity:	Neurokinin B belongs to the tachykinin Neurokinin B binds a family of GPCRs-in receptor 1 (NK1R), NK2R, and NK3R-to r effect ^[1] .	cluding neurokinin
	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	DMHDFFVGLM-
Neurokinin	B TFA	Cat. No.: HY-P0242A	NK-1 Antag	gonist 1	Cat. No. : HY-1066
-	Neurokinin B TFA belongs to the tachykinin fa Neurokinin B binds a family of GPCRs-includir receptor 1 (NK1R), NK2R, and NK3R-to media effect ^[1] .	amily of peptides. ng neurokinin	Bioactivity:	NK-1 Antagonist 1 is an antagonist of N the research of NK-1 related diseases ar cough, overactive bladder, alcohol depe	K-1 receptor , used in ad conditions such as
Clinical Data: Size:	>98% No Development Reported 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 25 mg	$\begin{array}{c} DMHDFFVGLM-NH_p\\ F_p & OH & F_p \\ F_p & OH \end{array}$	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	
NKP608		Cat. No.: HY-18006	Pavinetant (MLE-4901; A	ZD2624; AZD4901)	Cat. No.: HY-144
-	NKP608 is a non-peptidic derivative of 4-aminopiperidine which acts as a selective, specific and potent antagonist at the neurokinin-1 (NK-1) receptor both in vitro(IC50=2.6 nM) and in vivo.		Bioactivity:	Pavinetant (MLE-4901) is a neurokinin - antagonist.	3 receptor (NK3R)
Clinical Data: Size:	99.34% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg		Purity: Clinical Data: Size:	99.74% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	
Physalaemi	n	Cat. No.: HY-P0255	Rolapitant (SCH619734)		Cat. No.: HY-14
	Physalaemin, a non-mammalian tachykinin, bi neurokinin-1 (NK1) receptor with high affin		Bioactivity:	Rolapitant (SCH619734) is a potent, sele active neurokinin NK1 receptor antagor	
	>98% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	POLU-ADPIKEYQLM-NH ₂	Purity: Clinical Data: Size:	98.01% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	
Saredutant SR 48968; SR		Cat. No. : HY-106910	SB-222200		Cat. No.: HY-15
Bioactivity:	Saredutant is a selective NK2 receptor antag	onist.	Bioactivity:	SB 222200 is a selective, reversible and o antagonist of human NK-3 receptor(Ki= crosses the blood-brain barrier.	
	>98% No Development Reported 250 mg, 500 mg		Purity: Clinical Data: Size:	99.91% No Development Reported 10mM x 1mL in DMSO,	O, NH


Scyliorhinir		5.: HY-P1588	ktide		Cat. No.: HY-P018
Bioactivity:	Scyliorhinin II is a selective neurokinin-3 receptor agoni with a \mathbf{K}_{i} of 2.5 nM for neurokinin-3 receptor in rat cereb cortex.	st, Bioa	ctivity:	Senktide is a tachykinin NK₃ receptor agonist.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	тонтяциканими, Size:	cal Data:	99.56% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	
Serlopitant (VPD-737; MK			ostance l urokinin P		Cat. No. : HY-P020
Bioactivity:	Serlopitant is a selective Neurokinin-1 (NK-1) receptor antagonist.	Bioa	ctivity:	Substance P is a neuropeptide, acting as a neuro and as a neuromodulator.The endogenous recep P is neurokinin 1 receptor (NK1-receptor , NK	ptor for substance
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purit Clini Size:	cal Data:	98.07% Phase 1 1 mg, 5 mg, 10 mg, 25 mg	RPKPQQFFGLM-Nt
	P (1-7)(TFA) (1-7) Trifluoroacetate) Cat. No.	: HY-P1485A	ostance l	P 1-7	Cat. No. : HY-P148
Bioactivity:	Substance P (1-7)(TFA) is a fragment of the neuropeptide substance P (SP). Substance P (1-7)(TFA) gives depressor bradycardic effects when applied to the nucleus tractus solitarius.		ctivity:	Substance P (7-11) is a fragment of the neurope substance P (SP). Substance P (7-11) gives depre bradycardic effects when applied to the nucleus solitarius.	essor and
Purity: Clinical Data: Size:	99.20% No Development Reported 5 mg, 10 mg, 25 mg	۳۰۰۰ Puriti ۲۰۰۰ ۲۰۰۰ Puriti ۲۰۰۰ ۲۰۰۰ Size: ۲۰۰۰ ۲۰۰۰ Size:	cal Data:	>98% No Development Reported 5 mg, 10 mg	40
Substance I		Sub	ostance l	P 7-11	Cat. No. : HY-P149
Bioactivity:	Substance P (1-9) is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder.	Bioa	ctivity:	Substance P (7-11) is a C-terminal fragment of S which can cause an increase in the intracellular o concentration.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	تر کی مرتب برد Size:	cal Data:	>98% No Development Reported 5 mg, 10 mg, 25 mg	or grige
Tachykinin	angatonist 1 Cat. No.		netant 223412)		Cat. No.: HY-1455
Bioactivity:	Tachykinin angatonist 1 is a neurokinin receptor antagc extracted from patent US5968923, compound example 3		ctivity:	Talnetant (SB 223412) is a potent and selective I antagonist(ki=1.4 nM, hNK-3-CHO); 100-fold se hNK-3 versus hNK-2 receptor, with no affinity fo concentrations up to 100 uM.	lective for the
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	Purit Clini کرکرہے ب	cal Data:	99.44% Phase 2 10mM x 1mL in DMSO, 10 mg, 50 mg	HO HO

	ydrochloride /drochloride; SB 223412-A) Cat. No.: HY-:	Tradipitant 2A (VLY-686; LY686017) Cat. No.: HY-16732
Bioactivity:	Talnetant Hcl(SB 223412 Hcl) is a potent and selective NK3 receptor antagonist(ki=1.4 nM, hNK-3-CHO); 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 uM.	Bioactivity: Tradipitant is a neurokinin-1 (NK-1) antagonist.
Purity: Clinical Data: Size:	>98% C	Purity: 99.62% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg 100 mg
Vofopitant (GR 205171)	Cat. No.: HY	42 Y1 receptor antagonist 1 Cat. No.: HY-101704
Bioactivity:	Vofopitant is potent tachykinin NK_1 receptor antagonist, with pK ₁ s of 10.6, 9.5, and 9.8 for human, rat and ferret NK $_1$ receptor, respectively.	Bioactivity: Y1 receptor antagonist 1, an isomer of H-409/22, is a neuropeptide Y1 receptor antagonist.
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg, 100 mg	Purity: 95.03% Clinical Data: No Development Reported Size: 1 mg
[bAla8]-Ne (MEN 10210)	urokinin A(4-10) Cat. No.: HY	[Nle11]-Substance P
Bioactivity:	[bAla8]-Neurokinin A(4-10) is a neurokinin 2 (NK2) receptor agonist.	Bioactivity: [Nle11]-Substance P is a substance P analog that avoids methionine oxidation problems.
Purity: Clinical Data: Size:	98.17% No Development Reported 1 mg, 5 mg, 10 mg	Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg
[Sar9,Met(C	D2)11]-Substance P Cat. No.: HY	[Sar9] Substance P 12 Cat. No.: HY-P1738
Bioactivity:	[Sar9,Met(O2)11]-Substance P is a tachykinin NK₁ receptor selective agonist.	Bioactivity: [Sar9] Substance P is a potent and selective neurokinin (NK)-1 receptor agonist ^[1] .
Purity: Clinical Data: Size:	98.45% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	Purity: >98% Clinical Data: No Development Reported Size:



Neuropeptide Y Receptor

NPY receptor



none (mistorie dedectyld.

range of diseases.

Neuropeptide Y receptors are a class of G-protein coupled receptors which are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide. These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.

Neuropeptide Y (NPY) is a potent orexigenic neuropeptide, and antagonism of NPY Y1 and NPY Y5 receptors (NPYxR) is considered a potentially important anti-obesity drug target.

Neuropeptide Y (NPY) is widely distributed in the human body and contributes to a vast number of physiological processes. A number of other uses for modulators of NPY receptors have been implied in a

Neuropeptide Y Receptor Inhibitors & Modulators

BIIE-0246 (AR-H 053591)	Cat. No. : HY-101986	CGP71683 (CGP71683A)	hydrochloride	Cat. No. : HY-10772
Bioactivity:	² BIIE-0246 is a potent and highly selective nor neuropeptide Y (NPY) Y ₂ receptor antagoni 15 nM.	1-peptide	Bioactivity:	CGP71683 hydrochloride is a competitive receptor antagonist with a K_i of 1.3 nM, activity at Y1 receptor (K_{γ} >4000 nM) ar	e neuropeptide Y5 and shows no obvious
Purity: Clinical Data: Size:	99.0% No Development Reported 1 mg		Purity: Clinical Data: Size:	 K_i, 200 nM) in cell membranes. 99.63% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg 	Chi to to
FR252384			Galanin (1-	16), mouse, porcine, rat	
		Cat. No.: HY-U00335			Cat. No.: HY-P15
Bioactivity:	FR252384 is a neuropeptide Y-Y5 receptor a IC ₅₀ of 2.3 nM.	antagonist, with an	Bioactivity:	Galanin (1-16), mouse, porcine, rat is an hippocampal galanin receptor , with a K	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	HN N T	Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	GWTLNSAGYLLGPI
Galanin (1-	16), mouse, porcine, rat TFA	Cat. No. : HY-P1578A	Galanin (1-	30), human	Cat. No.: HY-P11
Bioactivity:	Galanin (1-16), mouse, porcine, rat (TFA) is an hippocampal galanin receptor , with a $\mathbf{K}_{\mathbf{d}}$ of	agonist of the	Bioactivity:	Galanin (1-30), human is a 30-amino acic acts as an agonist of GalR1 and GalR2 r both 1 nM.	I neuropeptide, and
Purity: Clinical Data: Size:	98.08% No Development Reported 500u g, 1 mg, 5 mg	$ \begin{array}{c} \text{GWTLNSAGYLLGPHAI} \\ \text{O} \underset{p \in \mathcal{P}_{p}}{\overset{p \in \mathcal{P}}{\underset{p \in \mathcal{P}_{p}}{\overset{p \in \mathcal{P}_{p}}{\underset{p \in \mathcal{P}_{p}}}{\underset{p \in \mathcal{P}_{p}}}{\underset{p \in \mathcal{P}_{p}}}{\underset{p \in \mathcal{P}_{p}}{\underset{p \in \mathcal{P}_{p}}}{\underset{p \in \mathcal{P}_{p}}{\underset{p \in \mathcal{P}_{p}}}{\underset{p \in \mathcal{P}_{p}}{\underset{p \in \mathcal{P}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}$	Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	Califyrein Taun canadalad
Galanin Red	ceptor Ligand M35	Cat. No. : HY-P1840	Galantide		Cat. No. : HY-P02
Bioactivity:	Galanin Receptor Ligand M35 is a high-affinit receptor ligand acting as a galanin receptor rat spinal cord, rat hippocampus and isolated islets. Galanin Receptor Ligand M35 exerts a l	y galanin antagonist in the mouse pancreatic	Bioactivity:	Galantide is a reversible and non-specific antagonist.	
Purity: Clinical Data: Size:	>98% No Development Reported	ONLINENDITEMACULARIENEG	Purity: Clinical Data: Size:	99.27% No Development Reported 500u g, 1 mg, 5 mg	OMUTRMOJITEADEADIT
HT-2157			JNJ-310200)28	
(SNAP 37889)		Cat. No.: HY-100717			Cat. No.: HY-144
Bioactivity:	HT-2157 (SNAP 37889) is a selective, high-aff competitive antagonists of galanin-3 recept ed	-	Bioactivity:	JNJ-31020028 is a selective brain penetra neuropeptide Y2 receptor with high affin pIC50=8.22 rat); >100-fold selective vers receptors.	ity(pIC50=8.07, human;
Purity: Clinical Data: Size:	98.0% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.51% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	

M40			MK-0557		
		Cat. No.: HY-P1025			Cat. No.: HY-15411
Bioactivity:	M40 is a potent, non-selective galanin recept	or antagonist.	Bioactivity:	MK-0557 is a highly selective, orally available new Y5 receptor antagonist with a ${\rm K_i}$ of 1.6 nM.	europeptide
Purity: Clinical Data: Size:	98.25% No Development Reported 500u g, 1 mg, 5 mg, 10 mg	ONTO BACKLOPPPILIE AND	Purity: Clinical Data: Size:	98.28% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg	A C C C C C C C C C C C C C C C C C C C
	ide Y (13-36), amide, human e Y (13-36), human)	Cat. No.: HY-P1480		ide Y (29-64), amide, human opeptide Y (29-64))	Cat. No.: HY-P0198
Bioactivity:	Neuropeptide Y (13-36), amide, human is a ne r receptor agonist.	uropeptide Y	Bioactivity:	Neuropeptide Y (29-64), amide, human is a biol 36-amino acid peptide.	logically active
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	FAEDANNYSALINOFALITION HIL	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	
Neuropept	ide Y (29-64), amide, human TFA	Cat. No.: HY-P0198A	Neuropept	ide Y 22-36	Cat. No. : HY-P1818
Bioactivity:	Neuropeptide Y (29-64), amide, human (TFA) is Alzheimer's disease (AD) and protects rat cortic against β -Amyloid toxicity.		Bioactivity:	Neuropeptide Y (22-36), a 15 amino acid peptic of Neuropeptide Y.	de, is a fragment
Purity: Clinical Data: Size:	95.02% No Development Reported 1 mg, 5 mg	 پلا	Purity: Clinical Data: Size:	>98% No Development Reported	SALRHYINLITRORY-NH2
Neuropept	ide Y(29-64)	Cat. No.: HY-P1601	Pancreatic	Polypeptide, bovine	Cat. No.: HY-P1537
Bioactivity: Purity: Clinical Data: Size:	Neuropeptide Y(29-64) is a 36 amino acid pept of Neuropeptide Y. >98% No Development Reported 1 mg, 5 mg	tide, a fragment	Bioactivity: Purity: Clinical Data: Size:	Pancreatic Polypeptide, bovine, a 36-amino acia chain polypeptide derived primarily from the pa inhibits secretin- and cholecystokinin-stimulate secretion; Pancreatic Polypeptide, bovine acts a of NPY receptor , with high affinity at NPYR4 . >98% No Development Reported 500u g, 1 mg, 5 mg	ancreas, d pancreatic
	Polypeptide, human reatic polypeptide)	Cat. No.: HY-P0199		Polypeptide, rat ic polypeptide)	Cat. No.: HY-P1532
Bioactivity:	Pancreatic Polypeptide, human is a C-terminall amino acid peptide, which acts as a neuropep Y4/Y5 receptor agonist.	*	Bioactivity:	Pancreatic Polypeptide, rat is an agonist of NPN with high affinity at NPYR4 .	receptor,
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg		Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	wy amount control of the control of

Peptide YY	(PYY), human	RF9
	Cat. No.: HY-P1514	
Bioactivity:	Peptide YY (PYY) is a gut hormone that regulates appetite and inhibits pancreatic secretion. Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors .	Bioac
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	Purity Clinic Size:
Velneperit		


Velneperit (S2367)		Cat. No.: HY-14423
Bioactivity:	Velneperit (S-2367) is a novel neuropeptide Y (NP receptor antagonist.	YY) Y5
Purity: Clinical Data: Size:	99.26% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	руг м H Q Q K

		Cat. No.: HY-1073
Bioactivity:	RF9 is a potent and selective Neuropeptic antagonist, with K ₁ s of 58±5 and 75±9 nM	
	hNPFF2R, respectively.	
Purity:	98.24%	
Clinical Data:	No Development Reported	HN_NH2 HN
Size:	10mM x 1mL in DMSO,	CONTRACT CONTRACT
	1 mg, 5 mg	AN O .



Neurotensin Receptor





HDAC (Histone deacetylase)

Neurotensin receptors are transmembrane receptors that bind the neurotransmitter neurotensin. Two of the receptors encoded by the NTSR1 and NTSR2 genes contain seven transmembrane helices and are G protein coupled. The third receptor has a single transmembrane domain and is encoded by the SORT1 gene. Neurotensin (NTS) is a 13-amino-acid peptide that functions as both a neurotransmitter and a hormone through the activation of the neurotensin receptor NTSR1, a G-protein-coupled receptor (GPCR). In the brain, NTS modulates the activity of dopaminergic systems, opioid-independent analgesia, and the inhibition of food intake; in the gut, NTS regulates a range of digestive processes.


Neurotensin Receptor Inhibitors & Modulators

Kinetensin			ML314		
(Kinetensin (h	uman))	Cat. No.: HY-P1255			Cat. No.: HY-166
Bioactivity:	Kinetensin is a neurotensin -like peptide isola pepsin-treated human plasma.	ated from	Bioactivity:	ML314 is a potent molecule agonist of NTR showed good selectivity against NTR2 and stimulate Ca2+ mobilization.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	99.72% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	ÎN ÎN
Neurotensi	n				
		Cat. No.: HY-P0234			
Bioactivity:	Neurotensin, a gut tridecapeptide, acts as a p mitogen for various colorectal and pancreation possess high-affinity neurotensin receptors	c cancers which			
Purity: Clinical Data: Size:	97.32% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	Pyr-LYENKPRRPYIL			



Opioid Receptor

HDAC Inhibitor: Vorinostat (SAHA)



HDAC (Histone deacetylase)

Opioid receptors are a group of G protein-coupled receptors with opioids as ligands. The endogenous opioids are dynorphins, enkephalins, endorphins, endomorphins and nociceptin. Opioid receptors are distributed widely in the brain, and are found in the spinal cord and digestive tract. Opioid receptors are molecules, or sites, within the body that are activated by opioid substances. Opioid receptors inhibit the transmission of impulse in excitatory pathways within the human body system. These pathways include the serotonin, catecholamine, and substance P pathways, which are all implicated in pain perception and feelings of well-being. Opioid receptors are further subclassified into mu, delta, and kappa receptors. All the

classes, while exhibiting differing modes of action, share some basic similarities. They all are driven by the potassium pump mechanism, which is found on the plasma membrane of the majority of cells.

Opioid Receptor Inhibitors & Modulators

ADL-5859	Cat. No.: HY-13044	Adrenorphin (Metorphamide) Cat. No.: HY-P1087
Bioactivity:	ADL5859 is a δ -opioid receptor agonist with Ki of 0.8 nM, selectivity against opioid receptor κ , μ , and weak inhibitory activity at the hERG channel.	Bioactivity: Adrenorphin is a opioid octapeptide, acting as a potent agonist of μ-opioid receptor, with K _i of 12 nM.
Purity: Clinical Data: Size:	99,65% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: 95.49% Clinical Data: No Development Reported Size: 1 mg, 5 mg
Alvimopan (ADL 8-2698;		Alvimopan dihydrate (ADL 8-2698 dihydrate; LY 246736 dihydrate) Cat. No.: HY-76657A
Bioactivity: Purity: Clinical Data: Size:	Alvimopan(LY 246736; ADL 8-2698) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery. IC50 Value: 1.7 nM (Mu-type opioid receptor) [1] Target: mu-opioid receptor in vitro: The dissociation rate of alvimopan from the >98% Launched 5 mg, 10 mg, 50 mg	Bioactivity: Alvimopan dihydrate (ADL 8-2698 dihydrate; LY 246736 dihydrate) is a peripherally acting mu-opioid receptor (PAM-OR, ICS0= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery. ICS0 Value: 1.7 nM (Mu-type opioid receptor) [1] Target: mu-opioid receptor in Purity: 98.02% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
	monohydrate monohydrate; LY 246736 monohydrate) Cat. No.: HY-76657	AR-M 1000390 hydrochloride Cat. No.: HY-101039A
Bioactivity:	Alvimopan monohydrate (ADL 8-2698 monohydrate; LY 246736 monohydrate) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery.	Bioactivity:AR-M 1000390 hydrochloride is an exceptionally selective, potent δ opioid receptor agonist with an EC ₅₀ of 7.2±0.9 nM for δ agonist potency.
Purity: Clinical Data: Size:	99.18% Launched 5 mg, 10 mg, 50 mg	Purity: 99.80% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Asimadolin (EMD-61753)	e Cat. No.: HY-107384	Aticaprant (CERC-501; LY-2456302) Cat. No.: HY-101718
Bioactivity:	Asimadoline is a potent κ opioid receptor agonist with IC_{50} s of 5.6 and 1.2 nM for guinea pig and human recombinant κ opioid receptor, respectively.	Bioactivity: Aticaprant (CERC-501) is a potent and centrally-penetrant kappa opioid receptor antagonist with a K _i of 0.807 nM.
Purity: Clinical Data: Size:	99.36% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	Purity: 99.24% Clinical Data: Phase 1 Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg
BAM-22P (Bovine adren	nal medulla-22P) Cat. No.: HY-P1331	BAN ORL 24 Cat. No.: HY-13222
Bioactivity:	BAM-22P, a highly potent opioid peptide, is a potent opioid agonist.	Bioactivity:BAN ORL 24 is a potent and selective NOP receptor antagonist. (IC50 values are 0.27, 2500, 6700 and > 10000 nM for NOP, κ-, μ- and δ-receptors respectively).
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	Purity: 95.07% Clinical Data: No Development Reported Size: 10mM x 1mL in Water, 10 mg, 50 mg, 100 mg

Bevenoprar (CB-5945; ADI		Cat. No.: HY-100122	Cebranopa (GRT6005)	dol	Cat. No.: HY-15536
Bioactivity:	Bevenopran is a peripheral µ-opioid receptor		Bioactivity:	Cebranopadol is an analgesic NOP and opioi with K ₁ s/ EC ₅₀ s of 0.9 nM/13 nM, 0.7 nM/1.2 nM, 18 nM/110 nM for human NOP, MOP, KC peptide (DOP) receptor, respectively.	d receptor agonist nM, 2.6 nM/17
	>98% No Development Reported 1 mg, 5 mg	anajain	Purity: Clinical Data: Size:	98.76%	
	dol ((1α,4α)stereoisomer) ,4α)stereoisomer)	Cat. No.: HY-15536A	CYT-1010		Cat. No. : HY-123534
Bioactivity:	Cebranopadol ((1α,4α)stereoisomer) is a stere cebranopadol. Cebranopadol is a potent agon ORL-1.		Bioactivity:	CYT-1010 is a mu-opioid receptor agonist e patent WO2013173730A2, with EC₅₀s of 13.1 on beta-arrestin recruitment and inhibition of production, respectively ^[1] .	nM and 0.0053 nM
	>98% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg	r → H → H → H → H → H → H → H → H → H →	Purity: Clinical Data: Size:	>98% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	
CYT-1010 h	ydrochloride	Cat. No.: HY-123534A	DAMGO		Cat. No. : HY-P0210
Bioactivity:	CYT-1010 hydrochloride is a mu-opioid recep extracted from patent WO2013173730A2, with and 0.0053 nM on beta-arrestin recruitment a cAMP production, respectively ^[1] .	n EC₅₀s of 13.1 nM	Bioactivity:	DAMGO is a $\mu\text{-opioid receptor}$ ($\mu\text{-OPR}$) set	ective agonist.
Purity: Clinical Data: Size:	>98% No Development Reported 100 mg, 250 mg, 500 mg		Purity: Clinical Data: Size:	98.10% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg	
Deltorphin ([D-Ala2]-Delt		Cat. No.: HY-P1013	Deltorphin (Deltorphin 1	I ; Deltorphin C)	Cat. No.: HY-P1336
Bioactivity:	Deltorphin 2 is a selective peptide agonist for receptor .	the δ opioid	Bioactivity:	Deltorphin I is a δ -opioid receptor agonist w and selectivity.	vith high affinity
Purity: Clinical Data: Size:	98.20% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	weeks the second	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	antito
Dermorphi	n	Cat. No.: HY-P0244	Dynorphin	A (1-10) TFA	Cat. No. : HY-P1594A
Bioactivity:	Dermorphin is a natural heptapeptide µ-opioi MOR) agonist found in amphibian skin.	id receptor (Bioactivity:	Dynorphin A (1-10) (TFA), an endogenous op binds to extracellular loop 2 of the κ -opioid Dynorphin A (1-10) (TFA) also blocks NMDA- with an IC ₅₀ of 42.0 μ M.	receptor.
Purity: Clinical Data: Size:	99.64% No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	૾ઌૢઌ૾ઌ૾ઌૢૼૡ	Purity: Clinical Data: Size:	95.04% No Development Reported 1 mg, 5 mg, 10 mg	

Dynorphin	A 1-10	Cat No. UV D1504	Dynorphin	B 1-13	Cot No. UV D1227
Bioactivity:	Dynorphin A (1-10) an endogenous opioid n		Bioactivity:	Dynorphin B (1-13) acts as an agonist on	Cat. No.: HY-P1337 opioid κ-receptor.
	extracellular loop 2 of the κ-opioid receptor (1-10) also blocks NMDA -activated current v 42.0 μM.				
Purity:	>98% No Development Reported		Purity:	>98% No Development Reported	
Size:	1 mg, 5 mg, 10 mg	YGGFLRRIRP	Size:	1 mg, 5 mg, 10 mg	YGGFLRRQFKVVT
Endomorpl	hin 1		Endomorph	nin 2	
		Cat. No.: HY-P0185			Cat. No.: HY-P0186
Bioactivity:	Endomorphin 1, a high affinity, highly selected the μ-opioid receptor , displays reasonable a kappa ₃ binding sites, with \mathbf{K}_{i} value between	affinities for	Bioactivity:	Endomorphin 2, a high affinity, highly select the μ-opioid receptor , displays reasonab kappa ₃ binding sites, with K _i value between	le affinities for
Purity:	98.15%	но	Purity:	>98%	но
Clinical Data: Size:	No Development Reported 10mM x 1mL in Water,	¥	Clinical Data: Size:	No Development Reported 5 mg, 10 mg, 25 mg	
5126.	5 mg, 10 mg, 25 mg		5126.	5 mg, 10 mg, 25 mg	
Endomorpl	hin 2 TFA		Gluten Exo	rphin B5	
		Cat. No.: HY-P0186A			Cat. No.: HY-P1742
Bioactivity:	Endomorphin 2 TFA, a high affinity, highly see of the μ -opioid receptor, displays reasonable kappa ₃ binding sites, with K _i value between ^[1] .	le affinities for	Bioactivity:	Gluten Exorphin B5 is an exogenous opio from wheat gluten, acts on opioid recep postprandial plasma insulin level in rats ^[1]	tor, increases
Purity: Clinical Data:	>98% No Development Reported	HO HOLF	Purity: Clinical Data:	>98% No Development Reported	Q
Size:	10mM x 1mL in Water, 5 mg, 10 mg, 25 mg		Size:		"Outuinde B
Gluten Exo	rphin C		Hemorphin	1-7	
		Cat. No.: HY-P1596			Cat. No.: HY-P0318
Bioactivity:	Gluten exorphin C is an opioid peptide derive gluten. Its IC_{50} values are 40 μ M and 13.5 μ M δ opioid activities in the GPI and MVD assay	Λ for μ opioid and	Bioactivity:	Hemorphin-7 is a hemorphin peptide, an peptide derived from the β-chain of hemorphic peptides exhibits antinociceptive and anti activities, activating opioid receptors and angiotensin-converting enzyme (ACE).	oglobin. Hemorphin hypertensive
Purity:	>98%	но	Purity:	99.65%	
Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg, 25 mg	and a carter of	Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg	and the
JDTic		Cat. No. : HY-10486	JDTic dihyc	Irochloride	Cat. No. 11V 10497
Disastinitari	IDTic is a highly calenting anterpreter (Rice ethilty	IDTis (dibudeschlagida) in a start	Cat. No.: HY-10487
Bioactivity:	JDTic is a highly selective antagonist for the μ receptor; without affecting the μ - or δ -opioid		Bioactivity:	JDTic (dihydrochloride) is a potent antagor receptors (KOR), blocking the κ -agonist antinociception.	
Purity:	>98%		Purity:	99.79%	
Clinical Data:	Phase 1	10 yr 10 u	Clinical Data:	Phase 1	"CCTL
Size:	5 mg, 10 mg, 50 mg	"COLLECTOR"	Size:	10mM x 1mL in Water,	"and a

JTC-801		Cat. No. : HY-13274	Kelatorpha	n	Cat. No.: HY-10827
Bioactivity:	JTC-801 is a selective opioid receptor-like1 antagonist, binding to ORL1 receptor with a b 8.2nM.	(ORL1) receptor	Bioactivity:	Kelatorphan is a full inhibitor of enkephali enzymes .	
Purity: Clinical Data: Size:	99.73% No Development Reported 5 mg, 10 mg, 50 mg	2	Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg	но на страната и стр
Loperamide (R-18553 (hyc	e hydrochloride Irochloride))	Cat. No.: HY-B0418A	LY-2940094	4	Cat. No. : HY-11445
Bioactivity:	Loperamide (hydrochloride) (R-18553 (hydroc opioid receptor agonist for the treatment of		Bioactivity:	LY-2940094 is a potent, selective and orally nociceptin receptor (NOP receptor) anta affinity (K_i =0.105 nM) and antagonist poten nM). LY-2940094 reduces ethanol self-adm	gonist with high ency (K_b= 0.166
Purity: Clinical Data: Size:	99.69% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	о-Стор ус. на	Purity: Clinical Data: Size:	99.56% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	
LY2795050		Cat. No.: HY-15708	Matrine (Matridin-15-	one; Vegard; α-Matrine)	Cat. No.: HY-N016
Bioactivity:	LY2795050 is a novel selective κ -opioid Reception antagonist (IC50=0.72 nM) and has the potent racer to image KOR in vivo. IC50 Value: 0.72 Receptor); 25.8 nM (κ -opioid) [1] Target: κ -opivito: LY2795050 displays full antagonist activ	ntial as a PET nM (κ-opioid pioid Receptor in	Bioactivity:	Matrine (Matridin-15-one) is an alkaloid for the Sophora genus. It has a variety of pharr effects, including anti-cancer effects, and a opioid receptor and u-receptor agonist.	nacological
Purity: Clinical Data: Size:	98.02% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	"Graces"	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg	
MCOPPB tr	iHydrochloride	Cat. No. : HY-13101	MT-7716 fr (W-212393)	ree base	Cat. No. : HY-107094.
Bioactivity:	MCOPPB 3Hcl is a nociceptin receptor agons 10.07; weaker activity at other opioid recepto 10.07 (pKi) Target: nociceptin receptor MCOP trihydrochloride is a trihydrochloride form of a new nonpeptide nociceptin/orphanin FQ pe	rs. IC50 value: PB MCOPPB that is	Bioactivity:	MT-7716 free base (W-212393) is a selectiv nociceptin receptor (NOP) agonist and pr treatment drug for alcohol abuse and relap	omising potential
Purity: Clinical Data: Size:	99.35% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	>98% No Development Reported	
MT-7716 h	ydrochloride /drochloride)	Cat. No.: HY-107094		nylclozapine ;; Desmethylclozapine; Normethylclozapine	e) Cat. No.: HY-G002
Bioactivity:	MT-7716 hydrochloride (W-212393 hydrochlo non-peptide nociceptin receptor (NOP) ago potential treatment drug for alcohol abuse ar prevention ^[1] .	onist and promising	Bioactivity:	N-Desmethylclozapine is a dengue virus inl agonist of δ-opioid receptor .	hibitor, and an
Purity: Clinical Data: Size:	>98% No Development Reported 100 mg, 500 mg, 250 mg	C C C	Purity: Clinical Data: Size:	98.66% No Development Reported 10mM x 1mL in DMSO,	

Naloxegol (NKTR-118; A	Z-13337019) Cat. No.: HY-A0118	Naloxegol (NKTR-118 or		Cat. No.: HY-A0118A
	Naloxegol (NKTR-118; AZ-13337019) is an opioid-receptor antagonist ^[1] .	Bioactivity:	Naloxegol oxalate (NKTR-118 oxalate; AZ-13337 an opioid-receptor antagonist ^[1] .	019 oxalate) is
Purity: Clinical Data: Size:	>98% Launched 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.90% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	F
Naltrindole	hydrochloride Cat. No.: HY-101177		tide AF (93-110), Human le AF (human))	Cat. No. : HY-P1246
Bioactivity:	Naltrindole hydrochloride is a highly potent and selective non-peptide $\pmb{\delta}$ opioid receptor antagonist with a K _i of 0.02 nM.	Bioactivity:	Neuropeptide AF (93-110), Human is an endoge peptide.	enous antiopioid
	99.68% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	AGEGLASOFWELAAPORF-INI,
Nociceptin (Orphanin FQ)	Cat. No .: HY-P0183	Nociceptin	(1-13), amide	Cat. No.: HY-P1317
Bioactivity:	Nociceptin, a heptadecapeptide, is the endogenous ligand of the nociceptin receptor, acting as a potent anti-analgesic.	Bioactivity:	Nociceptin (1-13), amide is a potent ORL1 (OP4 agonist with a pEC₅₀ of 7.9 for mouse vas defere of 0.75 nM for binding to rat forebrain membrar	ens and a K_i
Size:	99.79% No Development Reported 10mM x 1mL in Water, FGGFTGARKSARKLANG 1 mg, 5 mg, 10 mg, 25 mg	Purity: Clinical Data: Size:	>98% No Development Reported	FGGFTGARKSARK-NH ₂
Opioid rece	ptor modulator 1 Cat. No.: HY-U00420	ORL1 anta	gonist 1	Cat. No.: HY-112263
Bioactivity:	Opioid receptor modulator 1 is a opioid receptor modulator extracted from patent WO2014072809A2, Compound RA11 in EXAMPLE 7.	Bioactivity:	ORL1 antagonist 1 is an opioid receptor-like 1 () antagonist with an $\rm IC_{50}$ of 61 nM.	
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	0,5+0 0,5
PZM21	Cat. No. : HY-101386	Sinomenin (Cucoline hyd	e hydrochloride drochloride)	Cat. No.: HY-15122A
Bioactivity:	PZM21 is a potent and selective μ opioid receptor agonist with an EC_{50} of 1.8 nM.	Bioactivity:	Sinomenine hydrochloride is a blocker of the NF and also an activator of µ-opioid receptor .	-κ B activation
	99.45% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 100 mg	


SR17018		Cat. No.: HY-111454	Trimebutin	e	Cat. No.: HY-B038
Bioactivity:	SR17018 is an mu-opioid-receptor (MOR) age		Bioactivity:	Trimebutine is a drug with antimuscarini	
	with GTP _γ S, with an $\textbf{EC}_{\textbf{50}}$ of 97 nM.			agonist effects.	
Purity: Clinical Data:	98.0% No Development Reported	<i>~~</i>	Purity: Clinical Data:	>98%	[°]
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	ж ^с от	Size:	5 g	
Trimebutin	e maleate	Cat. No.: HY-B0380A		r-Phe-Met-OH alin; Methionine enkephalin)	Cat. No. : HY-P007
Bioactivity:	Trimebutine maleate is a drug with antimuscari opioid agonist effects.	nic and weak mu	Bioactivity:	Tyr-Gly-Gly-Phe-Met-OH regulates hum inhibits tumor growth via binding to the	
Purity:	99.95%	, j	Purity:	99.81%	
Clinical Data: Size:	Launched 10mM x 1mL in DMSO, 5 g	HO COLOH	Clinical Data: Size:	No Development Reported 10mM x 1mL in Water, 10 mg, 25 mg, 50 mg, 100 mg	"onkrida
Valorphin		Cat. No.: HY-P1599	Vanilpyruvi (Vanylpyruvic		Cat. No. : HY-1014
Bioactivity:	Valorphin is an endogenous hemoglobin β -cha with opioid analgesic activity, binds to rat mu- receptor , with an IC ₅₀ of 14 nM; Valorphin also anti-tumor activity.	opioid	Bioactivity:	Vanilpyruvic acid is a catecholamine met to vanillactic acid.	tabolite and precursor
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg		Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 10 mg	HO
ZT 52656A	hydrochloride	Cat. No.: HY-101582	[D-Ala2]leu	icine-enkephalin	Cat. No. : HY-P00
Bioactivity:	ZT 52656A is a selective kappa opioid agonist, prevention or alleviation of pain in the eye.	used for the	Bioactivity:	[D-Ala2]leucine-enkephalin, a delta opi degradation resistant long-acting Leu-en	-
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Ch Cr	Purity: Clinical Data: Size:	99.75% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg	hundro.
[Leu5]-Enke	ephalin lin; Leucine enkephalin; Leucyl-enkephalin)	Cat. No.: HY-P0288	[Leu5]-Enko (Leu-Enkepha	ephalin, amide lin amide)	Cat. No.: HY-P14
Bioactivity:	[Leu5]-Enkephalin is a pentapeptides with morp properties. [Leu5]-Enkephalin is a five amino ac peptide that acts as an agonist at opioid recep	id endogenous	Bioactivity:	[Leu5]-Enkephalin, amide is a δ opioid r	r eceptor agonist.
Purity: Clinical Data: Size:	99.72% No Development Reported 10mM x 1mL in Water,	"oriniinty	Purity: Clinical Data: Size:	>98% No Development Reported 10 mg, 25 mg	hinko.

[Met5]-Enkephalin, amide (5-Methionine-enkephalin amide) Cat.		prphin, bovine phin-7 (bovine); Bovine β-casomorphin-7)	Cat. No.: HY-P0179
Bioactivity: [Met5]-Enkephalin, amide is an agonist for δ opioid receptors as well as putative ζζ opioid receptors.	Bioactivity:	β-casomorphin, bovine ($β$ -casomorphin-7) is a or with an IC₅₀ of 14 μM in an Opioid receptors bind	
Purity:>98%Clinical Data:No Development ReportedSize:10 mg, 25 mg	 ຼຸດາໄດປເຊີຍ Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg	
<mark>β-Casomorphin, human</mark> (Human β-casomorphin 7) Cat.	No.: HY-P1481	nin, human	Cat. No.: HY-P1502
Bioactivity: β-Casomorphin, human is an opioid peptide, acts as ar of opioid receptor .		β-Endorphin, human, a prominent endogenous p in the hypophysis cerebri and hypothalamus, is ar opioid receptor , with preferred affinity for μ-opi and δ-opioid receptor ; β-Endorphin, human exh antinociception activity.	n agonist of oid receptor
Purity:>98%Clinical Data:No Development ReportedSize:5 mg, 10 mg, 25 mg	Purity: Clinical Data Size:	>98% : No Development Reported 1 mg, 5 mg, 10 mg	YOGHMTHIKIOTY, VT, MANARAKINKOH



Orexin Receptor (OX Receptor)

Hypocretin Receptor; HCRT Receptor



HDAC (Histone deacetylase)

gene has been localized to chromosome 6.

Orexin receptors (OX receptor) include orexin 1 receptor and orexin 2 receptor. Orexin receptor type 1 (Ox1R or OX1), is a protein that in humans is encoded by the HCRTR1gene. The orexin 1 receptor (OX1), is a G-protein coupled receptor expressed in the hypothalamus and involved in the regulation of feeding behaviour. OX1 selectively binds the orexin-A neuropeptide. It shares 64% identity with OX2. The OX2 receptors, also known as hypocretin receptor 2, are located primarily in the cerebral cortex, paraventricular hypothalamus, nucleus accumbens, subthalamic and paraventricular thalamus where they are thought to regulate sleep-wakefulness. The OX2 receptor displays equal affinity for Orexin A and Orexin B. The human OX2 receptor

Orexin Receptor (OX Receptor) Inhibitors & Modulators

Almorexan (ACT 078573)			nt hydrochloride B hydrochloride) Cat. No.: HY-10805/
Bioactivity:	Almorexant (ACT 078573) is a potent and competitive dual orexin 1 receptor (OX1)/ orexin 2 receptor (OX2) antagonist with \mathbf{K}_{i} values of 1.3 and 0.17 nM, respectively.	Bioactivity:	Almorexant hydrochloride (ACT 078573 hydrochloride) is a potent and competitive dual orexin 1 receptor (OX1)/ orexin 2 receptor (OX2) antagonist with K _i values of 1.3 and 0.17 nM, respectively.
Purity: Clinical Data: Size:	99.17% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	99.88% : Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Filorexant		GSK10598	
(MK-6096) Bioactivity:	Cat. No.: HY-15653 Filorexant (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding).	Bioactivity:	Cat. No.: HY-101534 GSK1059865 is a potent orexin 1 receptor antagonist.
Purity: Clinical Data: Size:	98.95% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.91% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
IPSU	Cat. No. : HY-13796	Lemborexa (E-2006)	ant Cat. No.: HY-1672!
Bioactivity:	IPSU is a selective, orally available and brain penetrant OX2R antagonist with a pK _i of 7.85.	Bioactivity:	Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia.
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	Purity: Clinical Data Size:	99.71% : Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
MK-1064	Cat. No. : HY-19914	MK-3697	Cat. No.: HY-1230:
Bioactivity:	MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia. target: 2-SORA [1] In vivo: MK-1064 promotes sleep and increases both rapid eye movement (REM) and non-REM (NREM) sleep in rats at OX2R occupancies	Bioactivity:	MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM.
Purity: Clinical Data: Size:	higher than the range observed for dual orexin receptor 99.97% Phase 1 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	99.19% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
Nemorexar (ACT-541468)		Orexin 2 R	eceptor Agonist Cat. No.: HY-1932(
Bioactivity:	Nemorexant (ACT-541468) is a potent orexin receptor antagonist extracted from patent WO2015083094A1, compound example 7, has IC_{50} s of 2 nM and 3 nM for Ox ₁ receptor and Ox ₂ receptor , respectively.	Bioactivity:	Orexin 2 Receptor Agonist is a potent (EC50 on OX2R is 23 nM) and OX2R-selective (OX1R/OX2R EC50 ratio is 70) agonist.
Purity: Clinical Data: Size:	99.47% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.72% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg


Orexin B, h (Human orexi		Cat. No.: HY-P1339	Orexin B, h (Human orexi		Cat. No.: HY-P1339
Bioactivity:	Orexin B, human is an endogenous agonist at with ${\bf K}_{\rm i} {\rm s}$ of 420 and 36 nM for OX1 and OX2, r		Bioactivity:	Orexin B, human (TFA) is an endogenou receptor with $\mathbf{K}_{j}\mathbf{s}$ of 420 and 36 nM for respectively.	s agonist at Orexin OX1 and OX2,
Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg		Purity: Clinical Data: Size:	>98% No Development Reported 500u g, 1 mg, 5 mg	$\label{eq:constraint} \begin{split} & \text{Reserves constraints} \\ & $
Orexin B, ra	at, mouse		SB-334867		
(Rat orexin B;	Orexin B (mouse))	Cat. No.: HY-P1349	(SB 334867A)		Cat. No.: HY-1089
Bioactivity:	Orexin B, rat, mouse is an endogenous agonis receptor with ${\bf K}_{\rm i}$ s of 420 and 36 nM for OX1 a respectively.		Bioactivity:	SB-334867 is a selective non-peptide or antagonist with a pKb value of 7.2. IC50 Target: orexin OX1 receptor in vitro: SB- the orexin-A (10 nM) and orexin-B (100 responses (pK(B)=7.27+/-0.04 and 7.23-	value: 7.2 (pKb) [1] 334867-A inhibited nM)-induced calcium
Purity: Clinical Data: Size:	95.54% No Development Reported 500u g, 1 mg, 5 mg	WOWE CONCERN DWORMACE THAT	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg	
SB-334867 (SB334867A fi		Cat. No. : HY-10895A	SB-408124		Cat. No.: HY-7006
Bioactivity:	SB-334867 free base is a selective non-peptid receptor antagonist with a pKb value of 7.2.	e orexin OX1	Bioactivity:	SB408124 is a non-peptide antagonist f of 57 nM and 27 nM in both whole cell respectively; exhibits 50-fold selectivity	and membrane,
Purity: Clinical Data: Size:	99.77% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	GH H	Purity: Clinical Data: Size:	98.27% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 100 mg	
SB-408124	Hydrochloride	Cat. No. : HY-76612	SB-649868 (GSK649868)		Cat. No.: HY-1080
Bioactivity:	SB408124 Hcl is a non-peptide antagonist for Ki of 57 nM and 27 nM in both whole cell and respectively; exhibits 50-fold selectivity over C	membrane,	Bioactivity:	SB-649868 is a potent and selective or a and OX_2 receptor antagonist ($pK_i = 9$ 1 and OX_2 receptor, respectively).	
Purity: Clinical Data: Size:	98.14% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.88% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 i	mg
SB-674042		Cat. No. : HY-10898	TCS 1102		Cat. No. : HY-1090
Bioactivity:	SB-674042 is a potent and selective non-pept receptor antagonist (Kd = 3.76 nM); exhibits 1 selectivity for OX1 over OX2 receptors.	ide orexin OX1	Bioactivity:	TCS 1102 is a potent, dual orexin recept values are 0.2 and 3 nM for OX2 and O respectively).	or antagonist (Ki
Purity: Clinical Data: Size:	99.70% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data: Size:	99.89% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	

TCS-OX2-2	9 Cat. No.: HY-100452
Bioactivity:	TCS-OX2-29 is a potent and selective OX2 receptor antagonist with IC50 of 40 nM. Displays >250-fold selectivity for OX2 over OX1.
Purity: Clinical Data: Size:	99.18% No Development Reported 5 mg, 10 mg, 50 mg, 100 mg



Oxytocin Receptor

OXTR



HDAC (Histone deacetylase)

Oxytocin, a hormone involved in numerous physiologic processes, plays a central role in the mechanisms of parturition and lactation. It acts through its receptor, which is a transmembrane receptor belonging to the rhodopsin-type class I G-protein-coupled receptor (GPCR) superfamily, while Gq/phospholipase C (PLC)/inositol 1,4,5-triphosphate (InsP3) is the main pathway via which it exerts its action in the myometrium. The main signaling pathway is the Gq/LPC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. Various peptide and nonpeptide antagonists have been developed as

potential tocolytic agents or research tools for the various Oxytocin functions. Many of these oxytocin receptor antagonists are used only as pharmacological tools, while others have tocolytic action.

Oxytocin Receptor Inhibitors & Modulators


Atosiban			Carbetocin	1	
(RW22164; R	WJ22164)	Cat. No.: HY-17572			Cat. No.: HY-1757
Bioactivity:	Atosiban(RW22164; Tractocile) is a nonapeptide desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTi inhibits the oxytocin-mediated release of inositi tripphereptate form	e ra). Atosiban ol	Bioactivity:	Carbetocin (Lonactene; Duratocin) is an obstetr control postpartum hemorrhage and bleeding a an agonist at peripheral oxytocin receptors.	5
Purity: Clinical Data: Size:	trisphosphate from the myometrial cell membra 99.09% : Launched 5 mg, 10 mg, 50 mg	ane. IC50 value	Purity: Clinical Data: Size:	98.0% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	- The start
Cligosiban (PF-3274167		Cat. No. : HY-15023	Epelsiban (GSK 557296)		Cat. No.: HY-10501
Bioactivity:	Cligosiban, a high oral bioavailability and good brain-penetrant non-peptide oxytocin recepto shows a high-affinity (\mathbf{K}_i =9.5 nM) and an excel selectivity versus the vasopressin receptors with	r antagonist, lent	Bioactivity:	Epelsiban (GSK 557296) is a potent, selective ar bioavailable oxytocin receptor antagonist, with for human oxytocin receptor.	nd orally
Purity: Clinical Data: Size:	99.85% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	P T C THEN NN	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	
L-368,899	hydrochloride	Cat. No. : HY-108677	L-371,257		Cat. No.: HY-1501
Bioactivity:	L-368,899 hydrochloride is a potent, selective, c bioavailable, non-peptide oxytocin receptor a I C₅₀s of 8.9 nM and 26 nM for rat uterus and hi oxytocin receptor, respectively, used as a tocoly	ntagonist, with uman uterus	Bioactivity:	L-371,257 is an orally bioavailable, non-blood-t penetrant, selective and competitive antagonist receptor (pA2=8.4) with high affinity at both th receptor (K_i =19 nM) and vasopressin V1a rec	t of oxytocin ne oxytocin
Purity: Clinical Data: Size:	98.00% : No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	H H H H H H H H H H H H H H	Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in DMSO, 5 mg	ورمافره
OT antago	nist 1	Cat. No.: HY-103650	OT antago	nist 1 demethyl derivative	Cat. No.: HY-1036
Bioactivity:	OT antagonist 1 (Compound 4) is a potent, sele antagonist with a ${f K}_{i}$ of 50 nM.	ctive Oxytocin	Bioactivity:	OT antagonist 1 demethyl derivative is the dem of OT antagonist 1. OT antagonist 1 (Compoun selective Oxytocin antagonist with a K _i of 50 n	d 4) is a potent,
Purity: Clinical Data: Size:	>98% : No Development Reported 250 mg, 500 mg	CLC No	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	
OT antago	nist 3	Cat. No.: HY-103649	OT-R antag (Oxytocin rec	gonist 1 eptor antagonist 1)	Cat. No.: HY-1501
	OT antagonist 3 is an oxytocin (OT) antagonist	extracted from	Bioactivity:	OT-R antagonist 1 is a new potent and selective molecular weight OT-R antagonist. OT-R antag- oxytocin-evoked intracellular Ca2+ mobilization	onist 1 inhibits
Bioactivity:	patent WO2007017752A1.			IC50 value: 8 nM Target: oxytocin receptor in vi antagonist 1 inhibitis IP3-Synthesis, rat OT-R (IC	tro: OT-R

OT-R antag (Oxytocin rec	gonist 2 eptor antagonist 2)	Cat. No. : HY-15015A	Oxytocin (α-Hypophan	nine; Oxytocic hormone)	Cat. No.: HY-17571
Bioactivity:	OT-R antagonist 2 is a nonpeptide low molecu antagonist. OT-R antagonist 2 inhibitis IP3-Syn OT-R (IC50 = 0.33 μ M).		Bioactivity:	Oxytocin (α -Hypophamine) is a mamr hormone; its actions are mediated by oxytocin receptors; ligand of oxytocin	specific, high-affinity
Purity: Clinical Data: Size:	99.74% No Development Reported 1 mg, 5 mg, 10 mg	d'allo	Purity: Clinical Data: Size:	98.68% Launched 5 mg, 10 mg	udd ywer.
Oxytocin a (α-Hypophan	cetate nine acetate; Oxytocic hormone acetate)	Cat. No. : HY-17571A	Retosiban (GSK 221149;	GSK 221149A)	Cat. No.: HY-1477
Bioactivity:	Oxytocin (α -Hypophamine) acetate is a mamn neurohypophysial hormone; its actions are me specific, high-affinity oxytocin receptors; ligan receptor.	ediated by	Bioactivity:	Retosiban (GSK221149A) is a potent a antagonist with a ${\bf K_i}$ of 0.65 nM.	nd selective oxytocin



P2Y Receptor

HDAC Inhibitor: Vorinostat (SAHA)



P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as ATP, ADP, UTP, UDP and UDP-glucose. To date, 12 P2Y receptors have been cloned in humans: P2Y1, P2Y2, P2Y4, P2Y5, P2Y6, P2Y8, P2Y9, P2Y10, P2Y11, P2Y12, P2Y13 and P2Y14. P2Y receptors are present in almost all human tissues where they exert various biological functions based on their G-protein coupling. P2Y2 is a potential drug target for treating cystic fibrosis. P2Y11 is a regulator of immune response, and a common polymorphism carried by almost 20% of North European caucasians give increased risk of myocardial infarction, making P2Y11 an interesting drug target candidate for treatment of myocardial

infarction. P2Y12 is the target of the anti-platelet drug clopidogrel and other thienopyridines.

P2Y Receptor Inhibitors & Modulators


AZD1283			BPTU		
	Cat	t. No. : HY-15799	(BMS-646786)	Cat. No.: HY-13831
Bioactivity:	AZD1283 is a potent antagonist of the P2Y12 recepto of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.		Bioactivity:	BPTU is a novel P2Y1 allosteric antagonist.	
Purity: Clinical Data: Size:	99.11% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	98.03% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Clopidogre		t. No. : HY-15283		I hydrogen sulfate ((S)-(+)-Clopidogrel bi	sulfate; Cat. No.: HY-17459
Bioactivity:	Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is u inhibit blood clots in coronary artery disease, peripher vascular disease, and cerebrovascular disease.		Bioactivity:	Clopidogrel is an antiplatelet agent which word platelets from sticking together and prevents the forming harmful clots.	
Purity: Clinical Data: Size:	>98% Launched 100 mg	of of the second	Purity: Clinical Data: Size:	97.95% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	HO-S O HO-S O O HO-S O O O HO-S
Clopidogre	l thiolactone Cat	t. No. : HY-15876	Diquafosol (INS365)	tetrasodium	Cat. No.: HY-B0606
Bioactivity:	Clopidogrel thiolactone is a P2Y12 receptor inhibitor, potent antiplatelet agent.	is a	Bioactivity:	Diquafosol tetrasodium is a P2Y2 receptor agor stimulates fluid and mucin secretion on the ocu a topical treatment of dry eye disease.	
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg		Purity: Clinical Data: Size:	99.93% Launched 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg	 ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
MRS 2578	Cat	t. No.: HY-13104	N6-(4-Hyd (Para-topolin	roxybenzyl)adenosine riboside)	Cat. No. : HY-18775
Bioactivity: Purity: Clinical Data: Size:	MRS 2578 is a potent P2Y6 receptor antagonist with I nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4, P2Y11 receptors. IC50 value: 37 nM [1] Target: P2Y6 re in vitro: MRS2578 selectively blocks P2Y6 receptor act versus activity at P2Y1, P2Y2, P2Y4 or P2Y11 receptors 95.67% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	and eceptor tivity	Bioactivity: Purity: Clinical Data: Size:	N6-(4-Hydroxybenzyl)adenosine is a inhibitor of aggregation induced in vitro by collagen and the range was demonstrated (IC50: 6.77-141 μ M). If 6.77-141 μ M Target: P2Y12receptor Anti-aggregation (A-(4-Hydroxybenzyl)) adenosine could involve a 99.66% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	eir activity 250 value: gation activity of
Oral antipla	atelet agent 1 Cat.	No.: HY-111755	Prasugrel (PCR 4099)		Cat. No. : HY-15284
Bioactivity:	Oral antiplatelet agent 1 is a potent antiplatelet ager an IC_{50} of 2.94 μ M in vitro as well as antithrombotic e in a rat model. P2Y receptor antagonist ^[1] .		Bioactivity:	Prasugrel (PCR 4099) is a platelet inhibitor with of 1.8 $\mu M.$	IC ₅₀ value
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	free free	Purity: Clinical Data: Size:	98.0% Launched 100 mg, 500 mg	

	ydrochloride		Prasugrel N		
(PCR 4099 (hy	/drochloride))	Cat. No.: HY-15284A	(PCR 4099 (M	laleic acid))	Cat. No.: HY-15284B
Bioactivity:	Prasugrel (PCR 4099) hydrochloride is a with IC $_{50}$ value of 1.8 $\mu M.$	a platelet inhibitor	Bioactivity:	Prasugrel (PCR 4099) Maleic acid is a pl IC $_{\rm 50}$ value of 1.8 $\mu M.$	atelet inhibitor with
Purity: Clinical Data: Size:	>98% Launched 10mM x 1mL in DMSO, 100 mg, 500 mg	-6-500 Ho	Purity: Clinical Data: Size:	>98% Launched 100 mg, 500 mg	-C-JC-C-
Suramin			Suramin so	odium salt	
		Cat. No.: HY-B0879	(Suramin hex	asodium salt; BAY-205; NF-060)	Cat. No.: HY-B0879A
Bioactivity:	Suramin is a polysulfonated naphthylu biological activities. Suramin is a DNA inhibitor with an IC_{50} of 5 μ M.		Bioactivity: Suramin sodium salt is a polysulfonated naphthylurea with various biological activities. Suramin sodium salt is a DNA topoisomerase II inhibitor with an IC ₅₀ of 5 μM.		dium salt is a DNA
Purity: Clinical Data: Size:	>98% Launched 50 mg	Johanana tan	Purity: Clinical Data: Size:	99.93% Launched 50 mg	janonorote 111
TAK-024			Ticagrelor		
		Cat. No.: HY-100254	(AR-C 126532	2XX; AZD6140)	Cat. No.: HY-10064
Bioactivity:	TAK-024 is a platelet inhibitor with IC	•	Bioactivity:	Ticagrelor (AZD6140) is a reversible ora antagonist for the treatment of platelet	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	™ÉQ. ™ÉQ.Qu	Purity: Clinical Data: Size:	99.98% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	$\sim r^{-1} r^{-1$



Prostaglandin Receptor





HDAC (Histone deacetylase)

Prostaglandin receptor, а sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Prostaglandin Receptor Inhibitors & Modulators

(+)-Clopros (D-Cloproster		Cat. No.: HY-107381	2-(E-2-deco	enoylamino)ethyl 2-(cyclohexylethyl) sulfide Cat. No.: HY-100287
Bioactivity: Purity: Clinical Data: Size:	 (+)-Cloprostenol is a prostaglandin F2α (PGF2α) as shows selective agonistic activity at the prostaglar receptor. 99.13% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg 		Bioactivity: Purity: Clinical Data: Size:	2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide is a compound that inhibits stress-induced ulcer and low toxicity, and can maintain the content of phospholipase A2 and prostaglandin E2 in ulcerated rats induced by water immersed restrained stress. >98% No Development Reported 1 mg, 5 mg, 10 mg
Aganepag			AGN 21067	
(AGN 210937)		Cat. No.: HY-19864	(Simenepag)	Cat. No.: HY-14898
Bioactivity:	Aganepag is a potent Prostanoid EP2 receptor as EC ₅₀ of 0.19 nM, and shows no activity at EP4 rece Aganepag can be used in the research of wound h reduction, scar prevention and wrinkle treatment a prevention	eptor. nealing, scar	Bioactivity:	AGN 210676 is a selective prostaglandin ${\sf EP_2}$ agonist extracted from patent US20070203222A1, Compound example 23, has an ${\sf EC_{50}}$ of 5 nM.
Purity: Clinical Data: Size:	prevention. >98% No Development Reported 500 mg, 250 mg	GH GH GH	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
AH 6809		Cat. No. : HY-10418	Aligeron	Cat. No.: HY-101602
Bioactivity:	AH 6809 is an EP and DP receptor antagonist with affinity for the cloned human EP1, EP2, EP3-III, and receptors.	nearly equal	Bioactivity:	Aligeron is a non-selective prostaglandin (PG) antagonist, and has vasodilatory properties.
Purity: Clinical Data: Size:	99.47% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg
AM211 (AM211 free a	cid)	Cat. No. : HY-13213	AMG-009	Cat. No.: HY-19499
Bioactivity:	AM211 is a potent, selective and orally bioavailabl prostaglandin D2 (PGD2) receptor type 2 (DP2) IC₅₀s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for huma guinea pig, and rat DP2, respectively.	e) antagonist, with	Bioactivity:	AMG-009 is a potent antagonist of prostaglandin D2 , with IC_{50} of 3 nM and 12 nM for CRTH2 and DP receptors, respectively.
Purity: Clinical Data: Size:	99.94% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg
Asapiprant (S-555739)		Cat. No. : HY-16763	AZ-1355	Cat. No. : HY-101692
Bioactivity:	Asapiprant is a potent and selective DP_1 receptor antagonist with a \mathbf{K}_i of 0.44 nM.		Bioactivity:	AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I $_2$ /thromboxane A $_2$ ratio in vitro.
Purity: Clinical Data: Size:	99.67% Phase 2 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	May and	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg

AZD1981		BAY-13169	
	Cat. No.: HY-1595)	Cat. No.: HY-11153
Bioactivity:	AZD1981 is a potent and selective CRTh2 antagonist; displaces radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8.4). IC50 value: Target: GPR44 antagonist in vitro: AZD1981 produced a concentration-dependent displacement of the [3H]PGD2-specific binding with a mean pIC50 of 8.4 ±	Bioactivity:	BAY-1316957 is a highly potent and selective EP4 receptor antagonist with an IC_{50} of 15.3 nM. Good oral bioavailability ^[1] .
Purity:	99.26%	Purity:	>98%
Clinical Data:			No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Size:	250 mg, 500 mg, 100 mg
Benorilate		BI-671800	
(Salipran)	Cat. No.: HY-10779	5	Cat. No.: HY-11414
Bioactivity:	Benorylate (Benoral) is the esterification product of paracetamol and acetylsalicylic acid. It has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit prostaglandin (PG) synthesis.	Bioactivity:	BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2), with IC ₅₀ values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cel
Purity:	99.80%	Purity:	99.06%
	No Development Reported		No Development Reported
Size:	10mM x 1mL in DMSO,	Size:	۱0mM x 1mL in DMSO,
	100 mg •		5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Bimatopros	st	Bunaprola	st
(AGN 192024)	Cat. No.: HY-B019	(U66858)	Cat. No.: HY-U0017
Bioactivity:	Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.	Bioactivity:	Bunaprolast (U66858) is a potent inhibitor of LTB₄ production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of lipoxygenase and TXB₂ release.
Purity:	96.97%	Purity:	>98%
Clinical Data: Size:	Launched 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg	Clinical Data: Size:	1 mg, 5 mg, 10 mg, 20 mg
BW 245C		Carbacycli	n
	Cat. No.: HY-10198	(Carbaprosta	cyclin; Carba-PGI2) Cat. No.: HY-11232
Bioactivity:	BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.	Bioactivity:	Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.
Purity:	99.14%	Purity:	99.0%
	No Development Reported		No Development Reported
Size:	10mM x 1mL in DMSO,	Size:	1 mg
CAY10471	Racemate	CAY10595	
(TM30089 Rad			Cat. No.: HY-11818
Bioactivity:	CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective prostaglandin D2 receptor CRTH2 antagonist, with a K _i of 0.6 nM for hCRTH2, selective over human thromboxane A2	Bioactivity:	CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a K_i of 10 nM.
	receptor TP (K $_{i^\prime}$ >10000 nM) or PGD2 receptor DP (K $_{i^\prime}$ 1		
Purity:	99.35%	Purity:	>98%
Clinical Data: Size:	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	Clinical Data: Size:	250 mg, 500 mg

244 Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

CGS 15435		CI-949		
	Cat. No.	: HY-100283		Cat. No.: HY-U00364
Bioactivity:	CGS 15435, a potent thromboxane (TxA_2) synthetase inh with an IC_{50} of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI $_2$	nibitor Bioactivity:	CI-949 is an allergic mediator release inhibitor inhibits histamine , leukotriene C_4/D_4 (LTC ₄ / thromboxane B_2 (TXB ₂) release with IC ₅₀ s or μ M and 0.1 μ M, respectively.	′LTD₄) , and
Purity:	synthetase and lipoxygenase enzymes. >98%	Purity:	>98%	
			No Development Reported	Q. A
Size:	1 mg, 5 mg, 10 mg	Ginical Data:	1 mg, 5 mg, 10 mg, 20 mg	
CJ-42794		Cloprosten	ol sodium salt	
(CJ-042794)	Cat. No	p.: HY-10797 (ICI 80996 soc		Cat. No.: HY-10841
Bioactivity:	CJ-42794 is a selective prostaglandin E receptor subtype (EP4) antagonist, inhibits [3H]-PGE2 binding to the huma receptor with a mean pKi of 8.5, a binding affinity that wa at least 200-fold more selective for the human EP4 receptor	n EP4 as tor	Cloprostenol sodium salt (ICI 80996 sodium s synthetic prostaglandin analogue, acts as a lu ^[1] , and is a PGF2α receptor agonist ^[2] .	
Purity: Clinical Data: Size:	than other human EP receptor subtypes (EP1, EP2, and EF 99.31% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity:	99.81% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	HQ HQ HQ HQ HQ HQ HQ HQ HQ HQ HQ HQ HQ H
CRTh2 anta	5	CRTH2-IN-		
	Cat. No.	: HY-112265 (Ramatroban	analog)	Cat. No.: HY-U00423
Bioactivity:	CRTh2 antagonist 1 is a ${\bf CRTh2}$ antagonist with an ${\bf IC}_{{\bf 50}}$ o nM	f 89 Bioactivity:	CRTH2-IN-1 (Ramatroban analog) is a selectiv receptor DP2 (CRTH2) antagonist with an IC human DP2 binding assay.	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg	Nog Chiff D-
Darbufelon	•	Dinoprost		
(CI-1004 mes	ylate) Cat. No.:	HY-101438A (Prostaglandi	n F2a; PGF2α)	Cat. No.: HY-1295
Bioactivity:	Darbufelone mesylate is a dual inhibitor of cellular PGF_{20} and LTB_4 production. Darbufelone potently inhibits PGH $IC_{50} = 0.19 \ \mu$ M) but is much less potent with PGHS-1 (IC 20 μ M).	S-2 (Dinoprost(Prostaglandin F2 α) is a naturally oc prostaglandin used in medicine to induce labor abortifacient.	
Purity:	>98%	→ Purity:	>98%	
Clinical Data: Size:	No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Clinical Data:	No Development Reported 5 mg, 10 mg	ny fan ad fan
	t <mark>romethamine salt</mark> (Prostaglandin F2a tromethamin HAM; Prostaglandin F2α THAM) Cat. No.	e E7046 : HY-12956A		Cat. No. : HY-10308
Bioactivity:	Dinoprost tromethamine salt is a naturally occurring prostaglandin used in medicine to induce labor and as ar abortifacient.	Bioactivity:	E7046 is an orally bioavailable and specific EP with IC_{50} of 13.5 nM and K _i of 23.14 nM, exhiactivities.	
Purity: Clinical Data:	98.0% Launched 10mM x 1mL in Water,	Purity: Clinical Data: Size:	99.60% Phase 1 10mM x 1mL in DMSO,	

EP1-antanc	pist-1	Cat. No.: HY-101695	Etersalate (Eterylate; Eth	erylate)	Cat. No.: HY-10160
Bioactivity:	EP1-antanoist-1 is a EP1 antagonist with a \mathbf{pK}_{i} \mathbf{pIC}_{50} of 8.5.	of 7.54 and an	Bioactivity:	Etersalate inhibits platelet function and decrease thromboxane A2 (TXA2) levels.	5e5
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	B B B C N O C M	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	Crock
Ethamsylat	e	Cat. No. : HY-B1074	Evatanepag (CP-533536 fr	•	Cat. No.: HY-1483
Bioactivity:	Ethamsylate is a haemostatic drug, also inhibits and action of those prostaglandins.	biosynthesis	Bioactivity:	Evatanepag (CP-533536) is an EP2 receptor sel prostaglandin E2 (PGE2) agonist that induces to formation with EC50 of 0.3 nM.	
Purity: Clinical Data: Size:	99.0% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	HO O O HO O H	Purity: Clinical Data: Size:	99.80% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	
Fevipiprant (NVP-QAW03		Cat. No. : HY-16768	Ginsenosid Chikusetsusar	e Ro (Polysciasaponin P3; Chikusetsusaponin ponin V)	1 5; Cat. No.: HY-N060
Bioactivity: Purity: Clinical Data: Size:	Fevipiprant(QAW039) is a selective, potent, reve competitive CRTh2 antagonist with an in vitro of constant KD value of 1.1nM at the CRTh2 recep value of 0.44 nM for inhibition of PGD2-induced shape change in human whole blood. IC50:0.44 98.73% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg	lissociation tor and an IC50 d eosinophil	Bioactivity: Purity: Clinical Data: Size:	Ginsenoside Ro (Polysciasaponin P3; Chikusets Chikusetsusaponin V) exhibits a Ca^{2+} -antagon effect with an IC ₅₀ of 155 μ M. Ginsenoside Ro production of TXA ₂ more than it reduces the a 98.69% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	istic antiplatelet reduces the
Grapiprant (CJ-023423; R	Q-0000007; AAT-007)	Cat. No. : HY-16781	GSK-26998	4A	Cat. No.: HY-1446
Bioactivity: Purity: Clinical Data: Size:	10mM x 1mL in DMSO,	Target: novel elective EP4	Bioactivity: Purity: Clinical Data: Size:	GSK-269984A is a Prostaglandin E2 Receptor with a pIC₅₀ of 7.9. >98% No Development Reported 1 mg, 5 mg	1 (EP1) antagonist
GSK726701	5 mg, 10 mg, 25 mg, 50 mg	Cat. No.: HY-112152	GW627368		کی کے کی معرفہ کر کی کھی کے کر کھی کر کھ Cat. No.: HY-1696
Bioactivity:	GSK726701A is a novel prostaglandin E2 recep partial agonist with a pEC₅₀ of 7.4.		Bioactivity:	GW627368(GW627368X) is a novel, potent and competitive antagonist of prostanoid EP4 recep with additional human TP receptor affinity(Ki=	l selective otor(Ki= 100 nM)
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Contraction of the second	Purity: Clinical Data: Size:	99.88% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg	han the second sec

Iloprost (Ciloprost; ZK	36374)	Cat. No.: HY-A0096	KF 13218		Cat. No.: HY-U0023
Bioactivity:	Iloprost (ZK 36374) is a synthetic analogue of p PGI2.	prostacyclin	Bioactivity:	KF 13218 is a potent, selective and long lasting thromboxane B2 (TXB2) synthase inhibitor w value of 5.3±1.3 nM.	
Purity: Clinical Data: Size:	99.06% Launched 10mM x 1mL in DMSO, 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 r	mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	C C C C C C C C C C C C C C C C C C C
KP496		Cat. No.: HY-U00253	KW-8232 f	ree base	Cat. No. : HY-10030
Bioactivity:	KP496 is a selective, dual antagonist for Leuko receptor and Thromboxane A2 receptor.	otriene D4	Bioactivity:	KW-8232 free base is an anti-osteoporotic ager reduces the biosynthesis of PGE2 .	nt, and can
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	rangto-va.	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	HO HO
L 888607		Cat. No .: HY-111271	L 888607 R	acemate	Cat. No.: HY-111271
Bioactivity:	L 888607 is a potent, and selective CRTH2 (als $_2$) agonist with a K _i of 0.8 nM.	o known as DP	Bioactivity:	L 888607 Racemate is a selective prostaglandin subtype 1 (DP1) antagonist, with K_{js} of 132 nM DP1 and thromboxane A2 receptor (TP), respec	1 and 17 nM for
Purity: Clinical Data: Size:	99.88% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	a Contraction of the second se	Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	
Laropipran (MK-0524)	t	Cat. No. : HY-50175	Latanopros (PHXA41)	t	Cat. No.: HY-B057
Bioactivity:	Laropiprant is a potent, selective DP receptor with \mathbf{K}_{i} values of 0.57 nM and 2.95 nM for DP Receptor, respectively.	-	Bioactivity:	Latanoprost is an agonist for the FP prostanoi and lowers intraocular-pressure (IOP).	d receptor,
Purity: Clinical Data: Size:	99.21% Phase 4 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	o h o H	Purity: Clinical Data: Size:	96.81% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	HQ HQ HQ
LCB-2853		Cat. No.: HY-101700	MF498		Cat. No. : HY-1079
Bioactivity:	LCB-2853 is an antagonist of thromboxane A receptor , with antiplatelet and antithrombotic		Bioactivity:	MF498 is a novel and selective E prostanoid rec receptor) antagonist, displayed strong binding the EP4 receptor with Ki of 0.7 nM.	
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	он С	Purity: Clinical Data: Size:	98.90% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	

Misoprosto	l Cat. No.: HY-B0610	MK-2894	Cat. No. : HY-10413	
Bioactivity:	Misoprostol(SC29333) is a synthetic prostaglandin E1 (PGE1) analog that is used to prevent gastric ulcers, to treat missed miscarriage, to induce labor, and to induce abortion.	Bioactivity:	MK-2894 is a highly potent and selective second generation EP4 antagonist.	
Purity: Clinical Data: Size:	99.0% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	98.10% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	
MK-2894 s	odium salt Cat. No.: HY-10414	MK-447	Cat. No. : HY-100297	
Bioactivity:	MK-2894 sodium salt is a highly potent and selective second generation EP4 antagonist.	Bioactivity:	MK-447 is a free radical scavenger, also a nonsteroidal antiinflammatory agent, and enhances the formation of the endoperoxide, PGH $_2$, and other prostaglandins .	
Purity: Clinical Data: Size:	98.09% No Development Reported 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	
MK-7246	Cat. No. : HY-15853	MK-7246 S	enantiomer Cat. No.: HY-15853A	
Bioactivity:	MK-7246 is a potent and selective CRTH2 antagonist with a K_i of 2.5±0.5 nM.	Bioactivity:	Bioactivity: MK-7246 S enantiomer is the less active enantiomer of MK-7246. MK-7246 is a potent and selective CRTH2 antagonist.	
Purity: Clinical Data: Size:	98.16% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	
MK-8318	Cat. No.: HY-112604	MRE-269 (ACT-333679)) Cat. No.: HY-79593	
Bioactivity:	MK-8318 is a potent and selective CRTh2 receptor antagonist with a K $_{\rm i}$ of 5.0 nM.	Bioactivity:	MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Size:	99.91% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg	
Nedocromi (FPL 59002)	l Cat. No.: HY-13448	Nedocrom (FPL 59002KP	il sodium ?; Nedocromil disodium salt) Cat. No.: HY-16344	
Bioactivity:	Nedocromil suppresses the action or formation of multiple mediators, including histamine , leukotriene C_4 (LTC_4), and prostaglandin D_2 (PGD_2).	Bioactivity:	Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine , leukotriene C_4 (LTC ₄), and prostaglandin D_2 (PGD ₂).	
Purity: Clinical Data: Size:	95.66% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	

OBE022		Cat No. 4V-110094	ONO-AE3-2 (AE 3-208)	208	Cat No. UV E000
		Cat. No.: HY-112284			Cat. No.: HY-5090
Bioactivity:	OBE022 is an oral and selective prostaglandin F receptor antagonist, with K _i s of 1 nM, 26 nM fc FP receptors, respectively.		Bioactivity:	ONO-AE3-208 is an EP4 antagonist, and su invasion, migration, and metastasis of pros	
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg	Chat C'	Purity: Clinical Data: Size:	98.65% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	çç Çç
p-Hydroxy	cinnamic acid	Cat. No. : HY-N2391	PF-0441894	48	Cat. No. : HY-1896
Bioactivity:	p-Hydroxycinnamic acid, a common dietary ph platelet activity, with IC₅₀s of 371 μM, 126 μM	enol, could inhibit	Bioactivity:	PF-04418948 is an orally active, potent and prostaglandin EP2 receptor antagonist w	selective
	B ₂ production and lipopolysaccharide-induced ₂ generation, respectively.			procession and a compete analysing in	
Purity: Clinical Data: Size:	99.85% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 500 mg	ностори	Purity: Clinical Data: Size:	99.60% Phase 1 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	о ^с о со
Prostaglan	din E1	Cat. No. : HY-B0131	Prostagland		Cat. No. : HY-10195
Bioactivity:	Prostaglandin E1 (PGE1) is a potent vasodilator the prostaglandin E1 (EP) receptor.		Bioactivity:	Prostaglandin E2 is a hormone-like substar in a wide range of body functions such as t relaxation of smooth muscle, the dilation a blood vessels, control of blood pressure, ar	ce that participate he contraction and nd constriction of
Purity: Clinical Data: Size:	98.0% Launched 5 mg, 10 mg, 50 mg	Сарана Новение Новени Новени Новени Новени Новени Н Новени Новени Новени Новени Новени Новени Новени Н Новени Новени	Purity: Clinical Data: Size:	inflammation. 98.01% Launched 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg	но но
Quinotolas (FR71021)	t sodium	Cat. No. : HY-U00027	Ralinepag (APD811)		Cat. No.: HY-1675
Bioactivity:	Quinotolast sodium in the concentration range inhibits histamine , LTC ₄ and PGD ₂ release in a concentration-dependent manner.		Bioactivity:	Ralinepag is a potent, orally bioavailable ar prostacyclin (IP) receptor agonist, with EC 530 nM and 850 nM for human and rat IP r receptor, respectively.	50 s of 8.5 nM,
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	O INI NN Na INNN	Purity: Clinical Data: Size:	98.87% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Q. Jor Q. C. e. I
Ramatroba (BAY u3405)	n	Cat. No.: HY-B0745	Rebamipid (OPC12759; P		Cat. No.: HY-B036
Bioactivity:	Ramatroban is a selective thromboxane A_2 (T IC_{50} =14 nM) antagonist, which also antagonize IC_{50} =113 nM) by inhibiting PGD_2 binding.	2	Bioactivity:	Rebamipide is an inducer of endogenous p oxygen-derived free radical scavenger.	rostaglandin and a
Purity: Clinical Data: Size:	99.16% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	H0_0 0=000-r	Purity: Clinical Data: Size:	99.78% Launched 10mM x 1mL in DMSO, 1 g, 5 g	


RO1138452 (CAY10441)	2	Cat. No. : HY-108912	RS-601	Cat. No.: HY-U00
Bioactivity:	RO1138452 is a potent and selective IP (prost antagonist. RO1138452 displays high affinity for In human platelets, pK _i is 9.3 ± 0.1 ; in a recombine	acyclin) receptor r IP receptors.	Bioactivity:	RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (Tx/ dual receptor antagonist, with antiasthmatic activities.
Purity: Clinical Data: Size:	receptor system, pK _i is 8.7±0.06. 98.21% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	1°0.0 [%] #5	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg
Selexipag (NS-304; ACT	-293987)	Cat. No. : HY-14870	Seratrodas (AA 2414)	t Cat. No.: HY-B(
Bioactivity:	Selexipag (NS-304) is an orally available and po for the Prostacyclin (PGI ₂) receptor (IP recepto	otent agonist	Bioactivity:	Seratrodast(AA 2414) is a potent and selective thromboxane A2 receptor (TP) antagonist.
Purity: Clinical Data: Size:	99.93% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Janes 12	Purity: Clinical Data: Size:	98.12% Launched المحكم الم محكم المحكم المح
Setipiprant (ACT-129968;		Cat. No. : HY-16635	Taprenepa (CP-544326)	g Cat. No.: HY-14
Bioactivity:	Setipiprant is an orally available, selective CRTH antagonist. CRTH2 is a G protein-coupled recep		Bioactivity:	CP-544326 is a potent and selective $prostaglandin$ E2 receptor agonist with an EC_{50} of 2.8 nM.
Purity: Clinical Data: Size:	98.17% Phase 3 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg	, Children , C	Purity: Clinical Data: Size:	99.26% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
Taprenepag (PF-04217329		Cat. No.: HY-19998	Terbogrel (BIBV 308SE)	Cat. No.: HY-19
Bioactivity:	Taprenepag isopropyl is a highly selective EP₂ agonist.	receptor	Bioactivity:	Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A2 synthase inhibitor, with both IC₅₀s of about 10 nM.
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg		Purity: Clinical Data: Size:	>98% Phase 2 1 mg, 5 mg, 10 mg, 20 mg
Terutroban (S-18886)		Cat. No. : HY-16991	TG4-155	Cat. No. : HY-18
Bioactivity:	Terutroban is a thromboxane-prostaglandin antagonist.	receptor	Bioactivity:	TG4-155 is a potent, brain-permeant and selective EP2 receptor antagonist with a \mathbf{K}_{i} of 9.9 nM ^{[1] [2]} . TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1 ^[1] . TG4-155 has an EP2 Schild K _R of 2.4 nM
Purity: Clinical Data: Size:	99.59% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	Ho to the total and the total	Purity: Clinical Data: Size:	A series of the

TG6-10-1		Tiaprost	
	Cat. No. : HY-16978	(Iliren)	Cat. No.: HY-111478
Bioactivity:	TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors ^[1] .	Bioactivity:	Tiaprost is a prostaglandin F $_{2\alpha}$ ($\textbf{PGF}_{2\alpha})$ analogue.
Purity: Clinical Data: Size:	99.28% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	98.0% No Development Reported 1 mg
Timapipran (OC000459)	t Cat. No.: HY-15342	Travoprost (Fluprosteno	t ol isopropyl ester; AL6221; Flu-Ipr) Cat. No.: HY-B0584
Bioactivity:	Timapiprant (OC000459) is a potent and selective D prostanoid receptor 2 (DP2) antagonist with IC50 of 13 nM.	Bioactivity:	Travoprost is used to treat glaucoma and ocular hypertension.
Purity: Clinical Data: Size:	95.12% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	99.99% Launched 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg
Treprostini (LRX-15)	Cat. No.: HY-100441	Treprostini (UT-15)	il sodium Cat. No.: HY-16504
Bioactivity:	Treprostinil (LRX-15) is a potent DP1 and EP2 agonist with EC₅₀ values of 0.6±0.1 and 6.2±1.2 nM, respectively.	Bioactivity:	Treprostinil sodium is a potent DP1 and EP2 agonist with EC₅₀ values of 0.6±0.1 and 6.2±1.2 nM, respectively.
Purity: Clinical Data: Size:	99.98% Launched 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg	Purity: Clinical Data: Size:	98.49% Launched 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg
YM158 free (YM-57158)			
Bioactivity:	Cat. No.: HY-U00355 YM158 free base is a potent and selective LTD ₄ and TXA ₂ receptor antagonist with pA ₂ values of about 8.87 and 8.81, respectively.		
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg + a function		



Protease-Activated Receptor (PAR)

Thrombin receptors



Protease activated receptors (PARs) are a family of four G-protein-coupled receptors (PAR1, PAR2, PAR3, and PAR4) that are self-activated by tethered peptide ligands exposed by proteolytic cleavage of the extracellular amino terminus. PAR1, PAR3, and PAR4 are activated by thrombin, whereas PAR2 and, to a lesser degree, PAR4, are activated by trypsin.

PAR1 is a thrombin-activated receptor that contributes to inflammatory responses at mucosal surfaces. PAR1 antagonism might be explored as a treatment for influenza, including that caused by highly pathogenic H5N1 and H1N1 viruses.

PAR2 receptors have been implicated in numerous physiological processes necessitating therapeutic intervention, especially pain and inflammation and syndromes with a strong inflammatory component, including colitis, gastritis, pancreatitis, asthma and pulmonary disease, and arthritis.


Protease-Activated Receptor (PAR) Inhibitors & Modulators

AC-55541		AZ3451	
	Cat. No.: HY-14350		Cat. No.: HY-112558
Bioactivity:	AC-55541 is a novel small-molecule protease-activated receptor 2(PAR2) agonist; activated PAR2 signaling in cellular proliferation assays, phosphatidylinositol hydrolysis assays, and Ca(2+) mobilization assays, with potencies ranging from 200 to 1000 nM. IC50 value: 200-1000 nM(EC50) [1] Target: PAR2	Bioactivity:	AZ3451 is a potent protease-activated receptor-2 (PAR2) antagonist with IC $_{50}$ of 23 nM.
Purity: Clinical Data: Size:	99.35% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	99.33% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
BMS-98612		GB-88	
	Cat. No. : HY-19837		Cat. No.: HY-120261
Bioactivity:	BMS-986120 is an antagonist of the Platelet Protease-Activated Receptor-4 (PAR4), with IC₅₀s of 9.5, 2.1 nM in human and monkey blood, respectively.	Bioactivity:	GB-88 is an oral, selective non-peptide antagonist of PAR2 , inhibits PAR2 activated Ca ²⁺ release with an IC_{50} of 2 µM ^[1] .
Purity: Clinical Data: Size:	>98% No Development Reported	Purity: Clinical Data: Size:	>98% : No Development Reported 500 mg, 250 mg
I-191	Cat. No.: HY-117793	PAR-4 Ago (PAR-4-AP; A	onist Peptide, amide AY-NH2) Cat. No.: HY-P1309
Bioactivity:	I-191 is a potent protease-activated receptor 2 (PAR2) antagonist ^[1] .	Bioactivity:	PAR-4 Agonist Peptide, amide (PAR-4-AP; AY-NH2) is a proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist.
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg	Purity: Clinical Data: Size:	>98% : No Development Reported ້າວກັບເປັນ 1 mg, 5 mg, 10 mg
-	nist Peptide, amide TFA FA); AY-NH2 (TFA)) Cat. No.: HY-P1309A	Protease-A	Activated Receptor-2 Activating Peptide Cat. No.: HY-P1308
Bioactivity:	PAR-4 Agonist Peptide, amide TFA (PAR-4-AP TFA; AY-NH2 TFA) is a proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist ^[1] .	Bioactivity:	Protease-Activated Receptor-2 Activating Peptide is an agonist of Protease-Activated Receptor-2 (PAR-2).
Purity: Clinical Data: Size:	99.93% No Development Reported می است 1 mg, 5 mg, 10 mg	Purity: Clinical Data: Size:	>98% : No Development Reported 5 mg, 10 mg
Protease-A	ctivated Receptor-2, amide Cat. No.: HY-P0283	Protease-A	Activated Receptor-4 Cat. No.: HY-P0297
Bioactivity:	Protease-Activated Receptor-2, amide (SLIGKV-NH $_2$) is a highly potent protease-activated receptor-2 (PAR2) activating peptide.	Bioactivity:	Protease-Activated Receptor-4 is the agonist of proteinase-activated receptor-4 (PAR4) .
Purity: Clinical Data: Size:	98.33% No Development Reported 10mM x 1mL in Water,	Purity: Clinical Data: Size:	98.35% : No Development Reported 5 mg, 10 mg, 25 mg

TFLLR-NH2	2		TFLLR-NH2	2(TFA)	
		Cat. No.: HY-P0226			Cat. No.: HY-P0226A
Bioactivity: TFLLR-NH2 is a selective PAR1 agonist with an EC_{50} of 1.9 μ M.		with an EC₅₀ of 1.9	Bioactivity:	TFLLR-NH2 (TFA) is a selective PAR1 1.9 μ M.	agonist with an EC₅₀ of
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg	ؿڗڂڕۯڋڹ ؿۺ	Purity: Clinical Data: Size:	99.29% No Development Reported 1 mg, 5 mg	n the second sec
Thrombin F	Receptor Activator for Peptide 5	TRAP-5 Cat. No.: HY-P1536	TRAP-6 (PA Peptide 6)	AR-1 agonist peptide; Thrombin Rece	ptor Activator Cat. No.: HY-P0078
Bioactivity:	Thrombin Receptor Activator for Peptid called Coagulation Factor II Receptor (1 Activated Receptor 1 (1-5), used in the heart disease (CHD).	-5) or Proteinase	Bioactivity:	TRAP-6 is a protease-activated recept	tor 1 (PAR1) agonist.
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg	سمية دېرې ور مسينه دېرې د مسينې	Purity: Clinical Data: Size:	99.84% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	
Vorapaxar					
(SCH 530348)		Cat. No.: HY-10119			
Bioactivity:	Vorapaxar is a protease-activated rece that inhibits thrombin-induced platelet				
Purity: Clinical Data: Size:	99.91% Launched 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	A Contraction of the second se			



Ras



HDAC (Histone deacetylase)

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the

absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Inhibitors & Modulators

1A-116		6Н05
14-110	Cat. No.: HY-104064	Cat. No.: HY-12408
Bioactivity: Purity: Clinical Data: Size:	1A-116 is a specific Rac1 inhibitor. 99.28% No Development Reported 10mM x 1mL in DMSO,	Bioactivity: 6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C). IC50 value: Target: K-Ras G12C 6H05 gives the greatest degree of modification, which allosterically modifies the oncogenic G12C mutant of highly homologous protein H-Ras without affecting wild-type K-Ras [1]. 6H05 can Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg
	5 mg, 10 mg, 25 mg, 50 mg, 100 mg	
6H05 TFA		AMG-510
	Cat. No.: HY-12408A	Cat. No .: HY-114277
Bioactivity: Purity:	6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C). IC50 value: Target: K-Ras G12C 6H05 gives the greatest degree of modification, which allosterically modifies the oncogenic G12C mutant of highly homologous protein H-Ras without affecting wild-type K-Ras [1]. 6H05 can 99.66%	Bioactivity: AMG-510 is a potent KRAS G12C covalent inhibitor ^[1] . Purity: 99.01%
	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	Clinical Data: No Development Reported Size: 250 mg, 500 mg
AMG-510 ı	racemate Cat. No.: HY-114277A	Antineoplaston A10 Cat. No.: HY-128553
Bioactivity:	AMG-510 racemate is the racemate of AMG-510. AMG-510 is a potent KRAS G12C covalent inhibitor.	Bioactivity: Antineoplaston A10, a naturally occurring substance in human body, is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer ^[1] .
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg	Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg
ARS-1323	Cat. No .: HY-U00416	ARS-1620 Cat. No.: HY-U00418
Bioactivity:	ARS-1323 is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.	Bioactivity: ARS-1620 is an atropisomeric selective KRAS^{G12C} inhibitor with desirable pharmacokinetics.
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	Purity: 98.02% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg
ARS-1630	Cat. No .: HY-U00417	ARS-853 Cat. No.: HY-19706
Bioactivity:	ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.	Bioactivity: ARS-853 is a selective, covalent KRAS ^{G12C} inhibitor with an IC_{50} of 2.5 μ M.
Purity: Clinical Data: Size:	98.01% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	Purity: 98.39% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

BQU57	Cat. No.: HY-12875	CASIN	Cat. No. 417 12974
	Cat. No.: HY-12875		Cat. No.: HY-12874
Bioactivity:	BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. The IC50 for BQU57 of 2.0 μ M in H2122 and 1.3 μ M in H358.	Bioactivity:	CASIN is a selective GTPase Cdc42 inhibitor with IC50 of 2 uM.
Purity:	98.0% ^{CF3}	Purity:	98.64%
	No Development Reported		No Development Reported
Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Size:	10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
CCG-1423		CCG-20397	/1
	Cat. No.: HY-13991		- Cat. No. : HY-108361
Bioactivity:	CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.	Bioactivity:	CCG-203971 is a second-generation RhoA /myocardin-related transcription factor A (MRTF-A) inhibitor. CCG-203971 potently targets RhoA/C-activated serum response element (SRE)-luciferase (IC $_{50}$ =6.2 μ M).
Purity:	99.92%	Purity:	98.0%
	No Development Reported		No Development Reported
Size:	10 mg, 50 mg, 100 mg, 200 mg	Size:	10 mg, 25 mg, 50 mg, 100 mg
CID-10677(00	Digeranyl k	pisphosphonate
	Cat. No.: HY-13452	(DGBP)	Cat. No.: HY-U00145
Bioactivity:	CID-1067700 is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 ($Rab7$) with a K_i of 13 nM.	Bioactivity:	Digeranyl bisphosphonate is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1.
Purity: Clinical Data: Size:	98.86% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg	Purity: Clinical Data: Size:	98.0% No Development Reported
EHop-016		EHT 1864	
	Cat. No.: HY-12810		Cat. No.: HY-16659
Bioactivity:	EHop-016 is a novel potent and selective inhibitor of Rac GTPase; inhibits Rac1 activity in MDA-MB-435 cells with an IC50 of 1.1 uM.	Bioactivity:	EHT 1864 is a small molecule inhibitor of Rac1 signaling; modulate $\gamma\mbox{-Secretase-mediated}$ APP processing.
Duritye	99.36%	Duritur	99.60%
Purity: Clinical Data:	No Development Reported	Purity: Clinical Data:	
Size:	10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Size:	No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
GGTI298		GGTI298 T	rifluoroacetate
	Cat. No.: HY-100876		Cat. No.: HY-15871
Bioactivity:	GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC ₅₀ values of 3 and > 20 μ M in	Bioactivity:	GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC ₅₀ of 3 μ M; little effect on Ha-Ras with IC ₅₀ of >20 μ M.
Purity:	vivo, respectively. 96.76%	Purity:	98.0%
· · · · · · · · · · · · · · · · · · ·	No Development Reported 10mM x 1mL in DMSO, 1 mg 5 mg 10 mg 25 mg 50 mg		No Development Reported 10mM x 1mL in DMSO,

K-Ras G120	C-IN-1	Cat. No .: HY-18604	K-Ras G120	C-IN-2	Cat. No.: HY-1860
Bioactivity:	K-Ras G12C-IN-1 is a novel and irreversible inhi mutant K-ras G12C extracted from patent WO 2 value: Target: K-ras G12C inhibitor		Bioactivity:	K-Ras G12C-IN-2 is a novel and irreversible inl mutant K-Ras protein.	nibitor of G12C
Purity: Clinical Data: Size:	98.82% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	çirti a ^{tı}	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	200 and
K-Ras G120	C-IN-3	Cat. No. : HY-18606	K-Ras(G120	C) inhibitor 12	Cat. No .: HY-1870
Bioactivity:	K-Ras G12C-IN-3 is a novel and irreversible inhi mutant K-ras G12C.		Bioactivity:	K-Ras(G12C) inhibitor 12 is a K-Ras(G12C) inhi half-maximum effective concentration (EC50) i inhibitor 12 in H1792 cells is 0.32 μ M.	bitor, the
Purity: Clinical Data: Size:	99.92% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	Jun Land
K-Ras-IN-1		Cat. No. : HY-18674	Kobe0065		Cat. No.: HY-1571
Bioactivity:	K-Ras-IN-1 is a K-Ras inhibitor, by binding to K- hydrophobic pocket that is occupied by Tyr-71 crystal structure.(the detailed information refer reference)	in the apo-Ras	Bioactivity:	Kobe0065 is a novel and effective inhibitor of interaction , competitively inhibiting the bindi to c-Raf-1 RBD with a K $_i$ value of 46±13 μ M.	
Purity: Clinical Data: Size:	98.06% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	S OH	Purity: Clinical Data: Size:	99.26% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg	
kobe2602		Cat. No. : HY-15717	KRas G12C	inhibitor 1	Cat. No .: HY-11249
Bioactivity:	kobe2602 is a novel and effective small-molecu inhibiting Ras–Raf interaction by SBDD; exhibits activity to competitively inhibit the binding of H c-Raf-1 RBD with a Ki value of 149 \pm 55 μ M.	le compound	Bioactivity:	KRas G12C inhibitor 1 is a compound that inhi extracted from patent US 20180072723 A1.	
Purity: Clinical Data: Size:	89.04% No Development Reported 10mM x 1mL in DMSO, 50 mg, 250 mg		Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	NO CONTON
KRas G12C	inhibitor 2	Cat. No.: HY-112492	KRas G12C	inhibitor 3	Cat. No. : HY-11249
Bioactivity:	KRas G12C inhibitor 2 is a compound that inhib extracted from patent US 20180072723 A1.		Bioactivity:	KRas G12C inhibitor 3 is a compound that inhi extracted from patent US 20180072723 A1.	
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	al Gran Regeleration	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	

KRas G12C	inhibitor 4 Cat. No.: HY-112494	KRAS G120	C inhibitor 5 Cat. No.: HY-114168
Bioactivity:	KRas G12C inhibitor 1 is a compound that inhibits KRas G12C , extracted from patent US 20180072723 A1.	Bioactivity:	KRAS G12C inhibitor 5 is a KRas G12C inhibitor extracted from patent WO2017201161A1, Compound example 147 ^[1] .
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
MBQ-167	Cat. No.: HY-112842	ML-098 (CID-7345532	2) Cat. No.: HY-19800
Bioactivity:	MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC₅₀s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.	Bioactivity:	ML-098 (CID-7345532) is an activator of the GTP-binding protein Rab7 with an EC₅₀ of 77.6 nM.
Purity: Clinical Data: Size:	99.26% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	99.87% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg
ML141 (CID-2950007) Cat. No.: HY-12755	MRTX-125	7 Cat. No.: HY-114436
Bioactivity:	ML141(CID-2950007) is a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase(IC50=200 nM) with low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).	Bioactivity:	MRTX-1257 is a selective, irreversible, covalent and oral active KRAS G12C inhibitor, with an IC_{50} of 900 pM for KRAS dependent ERK phosphorylation in H358 cells ^[1] .
Purity: Clinical Data: Size:	99.21% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg
NSC 23766	Cat. No. : HY-15723	NSC 23766	i trihydrochloride Cat. No.: HY-15723A
Bioactivity:	NSC 23766 is a specific inhibitor of the binding and activation of Rac GTPase , used for cancer treatment.	Bioactivity:	NSC 23766 trihydrochloride is an inhibitor of Rac1 activation.
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg	Purity: Clinical Data: Size:	99.10% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg
Oncrasin-1	Cat. No. : HY-16662	Pan-RAS-II	N-1 Cat. No.: HY-101295
Bioactivity:	Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations; also led to abnormal aggregation of PKCL in nucleus of sensitive cells but not in registration.	Bioactivity:	Pan-RAS-IN-1 is a pan-Ras inhibitor that disrupts the interaction of Ras proteins and their effectors.
Purity: Clinical Data: Size:	resistant cells. 98.74% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg


RBC8		Rho-Kinase	e-IN-1
	Cat. No.: HY-12873		Cat. No.: HY-100270
Bioactivity:	RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.5 μM in H2122 cell and 3.4 μM in H358 cell.	Bioactivity:	Rho-Kinase-IN-1 is a rho kinase inhibitor extracted from US 20090325960 A1, compound 1.008.
Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg
Rhosin	Cat. No.: HY-12646A	Rhosin hyc	Irochloride Cat. No.: HY-12646
Bioactivity:	Rhosin is a specific Rho inhibitor; binds to WT RhoA with an affinity ~0.4 uM Kd; does not interfere with the binding of Cdc42 or Rac1.	Bioactivity:	Rhosin hydrochloride is a specific Rho inhibitor; binds to WT RhoA with an affinity ~0.4 uM Kd; does not interfere with the binding of Cdc42 or Rac1. IC50 value: 0.4 uM(binding Kd) [1] Target: RhoA inhibitor Rhosin is specific to the interaction
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg	Purity: Clinical Data: Size:	between RhoA and its GEFs including LARG, DBL, LBC, p115 99.97% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg
	S-Farnesylthiosalicylic acid; Farnesyl	Y16	
Thiosalicylic A	Acid; FTS) Cat. No.: HY-14754		Cat. No.: HY-12649
Bioactivity:	Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.	Bioactivity:	Y16 is an inhibitor of G-protein–coupled Rho GEFs; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.
Purity: Clinical Data: Size:	98.72% Phase 2 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity: Clinical Data: Size:	97.78% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg
ZCL278	Cat. No. 119/12002		
Bioactivity:	Cat. No.: HY-13963 ZCL278 is a selective Cdc42 modulator that directly binds to Cdc42 and inhibits its functions with K_d of 11.4 μ M for Cdc42-ZCL278 affinity in surface plasmon resonance (SPR)		

	cdc42-2CL278 affinity in surface plasmon resonance (SF experiment.	'R)
Purity:	95.0%	
Clinical Data:	No Development Reported	. Le
Size:	10mM x 1mL in DMSO,	and the
	10 mg, 50 mg, 100 mg	



RGS Protein

Regulators of G-protein Signaling; Regulator of G-protein Signaling



HDAC (Histone deacetylase)

RGS (Regulators of G protein signaling) are protein structural domains that activate GTPases for heterotrimeric G-protein alpha-subunits. RGS proteins are multi-functional, GTPase-accelerating proteins that promote GTP hydrolysis by the alpha subunit of heterotrimeric G proteins, thereby inactivating the G protein and rapidly switching off G protein-coupled receptor signaling pathways. Upon activation by GPCRs, heterotrimeric G proteins exchange GDP for GTP, are released from the receptor, and dissociate into free, active GTP-bound alpha subunit and beta-gamma dimer, both of which activate downstream effectors. The response is terminated upon GTP hydrolysis by the alpha subunit, which can then bind the beta-gamma dimer and the

receptor. RGS proteins markedly reduce the lifespan of GTP-bound alpha subunits by stabilising the G protein transition state. All RGS proteins contain an RGS-box (or RGS domain), which is required for activity. Some small RGS proteins such as RGS1 and RGS4 are little more than an RGS domain, while others also contain additional domains that confer further functionality.

RGS Protein Inhibitors & Modulators

CCG 20376	59	CCG-63802	2
	Cat. No.: HY-U00431		Cat. No.: HY-70074
Bioactivity:	CCG-203769 is a selective G protein signaling (RGS4) inhibitor, which blocks the RGS4-Ga _o protein-protein interaction in vitro with an IC₅₀ of 17 nM.	Bioactivity:	CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4. CCG-63802 inhibits GTPase accelerating protein activity of RGS4 and blocks its
Purity: Clinical Data: Size:	99.93% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg	Purity: Clinical Data: Size:	95.0%
CCG-63808	3 Cat. No.: HY-70075		
Bioactivity:	CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins.		


Purity:97.0%Clinical Data:No Development ReportedSize:10 mg, 50 mg





Sigma Receptor

HDAC Inhibitor: Vorinostat (SAHA)



HDAC (Histone deacetylase)

Sigma receptor is a non-opioid receptor that binds diverse classes of psychotropic drugs. Sigma receptors are subdivided into two subtypes, sigma-1 and sigma-2. The sigma-1 receptor is a 25-kDa protein possessing one putative transmembrane domain and an endoplasmic reticulum retention signal. Sigma-1 receptors are highly expressed in deeper laminae of the cortex, olfactory bulb, nuclei of mesencephalon, hypothalamus, and Purkinje cells in the brain. Sigma-1 receptors are predominantly localized at the endoplasmic reticulum of both neurons and oligodendrocytes. From behavioral studies, sigma-1 receptors were shown to be involved in higher-ordered brain functions including memory and drug

dependence. The sigma-2 receptor (σ 2R) is a sigma receptor subtype which preferentially binds to siramesine and PB28. PGRMC1 was recently identified as the sigma-2 receptor. Unlike sigma-1 receptor, it has not yet been cloned. Activation of the receptor can cause apoptosis. A pharmacophore model based on benzooxazolone derivatives has been developed.

Sigma Receptor Inhibitors & Modulators


4-IBP		Cat. No.: HY-100155	AVex-73 hy (AE-37 hydro	/drochloride chloride)	Cat. No. : HY-101864
Bioactivity:	4-IBP is a selective σ 1 agonist with a high level σ for the σ 1 receptor (Ki = 1.7 nM) and a moderat the σ 2 receptor (Ki = 25.2 nM).		Bioactivity:	AVex-73 hydrochloride is a Sigma-1 Receptor an IC₅₀ of 860 nM.	agonist with
Purity: Clinical Data: Size:	98.90% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	0 ⁰⁰ 400,	Purity: Clinical Data: Size:	99.72% Phase 2 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	N- H-G
BD-1047 di	ihydrobromide		BD1063 dh	ydrochloride	
		Cat. No.: HY-16996A			Cat. No.: HY-18101
Bioactivity:	BD-1047 dihydrobromide is a selective function sigma receptors, shows antipsychotic activity in predictive of efficacy in schizophrenia.	-	Bioactivity:	BD1063 dhydrochloride is a potent and selecti receptor antagonist.	ve sigma 1
Purity: Clinical Data: Size:	98.18% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	C C → ↓ → N H → Br	Purity: Clinical Data: Size:	98.0% No Development Reported 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg	N H-G
Cutamesino (SA4503; AGY		Cat. No.: HY-14813		e dihydrochloride /drochloride); AGY94806 dihydrochloride)	Cat. No.: HY-1351
Bioactivity:	Cutamesine (SA4503; AGY-94806) is a selective receptor(r1R) agonist; high affinity for the sigm subtype labeled by (+)-[3H]pentazocine (IC50= 100-fold less affinity for the sigma 2 receptor.	a 1 receptor	Bioactivity:	Cutamesine dihydrochloride (SA4503 dihydroc potent Sigma 1 receptor agonist with an IC₅₀ guinea pig brain membranes.	
Purity: Clinical Data: Size:	>98% Phase 2 10 mg, 50 mg	0000	Purity: Clinical Data: Size:	98.74% Phase 2 10mM x 1mL in DMSO, 10 mg, 50 mg	QQQ. 10 10
Dimemorfa	n phosphate	Cat. No.: HY-B2215	Ditolylguar (1,3-Di-o-toly	nidine Iguanidine; DTG)	Cat. No.: HY-1421
Bioactivity:	Dimemorfan phosphate is a sigma 1 receptor a as a potent antitussive.	agonist, used	Bioactivity:	Ditolylguanidine (1,3-Di-o-tolylguanidine; DTG of sigma receptor (σ1/σ2 receptor) ^[1] .	i) is an agonist
Purity: Clinical Data: Size:	98.42% Launched 10mM x 1mL in DMSO, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.26% No Development Reported 10mM x 1mL in DMSO, 1 g	
E1R		Cat. No.: HY-116463	Noscapine ((S,R)-Noscap	ine)	Cat. No.: HY-13710
Bioactivity:	E1R is a positive allosteric modulator of sigma- receptors with cognition-enhancing activity ^[1] .		Bioactivity:	Noscapine is an orally administrable drug usec cough suppression, primarily mediated by its agonist activity, and possess anticancer activit o-receptor in vitro: Noscapine is a phthalideisc alkaloid from opium, is a recently discovered a	d worldwide for 5-receptor 7. Target: oquinoline
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg		Purity: Clinical Data: Size:	97.80%	

PRE-084 hy	drochloride Cat. No.: HY-18	Roluperido	one IN-101; MT-210)	Cat. No.: HY-19469
Bioactivity:	PRE-084 hydrochloride is a high affinity, selective σ 1 agonist, has an IC50 of 44 nM in the sigma receptor assay.	Bioactivity:	Roluperidone (CYR-101) is a novel cyclic amide has high equipotent affinities for 5-HT_{2A} and receptors (K_i of 7.53 nM and 8.19 nM for 5-H	sigma-2
Purity: Clinical Data: Size:	99.80% No Development Reported 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	sigma-2, respectively). 98.26% : No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg	
S1RA (E-52862)	Cat. No.: HY-1	S1RA hydr (E-52862 hydr		Cat. No .: HY-18099A
Bioactivity:	S1RA(E-52862) is a potent and selective sigma-1 receptor(σ 1R, Ki=17 nM) antagonist, showed good selectivity against σ 2R (Ki > 1000 nM).	Bioactivity:	S1RA Hcl(E-52862 Hcl) is a potent and selectiv receptor(σ 1R, Ki=17 nM) antagonist, showed g against σ 2R (Ki > 1000 nM).	
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg, 100 mg	Clinical Data Size:	99.57% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	H-GI
Sigma-2 re	ceptor antagonist 1 Cat. No.: HY-11	Sigma-LIG	AND-1	Cat. No. : HY-101626
Bioactivity:	Sigma-2 receptor antagonist 1 is a sigma-2 (σ-2) receptor antagonist.	Bioactivity:	Sigma-LIGAND-1 is a selective sigma recepto receptor IC₅₀ s of 16 nM at the DTG site, 19 nN site, and a K_i of 4000 nM at the dopamine D2	1 at the PPP
Purity: Clinical Data: Size:	>98% No Development Reported 500 mg, 250 mg	Purity: Clinical Data Size:	>98% : No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	otorno.
Siramesine (Lu 28-179)	Cat. No.: HY-1		e hydrochloride ydrochloride)	Cat. No.: HY-14221A
Bioactivity:	Siramesine(Lu 28-179) is a selective sigma-2 receptor agonist, which has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.	Bioactivity:	Siramesine(Lu 28-179) Hcl is a selective sigma- agonist, which has been shown to trigger cell o cells and to exhibit a potent anticancer activity	death of cancer
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 50 mg, 100 mg	Purity: Clinical Data Size:	99.91% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	ст. 2 то то
UNC0642	Cat. No.: HY-1	3980		
Bioactivity:	UNC0642 is a potent and selective ${\bf G9a/GLP}$ inhibitor, with an ${\bf IC}_{{\bf 50}}$ of less than 2.5 nM.			
Purity: Clinical Data: Size:	99.81% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	k n		



Somatostatin Receptor

SSTRs;SSTR



Somatostatin receptor is a family of G protein-coupled seven transmembrane receptors. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biological effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. Include SSTR1, SSTR2, SSTR3, SSTR4, SSTR5. SSTR1 is expressed in highest levels in jejunum and stomach. SSTR2 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in cerebrum and kidney. SSTR3 is functionally coupled to adenylyl cyclase. SSTR4 is a member of the superfamily of receptors having seven transmembrane

segments and is expressed in highest levels in fetal and adult brain and lung. SSTR5 is a member of the superfamily of receptors having seven transmembrane segments.

Somatostatin Receptor Inhibitors & Modulators

CYN 15480	6	Cat. No.: HY-P1202	CYN 15480	6 TFA	Cat. No.: HY-P12024
Bioactivity:	CYN 154806, a cyclic octapeptide, is a potent an somatostatin sst2 receptor antagonist, with pl	nd selective	Bioactivity:	CYN 154806 (TFA), a cyclic octapeptide, is selective somatostatin sst2 receptor an	
	8.58, 5.41, 6.07, 5.76 and 6.48 for human recom sst1, sst3, sst4 and sst5 receptors respectively ^[1]	binant sst2,		values of 8.58, 5.41, 6.07, 5.76 and 6.48 fc recombinant sst2, sst1, sst3, sst4 and sst5	or human
Purity: Clinical Data: Size:	>98% No Development Reported	-5000000000000000000000000000000000000	Purity: Clinical Data: Size:	99.97% No Development Reported 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg	
MK-4256			Octreotide		
		Cat. No.: HY-13466	(SMS 201-995	i)	Cat. No.: HY-P0036
Bioactivity:	MK-4256 is a potent and selective SSTR3 antag of 0.66 nM and 0.36 nM in human and mouse r assays, respectively.		Bioactivity:	Octreotide is a somatostatin analog that somatostatin receptor , mainly subtypes increases Gi activity, and reduces intracel production.	2, 3, and 5,
Purity: Clinical Data: Size:	98.63% No Development Reported 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg		Purity: Clinical Data: Size:	99.15% Launched 1 mg, 5 mg, 10 mg, 25 mg	romatorijasina kings optoji
Octreotide (SMS 201-995		Cat. No.: HY-17365	Pasireotide (SOM 230; SC		Cat. No.: HY-16383
Bioactivity:	Octreotide acetate, a long-acting synthetic anal somatostatin, inhibits growth hormone , gluca insulin more potently.	-	Bioactivity:	Pasireotide(SOM 230) is a stable cyclohey mimic that exhibits unique high-affinity b somatostatin receptors (subtypes sst1/2/ pKi=8.2/9.0/9.1/<7.0/9.9 respectively). IC 8.2/9.0/9.1/<7.0/9.9(pKi, sst1/2/3/4/5) [1]	inding to human 3/4/5, 50 value:
Purity: Clinical Data: Size:	99,78% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	Purity: Clinical Data: Size:	>98% Launched 1 mg, 5 mg, 10 mg	
	ditrifluoroacetate	Cat. No. : HY-79135	Pasireotide (SOM230 L-as	L-aspartate salt	Cat. No.: HY-7913
Bioactivity:	Pasireotide (ditrifluoroacetate) is a stable cyclol somatostatin mimic that exhibits unique high-a to human somatostatin receptors (subtypes s pK _i =8.2/9.0/9.1/<7.0/9.9, respectively).	ffinity binding	Bioactivity:	Pasireotide(SOM 230) is a stable cyclohex mimic that exhibits unique high-affinity b somatostatin receptors (subtypes sst1/2/ pKi=8.2/9.0/9.1/<7.0/9.9 respectively). IC 8.2/9.0/9.1/<7.0/9.9(pKi, sst1/2/3/4/5) [J]	inding to human 3/4/5, 50 value:
Purity: Clinical Data: Size:	95.06% Launched 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg		Purity: Clinical Data: Size:	99.44%	
SSTR5 anta	gonist 1	Cat. No.: HY-102037	SSTR5 anta	gonist 2	Cat. No.: HY-11419:
Bioactivity:	SSTR5 antagonist 1 is a potent, selective, and o available somatostatin receptor subtype 5 (SST with IC_{50} s of 9.6 and 57 nM for hSSTR5 and mS respectively. (Compound 25a) ^[1]	rally [R5) antagonist	Bioactivity:	SSTR5 antagonist 2 (compound 10) is a h active and selective somatostatin (rece) antagonist and has potential to treat type (T2DM) ^[1] .	ighly potent, oral ptor) subtype 5 (SSTR5)
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg	

	SSTR5 antagonist 2 TFA Cat. No.: HY-114191A Bioactivity: SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential to treat type 2 diabetes mellitus (T2DM) ^[1] .		Vapreotide acetate (RC-160 acetate; BMY-41606 acetate) Cat. No.			
			e 5 (SSTR5)	Bioactivity: Vapreotide acetate is a synthetic and the treatment of variceal bleeding; a activity. Sequence: Phe-Cys-Tyr-Trp-Lys-Val-Cys-Trp-N Cys2-Cys7).		also exhibits antitumor
	Purity: Clinical Data: Size:	>98% No Development Reported 250 mg	°°°, ₽0•°0,40°	Purity: Clinical Data: Size:	99.61% Phase 3 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 50 mg	естоноса на " " _{мо} Å


Cat. No.: HY-P0061A

 \mathcal{A}_{00}



TSH Receptor

Thyrotropin receptor; Thyroid-stimulating hormone Receptor



The thyrotropin receptor (TSHR), one of the primary antigens in autoimmune thyroid disease, is a target of both antigen-specific T cells and antibodies in patients with this condition. Autoantibodies to the TSHR (TSHR-Ab) act as thyroid stimulating factor (TSH) agonists in autoimmune hyperthyroidism (Robert Graves disease) but as TSH antagonists in autoimmune hypothyroidism (Hashimoto thyroiditis). The TSHR antigen is primarily expressed in the epithelial cells of the thyroid follicles, but TSHR mRNA and protein have been reported in a variety of cell types, some of which show evidence of receptor activity. TSH receptor (TSHR) plays an important role in the pathogenesis of thyroid disease, a TSHR antagonist could be a novel treatment.

TSH, acting through the TSH receptor, is the major stimulator of thyroid cell growth, differentiation and function.


TSH Receptor Inhibitors & Modulators

ML-109	Cat. No. : HY-114116	ML224 (NCGC00242	2364; ANTAG3)	Cat. No. : HY-12381
Bioactivity:	ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC $_{\rm 50}$ of 40 nM.	Bioactivity:	ML224(NCGC00242364; ANTAG3) is a agonist; inhibits TSH-stimulated cAMP = 2.3 μ M.	
Purity: Clinical Data: Size:	>98% No Development Reported 5 mg, 10 mg, 25 mg	Purity: Clinical Data Size:	99.12% : No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	
Org41841	Cat. No. : HY-100271			
Bioactivity:	Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and thyroid-stimulating hormone receptor (TSHR) with EC₅₀s of			
	0.2 and 7.7 $\mu M,$ respectively.			
Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg			



Urotensin Receptor

UT receptor



the peptide hormoneurotensin. The urotensin-II (UT) receptor is a Gq/11-protein-coupled receptor that mediates complex hemodynamic effects and influences neuromuscular physiology. The UT receptor displays greatest expression levels in the peripheral vasculature, heart and kidney, although they are found elsewhere, notably the central nervous system, at lower levels. The UT receptor produces potent but variable vasoconstrictor effects in some vascular beds, yet mediates vasodilation in others; it has also been implicated in osmoregulation.

Urotensin receptor (UT) is a G-protein coupled receptor which binds

HDAC (Histone deacetylase)


Urotensin Receptor Inhibitors & Modulators

Palosuran (ACT-058362)	Cat. No.: HY-10655			
Bioactivity:	Palosuran (ACT-058362) is a new potent and specific an of the human UT receptor with an IC50 of 3.6 ± 0.2 nM.	tagonist		
Purity: Clinical Data: Size:	99.99% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	HICK NO CHAPS		



Vasopressin Receptor

HDAC Inhibitor: Vorinostat (SAHA)



HDAC (Histone deacetylase)

Vasopressin receptors are a family of tissue-specific G protein-coupled receptors, which classified into V1, V2 and V3 subtypes. These three subtypes differ in localization, function and signal transduction mechanisms. Although all three of these proteins are G-protein coupled receptors (GPCRs), activation of AVPR1A and AVPR1B stimulate phospholipase C, while activation of AVPR2 stimulates adenylate cyclase. These three receptors for vasopressin have unique tissue distributions. AVPR1A are expressed in vascular smooth muscle cells, hepatocytes, platelets, brain cells, and uterus cells. AVPR1B are expressed in cells of the anterior pituitary and throughout the brain, especially in the pyramidal neurons of the

hippocampal CA2 field. AVPR2 are expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, in fetal lung tissue and lung cancer, the last two being associated with alternative splicing. AVPR2 is also expressed in the liver where stimulation releases a variety of clotting factors into the bloodstream.

Vasopressin Receptor Inhibitors & Modulators

Balovaptan (RG7314)		Cat. No.: HY-109024	Conivaptar (YM 087)	hydrochloride	Cat. No.: HY-18347A
Bioactivity:	Balovaptan is a highly potent and selective brain- vasopressin 1a (hV1a) receptor antagonist, with		Bioactivity:	Conivaptan (hydrochloride) is a non-peptide ant vasopressin receptor, with \mathbf{K}_{i} values of 0.48 and	
	39 nM for human (hV1a) and mouse (mV1a) receptor the research of autism.	otors, and is used		rat liver V1A receptor and rat kidney V2 receptor respectively.	r
Purity: Clinical Data: Size:	>98% No Development Reported 250 mg, 500 mg		Purity: Clinical Data: Size:	99.92% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	HC C
Fuscoside			L-371,257		
(OPC-21268)		Cat. No.: HY-15009			Cat. No.: HY-15010
Bioactivity:	Fuscoside (OPC-21268) is an orally effective, nonp $vasopressin$ V1 receptor antagonist with an IC_{50}		Bioactivity:	L-371,257 is an orally bioavailable, non-blood-bupenetrant, selective and competitive antagonist receptor (pA2=8.4) with high affinity at both the receptor (K_i =19 nM) and vasopressin V1a rece	of oxytocin e oxytocin
	98.0% No Development Reported 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	ofgan-y	Purity: Clinical Data: Size:	99.0% No Development Reported 10mM x 1mL in DMSO, 5 mg	ورمافرما
Lixivaptan (VPA-985; WA	Y-VPA 985)	Cat. No. : HY-14185	Mozavapta (OPC-31260;		Cat. No.: HY-18346
	Lixivaptan (VPA-985, WAY-VPA 985) is an orally ac selective vasopressin receptor V2 antagonist, wit of 1.2 and 2.3 nM for human and rat V2, respectiv	h IC ₅₀ values	Bioactivity:	Mozavaptan (OPC31260) is a orally effective, nor vasopressin V2 receptor antagonist with an IC ₅	
	99.57% No Development Reported 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	and an and a second sec	Purity: Clinical Data: Size:	98.94% Launched 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	S-N- S-N-
RG7713 (RO5028442)		Cat. No.: HY-12981	Terlipressir	1	Cat. No.: HY-12554
Bioactivity:			Bioactivity:	Terlipressin is a potent vasoconstrictor that acts receptors on arteriolar smooth muscle cells. Terl result in splanchnic vasoconstriction augmenting arterial blood pressure with beneficial circulatory effects that would be expected to also ameliorat	ipressin can 9 systemic 7 and renal
Purity: Clinical Data: Size:	99.49% Phase 1 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg	-N N N N N N N N N N N N N N N N N N N	Purity: Clinical Data: Size:	99.07%	
Tolvaptan (OPC-41061)		Cat. No.: HY-17000	WAY-15193 (VNA-932; W		Cat. No.: HY-19381
-	Tolvaptan is a selective, competitive arginine vaso receptor 2 antagonist with an IC50 of 1.28µM for ' inhibition of AVP-induced platelet aggregation. IC 1.28 uM (inhibition of AVP-induced platelet aggre Target: vasopressin receptor 2 Tolvaptan (OPC-41	pressin the 50 value: gation)	Bioactivity:	WAY-151932 is a vasopressin V₂-receptor ago 80.3 nM and 778 nM in human-V $_2$ binding and assay.	nist with IC₅₀ of
Purity: Clinical Data: Size:	99.92%		Purity: Clinical Data: Size:	>98% No Development Reported 1 mg, 5 mg, 10 mg, 20 mg	